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Abstract 
Aspergillus species are opportunistic mould pathogens that can cause a wide variety 
of pulmonary diseases. They are mainly caused by Aspergillus fumigatus (Munoz et 
al., 2006). Germination of conidia in hosts with a susceptible immune system is the 
first step in Aspergillus infection, and invasive aspergillosis (IA) is a major cause of 
mortality in transplant patients. Due to the increased occurrence of IA in high-risk 
populations, prophylaxis against IA is important. Prophylactic prevention of life 
threatening infections with drugs is now the preferred clinical strategy for these 
patients rather than treating the disease after it has become established. Inhaled 
amphotericin B (AmB) has potential for preventing IA and it has been reported to 
decrease the incidence of IA in solid organ transplant patients (Arthur et al., 2004). 
I have generated a new respiratory formulation of AmB (AmB-PMA) with a 
commercially available high purity, low polydispersity and non-toxic poly methacrylic 
acid sodium salt (PMA-Na). The chemical synthesis was optimized and showed that 
AmB-PMA complex was effective against A. fumigatus and was also less toxic than 
Fungizone in-vitro. The efficacy of AmB-PMA was determined in-vivo in BALB/c and 
C57BL/6 mice. Mice were infected intranasally with A. fumigatus CEA10 and treated 
with AmB-PMA by the nasal and nebulisation routes. In this thesis, the optimum 
routes of in-vivo administration, dosing regimens and treatment frequency were 
defined. Disease progression in A. fumigatus-infected BALB/c and C57BL/6 mice 
was monitored by histology, qPCR analysis of chemokine and cytokine responses in 
mouse lung, colony forming unit (CFU) and qPCR for Aspergillus ribosomal 28S 
rRNA. The results showed a significant reduction in CFU and DNA fungal load in 
AmB-PMA infected mice as compared to infected untreated mice. In addition, AmB-
PMA could also affect cytokine production by increasing IFN-γ production and 
reducing MIP-1β, TNF-α and IL-10 as compared to infected untreated mice. 
However, the increase in IFN-γ production was not statistically significant when 
compared to infected untreated mice. My thesis demonstrates that a new low-cost 
AmB based PMA-Na polymer antifungal drug can be successfully given by the 
aerosol route to immuno-suppressed mice by nebulisation to prevent IA. 
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Chapter 1 
1.1  Introduction 
1.1.1 Aspergillus 
Aspergillus species are opportunistic fungi that can cause a wide variety of clinical 
syndromes ranging from allergic bronchopulmonary aspergillosis to life-threatening 
angio-invasive diseases. The genus has around 180 species of which only 33 are 
related to human disease (Hope et al., 2005). The most common species of 
Aspergillus causing human diseases is Aspergillus fumigatus; less commonly 
infections are due to Aspergillus niger, Aspergillus terreus and Aspergillus flavus 
(Munoz et al., 2006).  
Aspergillus fumigatus (A. fumigatus) is the principal fungal pathogen that causes 
invasive aspergillosis (IA) in immuno-compromised patients. A. fumigatus causes 
different diseases which can be divided into three categories: (1) chronic cavitatory 
aspergillosis in persons with normal immune systems, (2) invasive aspergillosis in 
patients with suppressed immune systems, (3) allergic reaction to inhaled conidia in 
persons with hyperactive immune responses (Osherov & Romano; Daly & 
Kavanagh, 2001).  
 
1.1.1.1 The life cycle of Aspergillus 
1.1.1.2 Conidia 
The infectious life cycle of Aspergillus is shown in Figure 1 and it commences with 
the production of a spore form (known as conidia) that can spread easily into the air 
(Falvey & Streifel, 2007; Morris et al., 2000; Dagenais & Keller, 2009). Inhalation of 
these conidia by a host with a susceptible immune system is a first step in 
Aspergillus infection (Figure 2). The size of these conidia in A. fumigatus ranges from 
2 to 3.5 µm (Pasqualotto, 2008) and they are small enough to reach the pulmonary 
alveoli after they are inhaled. Once the conidia reach the alveoli, they germinate and 
produce hyphae-the vegetative form that has tropism for blood vessels (Lopes 
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Bezerra & Filler, 2004). The small size of conidia in A. fumigatus helps it to reach the 
pulmonary alveoli easily and cause invasive aspergillosis whereas other human 
fungal pathogens such as A. niger and A. flavus with larger conidia can be more 
easily removed by clearance in the upper respiratory tract (Dagenais & Keller, 2009). 
In addition to conidial size, the outer cell well of conidia is an important factor in the 
propagation of Aspergillus. The outer conidial surface contains rodlets that are 
associated with hydrophobic properties (Pasqualotto, 2008). These structures confer 
resistance to extreme atmospheric conditions, facilitate airborne dispersion of 
Aspergillus conidia and enable evasion of host immune surveillance (Romani, 2004). 
Furthermore, A. fumigatus is thermo-tolerant; it can tolerate temperatures above 
50°C and grows well at 37°C; this allows for sporulation in the human lung (Dagenais 
& Keller, 2009) (Figure 2). 
 
Figure 1 : The life cycle of A. fumigatus 
  
A. fumigatus produces conidiophore structures which produce conidial spores through the 
process of conidiation. Under certain environmental conditions, conidia can germinate and 
begin to undergo polarized growth, finally becoming hyphal cells. Hyphal cells will continue 
to grow and can ultimately form conidiophores. (Image of conidia reprinted from (Cramer et 
al., 2006) with permission; image of hyphae reprinted from W. J. Steinbach [Duke University 
Medical Center], with permission; image of conidiophore courtesy of A. Beauvais and J. P. 
Latge´ [Pasteur Institute, France], reprinted with permission (Shapiro et al., 2011). I have 
checked the American Society for Microbiology. As I am using this figure for personal use 
only in my PhD thesis, the journal gives me permission to do so.  
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Figure 2: The infectious life cycle of A. fumigatus 
Picture was taken from Dagenais & Keller, 2009. I have checked the American Society for 
Microbiology. As I am using this figure for personal use only in my PhD thesis, the journal 
gives me permission to do so.  
 
1.1.1.3 Factors affecting germination 
Dagenais & Keller suggested that the expression of unique stress response genes 
might be induced by growth at high temperatures. This confers extra virulence 
benefits. They compared growth rates of A. fumigatus, A. flavus and A. niger and 
demonstrated a correlation between the germination rate and pathogenic 
prevalence. Whilst the germination rates in these species are similar at temperatures 
up to 30°C, they are different at 37°C (Dagenais & Keller, 2009). Rodrigues et al 
reported an enhancing effect of albumin in germination and maturation of conidia in 
A. fumigatus in comparison to A. niger and A. flavus. Interestingly, albumin promotes 
the germination of A. fumigatus but the germination of A. niger and A. flavus 
decreased in the presence of albumin (Rodrigues et al., 2005; Pasqualotto, 2008). 
40 
 
1.1.1.4 Fungal cell wall composition 
The fungal cell wall (Figure 3) is a dynamic structure which determines the shape of 
the cell and protects fungi from osmotic pressure and other environmental stresses. 
The cell wall retains the plasticity to permit cell growth, cell division and formation of 
hyphae or conidia during the fungal life cycle. In addition, it also permits interaction 
with the surroundings.  The cell wall facilitates the binding to other cells and the 
substratum and also activates the signal transduction pathways by acting as a 
signalling centre. Disruption of fungal cell walls makes them very susceptible to lysis 
and death (Bowman & Free, 2006). The major constituents of the fungal cell wall are 
polysaccharides. These polysaccharides are important components of chitin, glucan, 
mannan and glycoproteins which, when cross-linked together, create a complex 
network that confers the structural properties of the fungal cell wall (Figure 3). 
 
     
Figure 3: The structure of the fungal cell membrane and cell wall 
Picture was taken from: http://www.doctorfungus.org/thedrugs/antif_pharm.php 
As I am using this figure for personal use only in my PhD thesis, the website gives me 
permission to do so. 
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1.1.1.4.1 Chitin 
Chitin is an important structural component of fungal cell walls (Figure 4). It is 
composed of long linear homopolymers of β-1, 4-linked N-acetylglucosamine. The 
synthesis of chitin is mediated by chitin synthase, an integral membrane enzyme that 
catalyzes the transfer of N-acetylglucosamine from uridine diphosphate (UDP)-N- 
acetylglucosamine into a growing chitin chain (Bowman & Free, 2006). Whilst chitin 
accounts only for 1-2% of yeast cell walls, it accounts for 10-20% of the cell walls of 
filamentous fungi such as Aspergillus and Neurospora (De Nobel et al., 2000; 
Bartnicki-Garcia, 1968). Chitin structures are also important for maintaining the 
osmotic pressure / osmolarity within cells. 
      
Figure 4 :Chemical structure of chitin 
Structure was drawn in ChemDraw. 
1.1.1.4.2 β-1,3-glucan 
The fungal cell wall is now introduced as a dynamic structure rather than an inert 
structure. As a result of chemical or mechanical stresses, it is continuously 
undergoing the processes of assembly and re-modelling during cell growth. Inoue et 
al., 1996 reported that: “the dynamic fungal cell wall functions as a protective barrier, 
providing structure and stability to the organism, as well as enabling the organism to 
penetrate or invade tissues”. The major structural constituents of the fungal cell wall 
are polysaccharides. It has been suggested that, the cell wall of yeast has less 
glucan than filamentous fungi (Inoue et al., 1996).  Glucan is a major polysaccharide 
which accounts for 50-60% of the fungal cell wall (Fleet, 1991; Kapteyn et al., 1999). 
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Glucans are composed of many glucose residues that are bound together in a chain 
through chemical linkages. The main component in glucan is β-1,3-glucan (65-90%). 
Mixed β-1,3 & β-1,4, and α-1,3 & α-1,4 linked glucans and also β-1,6-glucan have 
been found in other fungal cell walls (Bernard & Latge, 2001) (Figure 5). However, 
some studies have reported that β-1,6-glucan is not present in some fungi such as A. 
fumigatus.  
β-1,3-glucan consists of a chain of (1,3)-β-glucosyl residues linked through carbons 
1 and 3 by a glycosidic bond with a β-configuration to form the β-1,3-glucan 
backbone (Bowman & Free, 2006). The disruption of β-1,3-glucan synthesis 
prevents cell wall formation and also inhibits fungal growth (Bowman & Free, 2006). 
β-1,3-glucans normally exist as an insoluble structure, but when exposed to blood 
and other body fluids, are transformed to a soluble form. The soluble β-1,3-glucan is 
capable of modulating the immune system by inhibiting phagocytosis by leukocytes 
(Brown & Gordon, 2005). It can serve as a pharmacological target for some 
antifungal drugs such as micafungin and caspofungin. Furthermore, it is extensively 
used as an antigenic marker in the diagnosis of systemic mycoses (Pazos et al., 
2005).    
         
Figure 5: Chemical structures of β-(1,3) & (1,6)-glucans 
Picture was taken from Jatlas, 2009. 
1.1.1.4.3 Glycoproteins 
In addition to polysaccharides, glycoproteins are also present in the fungal cell wall. 
It was reported that glucans, chitin and glycoproteins are covalently cross-linked 
together to create a complex network. This complex network forms the core structure 
of the fungal cell wall. Glycoproteins are modified with both N-linked & O-linked 
43 
 
oligosaccharides and sometimes contain a glycosylphosphatidylinositol (GPI) 
anchor. The structure of these oligosaccharides is different between fungi (Fleet, 
1991; Brown & Catley, 1992; Bowman & Free, 2006). The GPI anchor contains 
oligosaccharides and lipid which are joined to proteins via their C-terminal sequence. 
Then, these proteins are released into the fungal cell wall or cell membrane. The 
functions of these proteins include protecting the cell against foreign particles, 
mediating adhesion for cell fusion, re-modelling the cell wall components and 
preserving the cell wall’s shape (Bowman & Free, 2006). 
C. albicans has mannoproteins in its cell wall which are glycosylated with mannans 
(Fleet, 1991; Brown & Catley, 1992; Bowman & Free, 2006). A. fumigatus contains 
galactomannan which is composed of galactose and mannose (Latge et al., 1994). 
They are released into the cell wall space where they combine to form the cell wall. 
Most fungal cell wall proteins are glycoproteins; 20-30% of the cell wall of 
filamentous fungi is composed of proteins (Bowman et al., 2006).  
1.1.1.5 A. fumigatus virulence factors 
To invade the host, A. fumigatus must be able to adhere and penetrate respiratory 
epithelial cells, particularly phagocytic cells, which are the first line of defence 
against infection (Latge et al., 1994). The involvement of adhesions, pigments, toxic 
molecules and enzymes of A. fumigatus is essential for the invasive process.   
1.1.1.5.1 Adhesins 
Conidia bind to various basement membrane proteins such as albumin, fibrinogen, 
fibronectin, collagen, surfactant proteins and laminin (Annaix, et al., 1992; Ansorg et 
al., 1994). This binding occurs via specific receptor ligands or by non-specific 
interaction. The rodlet fascicles in the cell wall layer of hyphal and conidial forms of 
A. fumigatus are composed of hydrophobic proteins (Thau et al., 1994; Wessels, 
1993).   
1.1.1.5.2 Pigment 
A. fumigatus strains with green conidia are more pathogenic than wild type strains 
without pigment. The cell wall of white A. fumigatus conidia are more permeable to 
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antifungal agents and are able to bind more strongly to complement (Verweij et al., 
1998). 
1.1.1.6 Invasive fungal diseases (IFD) 
Until the 1990s, Candida spp. were the commonest cause of invasive fungal 
infection (IFI) amongst immuno-suppressed patients (Koch et al., 2004). Since 
1990s, there has been a shift in the epidemiology of invasive fungal diseases. 
Different studies have shown that Aspergillus spp. now exceed Candida spp. as the 
most important cause of IFI in advanced healthcare settings. For example, Lass-Florl 
demonstrated that between 1992 and 2001, Aspergillus spp. and Candida spp. were 
responsible for 62% and 35% of IFIs, respectively (Lass-Florl, 2009).  
The inhalation of Aspergillus spores can have a number of outcomes depending 
upon the immune status of the host ranging from Aspergilloma and Chronic 
Necrotizing Pulmonary Aspergillosis (CNA) to Invasive Aspergillosis (IA) as outlined 
in Figure 6 below. 
 
 
 
 
 
 
 
 
 
Figure 6: The spectrum of pulmonary aspergillosis 
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1.1.1.6.1 Aspergilloma 
Aspergilloma is the most common form of aspergillosis. It is caused by overgrowth of 
A. fumigatus and formation of fungal balls inside cavities in the lung generated by a 
prior lung disease like tuberculosis. This fungus ball is composed of inflammatory 
cells, fungal hyphae, mucus, tissue debris and fibrin. The most common species of 
Aspergillus extracted from the lesions is A. fumigatus and then Fusarium and then 
Mucorales. Tuberculosis, bronchial cysts bronchiectasis, sarcoidosis, ankylosing 
spondylitis and other pulmonary infections may also lead to airway obstruction which 
leads to further colonisation of the lung by fungus (Hatziagorou et al., 2009). The 
fungus ball may move into the cavity but it is not able to invade the blood vessels 
and surrounding lung parenchyma (Tomee et al., 1994; Rafferty et al., 1983). In the 
majority of cases of aspergilloma, the size of the lesion remains stable, but in 10% of 
cases the size of lesion can decrease. In most cases, subclinical aspergilloma 
resolve spontaneously and without treatment (Gefter, 1992). 
Most patients with aspergilloma experience mild haemoptysis, but severe 
haemoptosis may occur in TB patients. In addition to mild haemoptosis, which has a 
2%-14% mortality rate, bleeding from bronchial blood vessels is a common symptom 
in patients with aspergilloma. Less commonly, patients may develop cough, fever 
and dyspnoea. Several risk factors have been related to a poor prognosis of 
aspergilloma. They include increasing size and number of lesions as seen in 
radiographs or CT chest scans, rising specific IgG titers, HIV infection, severe 
haemoptysis and underlying sarcoidosis (Stevens et al., 2000). 
The diagnosis of aspergilloma is based on serological and microbiological evidence 
of Aspergillus spp. in combination with chest radiographic features. CT scan and 
chest radiography are useful methods for diagnosis of pulmonary aspergilloma. 
Chest radiography is useful for demonstrating the mass in the chest cavity.  CT scan 
of the chest is necessary to see an aspergilloma that is not apparent on radiography. 
Aspergilloma may co-exist with another condition such as a neoplasm, haematoma, 
hydatid cyst, abscess and granulomatosis (Bandoh et al., 1999; Le Thi Huong et al., 
1995).   
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1.1.1.6.2 Chronic Necrotizing Pulmonary Aspergillosis 
Chronic necrotising aspergillosis (CNA) (also called semi-invasive and sub-acute 
invasive aspergillosis) was first described by Gefter et al. (Kousha et al., 2011).  
In patients with CNA, fungal hyphae damage lung cells and blood vessels over 
months or years. It usually occurs without vascular invasion or dissemination to other 
organs. It usually impacts middle-aged and elderly patients with weak immune 
systems, and is associated with chronic lung diseases such as cystic fibrosis, 
pulmonary tuberculosis, radiation therapy, pneumoconiosis, and lung infarction. It 
may also occur in patients with relatively mild systemic immuno-suppression, 
particularly neutropenia that is induced by long-term steroids administration, diabetes 
mellitus, alcoholism and chronic liver cirrhosis (Kousha et al., 2011). In addition to 
this, diseases like tuberculosis (TB), which remodel the structure of the pulmonary 
wall, present a permanently increased risk of CPA (Chandrasekar & Sobel, 2006). 
Antifungal treatment at this stage may or may not restrict the growth of the fungus.  
In CNA, there is local invasion of the lung tissue and a cavity with a fungal ball may 
form (as a secondary phenomenon) due to destruction of the lung by the fungus. 
Patients frequently complain of symptoms such as fatigue, weight loss of 1-6 
months’ duration, fever, cough and haemoptysis. These symptoms can vary from 
mild to severe (Denning, 2001). The radiograph and CT scan of the chest usually 
shows the colonisation, cavitary lesions in the upper lung, and pleural thickening. 
The radiological results tend to be progressive over weeks and months. The pleural 
thickening usually progresses to a broncho-pleural fistula which is usually considered 
to be an early indication of an invasive process (Kim et al., 2000).    
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1.1.1.6.3 Invasive Aspergillosis (IA) 
Invasive aspergillosis (IA) is a life-threatening disease in immuno-suppressed 
patients, hematopoietic stem cell, solid-organ transplant patients, AIDS, cancer 
patients and in patients with acute leukemia. Even with the advent of new antifungal 
therapies and improvements in immuno-suppression, the mortality rate in immuno-
compromised patients with IA remains at around 50% overall. The mortality rate is 
dependent on the site of infection, the immunological condition of the individual, and 
the treatment regimen applied (Lin et al., 2001; Dagenais & Keller, 2009). A. 
fumigatus is responsible for 90% of IA infections (Denning, 1998; Lopes Bezerra & 
Filler, 2004). The lung is usually the main target of the pathogen (up to 92% of cases 
of IA) with the skin and brain being the next common targets (Munoz et al., 2006). IA 
is a rapidly progressive and often fatal disease arising from the penetration and rapid 
dissemination of Aspergillus in the alveolar epithelium. The incidence of IA has been 
increasing during the last two decades due to increasing use of immuno-suppressive 
drugs and chemotherapy. The mortality rate of IA exceeds 50% in neutropenic 
patients and 70% in hematopoietic stem-cell transplantation (HSCT) recipients 
(Yeghen et al., 2000; Fukuda et al., 2003). Chemotherapy in response to 
haematological disorders such as leukemia can be an additional risk factor for IA. 
This is due to the key role of neutrophils in hyphal killing and stimulating the adaptive 
immune system (Feldmesser, 2006). The immuno-suppressive regimes following 
solid organ transplantation increase the incidence of A. fumigatus infections due to 
reactive oxygen intermediates (ROI) shortage in AMs (Latge, 2003).  The mortality 
rate in transplant recipients affected by IA ranges from 73%-94% (Paterson, 2005). 
 
1.1.1.7 Risk factors for IA 
Steinbach (2010) reported that the risk of IA in patients may be markedly increased 
by treatment with high dose immuno-suppressive drugs (e.g., corticosteroids). Other 
risk factors include respiratory virus infection, hyperglycemia, haematological 
malignancy, persistent neutropenia, cytomegalovirus (CMV) disease, impaired 
lymphocyte engraftment, cytotoxic chemotherapy and Aspergillus colonization. In 
addition to this, other patient populations who are at risk of IA include patients with 
chronic granulomatous disease, aplastic anemia, AIDS, recipients of solid-organ 
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transplants, and lung diseases such as chronic obstructive pulmonary disease and 
asthma. Patients in the ICU (intensive care unit) are also at increased risk of IA 
(Steinbach, 2010). 
 
1.1.1.8 Diagnosis of IA 
The diagnosis of IA is usually carried out with a combination of isolation of the 
microorganism, imaging techniques and histopathological evidence of invasion. This 
is because fungi often only reveal themselves at late stages of the disease process 
in clinical samples, and the presence of Aspergillus in culture does not always 
indicate true invasive infection (Munoz et al., 2006). 
1.1.1.8.1 Isolation of the microorganism and direct microscopy from 
clinical samples 
Whilst this is the simplest and cheapest method, the early diagnosis of IA in solid 
organ transplant patients is often difficult because fungal culture in these patients 
may not show the presence of the organism. For example, blood culture can be very 
insensitive in Aspergillus infections (Munoz et al., 2006; Paugam et al., 2010) (Figure 
7). 
                               
Figure 7:   Culture of A. fumigatus on an agar plate 
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1.1.1.8.2 Imaging techniques  
Revealing the lung lesions by CT scanning is a useful imaging technique for the 
diagnosis of IA. In immuno-deficient patients, diagnostic approaches are targeted to 
sinuses and lungs because mould infections affect these two anatomical locations 
most. A disadvantage of this technique is its high cost (Figure 8).  
 
                                   
 Figure 8:  CT scan of the chest, IA in leukaemia patients   
 Picture extracted from: http://www.life-worldwide.org/fungal-diseases/invasive-aspergillosis/ 
As I am using this figure for personal use only in my PhD thesis, the website gives me 
permission to do so.  
 
1.1.1.8.3 Microbiological diagnosis  
Microbiological diagnosis includes three groups of techniques: histopathological 
evidence of invasion; direct microscopy from clinical samples by isolation of the 
fungi; serological detection of antigens or antibodies (Munoz et al., 2006).   
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Histopathological examination of biopsy or autopsy tissue for determination of tissue 
invasion by filamentous fungi is another technique for the diagnosis of IA (De et al., 
2008; Barton, 2013) (Figure 9).  Histological evidence is difficult to obtain because of 
its invasive nature and because aspergillosis is often focal. In addition, there are 
sampling issues. The Aspergillus hyphae in tissue sections are also very narrow and 
difficult to distinguish from other fungi such as Fusarium and Scedosporium. But they 
can be distinguished easily from wider hyphae such as Rhizopus (Choi et al., 2004; 
Barton, 2013).   
Biopsy                Aspergillus in Sputum PAP (600x) 
                 
Figure 9: The spectrum of pulmonary aspergillosis  
Picture was taken from Kousha et al., 2011. As I am using this figure for personal use only in 
my PhD thesis, the journal gives me permission to do so. 
 
1.1.1.8.4 Diagnosis of IA with non-invasive procedures (molecular 
detection) 
The traditional microbiological methods such as direct microscopy and culture of 
clinical samples have low sensitivity. Therefore, they do not help to distinguish 
between colonisation and infection. They may only help to diagnose the infection in 
late stages of the disease. Due to these reasons, PCR-based methods for the 
detection of genomic fungal DNA and fungal cell wall components have been 
developed recently (Perfect et al., 2001; Kawazu et al., 2004). The key benefit of 
molecular detection is its high sensitivity. In PCR-based methods, the DNA of most 
fungi or particular Aspergillus spp. can be detected through primer and probe design 
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as explained in materials and methods (Barton, 2013). β-1,3-glucan and 
galactomannan are also used as useful markers for the detection of Aspergillosis 
infections. Galactomannan is also an early marker of IA in patients (Andrews & 
Weiner, 1981).  
Barton, (2013) reported that: ‘‘although other biomarkers such as GM and BDG 
could theoretically be applied to any specimen type, in practice it is only PCR-based 
methods for DNA detection that have been applied to a wide range of clinical 
specimens’’.   
 
1.1.1.9 The immune system 
The human body is protected against foreign micro-organisms and environmental 
substances. To function properly, an immune system needs to distinguish the foreign 
agents from its own healthy cells.  Some pathogens can rapidly evolve and adapt 
and thereby escape detection by the immune system. However multiple defence 
mechanism systems have evolved to detect the pathogens. These mechanisms can 
be divided into two categories: the innate and adaptive immune responses.   
A healthy person encounters many foreign substances on a daily basis which can be 
destroyed in a few minutes by the innate immune response. If the early response is 
evaded, adaptive immune responses are activated and they destroy the pathogen. 
Adaptive immunity also creates an immunological memory after the initial response 
to the pathogen. This leads to an enhanced response to subsequent encounter with 
the same pathogen.  
 
1.1.1.9.1 Airway colonisation 
A. fumigatus spores spread easily into the air. The human lungs are exposed to the 
respiratory pathogens such as A. fumigatus after the inhalation of spores. Each 
person may inhale up to 200 spores daily. Inhalation of these spores is a common 
occurrence due to their presence in the normal environment. These spores, in 
immuno-competent patients, are destroyed and do not cause disease. In contrast, in 
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immuno-compromised patients, the mucosal defences of the lung are depressed and 
this leads to fungal colonization. 
1.1.1.9.2 Interactions of Aspergillus with soluble lung components 
A. fumigatus spores encounter with mucosa includes the airway epithelia and the 
ﬂuid lining the respiratory system. This fluid consists of mucus, lipids, ions, proteins 
and water and they lead to the mucociliary clearance of inhaled particles. Pattern 
Recognition Receptors (PRRs) within this fluid contribute to host defence. They are 
divided into two groups; secreted PRRs and cell bound receptors as explained in 
more detail below. A. fumigatus can be recognised by collectins, mannose binding 
lectin (MBL) and surfactant protein A & D (SP-A & SP-D). These proteins have been 
shown in-vitro to contribute in fungal clearance by binding and agglutinating A. 
fumigatus spores and also enhancing the phagocytosis of A. fumigatus by alveolar 
macrophages and neutrophils (Allen et al., 1999; Allen et al., 2001; Dagenais & 
Keller, 2009) (Figure 10).  The importance of MBL and SP-A & SP-D have been 
demonstrated by Madan et al. and Kaur et al.; they showed that mice lacking MBL 
and SP are more susceptible to aspergillosis when compared to mice treated with 
recombinant MBL and SP (Madan et al., 2005; Kaur et al., 2007). 
PRRs are classified into three different groups. They are explained in more detail 
below (Table 1 & Table 2). 
1.1.1.9.2.1 Pattern Recognition Receptors (PRRs) 
The innate immune system is responsible for the ability of the host to respond to 
invading pathogens and to distinguish between host and non-host molecules. This 
recognition is based upon PRRs. There are some molecular structures on pathogens 
which are known as pathogen-associated molecular patterns (PAMPs). The PAMPs 
are recognised by PRRs (e.g. receptors on phagocytic cells). The recognition of 
Aspergillus spores and hyphae occurs through its binding to PRRs which are present 
as soluble and cell associated receptors (Akira et al., 2006; Janeway et al., 2008; 
Balloy & Chignard, 2009). 
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1.1.1.9.2.1.1 Secreted PRRs  
The secreted or soluble receptors facilitate the interaction of phagocytic cells with 
microorganisms. These receptors for A. fumigatus include:  
1.1.1.9.2 .1.1.1 Collectins 
Pulmonary collectins are a family of C-type lectins which are secreted by Clara cells 
and Type II cells. They bind carbohydrate moieties in a calcium-dependent manner. 
They bind to oligosaccharide or lipid structures on the surface of pathogens such as 
A. fumigatus which has a carbohydrate rich cell wall. The pulmonary collectins 
involved in the detection of A. fumigatus include surfactant proteins A (SP-A), 
surfactant proteins D (SP-D) and mannose binding protein (MBP) (Table 1 & Table 
2). 
1.1.1.9.2 .1.1.1.1 Surfactant proteins A & D 
SP-A and SP-D are produced by epithelial cells and Clara cells (Balloy & Chignard, 
2009). They are crucial for the host defence and also for lung function. They have 
chemotactic activity for different mononuclear leukocytes and have been shown to 
enhance the production of superoxide anion by macrophages and neutrophils 
(Wright, 1997) (Figure 10). Also, SP-A & SP-D augment the killing and phagocytosis 
of conidia by neutrophils and alveolar macrophages (Madan et al., 1997). Madan et 
al. reported that treatment with SP-D can increase the survival of immuno-
suppressed mice after infection with A. fumigatus. This could increase their survival 
rate to 60% as compared to untreated mice (0%) at 7 days after infection (Madan et 
al., 2001) (Table 1 & Table 2). 
1.1.1.9.2 .1.1.1.2 Mannose binding protein (MBP) 
MBP is a C-type lectin with various antimicrobial activities. It is able to bind to 
different carbohydrate structures. It has several biological functions and its 
requirement for all its actions is connected to the sugar ligands that are expressed 
on microbial surfaces (Neth et al., 2000). However, there are few studies about the 
interaction of MBP with relevant microorganisms. A. fumigatus showed strong 
binding to MBP. Neth et al. reported that MBP may have an important role in first line 
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immune defence against some pathogens (Neth et al., 2000). However, Hogaboam 
et al. reported that the absence of MBP had no impact on survival of immuno-
competent mice after infection with A. fumigatus (Hogaboam et al., 2004). These 
findings suggest that the effect of MBP in-vivo needs further investigation (Table 1 & 
Table 2). 
1.1.1.9.2 .1.1.2 Pentraxin-3  
Pentraxin-3 (PTX-3) is an anti-microbial protein produced by different cell types such 
as dendritic cell, neutrophils, macrophages and endothelial cells during inflammation. 
It is secreted as a multimeric protein in response to inflammatory mediators (Alles et 
al., 1994; Breviario et al., 1992). PTX-3 binds to galactomannan on Aspergillus 
spores and facilitates its recognition by the host’s immune system (Figure 10). The 
PTX-3 is produced by dendritic and mononuclear phagocytes in the presence of 
conidia (Garlanda et al., 2002). Garlanda et al. reported that PTX-3-deficient mice 
are more susceptible to IA (Garlanda et al., 2002; Chai et al., 2009). Monocytes and 
neutrophils from PTX-3 deficient mice showed less ability in fungal killing (Jaillon et 
al., 2007) (Table 1 & Table 2). 
 
1.1.1.9.2.1.2 Cell-bound receptors 
1.1.1.9.2.1.2.1 Toll-like receptors (TLRs) 
Mammalian Toll-like receptors are a class of proteins that play an important role in 
innate immune defence. They are a family  of  PRRs  that  have  been  shown  to  
play  an  essential role  in mediating and recognizing the cellular responses to 
microbial  molecular  patterns  in  innate  immune  responses. AMs, epithelial cells 
and neutrophils all express the TLRs except for TLR-3 which is not expressed by 
neutrophils (Balloy & Chignard, 2009). 
Bellocchio et al. (2005) reported that: “Amphotericin B can bind to TLR, resulting in 
cytokine and chemokine release. Binding to TLR-2 has been associated to release of 
pro-inﬂammatory cytokines”. TLR-2 and TLR-4 have been shown to play an 
important role in the detection of A. fumigatus by leukocytes (Balloy et al., 2005, 
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Bellocchio et al., 2004). Conidia and hyphae activate macrophages through TLR-2 
and TLR-4. TLR-2 recognises both spore and hyphal morphologies, but TLR-4 is 
only able to recognise the hyphal form (Netea et al., 2003) (Table 1 & Table 2). The 
role of TLR-4 in the recognition of A. fumigatus hyphae on human monocytes was 
reported by Wang et al. for the first time (Wang et al., 2001; Balloy & Chignard, 
2009; Dagenais & Keller, 2009).  
1.1.1.9.2.1.2.2 Dectin-1  
Dectin-1 is a C-type lectin-like receptor for fungal β-1,3-glucans (Brown & Gordon, 
2001; Brown et al., 2003). It is mainly expressed on neutrophils, macrophages and 
dendritic cells (Brown et al., 2002; Mezger et al., 2008). Dectin-1 interacts with β-1, 
3-glucans (dectin-1 + β-1,3-glucans) and results in macrophage activation, 
phagocytosis and induction of pro-inflammatory responses (Brown et al., 2003; 
Gersuk et al., 2006) (Figure 10). Dectin-1 also interacts with TLRs to modulate the 
immune response. Dectin-1’s interaction with TLRs enables innate immunity to 
phagocytose the conidia and to induce pro-inflammatory responses. It is activated in 
the presence of swollen A. fumigatus spores and triggers host pro-inflammatory 
responses (Gersuk et al., 2006; Hohl et al., 2005). It has been reported that blockade 
of dectin-1 increased the lung fungal burden and also decreased the inflammatory 
cytokine response (Steele et al., 2005; Werner et al., 2009). Dectin-1 is an important 
receptor for the host defence against A. fumigatus in immuno-competent and 
immuno-suppressed hosts (Werner et al., 2009). Dectin-1, TLR-2 and TLR-4 are the 
most important PRRs involved in the recognition of A. fumigatus (Table 1 & Table 2). 
1.1.1.9.2.1.2.3 DC-SIGN  
Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-
SIGN) is another C-type lectin present on the surface of macrophages and dendritic 
cells. These cells bind to galactomannan in the A. fumigatus membrane through DC-
SIGN and facilitate the internalisation of spores (Serrano-Gomez et al., 2004; Park & 
Mehrad, 2009) (Table 1 & Table 2). 
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Receptor 
types 
Receptor family Receptor Ligand 
    
Secreted  
receptors 
Collectin/ C-type lectin 
Collectin/ C-type lectin 
C-type lectin 
Pentraxin 
 
Surfactant protein A (SP-A) 
Surfactant protein D (SP-D) 
Mannose-binding protein 
Pentraxin-3 (PTX-3) 
Unknown 
β-1,6-glucan 
Mannose 
Galactomanan 
Cell-bound 
receptors 
Toll-like receptor (TLR) 
Toll-like receptor (TLR) 
Phagocytic receptor 
C-type lectin 
TLR-2 
TLR-4 
Dectin-1 
DC-SIGN 
Chitin 
Unknown 
β-1,3-glucan 
Unknown 
 
Table 1: Key receptors that facilitate the interaction of phagocytic cells with A. 
fumigatus 
 
 Resting Swollen Germling Hyphae 
Recognition DC-SIGN Dectin-1 
TLR-2 
TLR-4 
DC-SIGN 
Dectin-1 
TLR-2 
TLR-4 
 
Dectin-1 
TLR-2 
TLR-4 
 
Phagocytosis AM 
PMN 
EC 
AM 
PMN 
  
Intracellular 
killing 
 AM 
PMN 
  
Extracellular 
killing 
  PMN PMN 
TLR: Toll-like receptor, AM: alveolar macrophages, PMN: polymorphonuclear, EC: epithelial cell. 
Table 2: The innate immune system against different phenotypes of A. 
fumigatus 
Data was taken from Balloy & Chignard, 2009, reproduced with permission.       
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Figure 10: Stage-specific innate immune responses to A. fumigatus 
Inhaled spores bind to soluble receptors such as pentraxin-3, SP-A and SP-D. Conidial 
swelling happens within AM’s phagosomes and results in exposure of the β-glucan surface 
and triggers inflammatory responses. TLR-2 & TLR-4 contribute to host recognition of 
hyphae. Recruited neutrophils and AMs prevent conidial germination in immuno-competent 
hosts. There is evidence that neutrophils mediate fungal killing with oxidative mechanisms 
and lactoferrin production. Lactoferrin is a molecule that sequesters iron (Hohl & 
Feldmesser, 2007). I have checked American Society for Microbiology. As I am using this 
figure for personal use only in my PhD thesis, the journal gives me permission to do so. 
 
1.1.1.9.3 Interaction of Aspergillus with respiratory epithelia 
The airway epithelium is placed at the interface of the external environment and 
pathogens via TLR receptors (Bals & Hiemstra, 2004). It contributes to host 
defences through mucus production to enhance the production of chemokines, 
cytokines, surfactant proteins and soluble antimicrobial peptides. This response 
consists of the secretion of antimicrobial agents into the lumen of the airway and it 
also increases the production of cytokines and chemokines that initiate the 
inflammatory response. Epithelium cells express several TLRs that can help them in 
their response against microorganisms. Activation of TLRs on epithelial cells 
involves the stimulation of genes responsible for encoding the production of 
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chemokines, cytokines and antimicrobial peptides (Bals & Hiemstra, 2004). Despite 
the importance of epithelial cells in initiating the innate immune response against 
inhaled pathogen micro-organisms, few studies have tested the role of epithelia in 
the respiratory system against A. fumigatus. The airway epithelium contributes to the 
overall immune response to A. fumigatus. 
Epithelial cells likely contribute in initiating pro-inflammatory responses against A. 
fumigatus, but their contribution seems less than that of AMs. A. fumigatus conidia 
bind and are engulfed by different epithelial cells such as alveolar type II cells, the 
A549 respiratory epithelial cell line, human tracheal epithelial cells and nasal 
epithelial cells (Filler & Sheppard., 2006; Paris et al., 1997; Wasylnka & Moore., 
2002). Some A. fumigatus conidia, after engulfment by A549 epithelial cells, enter 
phagolysosomes and are then able to germinate and exit the phagolysosome without 
significant evidence of cell wall damage (Wasylnka & Moore., 2002 and 2003).  
In-vitro Aspergillus hyphae and germinating conidia are recognised by host PRRs on 
epithelia and this stimulates the production of chemokines (IL-8) and cytokines such 
as IL-6 and TNF-α (Balloy et al., 2008; Bellanger et al., 2009). The administration of 
corticosteroids can reduce the production of these chemokines and cytokines.  
There are different fungal products which contribute to the ability of A. fumigatus to 
germinate and invade surrounding lung tissue. These fungal products may increase 
colonisation after lung injury and also attachment to epithelial cells. These fungal 
products include proteases, gliotoxin, fumagillin, helvolic acid and sialic acid on the 
spore’s surface (Amitani et al., 1995; Dagenais & Keller, 2009). 
These conidial components bind to epithelial cells and likely are able to enhance 
their pathogenicity by enhancing adhesion and colonization of epithelia (Dagenais & 
Keller, 2009). Sialic acid residues on conidia contribute to binding and uptake of A. 
fumigatus into epithelial airway. Pathogenic species of Aspergillus are able to 
produce more sialic acid than non-pathogenic species. Adhesion to fibrinogen and 
fibronectin is partially mediated by sialic acid residues (Annaix et al., 1992; Bouchara 
et al., 1997). Gliotoxin is a mycotoxin produced by A. fumigatus and it has immuno-
suppressive properties. It may cause apoptosis in some cell types such as 
neutrophils, macrophages and epithelial cells.  
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Therefore, A. fumigatus binds to respiratory epithelial cells and membrane proteins 
and attacks epithelial cells to escape host defences and establish infection.  
 
1.1.1.9.4 Interaction of Aspergillus with alveolar macrophages 
Alveolar macrophages are the primary and critical phagocytic cell in host defence 
against Aspergillus spores. They phagocytose Aspergillus spores in an actin-
dependent manner. This process is mediated by binding of the host cell PRRs to 
PAMPs which results in stimulation of pro-inflammatory responses which are 
characterised by the production of chemokines and cytokines (Cenci et al., 2001; 
Mehrad et al., 1999). Dectin-1, TLR-2 and TLR-4 are the most important host PRRs 
involved in detection of A. fumigatus. Netea et al. demonstrated that hyphae activate 
macrophages via TLR-4 whereas TLR-2 recognizes both hyphal and conidial forms 
(Netea et al., 2003).  
Alveolar macrophages are able to destroy swollen conidia in phagolysosomes by 
acidification of the phagolysosome and also reactive oxygen species (ROS) 
(Ibrahim-Granet et al., 2003; Philippe et al., 2003). Immuno-suppressed patients are 
susceptible to IA due to reduced macrophage function from chemotherapy and 
corticosteroid-mediated suppression which results in the ability of A. fumigatus to 
escape from host defence mechanisms (Dagenais & Keller , 2009) (Figure 11). 
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Figure 11: The interaction of A. fumigatus with phagocytic cells 
Alveolar macrophages engulf spores through binding the host cells PRRs to PAMPs. 
Swollen spores expose β-1,3-glucans for recognition by dectin-1. Dectin-1 + β-1,3-glucans 
result in macrophage activation, phagocytosis and induction of pro-inflammatory responses. 
Fungal products such as gliotoxin, catalases, proteases, elastases, phospholipases, 
superoxide dismutases, and melanin contribute to A. fumigatus pathogenicity in immuno-
suppressed hosts by escaping from host defences. Picture was taken from Dagenais & 
Keller, 2009. I have checked the American Society for Microbiology. As I am using this figure 
for personal use only in my PhD thesis, the journal gives me permission to do so. 
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1.1.1.10 Host defence mechanisms following infection with A. 
fumigatus 
 
1.1.1.10.1 Innate immunity 
The innate immune system is the first line of lung antimicrobial defence. It provides 
the initial defence against pathogens and stimulates the adaptive immune system. It 
comprises the cells and other mechanisms which first protect the host from infection. 
The cells of innate immunity detect and respond to pathogens in a generic way but it 
does not provide long-lasting immunity for the host.  
 
1.1.1.10.1.1 The cells of the innate immune system 
1.1.1.10.1.1.1 AMs and phagocytosis 
Alveolar macrophages (AMs) constitute the first line of defence against inhaled 
spores that have reached the alveoli. Upon arrival of A. fumigatus conidia in the lung, 
AMs can destroy the conidia with phagocytosis and secretion of a variety of pro-
inflammatory cytokines. AMs are responsible for the phagocytosis of Aspergillus 
conidia and the start of a pro-inflammatory response that recruits neutrophils to the 
site of infection. The phagocytosed conidia are killed by reactive oxygen 
intermediaries (ROI) (Hope, 2009). 
AMs are believed to orchestrate the inflammatory responses to A. fumigatus by 
binding their PRRs to fungal cell walls motifs. The main PRRs on the surface of 
macrophages are TLR-2, TLR-4 and dectin 1 which recognise the polysaccharide 
PAMPs on the surface of A. fumigatus. The PRRs-PAMPs binding results in 
production of chemokines and cytokines which stimulate neutrophil recruitment and 
subsequent antigen-specific immunity (Ibrahim-Granet et al., 2010). This production 
of chemokines and cytokines stimulates the recruitment of innate immune cells and 
host antimicrobial responses against Aspergillus infections. It also enables 
stimulation of the adaptive immune response (Romani, 2004). 
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The secretion of cytokines and phagocytosis by macrophages eliminates the spread 
of spores in the lungs. Chignard et al., in a murine model of IA, demonstrated that 
only a small inoculum of A. fumigatus spores can be destroyed by AMs (Chignard et 
al., 2007). However, a larger amount of conidia can overwhelm the capacity of the 
local immune system and other effector cells need to be recruited to the site of 
infection.  
The molecular mechanisms of macrophages for the killing of A. fumigatus spores 
have been studied. Some evidence shows that the impairment in macrophages of 
reactive oxygen species (RO) production leads to host susceptibility to fungal 
infections. For example, chronic granulomatous disease results from impairment of 
macrophages in the production of RO. Other studies suggest that the AMs can kill 
spores through non-oxidative mechanisms (Schaffner et al., 1982). Macrophage 
colony stimulating factor in conjunction with superoxide anion production can cause 
damage to A. fumigatus hyphae. This was observed in rabbit AMs and also in human 
monocyte-derived macrophages (Roilides et al., 1995). 
In addition, some in-vitro studies suggest that nitric oxide production may not be 
necessary for fungal killing by macrophages. Gross et al. reported that the IFN-γ 
treated macrophages were able to produce more nitric oxide which was associated 
with more conidial killing (Gross, et al., 1999). Other studies showed that mice 
deficient in the production of nitric oxide have the same ability to kill conidia as AMs 
in wild type mice (Philippe et al., 2003). Recently, it has been reported that AMs 
depleted mice are not susceptible to inhaled A. fumigatus spores. These mice had 
sufficient neutrophil recruitment, cytokine responses and limited tissue invasion 
(Mircescu et al., 2009). This means that AMs play an essential role in orchestrating 
the immune system but their function alone is not enough to win the battle against A. 
fumigatus (Chai et al., 2011). 
The effect of steroids on macrophages in IA disease has also been studied. Steroid 
treatment significantly increases IA infections by reducing the activity of 
macrophages in killing conidia. This was due to a reduction in reactive oxygen 
species production (Philippe et al., 2003). The impairment in production of reactive 
oxygen might be an important contributing factor to the susceptibility of corticosteroid 
treated mice to A. fumigatus infections (Park & Mehrad, 2009). In addition to this, 
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suppression of Th1 cytokine (IFN-γ) production can also increase the susceptibility of 
corticosteroid treated mice to A. fumigatus infections.  
A rodlet layer consisting of RodA proteins exists on the surface of A. fumigatus 
conidia. It acts as a mask by covering the surface of β-1,3-glucan from detection by 
the immune system. This accounts for reduced immune system activation after 
inhalation of A. fumigatus spores (Aimanianda et al., 2009). 
1.1.1.10.1.1.2 Neutrophils 
Neutrophils have been shown to be responsible for hyphal killing (Schaffner et al., 
1982). They have an important role in the removal of A. fumigatus. Neutropenic 
patients are at high risk of developing IA. It has been demonstrated that neutrophils 
can induce fungal hyphae killing as well as killing of conidia through production of 
oxidative antimicrobial products (Diamond & Clark, 1982; Levitz & Diamond, 1985). 
Neutrophils bind to hyphae but the size of hyphae prevents their phagocytosis by 
neutrophils. The contact between hyphae and neutrophils induces the oxidative and 
non-oxidative mechanisms that mediate hyphal killing (Diamond and Clark, 1982; 
Roilides et al., 1993). The hyphal killing by neutrophils is rapid with almost 50% of 
hyphae killed within 2 h (Roilides et al., 1993). The production of reactive oxygen 
species (ROS) by neutrophils is considered to be an important mechanism. 
Phagocytes in chronic granulomatous disease patients are unable to destroy the 
engulfed fungi via ROS resulting in an enhanced susceptibility of these patients to 
fungal infection (Roos, 1994). Another neutrophil mediated mechanism is 
myeloperoxidase, an enzyme in neutrophils, which catalyses the conversion of 
hydrogen peroxide and chloride anions to hydrochlorous acid (Klebanoff, 2005). In 
addition to these two mechanisms, neutrophils produce cytokines and chemokines. 
Neutrophil serine proteases activate cytokines and this results in enhancement of the 
inﬂammatory response. In addition, neutrophils induce chemokine receptors in 
bronchial epithelial cells. Several studies have reported that IFN-γ increases the 
neutrophil oxidative response and their ability to destroy hyphae (Roilides, et al., 
1993). Prophylactic administration of IFN-γ results in protection of the host from 
fungal infection including IA. There is also evidence that neutrophils mediate fungal 
killing without oxidative mechanisms. For example, neutrophils are able to produce 
lactoferrin when interacting with Aspergillus spores which has been shown to be 
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important in increasing fungal killing (Levitz & Diamond, 1985). Pentraxins are also 
localized to neutrophils and have been shown to be important in resistance to 
Aspergillus infection (Jaillon et al., 2007). 
It has been reported that the fungal burden is increased in mice with depleted 
neutrophils (within 3 h). This is in contrast to AMs depleted mice. Another study 
reported that mice with neutrophil depletion at 6 h or 24 h after infection had a 
normal survival rate (Svirshchevskaya et al., 2009). After steroids treatment, 
neutrophils are not able to inhibit hyphal growth and hyphal tissue invasion. This 
results in a large degree of tissue inflammation and necrosis (Ibrahim-Granet et al., 
2010) (Figure 12). 
1.1.1.10.1.1.3 Natural killer cells (NK) 
Natural killer (NK) cells are another important cell type in innate immune defences 
against pulmonary fungal pathogens. NK cells were thought to act against tumours 
and viruses only, but recently have been shown to also act against fungi and 
bacteria (Newman & Riley, 2007). In a neutropenic host with A. fumigatus infection, 
NK cells are the main cells responsible for producing IFN-γ. It has been shown that 
depletion of NK cells can reduce the production of IFN-γ and increase the incidence 
of pulmonary fungal infections (Park & Mehrad, 2009). Schmidt et al. showed that 
NK cells have antifungal activity against hyphae. Bouzani et al. found that NK cells 
infected with A. fumigatus promote Th1 T-cell secreting TNF-α and IFN-γ. The 
secretion of these cytokines was only induced in the presence of the germinated 
form of A. fumigatus (Bouzani et al., 2011). 
However, A. fumigatus can also reduce the expression of cytokines IFN-γ and GM-
CSF by NK cells (Schmidt et al., 2011). In addition to these, Morrison et al. showed 
that the recruitment of NK cells by the chemokine MCP-1 is also required for A. 
fumigatus clearance in the lungs (Morrison et al., 2003); the antifungal activity of NK 
cells was also mediated by mediators such as perforin, granulysin and granzymes 
(Schmidt et al., 2011). 
Most of the studies on NK cells have concentrated on NK cells obtained from mouse 
spleen and human peripheral blood. After spleen, lungs contain the largest numbers 
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of NK cells. NK cells contribute to early production of IFN-γ in the lung. The depletion 
of NK cells and the absence of IFN-γ production results in susceptibility of the host to 
Aspergillus infection (Park & Mehrad, 2009). 
1.1.1.10.1.1.4 Monocytes 
Although AMs and neutrophils provide a defence against Aspergillus infection, 
human studies indicated that circulating monocytes also contribute to antifungal 
immunity.  Monocytes circulate in the blood and during inflammation migrate into the 
pulmonary tissues to differentiate into macrophages. Circulating monocytes are 
categorised into two subsets based on their expression of CD14, CD16 (Ziegler-
Heitbrock, 2007) and CCR2, CCR5 & CX3CR1 chemokines (Weber et al., 2000). 
Human monocyte subsets are defined as CD14+CD16− and CD14+CD16+. 
Monocytes are also able to ingest Aspergillus spores and are even capable of 
inducing damage to hyphae (Diamond, 1983; Chai et al., 2009; Simitsopoulou et al., 
2008). Different monocyte subtypes have different anti-Aspergillus functions. Both 
CD14+CD16− and CD14+CD16+ monocytes subsets effectively phagocytose resting 
conidia but only CD14+CD16− monocytes are more effective in inhibiting conidial 
germination. In contrast, CD14+CD16+ monocytes do not inhibit conidial germination. 
However, they play an important role in increasing the inflammatory responses 
through production of TNF-α (Serbina et al., 2009). Although, these subsets have 
different responses against conidia, their responses are similar against germinated 
conidia (Serbina et al., 2009). The differences in cytokine responses between these 
two monocyte subsets could explain the differences in conidial uptake (Serbina et 
al., 2009) (Figure 12). 
1.1.1.10.1.1.5 Platelets 
In addition to neutrophils, AMs, NK and monocytes cells, platelets also contribute to 
antifungal immunity. They act by adhering to the cell wall of Aspergillus hyphae and 
preventing hyphal elongation and causing hyphal damage (Christin et al., 1998; 
Perkhofer et al., 2008). In addition to this cell wall damage, the platelets are also 
able to enhance neutrophil-mediated fungicidal effects (Latge et al., 1999). It has 
been demonstrated that Aspergillus hyphae stimulate platelets and this results in an 
enhanced IL-8 cytokine response in monocytes (Rodland et al., 2010). The optimal 
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activation of platelets requires opsonization of hyphae with heat-inactivated plasma. 
However, the role of platelets in Aspergillus infections needs to be investigated in 
more depth (Figure 12). 
1.1.1.10.1.1.6 Epithelial cells 
Alveolar epithelial cells have received less attention in the recognition of Aspergillus 
even though they are the ﬁrst cells to encounter inhaled spores (Park & Mehrad, 
2009). The epithelium of the upper airways and of the tracheal and bronchial tract of 
the lower respiratory system consists of different cell types such as mucus-secreting 
and ciliated cells. Inhaled spores are trapped in mucus and then removed by the 
ciliary action of the respiratory epithelium. The human nasal epithelial cells can bind 
and internalise Aspergillus conidia. Most inhaled A. fumigatus spores are removed in 
immuno-competent people in this way. However, it has been demonstrated in-vitro 
that A. fumigatus metabolites cause damage to epithelial cells and also enable 
escape from beating cilia (Amitani et al., 1995). The alveolar epithelial cell line 
(A549) can bind to conidia and hyphae and ingest conidia and produce IL-6 (Botterel 
et al., 2008). The A. fumigatus spores reaching the alveoli are confronted with two 
other types of epithelial cell: type I and II pneumocytes. Type II pneumocytes, by 
secreting pulmonary surfactant, are able to decrease the surface tension at the air-
liquid interface, thus facilitating the expansion of alveolar cells during inspiration 
(Balloy & Chignard, 2009). 
Epithelial cells express the cationic antimicrobial peptide β-defensin 2. These 
peptides, in addition to their antimicrobial activity, are also chemotactic for T 
lymphocytes and dendritic cells. Surfactant protein D inhibits the binding of 
Aspergillus spores to epithelial cells in the lung (Hope, 2009). 
Many intracellular pathogens such as Mycobacterium tuberculosis, Chlamydia 
pneumoniae and Legionella pneumophila enter epithelial cells and multiply within 
these cells.  A. fumigatus conidia can bind to respiratory epithelium cells and can 
enter the acidic organelles of these cells. The discovery of this mechanism suggests 
that A. fumigatus might, like other intracellular pathogens, use respiratory epithelium 
cells as a refuge from the action of phagocytes and as a starting point for 
dissemination throughout the body (Balloy & Chignard, 2009) (Figure 12).  
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Figure 12: Innate immune responses to Aspergillus infections 
AMs are active against inhaled Aspergillus conidia. After activation of PRRs, pro-
inflammatory (IFN-γ, TNF-α, IL-6 & PTX-3) and anti-inflammatory cytokines (IL-4 & IL-10) 
mediate the inflammatory response. Neutrophils have several microcidial actions against 
Aspergillus spores & hyphae. Some of these actions are shown in Figure 12. Oxidative 
killing, degranulation, phagocytosis and neutrophil extracellular traps formation (NET). 
Monocytes circulate in the blood and then migrate into the pulmonary tissues to differentiate 
into macrophages. Picture was taken from Chai et al., 2011. I have checked the Future 
Medicine Ltd. As I am using this figure for personal use only in my PhD thesis, the journal 
gives me permission to do so. 
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1.1.1.10.2 Cytokines in host defence against Aspergillus infection 
1.1.1.10.2.1 Acquired immunity (T-cell immunity)                                                
Cell mediated immune responses and Type 1 & 2 T-cell responses have been 
studied in fungal infection. CD4 T-cells have antifungal defence activity. They 
represent the T-helper (Th) cell population. For their function, the CD4 cells require 
antigen presenting cells and MHC Class II restricted antigen presentation. The 
presentation of antigen to T cells by macrophages and dendritic cells results in 
cytokine production. This cytokine production organizes the recruitment of different 
leukocyte cell types. The cytokines stimulated by T-cells are the main determinant of 
fungicidal effector cell responses. In addition to cytokine production, CD4 T-cells are 
able to kill fungi through direct cell contact. The direct fungicidal effect of CD4 cells 
relies on granulysin as the fungicidal mediator (Zheng et al., 2007).   
Naïve CD4 T-cells become activated and produce IL-2 after antigen recognition. The 
interaction between IL-2 and its receptor results in the emergence CD4 T-cells 
(Letourneau et al., 2010; Minami et al., 1993). After this, by expressing different 
patterns of genes, they differentiate into different phenotypes. These genes 
determine their function in the adaptive immune response. The differentiation of CD4 
T-cells into Th1, Th2 and Th17 is instructed by cytokine expression. Th1 plays an 
important role against some fungi and intracellular microorganisms. Th2 enables 
defences against extracellular pathogens such as parasites (Mosmann & Coffman, 
1989; Paul & Seder, 1994). Th17 seems to have a critical role against some fungi 
and extracellular bacteria. The transcriptional factor T-box transcription factor T-bet 
and GATA-3 play important roles in Th1 differentiation and Th2 cell development, 
respectively (Zhu et al., 2006). Th1 differentiation is instructed by the action of IFN-γ 
and IL-12 which leads to expression of T-box transcription factor T-bet. Th2 CD4 T-
cell differentiation depends on IL-4 and GATA-3 action (Zhu et al., 2006). IL-12 is 
secreted by dendritic cells and also induces IFN-γ release by acting on NK cells. It 
also directs the differentiation of CD4 Th1 cells. Patients with disorders in IL-12 
receptor are more susceptible to fungal infections. IL-12 mediates a protective effect 
in IA by promoting Th1 T-cell differentiation (Cenci et al., 2001). 
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The cytokines expressed by Th1 and Th2 cells induce their own subset development 
and they down-regulate the expression of opposing subset. For example, IL-12 is 
released by Th1 and down-regulates the expression of IL-4 which is expressed by 
Th2. IL-12, from dendritic cells, plays an important inductive role in Th1 cells. Th1 
cells are characterised by secretion of TNF-α, IFN-γ and GM-CSF.  
Th2 cells are important for the secretion of IL-4, IL-5, IL-9, IL10 and IL-13. IL-4 is the 
main cytokine for Th2 differentiation (Le Gros et al., 1990, Swain et al., 1990). Th17 
cells are characterised by the production of IL-21, IL-22, IL-17a and IL-17f (Yao et 
al., 1995; Zhu & Paul, 2008). IL-17a and IL-17f recruit neutrophils to the site of 
infection in fungal infections. CD4 T-cells mediate Th1 protection of the host against 
fungal infections. In contrast, Th2 has a detrimental role in fungal infections (Korn et 
al., 2007; Zhu & Paul, 2008).    
 
1.1.1.10.2.1.1 Role of (Th1 CD4 T-cells) in host defence against 
Aspergillus infection 
CD4 T-cells play a significant role in destroying fungal pathogens. Th1 cells are 
characterised by secretion of TNF-α, IFN-γ and GM-CSF. Th1 responses lead to 
resistance to fungal infections because they activate NO and superoxide production 
and also activate macrophage inflammatory responses (Puccetti et al., 1995). 
The expansion of Th1 T-cells is continued by down-regulating GATA and inducing 
the expression of IFN-γ and the transcription factor T.bet (Usui et al., 2006). In the 
absence of T.bet, IFN-γ production is significantly diminished and Th1 differentiation 
is impaired. Impairment of Th1 CD4 T-cells results in a greater susceptibility to 
fungal infections.  
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1.1.1.10.2.1.1.1 TNF-α 
Tumor necrosis factor-a (TNF-α) is a 17-kDa pro-inflammatory cytokine with 
immuno-regulatory properties that is secreted by Th1 T-cells, neutrophils, 
macrophages, monocytes and epithelial cells. TNF-α plays a significant role in the 
host response against fungal infections. TNF-α is able to stimulate the expression of 
chemokines and leukocyte adhesion molecules. This results in recruitment of 
polymorphonuclear leukocytes, improved phagocytosis and fungal killing (Filler et al., 
2005).  
Balloy & Chignard, (2009) reported that: ‘‘The beneficial effects of TNF-α 
administration in vivo may be due to this cytokine increasing both the fungicidal 
effects of neutrophils against hyphae and the phagocytic activity of macrophages.’’ 
But, despite its positive outcomes, its utility is inhibited in clinical practice because of 
its toxicity.  
TNF-α in-vitro enhances phagocytic activity of AMs and also increases the capacity 
of neutrophils in hyphal killing (Roilides et al., 1998). TNF-α indirectly contributes to 
neutrophils chemotaxis through secondary mechanisms such as induction of 
adhesion molecules and stimulation of neutrophil-chemotactic chemokines (Phadke 
& Mehrad, 2005). 
TNF-α and lymphotoxin (LT) are important for host immune responses against A. 
fumigatus infection. The level of TNF-α increases in mouse lung infected 
intratracheally and intranasally with A. fumigatus (Filler et al., 2005). The maximum 
production of TNF-α in A. fumigatus infection depends on the presence of IL-12 and 
1L-18 expression. TNF-α production is inhibited in-vivo in a murine model of IA after 
administration of corticosteroids (Balloy et al., 2005). 
In immuno-competent and immuno-suppressed mice, TNF-α is secreted in the lungs 
following intra-pulmonary challenge with A. fumigatus. TNF-α neutralisation leads to 
a decrease in neutrophil recruitment and an increase in fungal burden (Mehrad et al., 
1999; Phadke & Mehrad, 2005). 
Cenci et al. reported that TNF-α / LT knockout mice are more susceptible to A. 
fumigatus infections (Cenci et al., 1998). In another study, Roilides et al. 
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demonstrated that the recruitment of neutrophils and AMs to the site of infection was 
normal in TNF-α / LT knockout mice.  This data suggested that TNF-α and LT are 
more important for increasing leukocyte killing of A. fumigatus than for recruitment of 
leukocytes (Roilides et al., 1998).  
1.1.1.10.2.1.1.2 IFN-γ 
Type II interferon (IFN-γ) is an important cytokine for host protection against fungal 
infections. It has a major immuno-modulatory role. IFN-γ is expressed by T and NK 
cells and also by macrophage antigen presenting cells (Munder et al., 1998). IFN-γ is 
the Th1 cytokine that stimulates macrophages and other cell-mediated immune 
responses. It is a critical mediator in the host response to Aspergillus infections 
(Rivera et al., 2005). 
 Current antifungals often fail in treating invasive fungal infections effectively in 
immuno-suppressed patients. Some studies have reported that cytokines such as 
IFN-γ can be a potent adjunct to conventional antifungal drugs. The antifungal 
activity of IFN-γ was found to be due to the activation of cell mediated immunity and 
it acted in synergy with AmB (Capilla et al., 2006). Segal et al. (2006) reported that: 
“knowledge of the immuno-pathogenesis of fungal infections has paved the way to 
promising strategies for immuno-therapy. These include strategies that increase 
phagocyte number, activate innate host defence pathways in phagocytes and 
dendritic cells, and stimulate antigen-specific immunity (e.g., vaccines).” 
 There is evidence to show that the susceptibility of the host to invasive fungal 
infections is related to impaired IFN-γ production in the lung. Armstrong-James et al., 
2009 reported that death due to aspergillus infection is related to the inflammatory 
cell infiltrate at the site of infection, reduced levels of IFN-γ, and increased levels of 
IL-17a, IL-5 and TNF-α. In contrast, clearance of infection in immuno-competent 
mice occurred within 24 h and was associated with a high level of IFN-γ and a lower 
level of TNF-α and an increased expression of several genes that encode for 
proteins that are involved in innate pathogen clearance and the control of 
inflammation (Armstrong-James et al., 2009). These observations led to the 
successful evaluation of recombinant IFN-γ therapy against IA in patients who were 
receiving T cell-directed immuno-suppressive drugs (Armstrong-James et al., 
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2010). IFN-γ therapy has also been shown to decrease systemic candidiasis 
(Kullberg et al., 1993; Stevens et al., 2000). Prophylaxis with IFN-γ administration 
also decreases Aspergillus infections in patients with chronic granulomatous disease 
and in neutropenic patients (Gallin, 1991; Stevens et al., 2000). 
 Herbst et al. have demonstrated there is IFN-γ anergy in a new transplant immuno-
suppressive drugs based mouse model of IA (Herbst et al., 2013). Kino et al. 
reported that calcineurin inhibitors such as FK-506 are responsible for the inhibition 
of T cell-dependent IFN-γ production (Kino et al., 1987). Bouzani et al. have shown 
that the hyphal form of A. fumigatus is very immunogenic and is capable of up-
regulating cytokines such as TNF-α and IFN-γ. They demonstrated that the IFN-γ 
released by NK cells directly destroyed A. fumigatus (Bouzani et al., 2011). 
Depletion of IFN-γ and NK cells results in a more severe IA infection. The anti-
Aspergillus effect of NK cells is limited to IFN-γ production. 
1.1.1.10.3 Alternative activation of macrophages 
iNOS 
Inducible nitric oxide synthase (iNOS) is a family of enzymes which catalyze the 
production of nitric oxide (NO). NO is an effective antimicrobial compound which is 
produced in professional phagocytes through the action of iNOS enzyme on L-
arginine (Mozaffarian et al., 1997). Macrophages are activated by at least two 
different pathways that both involve iNOS and arginase (Figure 13). These enzymes 
can be regulated by cytokines secreted by both Th1 and Th2 T-cells. Th1 cytokines 
stimulate iNOS but Th2 cytokines induce arginase (Modolell et al., 1995; Kropf et al., 
2004). This antimicrobial mechanism of phagocytic cells can be inhibited by 
corticosteroids and it was reported to be effective in fungal killing (Granger et al., 
1988). The killing of conidia by AMs is inhibited by corticosteroids in healthy people 
and in patients with chronic granulomatous disease who are unable to produce ROI 
(Michaliszyn et al., 1995). Michaliszyn et al. reported that NO is not involved in the 
fungicidal activity of AMs against A. fumigatus spores (Michaliszyn et al., 1995). 
Since its discovery as a biological molecule in 1980, NO has been shown to have a 
key role as a signalling molecule and a regulatory effector molecule of innate 
immunity. iNOS is expressed after cell activation and can be produced for long 
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periods of time (Kröncke et al.,1998). In another study by Philippe et al. the 
conidicidal activity of AMs was studied using the contributions of NADPH oxidase 
and iNOS (Philippe et al., 2003). They demonstrated that iNOS has no role in the 
killing of A. fumigatus spores. 
In contrast, Gross et al. have demonstrated that NO production by rat AMs was low 
when induced by A. fumigatus conidia whereas this response was increased after 
co-stimulation of AMs with IFN-γ. They have shown that A. fumigatus stimulates a 
signiﬁcant increase in NO production by AMs (Gross et al., 1999). 
In addition, it has been demonstrated that AmB can induce the production of TNF-α 
and IFN-γ in-vitro. This increases the production of NO in macrophages; thus the 
antifungal effects of AmB could be mediated via NO (Tohyama et al., 1996; 
Mozaffarian et al., 1997). The effect of AmB on NO production was tested against 
Cryptococcus neoformans in-vivo (Lovchik et al., 1997; Mozaffarian et al., 1997).                                             
             
Figure 13: Pathway of NO production 
This picture represents the pathway of NO production. TNF-α and IFN-γ increase iNOS 
expression resulting in enhanced NO production. Picture was taken from Mozaffarian et al., 
1997. I have checked the American Society for Microbiology. As I am using this figure for 
personal use only in my PhD thesis, the journal gives me permission to do so.  
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1.1.1.10.2.1.2 Role of Th2 CD4 T-cells in host defence against 
Aspergillus infection 
1.1.1.10.2.1.2 .1 IL-10 
IL-10 is an anti-inflammatory cytokine. IL-10 inhibits the action of macrophages, NK, 
monocytes and Th1 cells during infection. It is also known as human cytokine 
synthesis inhibitory factor (CSIF) (Eskdale et al., 1997). It is produced by Th2 
lymphocytes, macrophages, monocytes, B & T cells, mast cells and dendritic cells. 
The secretion of IL-10 by activated macrophages is a key early host defence 
mechanism against invasive fungal infections (Bhatia et al., 2011). The expression of 
IL-10 in response to Dectin-1 is regulated by the calcineurin pathway in neutrophils 
(Greenblatt et al., 2010; Bhatia et al., 2011). 
IL-10 decreases the stimulation of Th1 cytokines, MHC class II expression and co-
stimulatory molecules on macrophages. It also blocks the activity of NF-KB (Rousset 
et al., 1992). IL-10 inhibits the production of pro-inflammatory cytokines such as IFN-
γ, TNF-α, IL-12, IL-18, IL-6 and NO (Fiorentino et al., 1991; de Waal Malefyt et al., 
1991). It also prevents the recruitment of cells during inflammation by inhibiting the 
production of CXC and CC chemokines (Moore et al., 2001). In addition, IL-10 is 
able to enhance B cell proliferation and antibody production (Rousset et al., 1992).  
The effect of IL-10 on infection is different for each microorganism. In some cases, 
IL-10 contributes to resistance of the host to bacterial infections whereas in other 
instances IL-10 has a deleterious effect on the infection (Clemons et al., 2000). IL-10 
has a deleterious effect on fungal infections. Roilides et al. reported that the pre-
treatment of mononuclear cells with IL-10 in-vitro could decrease the capacity of 
cells to damage Aspergillus hyphae, but phagocytic activity for spores and the 
inhibition of germination was augmented (Roilides et al., 1997).  Therefore, IL-10 
could be providing a sanctuary for progression of the infection. It has no direct 
impact on the morphology of A. fumigatus.  
Clemons et al. reported that IL-10 deficient mice showed more resistance to 
systemic fungal infection when compared to wild type mice. They speculated that 
this might be associated with high Th2 or low Th1 responses, or down-regulation of 
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macrophage responses in wild type mice as compared to knockout mice (Clemons et 
al., 2000). 
Roilides et al. suggested that the host response to fungal infections could be 
improved by reversal of the immuno-suppressive effects of IL-10 (Roilides et al., 
1997). This suggestion has been verified by neutralization of IL-10 or IL-4 and 
improving the resistance of susceptible mice to IA. In contrast, in a mouse model of 
allergic bronchopulmonary aspergillosis, IL-10 had a beneficial effect on host 
resistance to infection. The lack of IL-10 in this murine model resulted in increased 
mortality and severe pulmonary inflammation. The role played by IL-10 is therefore 
inhibiting the IFN-γ driven inflammatory response and is also modulating the allergic 
inflammatory response to Aspergillus (Grunig et al., 1997). 
 
1.1.1.11 The effect of immuno-suppression on the development of 
IA 
It has been known for a long time that immuno-suppressive drugs can increase 
susceptibility to IA in both animal models and in patients (Bodey & Vartivarian, 1989; 
Cenci et al., 1998). 
Corticosteroids have an important role in IA progression (Berenguer et al., 1995; 
Andriole, 1993). But, there is a lack of knowledge about their effect on interaction of 
A. fumigatus with the immune system. Schaffner et al. reported that glucocorticoids 
have a role in the impairment of the anti-conidial activity of macrophages (Schaffner, 
1985). It has been reported that inﬁltration by PMNs is also suppressed by 
corticosteroids. For example, hydrocortisone is able to suppress PMN production in 
response to both opsonized and nonopsonized hyphae (Roilides et al., 1993). In 
contrast to cortisone, cyclosporin A and other calcinurium inhibitor drugs do not 
inhibit the antifungal activity of AMs and PMNs (Roilides et al., 1994). However, they 
may cause immuno-suppression of phagocyte related antifungal activity in-vitro 
when used in combination with corticosteroids.  
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Tacrolimus and hydrocortisone are important immuno-suppressive drugs for the 
management of transplant patients. The mechanism of action of these two immuno-
suppressive drugs is described below:   
1.1.1.11.1 FK-506 (Tacrolimus) 
FK-506 is an immuno-suppressive drug that is used after organ-transplantation to 
decrease the incidence of organ rejection.  It is a potent T-lymphocyte agent that 
was discovered in 1984. The immuno-suppressant FK-506 is produced by the 
fungus Streptomyces tsukubaensis. It has a mechanism of action similar to that of 
cyclosporine A. FK-506 was licensed for use in organ transplantation in 1994 and it 
has replaced cyclosporine A because of the improved outcomes (Moore et al., 
1994; Watson & Dark, 2012).  In fungi, both of these drugs are recognized to inhibit 
the calcinueurin signalling pathway, which is known to be important in conidia 
germination and tissue invasion. It has been reported that FK-506 acts by inhibiting 
IL-2 production and lymphocyte responses in-vitro. Nephrotoxicity is its main toxic 
side-effect (Fox & Heitman, 2002). 
1.1.1.11.1.1 Chemical structure of FK-506 
FK-506 is a neutral and hydrophobic compound which is a 23-membered macrolide 
lactone. Its molecular formula is C44H69NO12 and its molecular mass is 804.018 g / 
mol (Figure 14). It crystallizes to colourless prisms. It is stable at room temperature 
as a powder but less stable in solution (Wallemacq & Reding, 1993). 
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Figure 14: The chemical structure of FK-506  
Structure was drawn in ChemDraw. 
 
1.1.1.11.1.2 Mechanism of action 
The studies of Thomson & Kineo et al demonstrated that FK-506 is able to suppress 
the generation of T-cells and human and murine lymphocyte activity. FK-506 inhibits 
the expression of IL-2 receptors on activated T-cells. It is also able to inhibit the 
expression of IL-2 receptor on CD4+ Th cells and CD8+ suppressor T-cells (Kino et 
al., 1987 & Thomson, 1989; Wallemacq & Reding, 1993). 
The therapeutic studies of this drug have demonstrated that FK-506 works by 
inhibition of the action of calcineurin (CaN). Jorgensen et al. (2003) reported that: 
‘‘Calcineurin has been found to play a role in many regulatory proteins, signalling 
pathways, dynamic structural proteins and ion channels, but the identification of 
calcineurin as a signalling molecule in the immune system revealed that it was also 
important for transcriptional regulation’’. 
FK-506 binds to the FK-506 binding protein (FKBP) to create a complex (FK-506-
FKBP). This complex binds to CaN and inhibits its action. The (FK-506–FKBP–CaN) 
complex inhibits the activation of the cytoplasmic component of the nuclear factor of 
activated T-cells (NF-ATc) which results in it being unable to enter the cell nucleus. 
This results in a failure to activate the genes regulated by NF-ATc. These genes 
include those necessary for T-cell activation such as the IL-2 gene (Figure 15).  
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Figure 15: The mechanism of action of FK-506 (tacrolimus) 
Picture was taken from Stepkowski, 2000. I have checked the Cambridge University Press. 
As I am using this figure for personal use only in my PhD thesis, the journal gives me 
permission to do so.  
   
1.1.1.11.2 Hydrocortisone 
Hydrocortisone known as cortisol, is a steroid hormone that is produced by the 
adrenal glands. This hormone is produced in response to stress. It has immuno-
suppressive and anti-inflammatory properties. After organ transplantation, 
hydrocortisone is used to prevent rejection of the newly transplanted organ. Its 
molecular formula is C21H30O5 and its molecular mass is 362.460 g/mol (Figure 16). 
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Hydrocortisone activates anti-inflammatory pathways. It down-regulates the 
expression of IL-2 and this means that Th2 T-cells cannot be activated. As a result, 
Th1 T-cells predominate (Scott, 2011). 
Latge, (1999) reported that: ‘‘cortisone has been proposed to act directly on A. 
fumigatus to enhance the metabolic activity of hyphae and stimulate moderate 
growth’’ (Ng et al., 1994; Roilides et al., 1993). However, Sarfati et al. reported that 
the addition of cortisone to axenic medium in-vitro did not increase the hyphal growth 
rate of Aspergillus. They proposed that the target of glucocorticoid drugs is 
phagocytic cells and not the fungus (Latge, 1999).  
After steroid treatment, neutrophils are not able to inhibit hyphal growth. This results 
in severe tissue inflammation and necrosis (Ibrahim-Granet et al., 2010). In addition, 
steroid treatment increases the incidence of IA infection by reducing the activity of 
macrophages in conidia killing. This might be due to a reduction in reactive oxygen 
species production (Philippe et al., 2003). The lack of the production of RO species 
may act as an important contributing factor to the susceptibility of corticosteroid 
treated mice to Aspergillus infections (Park & Mehrad, 2009) (Figure 17).  
 
Figure 16: The chemical structure of hydrocortisone 
Structure was drawn in ChemDraw. 
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Figure 17: This picture represents the role of the innate immune response 
against A. fumigatus and its modulation by immuno-suppressive drugs 
AMs, as the main resident cells of the lung alveoli, along with neutrophils are recruited 
during inflammation. They are the key cells involved in the phagocytosis of A. fumigatus. 
This picture represents the effect of the immuno-suppressive drug (cortisone) on the 
modulation of innate immune responses. Picture was taken from Latge, 1999. I have 
checked the American Society for Microbiology. As I am using this figure for personal use 
only in my PhD thesis, the journal gives me permission to do so. 
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1.1.1.12 New murine model of solid organ transplant pulmonary 
aspergillosis 
An animal model that reflects the immuno-suppressive drug regimen used in organ 
transplantation patients is required to understand the pathogenesis of IA infections in 
these patients. Immuno-suppression in organ transplant patients currently consists of 
a steroid in combination with a calcineurin inhibitor. 
The murine steroid-mediated immuno-suppressive model of pulmonary Aspergillosis 
is used to characterise IFIs in organ transplant patients. But this model does not 
represent the eukaryotic calcineurin pathway which is important for both virulence 
and antifungal drug resistance. It also does not take into account the impact of 
calcineurin inhibitors on transplant immunity to IFIs. To address these two issues, a 
novel transplant immuno-suppression model of FK-506 in combination with 
hydrocortisone for pulmonary aspergillosis was created by Armstrong-James & 
Shaunak (Herbst et al., 2013).  
The essential requirements for this model are listed below:  
Herbst et al. (2013) reported that: ‘‘(i) to account for the compound effects of different 
transplant immuno-suppressive drugs on disease outcome; (ii) the pharmacokinetics 
of immuno-suppressive drug are relevant to drugs used in human transplantation; 
(iii) it should show the suitable route of infection and organ specificity of the disease; 
(iv) the genetic tractability of the murine model, (v) a disease pathology in mice that 
reflects the disease in humans; and (vi) cross-correlation with existing models of 
aspergillosis in mice’’.  
This new murine model, which was reported by Herbst et al. addressed all these 
issues (Herbst et al., 2013). 
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1.1.1.13 The impact of FK-506 and hydrocortisone on IFN-γ 
production 
Tsuda et al. have demonstrated the effects of tacrolimus on cytokine production from 
CD4+ Th1 cells. Tacrolimus inhibited IL-4, IL-17 and IFN-γ production from T-cells. It 
also blocked T-cell differentiation into Th1, Th2 and Th17 cells when used at a low 
concentration (Tsuda et al., 2012). This drug may also have an important role in the 
treatment of inflammatory T cell-mediated disorders by blocking these cytokine 
signals. FK-506 inhibits the production of IFN-γ, TNF-α, IL-2, IL-6 and IL-8. It also  
suppresses Th1 cells over Th2 cells.  
                                                                                                              
1.1.1.14 Drug Therapy (Antifungal agents) 
A summary figure showing the timeline for the discovery of fungal infections and the 
subsequent development of antifungal drugs is shown in Figure 18. 
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The currently most commonly available drugs targeted against fungal infections such 
as Aspergillus include amphotericin B deoxycholate, azoles such as itraconazole, 
echinocandins and lipid formulations of AmB (Grant & Clissold, 1989; Menichetti et 
al., 1999; Singh et al., 2001). However, resistance to itraconazole in Aspergillus was 
reported for the first time in 1997 in three clinical isolates from California (Denning et 
al., 1997; Howard et al., 2009). Recently, new derivations of AmB have been 
developed to decrease the toxicity of this drug. A number of different drug-carrier 
systems have been tested with AmB because it is easily amenable to drug targeting 
studies (Torrado et al., 2008). The main advantages of these new formulations of 
AmB are reduced toxicity and increased solubility. 
1.1.1.14.1 Flucytosine  
Flucytosine is a nucleic acid synthesis inhibitor causing miscoding of RNA and 
interference with thymidylate synthetase. It is used in the treatment of fungal 
infections caused by sensitive microorganisms. It has been reported that it has 
activity against some filamentous fungi, candida spp. and Cryptococcus spp. Due to 
the rapid appearance of resistance to flucytosine, it must be used in combination 
with other antifungal drugs. Bennett et al. have reported that flucytosine can be 
combined with AmB and that it is useful for treating patients with cryptococcal 
meningitis (Bennett et al., 1979; Enoch et al., 2006). Side effects of flucytosine are 
dose-dependent and are manageable if peak drug levels are kept below 100 mg l-1 
(Vermes et al., 2000; Enoch et al., 2006). 
1.1.1.14.2 Azoles 
Azoles are sub-divided into 2 groups; triazoles such as itraconazole, fluconazole, 
and imadizoles such as ketaconazole. Salah A et al. (2010) suggested that: "The 
introduction of the azole class of antifungal drugs with the licensing of miconazole in 
1979 was the beginning of a new era in therapy for systemic fungal diseases." 
Application of miconazole is restricted due to its high toxicity. After miconazole, three 
azoles drugs, itraconazole, fluconazole and ketaconazole have been developed in 
order to decrease this toxicity. A new generation of azoles such as posaconazole, 
voriconazole, albaconazole and ravuconazole are used for treating serious fungal 
infections. Antifungal activity of azoles is via inhibition of the fungal cytochrome P-
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450 enzyme that is involved in ergosterol biosynthesis (Salah A et al., 2010) (Figure 
19). This results in abnormalities in chitin synthesis, membrane bound enzyme 
activity, and disruption of fungal membrane permeability (Walsh et al., 2000; De 
Beule & Van Gestel, 2001). Some of these important azoles are listed below: 
1.1.1.14.2.1 Itraconazole 
Itraconazole is a triazole antifungal agent that is used to treat infections due to 
moulds and yeasts. It is available in oral capsule form (since 1992) and oral solution 
form (since 1997) and intravenous formulation (since 1999). In oral solution and 
capsule forms, it is marketed as Sporanox. In terms of bioavailability and absorption, 
the oral solution form of itraconazole is better than the oral capsule form. 
As with other azoles, itraconazole inhibits the sterol biosynthesis pathway by 
inhibition of cytochrome P450 14alpha-demethylase (Sheehan et al., 1999) (Figure 
19). The use of the capsule form is limited because of its inconsistent bioavailability. 
It may cause headaches, hypertension, oedema and hypokalemia (Denning et al., 
1989). 
1.1.1.14.2.2 Fluconazole 
Fluconazole is a bis-triazole antifungal agent. Fluconazole is marketed as Diflucan. 
An oral and intravenous formulation of fluconazole is available on the market. Its 
mechanism of action is similar to itraconazole. Fluconazole has limited activity 
against Aspergillus spp. and other mould fungi (Bodey, 1992; Denning et al., 1992). 
Primary resistance to fluconazole has been reported in A. fumigatus organisms that 
have never been exposed to the given drug in a host (Salah A et al., 2010). In 
comparison with other azoles, fluconazole is tolerated very well with fewer drug 
interactions. It may cause hepatotoxicity. 
1.1.1.14.2.3 Ketoconazole 
Ketoconazole is an imidazole antifungal agent. It is a highly lipophilic compound and 
is marketed as Nizoral. It has been formulated in tablets, dandruff shampoo and 
cream formulations. Ketoconazole acts by inhibition of cytochrome P450 14alpha-
demethylase (P45014DM) (Figure 19). It has less affinity for fungal cell membranes 
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compared to fluconazole and itraconazole. It has thus more potential impact on 
mammalian cell membranes and may cause toxicity (Como & Dismukes, 1994). 
There have been some reports of treating IA with this agent. However, in some 
patients treated with ketoconazole, abscesses were seen and therefore, 
ketoconazole is not recommended for treating patients with IA. Some studies have 
reported that ketoconazole combined with AmB, is superior to AmB alone against 
fungal infections in kidney infections (George et al., 1993). The main side effects of 
ketoconazole are nausea, vomiting, anorexia (Como & Dismukes, 1994) and 
hepatoxicity (Lewis et al., 1984).  
 
1.1.1.14.2.4 Voriconazole 
Voriconazole is structurally related to fluconazole. It was developed by Pfizer. 
Voriconazole has activity against Aspergillus spp., Candida spp., Histoplasma 
capsulatum and Penicillium marneffei. It is considered to be a fungistatic agent 
against some fungi such as Cryptococcus neoformans and Candida spp. and a 
fungicidal agent against Aspergillus spp. It is available as an oral and intravenous 
formulation. Transient visual disturbance is an important side effect of voriconazole 
(Sheehan et al., 1999).  
1.1.1.14.2.5 Posaconazole 
Posaconazole is an extended-spectrum triazole with in vitro and in vivo activity 
against a broad range of filamentous fungi including Aspergillus species (Denning et 
al., 1994). Posaconazole is active in vivo against several models of experimental 
disseminated aspergillosis (Oakley et al., 1997). It shows excellent in-vitro activity 
against Aspergillus spp. as compared to other azoles and is highly active against A. 
fumigatus, A. flavus, and A. terreus (Pfaller et al., 2002). Posaconazole is a lipophilic 
weak base and has a chemically similar structure to itraconazole. It is available only 
as an oral suspension. There is much less clinical experience with this antifungal in 
comparison with other azoles. Consequently its safety profile may need to be fully 
understood (Gubbins & Anaissie, 2009). It works by impairing the functions of certain 
membrane-bound enzyme systems which results in inhibiting fungi growth. It does 
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this by inhibiting the synthesis of ergosterol by inhibiting of the enzyme lanosterol 
14α-demethylase and accumulation of methylated sterol precursors (Brunton et al., 
2006). 
1.1.1.14.3 Echinocandins 
Echinocandins are the newest class of antifungal drugs. They act by inhibition of 
synthesis of β-1,3-glucan which is an important polysaccharide in the fungal cell wall 
(Walker et al., 2010; Chandrasekar & Sobel, 2006; Salah A et al., 2010) (Figure 19). 
Resistance to echinocandins in fungi has been reported in several laboratories. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Sites of action of different antifungal drugs 
Picture was taken from Gubbins & Anaissie, 2009. Under the fair dealing and Elsevier policy, 
as I am using this figure for personal use only in my PhD thesis, the journal gives me 
permission to do so.  
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1.1.1.14.4 Amphotericin B 
Amphotericin B (AmB) is a polyene antifungal drug extracted from Streptomyces 
nodosus in 1955 (Figure 20). For more than a half-century and despite the advent of 
other antifungal drugs such as echinocandins and triazoles for treatment of systemic 
mycoses, AmB is still an active antifungal agent for the management of infections 
with fungi such as A. fumigatus and Candida albicans.  AmB is a potent antifungal 
agent against most moulds, yeasts and dimorphic fungi such as Cryptococcus 
neoformans, Candida spp., Histoplasma capsulatum, Blastomyces dermatitidis and 
mucormycosis (Salah A et al., 2010). AmB has been used broadly to treat IA in 
immuno-compromised and transplant patients who are undergoing immuno-
suppressive therapy (Torrado et al., 2008). The name AmB refers to its amphoteric 
property as it contains carboxylate and amine functional groups. AmB is classified as 
an amphipathic molecule due to the asymmetric distribution of hydroxyl polar groups 
on the molecule and conjugated hydrocarbon polyene on the other side (Adediran, 
2009). AmB is a yellow powder which has a very poor solubility in water. It has 
different functions on fungal and mammalian cells; AmB inhibits membrane enzymes 
like Na+/K+-ATPase in mammalian cells (Vertut-Doi et al 1988) and proton ATPase 
in fungal cells (Surarit & Shepherd, 1987; Vyas & Gupta, 2006). The clinical 
application of AmB is limited because of its toxicity, particularly its nephrotoxicity, 
and its severe side effects such as chills, vomiting, fever, anaemia, hypoxia, 
phlebitis, hypertension and hypotension (Salah A et al., 2010). However, unlike other 
antifungal agents, it has not generated any resistance in fungi. Because of this, 
much effort has been put into developing novel formulations of AmB with less 
toxicity. Recently, some successful results from the design of less toxic formulations 
of AmB such as liposomal have been reported. 
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Figure 20: Structure of AmB   
Picture was taken from Adediran, 2009. 
 
1.1.1.14.4 .1 The Mode of Action of AmB 
AmB exerts its effect by increasing the permeability of microbial membranes by 
interacting with ergosterol in cellular membranes (Figure 19).  It creates ion channels 
that disrupt the membrane function and this leads to cell death (Kasai et al., 2008). 
In addition, AmB induces oxidative activity which enables it to disrupt the metabolism 
of the fungal cell (Brajtburg et al., 1990). Furthermore, AmB modulates the immune 
response. This immuno-modulatory property is another mechanism of action of AmB. 
It acts by increasing the host immune response; however this effect is also related to 
the toxicity of this antifungal drug (Figure 21). 
It is proposed that after addition of AmB to cells, ion permeable channels are formed 
in two stages: (A) formation of a non-aqueous channel (B) formation of an aqueous 
pore. The non-aqueous channel is permeable to monovalent cations whilst the 
aqueous channel is permeable to cations and anions. Gray et al. reported that, this 
channel formation is a secondary mechanism of AmB; it is not required to induce 
fungal cell killing (Gray et al., 2012).  
Hence, AmB can create 2 types of channels: SLC (single-length channel) and DLC 
(double-length channel). SLC formation occurs when AmB is administered to one 
side of the membrane and DLC is a channel where 2 SLCs bind to both sides of the 
membrane (Baginski et al., 2002). Ergosterol channels form by binding eight 
ergosterol molecules instead of eight molecules of cholesterol in a cholesterol 
channel (Baginski et al., 2002).  
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AmB stimulates cytokine, chemokine and prostaglandin production in human and 
murine cells. In addition, AmB induces the production of ROIs and NO. AmB 
increases the antifungal activity of AMs and PMN against conidial and hyphal forms 
of A. fumigatus (Roilides et al., 2002). The combination of AmB with IFN-γ increases 
the antifungal activity of AmB by acting as an adjuvant. The effect of AmB on Th 
cells was evaluated by Cenci et al. It was found that AmB induced a protective Th1 
response with depletion of IL-4 (Cenci et al., 1997).  
AmB has been shown to have an immuno-suppressive effect. Becker et al. have 
shown a decrease in the expression of IL-6 and MIP-2 in neutropenic rats with IA 
after treatment with AmB (Becker et al., 2003). Also, Choi et al. reported that pre-
treatment of THP-1 cells with AmB that are infected with A. fumigatus spores results 
in a decrease in TNF-α expression (Choi et al ., 2010).  
Furthermore, Reeves et al. have shown that AmB increases the release of the 
gliotoxin (an immuno-suppressive agent) from A. fumigatus (Reeves et al., 2004). 
Gliotoxin changes the immune responses to Aspergillus (Waring, 1990) and inhibits 
the function of macrophages (Bertout et al., 2002). Sutton et al. (1995) reported that: 
‘‘the immuno-suppressive properties of gliotoxin have been evaluated for 
suppressing the whole body immune response prior to organ transplantation’’. 
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Figure 21: The mechanism of action of AmB on fungal cells 
AmB binds to the fungal membrane and creates pores resulting in fungal death. AmB 
induces the production of ROS. AmB by affecting mitochondrial activity also contributes to 
an oxidative burst. The presence of free radicals has an impact on DNA, protein, 
mitochondria and membrane resulting in fungal death. Picture was taken from Mesa-Arango 
et al., 2012. Under the terms of the Creative Commons Attribution Licence, as I am using 
this figure for personal use only in my PhD thesis, the journal gives me permission to do so.  
 
1.1.1.14.4.1.1 Toxicity of AmB in mammalian cells 
As fungi and mammals are both eukaryotes, every antifungal agent used for 
treatment might also have an effect on mammalian cells. Ergosterol and cholesterol, 
as two important steroids, play a vital role in the eukaryotic membrane. Cholesterol is 
the main steroid in mammalian cell membranes and ergosterol is the main fungal 
membrane steroid. Ergosterol and cholesterol have similarity in structure so both can 
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become targets for antifungal drugs such as AmB (Figure 22). Unfortunately, the 
interaction of AmB with cholesterol in mammalian cell membranes is not negligible. It 
has been suggested that this interaction could be responsible for the toxicity of AmB 
in mammalian cells. The structure of ergosterol is different from cholesterol in having 
an extra methyl group (CH3) in its side chain and 2 extra double bonds (C=C), one in 
the ring structure and the other one in the side chain (Baginski et al., 1989). These 
minor differences result in a higher affinity of AmB for ergosterol than cholesterol 
(Herve et al., 1989; Baginski et al., 2002). The presence of an additional C=C in the 
structure of ergosterol strengthens the electrostatic interaction between ergosterol 
and AmB (Baginski et al., 1997; Baginski et al., 2002). 
Due to the toxicity of AmB, it is usually administered as an infusion over a period of 
time. Toxic side effects can be present in patients after 1-3 hours of AmB infusion. 
These side effects are vomiting, anaphylaxis, fever nausea, rigors and pulmonary 
congestion (Cleary et al., 1988; Deray, 2002). In some cases, these toxic effects can 
result in nephrotoxicity, leukopenia, thrombocytopenia, hepatotoxicity and other 
organ damage. This is because of an increase in the concentration of free 
intracellular calcium (Sabra et al., 1990). The interaction of AmB with cholesterol in 
mammalian cell membranes results in renal dysfunction. This can lead to polydypsia 
and to a reduction in the concentrating ability of the kidney (Mayer et al., 2002). 
 
1.1.1.14.4.1.2 AmB-Sterol interactions 
It has been suggested that two types of interactions exist between AmB and sterols. 
A strong hydrogen bonding is present between sterol and AmB molecules (Baginski 
et al., 2002). In addition to hydrogen bonding, weak Van der Waal’s forces are also 
reported to help the interaction between the hydrophobic tail of AmB and sterols 
(Paquet et al., 2002).  
AmB can interact with ergosterol in fungal cell membranes. It can also interact with 
cholesterol in mammalian cell membranes. The use of AmB as an important 
antifungal agent is because of the higher affinity of AmB for ergosterol rather than for 
cholesterol in membranes (Baran & Mazerski, 2002; Archer & Gale, 1975). There are 
minor differences in the structure of ergosterol and cholesterol. The structure of 
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ergosterol is different from cholesterol in having an extra methyl group (CH3) in its 
side chain and 2 extra double bonds (C=C), one in a ring and the other one in the 
side chain (Baginski et al., 1989) (Figure 22). The presence of an additional C=C in 
the structure of ergosterol can reduce the intermolecular distance to AmB and 
thereby strengthen the electrostatic interaction between ergosterol and AmB 
(Baginski et al., 1997; Baginski et al., 2002). Findings from Readio and Bittman 
showed that the binding affinity of AmB to cholesterol was Ka = 5.2 x 104 M-1 
compared to that of AmB to ergosterol which was Ka = 6.9 x 105 M-1 (Readio & 
Bittman, 1982). 
(A)                                                                                (B) 
 
 
(A)                                                                (B)  
Figure 22: (A) Structure of Cholesterol (B) Structure of Ergosterol  
Picture taken from www.doctorfungus.org 
As I am using this figure for personal use only in my PhD thesis, the website gives me 
permission to do so.  
 
1.1.1.14.4.2 Aggregation of AmB 
As mentioned previously, AmB has both amphiphilic and amphoteric behaviour. 
Because of these properties, AmB is only weakly soluble in organic and aqueous 
solvents. As a consequence of its insolubility, AmB is often toxic in human cells. 
AmB in water creates a mixture of soluble monomers and the larger aggregates that 
are insoluble oligomers. This aggregation state can be determined by UV 
spectrophotometry. Soluble monomeric AmB has been reported to not show toxicity, 
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but aggregated forms of AmB show toxicity in the body.  AmB in its monomeric form 
is characterized by a spectral peak at 406 - 409 nm (Figure 23, peak 4). At higher 
concentrations of AmB, it appears that AmB molecules are able to interact with each 
other to form oligomers. Aggregates of oligomers are characterised by an absorption 
peak at 328 - 340 nm (Figure 23, peak 1) (Torrado et al., 2008). Torrado et al. (2008) 
suggested that: "The proportion of each association form has been shown to depend 
on different factors, such as AmB concentration, the medium in which the drug is 
dispersed, the action of surfactants and other excipients such as serum albumin, the 
way the dispersions are prepared, or even the temperatures they have been 
exposed to". AmB-solvent interactions and also the pH of water determines the 
formation of monomer and aggregate states. For example, addition of methanol (as 
a co-solvent) to water can change the aggregated state of AmB to the soluble 
monomeric state (Figure 23) (Torrado et al., 2008). 
 
Figure 23: Represents the UV Spectrum of AmB 
AmB is in an aggregated state at 328 nm (Peak 1) and a monomeric state at 409 nm (Peak 
4). There are two additional peaks between 300 - 450 nm which remain unchanged. Figure 
was taken from (K. Corware PhD thesis, 2010) with permission. 
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1.1.1.14.4.3 Different formulations of AmB 
As the usefulness of AmB is limited by its toxicity, new less toxic derivations of AmB 
have been developed with the additional advantage that these formulations of AmB 
also increase its solubility. 
 
1.1.1.14.4.3.1 Fungizone 
Fungizone is a micellar formulation of AmB which is marketed by Bristol-Myers 
Squibb Co. It has been available from 1958 for treatment of life-threatening 
infections caused by fungi. It has been considered as the ‘‘gold standard’’ of AmB 
formulations against which other formulations are compared. Fungizone has a 1:2 
ratio of AmB:deoxycholate (a natural detergent present in bile) which forms a 
colloidal dispersion of large aggregates. It is administered intravenously and slowly 
over several hours (Torrado, 2008). Fungizone costs £3.59 in the UK for a single vial 
containing 50 mg AmB (British National Formulary, 2012). Whilst Fungizone has a 
wide range of clinical usage, 30 - 50% of patients treated with Fungizone show side 
effects such as renal damage (Adams & Kwon, 2003). This highlights the need for a 
new and modified form of AmB to create a more effective drug for the treatment of 
IA.  
1.1.1.14.4.3.2 Lipid formulations of AmB 
The strong lipophilic properties of AmB can promote the encapsulation or binding of 
AmB into lipid complexes or liposomes and a reduction in toxicity. Vyas & Gupta, 
(2006) reported that: "there are three ways by which the therapeutic index of AmB 
might be improved: (i) increasing the selectivity of polyene induced damage to fungal 
as opposed to mammalian cells; (ii) decreasing toxicity to host cells bearing LDL 
receptors; and (iii) decreasing toxicity for cells of the immune system and thereby 
protecting the immuno-stimulatory activity". Approaches applied to solve these 
issues involved the formulation of AmB with lipid. In the beginning of the 1990s, the 
application of lipid formulations of AmB increased for the management of related 
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invasive fungal infections. Three lipid formulations of AmB are available: a lipid 
complex, a colloidal dispersion and a liposomal formulation. These three forms of 
AmB differ from each other in their shape, lipid composition, clinical effects and 
pharmacokinetic behaviour (Herbrecht et al., 2003). 
1.1.1.14.4.3.2.1 AmB colloidal dispersion (Amphocil and Amphotec) 
Liposome technology has developed another kind of AmB formulation marketed as 
Amphotec in the USA and Amphocil in Europe. Amphotec is a formulation of AmB 
with cholesterol sulfate bilayers in equimolar concentrations (Torrado et al., 2008). It 
has been reported that Amphotec and Amphocil are less toxic to patients compared 
to Fungizone (White et al., 1998). Herbrecht et al. reported that Amphocil has a disk-
like structure of 4 nm thickness and 120 - 140 nm in diameter (Herbrecht et al., 
2003). 
1.1.1.14.4.3.2.2 AmB lipid complexes (Abelcet) 
 Abelcet is AmB in a lipid complex created by Elan Corporation.  This complex is a 
suspension of AmB complexed with two phospholipids, DMPG 
(dimyristoylphosphatidylglycerol) and DPMC (dimyristoylphosphatidylcholine) at a 
molar ratio of 7:3. The ratio of AmB:lipid in this complex is 1:3. It has a particle 
ribbon-like shape with a size of 1,600 - 11,600 nm in length (Herbrecht et al., 2003). 
Abelcet is recognised as second line therapy for the treatment of patients who are 
not responding to Fungizone treatment or who have renal impairment (Enoch et al., 
2006). However, because of its particle size and colloidal nature, it can be removed 
from the circulation quickly resulting in an increased risk of hepatic disorders. 
1.1.1.14.4.3.2.3 Liposomal AmB (AmBisome) 
This form of AmB is produced by Gilead Sciences and marketed as AmBisome. This 
lipid based delivery system was produced to increase the efficacy of the compound 
by decreasing its toxicity. In AmBisome, the AmB is encapsulated in unilamellar 
liposomes which are composed of cholesterol, distearoylphosphatidylglycerol and 
phosphatidylcholine at a ratio of 5:4:10 (Herbrecht et al., 2003). The phospholipids 
organize into bilayer structures when water is added to AmBisome. On increasing 
the temperature, these bilayer structures can change from a gel state to a crystalline 
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and liquid form. This phase transition temperature (Tc) is necessary in the design of 
a liposome because it increases the permeability of Ambisome. Liposomes that are 
created for drug delivery should be designed from phospholipids with a Tc above 
37°C. Distearoylphosphatidylglycerol has a Tc of 55°C and phosphatidylcholine has 
a Tc of 50-60°C. The high Tc aids the stability of AmB in liposomes in physiological 
conditions (Adler-Moore & Proffitt, 2002). Less than 1% nephrotoxicity, minimal side 
effects and considerably less renal damage are seen with AmBisome compared to 
other AmB formulations (Walsh et al., 1999; Sundar et al., 2010). AmBisome is very 
expensive but highly effective for treating invasive fungal infections. This means it is 
not affordable to poor patients in developing counties.   
 
1.1.1.15 Biomedical application of polymers 
Polymers have been used widely in healthcare products and in medicine for many 
years. For instance, poly(L-lactic acid) has been used in dissolvable stitches and 
wound dressings. Carmustine is used in the therapy of brain tumours. In order to 
create a long term depot of this drug, it is combined with two polymers sebacic acid 
and (carboxyphenoxypropane) (Brem et al., 1995).   
Recently, some new kinds of polymers have been designed by incorporation of two 
(diblock copolymers) or three different polymers (triblock copolymers).  An example 
of a diblock co-polymer is PEO-block-PBLA (poly(ethylene oxide)-block-poly(b-
benzyl-L-aspartate). The micelle forming capability of this diblock copolymer consists 
of poly(ethylene oxide) (PEO) which forms a shell around a core-forming poly(L-
amino acid).  
In some polymeric drugs, it has been shown that the polymer itself has biological 
activity, for example the sulphated polysaccharide dextrin 2-sulphate has been 
reported to have anti-HIV-1 activity (Shaunak et al., 1994).   
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1.1.1.15.1 Polymers in drug delivery systems 
Developments in bioengineering and biotechnology have led to the increasing use of 
polymers in biomedical science. Polymer carriers are important in the design and 
preparation of control drug formulations in drug delivery systems (DDS) (Mathiowitz, 
1999; Kydonieus, 1992; Baker, 1987; Elvira et al., 2005). DDS can increase 
bioavailability of low molecular weight drugs, control the release of highly toxic drugs, 
help targeting to cells (e.g. macrophages), and facilitate slow release of water 
soluble drugs (Elvira et al., 2005).  
The main advantages of using polymers are the many possibilities to merge the 
hydrophilic and hydrophobic components of a polymer and a drug. The interaction of 
polymer-solvent, polymer-polymer and polymer-drug offers many different 
formulations with specific functions (Elvira et al., 2005). There have been many 
attempts to alter an insoluble and toxic drug by covalently conjugating it with a water 
soluble polymer. With this polymer-drug interaction, researchers have been able to 
reduce systemic toxicity and increase blood circulation times.    
Polymers can be either natural or synthetic and they have a broad range of 
properties that make them very attractive when used in drug delivery systems. 
Synthetically made polymers can be specifically designed to incorporate the required 
drug of interest. These properties can result in improved stability, increased 
bioavailability and increased drug solubility. Examples of such synthetic drug delivery 
polymers are PEG (poly(ethyleneglycol) and HPMA (poly(N-
hydroxyproplmethacrylamide). Other polymers can be naturally occurring ones such 
as albumin and dextran. Application of these naturally occurring polymers can, 
however, be limited in drug delivery systems because of two major disadvantages:  
a) many purification steps are often required to generate a medicinally acceptable 
compound, and b) high immunogenicity (Harris, 2006).   
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1.1.1.15.2 Polymethacrylic acid sodium salt polymers (PMA-Na) 
Polymethacrylic acid is a new microparticle which includes both polymethacrylic acid 
and polyacrylic acids (Figure 24). It has been shown that microparticles contribute to 
the bioavailability of orally administered drugs and that they can also expand the 
residence time of dosage forms (Serra et al., 2006; Peppas & Sahlin., 1996). Due to 
the responsiveness of PMA-Na to changes in pH, it also has desirable properties 
which can be applied for therapeutic purposes (Jeong & Gutowska, 2002). At a pH 
below 4, PMA-Na is arranged into a hypercoiled form in order to reduce hydrophobic 
interactions. This enables PMA-Na to ionise easily. In addition to this, it has been 
reported that PMA only decomposes at high temperatures (200ºC); thus is relatively 
stable. The encapsulation of PEG into a co-polymer hydrogel of PMA has been 
shown in rabbits to allow the organized release of a steroid that is used to treat 
allergic rhinitis patients (Nakamura et al., 1999). It has been shown that attachment 
of specific entities such as a thiol to the surface of a polymer can be effective in 
altering their mucoadhesion behaviour (Dufresne et al., 2005; Wood et al., 2008; 
Sajeesh et al., 2010). It was also found that cyclodextrin-complexed insulin, 
incorporated into a PMA hydrogel, had a beneficial effect when tested in diabetic rats 
(Sajeesh et al., 2010). It led to insulin loaded into PMA being gradually released in-
vitro for more than 5 hours (Sajeesh & Sharma, 2004). 
 
Figure 24: Chemical structure of PMA-Na 
Structure was drawn in ChemDraw. 
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1.1.1.16 Different AmB administration methods   
In this section, I will describe the current AmB based formulations and methods of 
treating fungal disease and their inherent problems. As there has also been 
extensive use of AmB in the treatment of leishmania, I will also include a brief 
discussion of treatment of this pathogen as there are associated problems which are 
common to both. 
 
1.1.1.16.1 Oral AmB delivery systems 
The first studies using oral AmB administration in-vivo were performed in 1955 
(Jambor et al., 1955). The benefit of this route of treatment was illustrated for the first 
time on the protozoan Leishmania donovani, a parasite. In fungal infections, the oral 
administration of AmB is suitable only for the eradication of fungal colonisation in the 
mouth. Further studies demonstrated that oral administration resulted in very poor 
absorption of AmB and a failure to increase the blood serum level. Therefore, oral 
formulations of AmB were deemed to be of no clinical value (Littman et al., 1958; 
Kravetz et al., 1961). 
The low bioavailability of orally administrated drugs depends on the solubility of that 
drug. In addition to solubility, stability is another important requirement in oral drug 
administration. In order that a drug achieves high efficacy, it needs to be stable in 
acidic gastric environments and also needs to be protected from enzyme 
degradation. This enables the requisite release of the drug in a monomeric form at 
the site of action.  The oral formulation of AmB has recently been developed to 
increase its absorption and to protect the AmB from degradation in the gastric 
environment (Thornton & Wasan, 2009). 
Polymeric nanoparticles which encapsulate the drug have been used as an oral 
delivery system to shield a molecule’s unfavourable characteristics. This technique is 
used to improve the solubility of a range of water insoluble drugs (Thornton & 
Wasan, 2009). 
A nano-suspension of AmB was created by high pressure homogenization to 
improve the uptake of AmB from the gastrointestinal tract. Nano-suspensions work 
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by enhancing AmB contact time with the gut wall and increasing AmB uptake by 
adhering to the gastrointestinal mucosa (Golenser & Domb, 2006). The nano-
suspension is developed by making an AmB suspension in an aqueous solution of 
Pluronic F68, Tween 80 and sodium cholate followed by homogenisation under high-
pressure. This results in particles of nano-meter size as measured by spectroscopy 
(Kayser et al., 2003). An oral cochleate formulation of AmB is another AmB 
formulation which has been developed to improve the efficiency of oral therapy. 
Cochleate is a new lipid-based delivery method for oral administration of 
hydrophobic drugs (Santangelo et al., 2000). Poly(lactide-co-glycolode) (PLGA) is 
another nanoparticle developed for encapsulating AmB for oral administration. The 
cochleate and PLGA formulated AmB have been tested in immuno-suppressed 
mouse models of aspergillosis and candidiasis and have demonstrated a reduced 
level of mortality (Delmas et al., 2002; Wasan et al., 2009). However, whilst dose 
dependent eradication in fungal load was reported for lungs, kidney and spleen, full 
eradication of the pathogen was only achieved in the lungs (Thornton & Wasan, 
2009). In addition to this, oral administration caused systemic toxicity which has not 
been observed in pulmonary AmB administration. 
AmB is, however, poorly absorbed after oral administration and therefore is not 
suitable for prophylaxis. The oral administration of other antifungal drugs such as 
itraconazole and voriconazole to treat lung infection is also limited by their poor 
absorption into the solid organs. 
      
1.1.1.16.2 Intravenously 
Antifungal therapy is usually administrated intravenously through a central venous 
catheter. It is the most common mode of drug administration for the treatment of IA. 
The utility of intravenous AmB is limited by its toxicity following intravenous injection 
and it can result in hypokalaemia, anaemia and nephrotoxicity. AmB after 
intravenous injection of AmB concentrates mainly in the spleen and liver. This may 
be the reason for treatment failure of IA and has led to a greater focus on improving 
drug delivery methods for the lungs (Ruijgrok et al., 2000). 
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1.1.1.16.3 Aerosolised delivery systems 
The aim of any successful antimicrobial regimen is to destroy the pathogenic 
organism by achieving adequate drug concentrations to yield a maximum effect at 
the site of infection. Traditionally this has been achieved by injection of drugs into the 
systemic circulation. In the context of lung infections, this method is inefficient and 
poorly targeted. Aerosolised drug administration, on the other hand, delivers a drug 
via air particles that are inhaled and absorbed directly into the lungs thereby by-
passing the circulatory system. This is important when the drug is required to be 
delivered reliably to the site of infection in the lungs. It should also be a very safe and 
cost-effective method of treatment (Ruijgrok et al., 2000). 
For decades, the treatment of fungal infections has been limited to intravenous AmB 
therapy. The aerosolisation of AmB is, therefore, potentially an effective system for 
the prevention of pulmonary infections because the drug can be delivered and 
concentrated at the site of infection with minimal systemic exposure. Compared to 
intravenous administration, the aerosol delivery is quick, convenient and painless. 
Aerosolised administration also delivers drugs to the respiratory system with minimal 
systemic toxicity. This aerosolised delivery is currently limited to AmB products only, 
although delivery of other antifungal drugs such as voriconazole, itraconazole and 
caspofungin is under investigation (Le & Schiller, 2010). The primary mode for 
pulmonary delivery of an antimicrobial via aerosol is via nebulisation. The optimal 
drug deposition into the airway and lower respiratory system requires considerable 
refinement of suitable administration technologies and techniques (Flume & Klepser, 
2002). The degree of pulmonary penetration is affected by the physical properties of 
the antimicrobial agent such as its viscosity, size, osmolality, pH and surface tension. 
The size of the particle is the main factor in determining effective aerosol deposition 
into small airways. The best particle size for aerosol delivery is 1-5 µm. Particles of 
less than 1 µm size are eliminated from the respiratory system during exhalation, 
whereas particles greater than 5 µm settle in the oropharynx and are then swallowed 
(Kuhn, 2002). In addition to particle size, viscosity also contributes to the 
effectiveness of aerosol delivery. It makes a contribution to the rate of aerosolisation 
which decreases when drug viscosity is more than 1.5 centipoises (Bayat & Cook, 
2004).   
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Sole, (2008) reported that: ‘‘Administration of a nebulised antibiotic achieves high 
local concentrations of the drug and helps to overcome the physical, chemical and 
biological barriers at the focus of the pulmonary infection, which is rarely achieved by 
systemic antibiotics other than with toxic doses’’. The efficiency of inhaled 
antimicrobials is dependent on their accurate route of administration. In this respect, 
several features should be considered during administration:  
1) The solution of the drug needs to be isotonic. 
(2) Use of nebulisers is recommended for producing particles of 1-5 µm in size for 
delivery to the lower respiratory tract system (Sole, 2008). Pulmonary deposition of 
some other formulations of AmB, such as AmB lipid complex (ABLC), was analysed 
in-vitro in a patient with a lung transplant. Different factors have an impact on the 
pulmonary dose received; however, there are not enough studies to determine the 
appropriate dose for prophylaxis with AmB by aerosolisation.  The frequency of 
administration of AmB by inhalation is another aspect which needs to be 
investigated. According to other studies, a satisfactory concentration of AmB in 
bronchoalveolar lavage (BAL) was achieved 24 hours after aerosolisation (Sole, 
2008). 
1.1.1.16.3.1 Aerosolisation of AmB products 
Aerosol administration is likely to become an increasingly important drug delivery 
method for the prophylaxis and treatment of IA. The poor systemic distribution of 
AmB to the lungs results in the need for higher doses which also increases the risk 
of adverse effects in patients. AmB aerosolisation however results in concentration-
dependent pharmacodynamics and optimal fungicidal activity. The large molecules 
of different intravenous AmB formulations, when aerosolised, generate potent small 
particles with defined diameter ranging from 0.90 to 2.43 μm. These differences in 
particle size in various AmB formulations have an effect on both the half-life and 
alveolar distribution of AmB in the lungs. The pharmacokinetic properties of 
aerosolised AmB have been estimated using different doses of AmB formulations 
with different types of nebulisers (Monforte et al., 2003; Diot et al., 1995). For 
example, Beyer et al. reported that nebulisation of Fungizone (AmB + deoxycholate) 
using RespirGard II and PariBoy nebulisers generates particles that penetrate into 
the nasopharynx, alveoli and trachea (Beyer et al., 1994). Another pharmacokinetics 
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pulmonary distribution study demonstrated effective ABLC nebulisation over 30 min 
using a breath-actuated jet nebuliser (Corcoran et al., 2006). In addition to these, L-
AmB coated with macrophage specific ligands (O-palmitoyl mannan or O-palmitoyl 
pullulan) generated an increased concentration of AmB in alveolar macrophages 
after nebulisation. This formulation resulted in greater localization in the lungs as 
compared to aerosolised Fungizone alone (Vyas et al., 2005). 
To date evidence of the clinical efficacy of nebulised antifungal drugs is restricted to 
different formulations of AmB although other antifungal agents such as itraconazole, 
voriconazole and caspofungin are currently under investigation (Le & Schiller, 2010). 
 
1.1.1.16.3.2 Aerosolisation of other antifungal agents 
In addition to nebulisation of different formulations of AmB, other antifungal agents 
have also been studied for aerosolisation. For example, itraconazole has been 
evaluated for aerosolisation as a prophylactic antifungal drug against IA caused by 
A. fumigatus and A. flavus in immuno-suppressed mice. Itraconazole was 
aerosolised using a novel method that sprayed the drug, which has poor aqueous 
solubility, into a liquid (Alvarez et al., 2007; Hoeben et al., 2006). The aerosolisation 
studies of itraconazole in mice verified that the drug reached a therapeutic 
pulmonary concentration 1 h after nebulisation while the serum level was at 25 to 50 
times lower concentration (McConville et al., 2006; Vaughn et al., 2006). 
Aerosolisation of caspofungin has been studied using 3 different nebulisers. It has 
been shown to be effective in reducing the percentage mortality of IA in a rat model. 
However, additional in-vivo studies are required to evaluate the aerosolisation of 
caspofungin (Kurtz et al., 1995; Le & Schiller, 2010). 
Furthermore, an intravenous formulation of voriconazole has been evaluated for 
aerosolisation at low doses in humans. Voriconazole has been nebulised at 10 
mg/ml for 30 min. The characterisation and evaluation of voriconazole inhalation 
demonstrated that the maximum pulmonary concentration was 1.5 times more than 
the plasma concentration (Tolman et al., 2009; Le & Schiller, 2010). 
Suitable nebulisers for aerosol delivery are listed below: 
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1.1.1.17 Nebulisers 
Nebulisers were first introduced in 1874 as instruments for changing liquid into a fine 
spray (Muers, 1997). 
They are now used extensively for the administration of medications by inhalation for 
the treatment of asthma, cystic fibrosis and other respiratory diseases. Nebulisers 
use oxygen and ultrasonic power or compressed air to break the drug into small 
aerosol droplets. By producing smaller aerosol particles, they make it possible for a 
larger proportion of the drug to reach deep regions of the lungs (Muers, 1997).  
Each type of nebuliser has several parameters which need to be optimised. These 
include: 
The particle mass which is the fraction of the drug that leaves the inhaler during 
nebulisation. The inhaled mass can be explained as the fraction of the nebulised 
drug that is inhaled by the patient. The inhaled mass differs between different types 
of nebulisers. Thus, the efficiency of inhaled drugs can depend upon the type of 
delivery system used (Diot et al., 2001; Faurisson et al., 1996). 
The output rate in a jet nebuliser is described by the particle mass and the particle 
size distribution. Output also depends on the flow rate and type of nebuliser.  
There are different types of nebulisers such as jet nebulisers, ultrasonic wave 
nebulisers and vibrating mesh nebulisers (Laube et al., 2000). These different kinds 
of nebulisers are explained in detail below. 
 
1.1.1.17.1 Jet nebulisers 
The most common type of nebuliser is the jet nebuliser in which compressed air is 
used to propel the drug solution and to form liquid droplets. These small particles 
enter the respiratory system and they are then delivered into lung tissue. The optimal 
particle size aerosolised via this nebuliser is 1-5 µm. A drug volume of 4-6 ml and a 
flow rate of 7-8 litres/min is recommended for this type of nebuliser, of which 1-3 ml 
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is the dead volume and fails to be nebulised (Hess et al., 1996). To improve drug 
delivery with jet nebulisers an increase in the wetness of plastic surfaces and a 
decrease in their internal surface area is required.    
The major advantages of the jet nebulisers are that they are cost-effective and 
disposable. The main disadvantages of these nebulisers are the operational set-up, 
the loss of drug during exhalation, and the need for a power source (Hess et al., 
1996). 
Jet nebulisers are often used in the pharmaceutical and biotechnologies industries 
for the development of new drugs because they have the capacity to deliver high 
doses of medication with lower development costs (Kesser & Geller, 2009).  
Vented, unvented, breath-actuated and breath-enhanced nebulisers are all different 
types of jet nebulisers (Kesser & Geller, 2009). AeroEclipse II (Trudell Medical 
International) is a breath-actuated jet nebuliser and was used by me for my studies. 
AeroEclipse II BAN and PARI-LC Plus are the most common forms of jet nebuliser. 
 
1.1.1.17.2 Ultrasonic wave nebulisers  
Ultrasonic wave nebulisers are the least common form of nebuliser. They were 
invented in 1964. They generate high frequency ultrasonic waves which cause 
mechanical vibration of the fluid. Upon contact with the liquid reservoir, these 
vibrating elements aerosolise the surface of the solution and produce a vapor mist 
with a diameter of 1-6 µm. The advantages of ultrasonic nebulisers are that they are 
fast for drug delivery, are portable and they require minimal patient coordination.  
However, they are larger and more expensive than jet nebulisers and are more 
susceptible to contamination and mechanical breakdowns (Knoch & Finlay, 2002; 
Shirk et al., 2006). In addition to this, they are not suitable for aerosolisation of drugs 
in suspensions or for high viscosity liquids (Tiddens & Devadason, 2007; Zimmerer 
et al., 2004). Beurer nebuliser IH30 and Omron NE-U17 are the most common form 
of ultrasonic nebulisers (Knoch & Finlay, 2002). 
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1.1.1.17.3 Vibrating Mesh Nebulisers 
The novel generation of aerosol delivery system uses vibration to produce aerosol 
droplets. Vibrating mesh nebulisers were invented in 2005. Some of the problems 
with the ultrasonic wave nebuliser, such as the loss of liquid waste and undesired 
heating of the medical liquid, have been solved by the vibrating mesh nebuliser. 
Manunta et al. (2011) reported that: ‘‘the vibrating mesh nebuliser has the potential 
advantage of lower shearing forces and a more efficient aerosolisation process, with 
a negligible residual volume following nebulisation’’. Due to low shearing forces on 
the fluid, fragile molecules such as genes and proteins may be delivered by this type 
of nebuliser (Knoch & Keller, 2005).   
Vibrating mesh nebulisers are electronic devices that have some advantages over 
the other two types of nebulisers. They are fast, portable and quiet. They operate 
with batteries and do not required compressed air. The mesh aerosolises the entire 
drug solution so that there is minimal residual dose and little drug waste. The size of 
the particles aerosolised by a vibrating mesh nebuliser depends upon the 
physicochemical properties of the drug and the size of the holes in the mesh (Knoch 
& Keller, 2005). One of the disadvantages to these nebulisers is the potential to 
block the holes in the mesh. The regular replacement of mesh is therefore necessary 
to keep it at optimal operation. This type of nebuliser is also very expensive. 
Currently, there are three vibrating-mesh devices; the Omron NE-U22V MicroAir 
nebuliser, Aerogen’s OnQ aerosol generator and Pari’s eFlow TouchSpray 
technologies (Kesser & Geller, 2009). Both the Omron NE-U22V Micro Air nebulizer 
and Aerogen Aeroneb Go have been used for general purposes in recent years.  
The Omron Micro Air nebuliser has a large particle size distribution. This reduces the 
overall effectiveness of this device as compared to a jet nebuliser. The Aeroneb Go 
nebulises all of the fluid as an aerosol (Geller & Kesser, 2005).  
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1.1.1.18 Project Aims 
The main aim of this thesis is to create a safe and cost-effective nebulised AmB 
which could be given to patients before organ transplantation to prevent IA occurring 
post-transplantation. This drug will be tested for efficacy in a mouse model of IA. 
Several antifungal prophylactic drugs have already been developed to decrease the 
incidence of IFI among lung transplant patients (Covarrubias & Milstone, 2005; 
Magill, 2006; Husain et al., 2006; Borro et al., 2008). However, the utility of these 
drugs are limited because of concerns of safety, efficacy and cost. Currently there is 
no water soluble AmB based drug with low side effects that is suitable for preventing 
IA. Previous projects undertaken by Debbi Harris and Karina Duarte Corware in Prof 
Shaunak’s lab determined that AmB can be incorporated into polymethacrylic acid 
sodium salt (PMA-Na) to create an AmB-PMA complex. Initially AmB-PMA was 
originally developed by incorporation of AmB into PMA with a molecular weight (18 
kDa) for use in the treatment of Cutaneous leishmaniasis.  
The aim of my thesis was to take these previous studies forward by synthesizing a 
much smaller AmB-PMA molecule using lower molecular weight PMA-Na and by so 
doing, reduce the overall size of the molecule to enable its safe and reliable 
administration by nebuliser to lung tissue. Inhaled AmB provides a useful opportunity 
for preventing IA as it has already been reported to decrease the incidence of IA in 
solid organ transplant populations (Arthur et al., 2004). 
To achieve this aim, it is necessary to: (1) optimise the chemical synthesis of AmB-
PMA; (2) test its biological activity; (3) determine the correlation between the 
biological and chemical properties of AmB-PMA; (4) test it for its ability to protect 
BALB/c mice immuno-suppressed with steroids and tacrolimus and infected with A. 
fumigatus. 
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Chapter 2 
2.1: Material and Methods 
 
2.1.1 In-vitro studies 
2.1.1.1 AmB-PMA synthesis using polymethacrylic acid sodium salt 
(PMA-Na) 
All glassware, magnetic stir bars and plastic were sterilized to remove endotoxin by 
autoclaving (121°C 15 min x 2 cycles) and dried in an oven overnight. Endotoxin-free 
AmB was used in all syntheses. 50 mg PMA-Na was dissolved in 10 ml endotoxin-
free water for injection (B Braun) and allowed to solubilize by shaking on a rotary 
shaker (35 rpm) at room temperature overnight. On the day of synthesis, 9.7 ml 
dimethyl sulfoxide (DMSO, Sigma-Aldrich) was added to 50 mg of AmB sealed under 
argon, and stirred for 3 h. 10 ml of 5 mg/ml PMA-Na solution (size range 1.2 kDa, 1.7 
kDa, 3.1 kDa, 8 kDa and 18 kDa) was treated twice with activated charcoal (12.5 mg, 
25% w/w) in microfuge tubes to remove endotoxin. After each treatment, the 
charcoal-PMA slurry was centrifuged in a microfuge at 13,000 g for 8 min. The 
supernatant was then carefully removed and filtered twice through a 0.2 m filter to 
remove any non-solubilised particles. The AmB solution (2 ml) was then added to a 
round-bottom glass flask and 1 N NaOH (100 μl, 15 μl per 3 sec) added dropwise 
(using a multi-streamer  Eppendorf pipette), followed by the addition of the PMA-Na 
solution (2 ml) using a multistreamer pipette followed by the addition of 8 ml of water 
for injection. This mixture was left to stir on a magnetic stirrer at 245 rpm for 1 h at 
room temperature before transferring the reaction solution into either a pre-wetted 
Float-a-Lyzer (500-1,000 Da cut-off) or a Slide-a-Lyzer cassette (2 kDa or 3.5 kDa 
cut-off). The dialysis chambers were submerged in sterile water for irrigation in a 2 L 
Nalgene bottle and left stirring for 4 h at 4°C. After 4 h dialysis, the dialysate AmB-
PMA was removed from the cassette and the pH readjusted to the same pH as 
before the dialysis was started (i.e. this should be pH 12 - 12.5 - Adjustment with 
NaOH 1N). Then, the solution was transferred back into the cassette and dialysis 
continued in fresh water for irrigation at 4⁰C for 20 h. After overnight incubation, the 
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dialysate solution was removed from the cassette and the pH rechecked. The 
solution was then passed through a filter (0.2 μm) into an amber glass vial and 
frozen for 1 h at -20°C followed by 18 h at -80°C and then lyophilized for 72 h to yield 
a yellow powder (Figure 25). 
 
 
Figure 25: Schematic illustrating the association between AmB and PMA 
during AmB-PMA synthesis  
In the presence of NaOH and H2O, AmB and PMA interact with each other via electrostatic 
interactions to form AmB-PMA. Picture was taken from (K. Corware PhD thesis, 2010), with 
permission. 
 
2.1.1.2 Chemical and physical characterisation of AmB-PMA 
2.1.1.2.1 Quantitation of AmB loading (UV spectrophotometry) 
UV spectrophotometry was performed using a Jenway 6507 Series UV-visible 
spectrophotometer. AmB absorbs UV light at a wavelength of 300-450 nm 
(Vandermeulen et al., 2006). To determine the percentage of AmB in the 
111 
 
synthesised complex, the optical density (OD) of AmB-PMA was measured at 409 
nm. One vial of Fungizone (consisting of 50 mg AmB) was dissolved in 16.7 ml of 
water for injection to yield a concentration of 3 mg/ml. The standard curve was 
created using serial dilutions of Fungizone (1.05-6 µg/ml) in 50% methanol/water. 
Absorbance was measured 3 times at 409 nm.  
To determine AmB loading within the compound, a sample was solubilised in fresh 
water for injection to a concentration of 1 mg/ml and then further diluted to a final 
concentration of 10 µg/ml in 50% methanol. The absorbance of samples was 
measured 3 times at 409 nm on a UV spectrophotometer and the absorbance 
spectra data exported to GraphPad Prism software to calculate the percentage of 
AmB loading within the compound.  
2.1.1.2.2 Dynamic light scattering (DLS) 
DLS is a technique that is used to determine the size distribution profile of small 
molecules and particles within a suspension or polymers in solution. It can be used 
to determine the size of particles in AmB-PMA and the results compared with the 
size of the particles in Fungizone. Samples were solubilised in water for injection at a 
concentration of 1.5 mg/ml AmB and measured 10 times using a Brookhaven 
instrument Corp (ZetaPALS particle sizing). 
2.1.1.2.3 Determination of pH-dependent solubility of AmB-PMA in 
water 
AmB-PMA samples were reconstituted in water for injection at a concentration of 1 
mg/ml AmB. The pH of each dissolved AmB-PMA construct in water was 7.3. It 
remained in solution after centrifugation. The pH was adjusted to 6 and 5 using Tris 
1M (pH 4) until the clear solution went turbid. The samples were then centrifuged at 
1,800 rpm for 5 min to yield a yellow pellet. The supernatants were transferred to a 
flat-bottom plate and the OD measured at 409 nm and the pellet then dissolved in 
DMSO to confirm that it was free AmB. The results were expressed as the 
percentage of AmB solubility at the given pH compared to AmB-PMA at pH 7.3 
(100% solubility). 
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2.1.1.3 Endotoxin assay  
The limulus amebocyte lysate (LAL) gel clot assay was used to determine the level 
of endotoxin or lipopolysaccharide (LPS) in samples. LAL (Pyrotell, Associates of 
Cape Code Incorporated) reacts with LPS or bacterial endotoxins resulting in 
formation of a gel clot. The presence of endotoxin in samples at a sensitivity of 0.06 
EU/ml can be detected by this method. 100 µl of each sample was added to 100 µl 
of LAL in endotoxin-free glass tubes (Cape Cod Associates) and incubated for 1 h at 
37⁰C. After a 1 h incubation, each sample was carefully inverted and examined for 
the presence of a gel clot. LPS (25 ng /ml) and endotoxin-free water were used as 
positive and negative controls, respectively. Batches of synthesized drugs that were 
endotoxin-free were used in the in-vitro and in-vivo studies. 
 
2.1.1.4 Biological characterisation of AmB-PMA in-vitro 
 
2.1.1.4.1 Culture media and washing buffers 
Culture medium for primary human cells was RPMI 1640, 330 μg/ml L-glutamine, 
200  μg/ml streptomycin and 200 IU/ml penicillin (Invitrogen) supplemented with 10% 
heat-inactivated foetal calf serum (FCS, Sera Labs). All primary cells were 
maintained at 37°C, 5% CO2 in a humidified atmosphere. The washing buffer was 
phosphate buffered saline (PBS, Sigma-Aldrich). Serum-free culture medium was 
RPMI 1640, 330 μg/ml L-glutamine, 200 μg/ml streptomycin and 200 IU/ml penicillin 
buffered. 
Culture medium for the A549 cell line was DMEM with 200 μg/ml streptomycin and 
200 IU/ml penicillin supplemented with 10% heat-inactivated FCS.  
Culture medium for the U937 cell line was RPMI 1640, 330 μg/ml L-glutamine, 200 
μg/ml streptomycin and 200 IU/ml penicillin plus 10% heat inactivated FCS. 
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Culture medium for the Calu-3 cell line was DMEM: F12 with Glutamax (ref 31331-
028) and 200 μg/ml streptomycin and 200 IU/ml penicillin supplemented with 10% 
FCS. 
 
2.1.1.4.2 Culture of primary human cells 
2.1.1.4.2.1 Isolation of monocyte-derived macrophages 
Blood was  obtained  from  the National Blood service in  the  form  of  screened  
buffy  coat  residues  pooled from three healthy  blood  donors. Blood was diluted 1; 
1 with PBS and 35 ml layered over 15 ml of Ficoll-Plaque (GE Healthcare). 
Peripheral blood mononuclear cells (PBMCs) were separated from red blood cells by 
centrifugation for 30 min at 2,000 g in a Sorvall Legend RT centrifuge. The interface 
layer cells were washed twice with 45 ml PBS. The cells were re-suspended in 20 ml 
of RPMI 1640 culture medium containing 10% FCS. The cells were then seeded into 
sterile 14 cm Petri dishes (VWR) and allowed to adhere for at least 1 h at 37°C.   
After a 1 h incubation, non-adherent cells were removed and monocytes washed in 
PBS (25 ml). Then, monocytes were allowed to grow for at least 3-5 days in culture 
medium to differentiate into macrophages. 
When PBMC’s or monocytes were needed for immuno-modulatory experiments, the 
monocytes were seeded in culture media and incubated overnight before use.  
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2.1.1.4.3 Culture of human cell lines 
2.1.1.4.3.1 U937 cell line (human monocyte lymphoma) 
Cells  were  maintained  in  RPMI 1640 culture  medium with 10% heat inactivated 
FCS and  split  at  least  once  a  week (1:4) to  maintain their growth. Before use, 
the non-adherent cells were centrifuged at 1,600 rpm for 5 min and washed in PBS. 
The supernatant was removed and the cells re-suspended in RPMI 1640 plus 10% 
FCS. 
 
2.1.1.4.3.2 A549 cell line (human alveolar epithelial cells) 
The A549 cell line was cultured in DMEM with 200 μg/ml streptomycin and 200 IU/ml 
penicillin supplemented with 10% heat-inactivated FCS. The A549 cell layer was 
trypsinised with 2 ml Trypsin and EDTA solution and then split 1:5 twice a week. 
 
2.1.1.4.4 Determine the antifungal activity of AmB-PMA with MIC 
test 
In order to determine the antifungal activity of AmB-PMA in-vitro, the efficacy of 
AmB-PMA against fungi first had to be established using minimum inhibitory 
concentration (MIC) tests by the CLSI (Clinical and Laboratory Standards Institute) 
method (Pfaller et al., 2006).  
2-5 day-old A. fumigatus conidia were harvested from Sabouraud dextrose agar 
(SDA) plates with a sterile L-shape spreader (VWR) in 0.1% Tween 20 and filtered 
through a sterile wool filter. Conidia were re-suspended in sterile saline and 
enumerated using a haemocytometer. Conidia were then adjusted to a final 
concentration of 104-105 conidia/ml. Doubling dilutions of AmB or the equivalent 
loading of AmB-PMA in 100 l of RPMI 1640, 2% glucose, 0.165 mol/l MOPS (3-(N-
morpholino) propanesulfonic acid) pH 7.0 covering the range 16 g/ml to 15.6 ng/ml, 
were then dispensed in quadruplicate into 96-well plates. Microtitre plates were then 
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inoculated with 100 µl of conidia (104-105 conidia/ml) per well. The control well 
contained 100 µl of sterile medium and 100 µl of inoculum suspension. The 
microtitre plates were incubated in a sealed container at 37°C for 48 h and then 
assayed using a microscope for signs of fungal growth. The MIC was determined as 
the cut-off concentration beyond which no fungal growth was observed in any of the 
quadruplicate wells. 
 
2.1.1.4.5 Cytotoxicity of PMA-Na and AmB-PMA in fungal & human 
cell cultures 
2.1.1.4.5.1 Haemolysis assay  
This assay was performed to determine the potential of the drug (either AmB-PMA or 
Fungizone) to lyse red blood cells (RBCs) and release haemoglobin. Doubling 
dilutions of AmB-PMA (1.56-100 µg/ml) in 100 µl of RPMI 1640 were dispensed in 
triplicate into each well of a 96 well V-shape bottom microtitre plate (Costar). Then 
100 µl of RPMI 1640 containing 2% v/v washed RBCs was added to each well to 
give a final volume of 200 µl. For the 100% haemolysis controls, a 1% (v/v) solution 
of the detergent Triton X-100 was used. Plates were incubated for 1 h at 37°C 
followed by centrifugation at 1,600 rpm for 5 min in a Thermo Heraeus Labofuge 
400R centrifuge. The haemoglobin-containing supernatant was then transferred to a 
96 well flat-bottom plate and the OD measured at 570 nm in a power wave plate 
reader. The percentage haemolysis was calculated relative to Triton X-100 treated 
cells (100% haemolysis) and untreated wells (0% haemolysis). Results were pooled 
and plotted in triplicate (mean ± SEM).  
2.1.1.4.5.2 MTT viability assay 
This assay was conducted to determine the toxicity of AmB-PMA against primary 
human monocytes, monocyte-derived macrophages (MDMs), U937 cells (human 
monocyte lymphoma) and A549 (a human alveolar epithelial cell line). The metabolic 
conversion of MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) to 
a blue formazan dye was used as the readout. Doubling dilutions of AmB-PMA 
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(12.5-300 µg/ml) in 100 µl of RPMI 1640 per well were dispensed into a 96 well 
microtitre plate (in triplicate) and 1,000,000 cells added to each well to give a final 
volume of 200 µl. Plates were incubated for 3 h in a humidified chamber at 37°C, 5% 
CO2.  Fungizone was used as a positive comparison with the amount of AmB being 
at the same concentration as the AmB in AmB-PMA. Triton X-100 (2% v/v) and 
untreated cells were used as positive and negative cytotoxicity controls respectively. 
After a 3 h incubation, MTT reagent (50 μl of a 5 mg/ml solution made up in 
phosphate buffered saline (PBS)) was added and the plate incubated for a further 3 
h. The plate was then centrifuged at 1,600 rpm for 5 min and the supernatant 
carefully removed. DMSO (100 μl) was added to dissolve the purple formazan 
crystals. Cellular viability was determined by measuring the OD of each well at 570 
nm. Cell viabilities were measured in triplicate, relative to untreated cells (100% 
viability) and Triton X-100 treated cells (0% viability). 
 
2.1.1.4.6 Immuno-modulatory effects of AmB-PMA on cytokine and 
chemokine mRNA levels in treated human MDMs 
One million cultured MDMs /well were adhered in 24 well tissue culture plates for 18-
24 h before incubation with the test compounds for 3 h at 37°C, 5% CO2. Ultrapure 
LPS (25 ng/ml) and unstimulated cells acted as positive and negative controls, 
respectively. Supernatants were then removed and Tri Reagent (500 µl) was added 
to the wells. The cells were then homogenized and the cell lysate stored at -20°C for 
subsequent RNA extraction.   
 
2.1.1.4.7 RNA extraction and reverse transcription 
RNA was extracted according to the manufacturer’s instructions (Sigma-Aldrich). 
The RNA was solubilized in 50 µl RNAase-free water and the optical density 
measured using a Nano drop ND-1000 (Thermo Scientific). RNA was reverse 
transcribed to cDNA using a Qiagen QuantiTect Reverse Transcription (RT) kit 
according to the manufacturer’s instructions (Qiagen). Importantly, this kit includes a 
DNAse digestion step that removes any contaminating genomic DNA. The cDNA 
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product was diluted to a final volume of 80 µl by adding 60 µl of RNAase-free water 
just prior to PCR amplification. 
2.1.1.4.8 Quantitative real-time PCR for human cells 
The levels of IFN-γ, TNF-α, IL-6 and MIP-1β mRNA in treated human cells were 
measured using real-time quantitative polymerase chain reaction (RT-PCR) in a 
RotorGene 3000 (Corbett Research). This method was used both on human and 
mouse samples. The PCR product was determined by measuring the binding of a 
fluorescent dye (Sybr Green, Sigma-Aldrich). This dye binds to double stranded DNA 
and emits fluorescence that is proportional to the copy number of the PCR product 
generated. In a typical reaction, diluted cDNA (2 μl), 2 x Sybr Green Jumpstart Taq 
Readymix (10 μl, Sigma-Aldrich), reverse and forward primers (0.25 µM) and 
RNase-free water were added together in a final reaction volume of 20 μl.  
The primers and PCR conditions used are detailed in the tables below and have 
been described previously (Corware et al., 2011). Briefly, selection of primers was 
based on the following criteria:  
1) For efficient amplification, the product size was between 150 and 200 base pairs. 
2) Primers were in two different exons in the mRNA sequence. 
3) The absence of reactivity with other non-target sequences was determined by 
BLAST searches of the NCBI DNA database.  
4) A moderate (55-60ºC) annealing temperature with guanidine:cytidine content 
around 50%.  
5) Minimum secondary structure within the product.  
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Gene Forward primer sequence Reverse primer sequence 
HPRT GCTCGAGATGTGATGAAGGAGAT TCCCCTGTTGACTGGTCATTAC 
MIP-1β ACCCTCCCACCGCCTGCTGC GTTCCAGGTCATACACGTACTC 
TNF-α AGGCGGTGCTTGTTCCTCA GTTCGAGAAGATGATCTGACTGCC 
IFN-γ AAACGAGATGACTTCGAAAAGCTGA CTTCGACCTCGAAACAGCATCTGACT 
IL-6 CACACAGACAGCCACTCACCTC CTGCCAGTGCCTCTTTGCTG 
Table 3: Primer sequences of human chemokine and cytokine genes 
 
2.1.1.4.9 Human plasmid standards for the generation of absolute 
copy numbers 
2.1.1.4.9.1 Human plasmid synthesis 
Dr Ian Teo has generated a human multi-gene plasmid pCCy14 containing 
sequences of 5 cytokines, 7 chemokines and 2 housekeeping genes (Figure 26).  
This plasmid was used in my qPCRs to generate standard curves from which the 
copy numbers of all of the genes studied could be accurately determined.   
To create a plasmid, the desired target sequences were amplified using these 
primers in the RotorGene (Corbett Research). They were analysed using agarose 
gel electrophoresis (2.5 %) in order to check for their purity as being a single band of 
the correct base pair size. 
The PCR product was then ligated into a TOPO TA cloning Vector (Invitrogen). It 
was carried out according to the manufacturer’s instructions. 1 µl of salt solution and 
1 µl of TOPO vector were added to the 4 µl of PCR product.  The reaction was mixed 
and incubated for 5 min at room temperature. After 5 min of incubation, the TOPO 
was constructed into competent E.coli. The competent cells DH5α or TOP10 were 
thawed on ice prior to being transformed as follows; 25 μl of competent cells were 
added to reaction tubes containing 2 μl ligation mixture. The reaction mixture was 
incubated on ice for almost 30 min and then heat-shocked for 30 sec at 42ºC without 
shaking. The tube was then transferred to ice. S.O.C medium or Luria Base (LB) 
broth (250 μl, Sigma-Aldrich) was added and the cells were incubated at 37ºC for 1 
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hr with shaking at 200 rpm. After a 1 h incubation, the solution was transferred into 5 
ml LB broth containing ampicillin (100 μg/ml) and shaken for 1 h to allow expression 
of the antibiotic resistance genes. An aliquot of this mixture was then plated onto 
prepared LB agar plates containing ampicillin (100 μg/ml). Plates were incubated 
overnight at 37ºC and the following day, 10 colonies were selected to ascertain both 
positive and negative transformation. Colonies were inoculated into LB broth 
containing ampicillin (100 μg/ml) in a 96-well plate and incubated at 37ºC for at least 
8 h followed by centrifugation at 13,000 rpm for 5 min. The supernatant was 
removed and the pellet resuspended in water and heated at 95ºC for 5 min to lyse 
the cells.  After centrifugation at 13,000 rpm for 5 min, the PCR was carried out with 
2 µl of the supernatant using the relevant primers. Colonies that were thus confirmed 
to contain the plasmid were subsequently cultured in a large volume as described.  
The plasmid was isolated by a GeneElute Plasmid mini-preparation kit (Sigma-
Aldrich) and the copies number of the plasmid established as detailed below:  
Total base pairs in plasmid (vector + insert) x molecular weight of 1 base pair (660 g) 
The number of molecules in 1 ng DNA was calculated as follows: 
n = 6 x 1023 (molecules in 1 mole) / plasmid molecular weight 
The optical density was measured at 260 nm and the concentration was determined.  
Finally, the number of molecules (copies) of plasmid in 1 μl was established by:  
Concentration (μg / ml) x number of molecules 
The plasmid was linearised using restriction enzymes to enable efficient amplification 
in PCR.  EcoR1 and Not 1 restriction enzymes were used to cut the plasmid.  The 
plasmid was then diluted in nuclease-free water to a final stock concentration of 108 
copies per μl.  A standard curve was constructed with serial 10-fold dilutions in λ 
DNA (5 ng/ml) from 20 – 2x107 copies.  Quantitative real time PCR was performed 
using the RotorGene thermal cycler and the relevant primers used in order to 
determine the efficiency of amplification.   
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Figure 26: Human multigene plasmid pTTSccy 14 
Once the samples were inserted into the PCR machine, the reaction was initiated by 
denaturation of the double stranded DNA and the anti-Taq-antibody present in the 
Sybr Green mix. The DNA amplification continued for 40 or 45 cycles. The cycle 
temperature at which the fluorescent data was acquired for quantification was 
determined by the melting temperature (Tm) of the PCR product. Fluorescence 
acquisition was set at 2-4°C below the Tm (i.e the temperature where half of the 
bona-fide double-stranded product was completely denatured).This restricted the 
detection of non-specific products with a lower melting temperature and also limited 
the formation of primer dimers and incorrect quantification (K. Corware PhD thesis, 
2010). To confirm the accuracy of amplification, PCR products were run on an 2% 
agarose sizing gel and shown to be of the correct size. 
The PCR reaction conditions are shown in the table below (Table 4). 
 Temp °C Time 
Activation of polymerase 95 3 min 
Amplification of PCR product (x40)   
     1: Denaturation 95 5 sec 
     2: Primer annealing Gene dependent 2 sec 
     3: Extension 72 8 sec 
     4: Fluorescence acquisition Gene dependent 8 sec 
Table 4: Cycle of a PCR 
This table defines the details of the PCR reaction after the sample had been loaded into the 
PCR machine. 
 
 
 
 
121 
 
 
2.1.2 In-vivo studies 
 
2.1.2.1 Mice 
All mouse studies were approved by the Home office-United Kingdom. Animal 
experiments were carried out at the South Kensington campus, Imperial College 
London under Home Office Project Licence PPL 70/7324. BALB/c and C57/BL6 
male mice (18-20 gram) were purchased from (Harlan Ortech, UK). The animals 
were housed in groups of 4-5 mice in vented cages. They were fed with food and 
drank autoclaved water regularly. Ciprofloxacin (64 mg/L, Sigma-Aldrich) and 
tetracycline hydrochloride (1g/L, Sigma-Aldrich) were added to the autoclaved 
drinking water as prophylaxis against bacterial infections. The mice drank only 
antibiotic supplemented water from day one before starting the immuno-suppression 
drug regimen. 
 
2.1.2.2 Construction of a chamber for nebulising 4 mice at a time 
The aim of this PhD thesis was to create and evaluate a method for effectively 
delivering nebulised AmB-PMA to the mice as a prophylactic treatment against 
Aspergillus infection. I therefore had to devise and construct a new but simple 
apparatus that could achieve this objective. As there is relatively little information 
about delivery of nebulised drugs to mice, and no commercial mouse dedicated 
apparatus, I went to Great Ormond Street Hospital to discuss protocols and 
apparatus with a team who had published on this subject recently (Manunta et al., 
2011).  
It was then decided to adapt the use of a nebuliser designed for the clinical delivery 
of anti-asthma drugs; the AeroEclipse II nebuliser. It would deliver AmB-PMA via a 
portal into a sealable vented chamber in which up to 4 mice could be placed at a 
time. The construction of the nebulisation chamber is shown in Figure 27. Before 
coming to a final decision, two nebulisers (AeroEclipse II and Aeroneb Pro) were 
tested. The advantages and disadvantages of each nebuliser are listed below: 
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Advantages of the AeroEclipse II nebuliser: 
 Only a small amount of the drug is wasted with the AeroEclipse II nebuliser. 
 It has high output efficiency.    
 Low residual volume in the medication cup (0.3 ml). 
 Drug can be delivered continuously as well as intermittently. 
 Cost-effective. 
Disadvantages of AeroEclipse II nebuliser:   
 It has high shear forces. 
 It is not autoclavable. 
Advantages of Aeroneb Pro nebuliser: 
 Lower shearing forces. 
 It is autoclavable at 132°C-135°C. 
 It is more efficient for the aerosolisation process. There is a negligible residual 
volume following nebulisation. 
 Low residual volume in the medication cup of 0.1 ml. 
Disadvantages of the Aeroneb Pro nebuliser:   
 Some of the drug was wasted. 
 It tended to block during the nebulisation procedure. 
 It was expensive. 
On the basis of the criteria listed above, I decided that the AeroEclipse II nebuliser 
was the most cost-effective means of drug delivery for my experiments. 
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Figure 27: The construction of the nebulisation chamber with AeroEclipse II 
nebuliser 
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2.1.2.3 Preparation of AmB-PMA 
On the day of the experiment, AmB PMA (3.5 kDa) was reconstituted to the required 
concentration in sterile water for injection and then filtered through a 0.2 µm filter and 
administered either intranasally or via the nebuliser. 
2.1.2.4 Testing the efficacy of nebulised AmB delivery for the 
prevention of a fungal infection ex-vivo 
I then had to test the efficacy of this AmB delivery method for the prevention of a 
fungal infection. This was done by nebulising different doses of the AmB-PMA (200 
and 300 µg/ml delivered over 30 min with the volume increased to 3 ml onto a 
Sabouraud dextrose agar (SDA) plate placed inside the chamber. The SDA plate 
was kept inside the box and the AmB-PMA nebulised into the box. The aerosol was 
generated using the AeroEclipse II nebuliser. The nebuliser was connected to the 
perspex box on one side and a pressurised air source to the other side. It was 
operated by an air cylinder at 3 bar pressure and 8 litres/min air flow. Then, A. 
fumigatus (1x107) was plated onto the plate and incubated for 24 h at 37◦C to find the 
most effective dose of AmB-PMA for prevention of fungal growth. 
2.1.2.5 Time of AmB-PMA exposure 
Once it had been demonstrated that aerosolised AmB-PMA was effective at 
inhibiting Aspergillus growth on agar plates, I went on to test the drug on mice in the 
absence of immuno-suppression and / or infection to determine if it was lethal at the 
chosen dose of the drug. This was done by administering the drug either intra-
nasally or by nebulisation. 
The mice were exposed to AmB-PMA aerosols for 45 min in a non-continuous mode. 
The AmB-PMA was nebulised into the chamber for 30 sec and then the nebulisation 
stopped for 1 minute to allow the mice to inhale all of the particles inside the box. 
The nebulisation was continued intermittently for 45 min. The chamber lid was kept 
closed during the aerosolisation and it was placed in a class II cabinet. 
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2.1.2.6 AmB-PMA treatment regimens 
Drug treatment was carried out via nebulisation or intranasal administration at the 
concentrations shown. During the course of these studies, the AmB-PMA was 
administrated at three different time points: 
a) Prophylaxis for 4 days before infection. 
b) Prophylaxis for 3 days before infection and on the day of infection. On the day 
of infection, AmB-PMA nebulisation was performed in the morning and spores 
were inoculated in the afternoon. 
c) Prophylaxis for 4 days before infection and treatment for 2 days after infection 
(more details are provided in Table 10). 
2.1.2.7 AmB-PMA intranasal administration 
The mice were placed in an anaesthetising chamber and anaesthetised by 
isoflourane (Abbott) inhalation. Each mouse was then removed, kept in a vertical 
position, and AmB-PMA (15 µl) administrated slowly into the  nose using a  sterile 
Eppendorf filter tip until all the drug had been inhaled completely and breathing had 
returned to normal. The mice were monitored until they woke up.  
2.1.2.8 Nebulisation of AmB-PMA with AeroEclipse II nebuliser 
The AeroEclipse II nebuliser was connected to the aerosolisation chamber through a 
portal in the perspex box. The nebuliser was driven by air from a medical air cylinder 
(BOC) at 3 bar pressure and with a flow rate of 7-8 litres per minute. The flow meter 
and regulator were provided by Therapy Equipment Ltd. Typically 4 mice were kept 
inside the box and were exposed to the nebulised AmB-PMA for 45 min. The AmB-
PMA was nebulised into the chamber for 30 sec and the nebulisation then stopped 
for 1 min to allow the mice to inhale all the AmB-PMA particles inside the box. The 
nebulisation was continued intermittently for 45 min. At the end of each nebulisation, 
the chamber and nebuliser were washed and sterilized with 70% ethanol and then 
used for another 4 mice. 
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2.1.2.9 Immuno-suppression regimens 
The immuno-suppression regimens used were based upon those previously 
described and published by Herbst et al., 2013. BALB/c mice were immuno-
suppressed with hydrocortisone acetate (Hydrocortistab, Sovereign) in combination 
with FK-506 (Prograf, Astellas). The immuno-suppressive drugs were obtained via 
the pharmacy at Hammersmith Hospital.   
2.1.2.9.1 Hydrocortisone acetate (Hydrocortistab, Sovereign) 
Hydrocortisone acetate was supplied as an aqueous suspension of 25 mg/ml. 125 
mg/kg hydrocortisone acetate was given subcutaneously at day -3 and day -1 before 
infection, and at day +2 and +5 after infection.   
2.1.2.9.2 FK-506 (Tacrolimus, Prograf, Astellas) 
FK-506 was supplied as a concentrate for intravenous infusion at a concentration of 
5 mg/ml. It was diluted in 5% dextrose to obtain the working concentration of 1 mg/ml 
and drawn up into sterile syringes in appropriate aliquots and frozen at -20°C until 
use. FK-506 was injected intraperitoneally and daily from day -3. FK-506 was 
prepared fresh for each experiment. 
 
2.1.2.10 A. fumigatus growth conditions  
2.1.2.10.1 Sabouraud dextrose agar preparation 
Sabouraud dextrose agar (SDA, Oxoid) is a type of agar containing a high dextrose 
concentration. It is a selective medium that is formulated to allow growth of fungi 
such as A. fumigatus. It was prepared by suspending 65 g of agar powder in one litre 
of purified water. It was then boiled for a few minutes to dissolve it. The medium was 
then autoclaved at 121°C for 15 min and 20 ml poured into sterile 90 mm petri dishes 
and stored at 4°C until use. 
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2.1.2.10.2 A. fumigatus spore preparation 
The human isolate of A. fumigatus strain CEA10 was obtained from Dr Elaine 
Bignell. A glycerol stock of conidia from A. fumigatus strain CEA10 was grown on 
Sabouraud dextrose agar and incubated at 37°C for 3-5 days. 
The 3-5 day old conidia were harvested on the day of infection The A. fumigatus 
spores were harvested by flooding the surface of the agar with sterile 0.1% Tween 
20/H2O and the conidia harvested. The suspension was then ﬁltered through a 
sterile wool ﬁlter (Miracloth, CAL Biochem) to remove the mycelium. The suspension 
was washed twice with 0.1% Tween 20/H2O followed by one wash with saline. It was 
then concentrated by centrifugation at 4,000 rpm for 5 min in an IECcentra-3M 
centrifuge and the pellet resuspended in saline. Conidia were quantiﬁed by counting 
with a haemocytometer.  
2.1.2.11 Infection of mice 
The mice were placed in the induction chamber of an anaesthetic machine and 
anaesthetised by isoflourane (Abbott) inhalation. The conidia were counted with a 
haemocytometer and 5x106 A. fumigatus CEA10 spores in 40 μl of normal saline 
inoculated intranasally using a sterile Eppendorf filter tip, as described in Herbst PhD 
thesis, 2013. Mice were kept in a vertical position until the inoculum has been 
inhaled completely and breathing had returned to normal. The mice were monitored 
until they woke up. 
I was not involved directly in the creation of mouse model. According to the S. Herbst 
PhD thesis, 2014 the A. fumigatus CEA10 inoculum was titrated in the 
hydrocortisone model to achieve ~50% mortality. In the hydrocortisone model, for 
BALB/c mice 1x106 and for C57BL/6 mice 1x105 conidia / mouse was used. But in 
HC / FK-506 model, she found that 5x106 was the best dose for infecting the mice.  
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2.1.2.12 AmB-PMA administration in-vivo 
The general protocol for administration of AmB-PMA is illustrated diagrammatically in 
Figure 28. Animals were immuno-suppressed with hydrocortisone and FK-506 at the 
indicated time points and then treated prophylactically with AmB-PMA administered 
intranasally or by nebulisation for varying times. Animals were then infected with A. 
fumigatus conidia and culled at different time points as indicated in the individual 
experimental protocols. 
 
 
Figure 28: A diagram for the general protocol for AmB-PMA administration in-
vivo  
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2.1.2.12.1 AmB-PMA intranasal administration in BALB/c mice  
The aim of this experiment was to determine the feasibility of AmB-PMA prophylaxis 
via intranasal administration.   
AmB-PMA was administrated intranasally in the range of 15-40 µg AmB. 40 µg AmB 
was the initial test dose by intranasal administration. In the second animal 
experiment, the initial dose of 40 µg AmB was decreased by almost 2 fold to 15 µg 
AmB-PMA and given nasally to BALB/c mice. All mice were immuno-suppressed 
with HC and FK-506. HC was given on days -3 and -1. FK-506 was injected every 
day starting on day -3 and continued until day +1. The details of each experiment are 
summarised in the Table 5 below. 
Treated  
with… 
Mouse 
strain 
Dose 
(µg/ml) 
Mice 
(n) 
 
Intranasally Days of 
prophylaxis 
End of 
expt 
(day) 
HC+ FK-506 +  
infection (control) 
BALB/c None 4 None N/A +2 
AmB-PMA (3.1 kDa) 
(control) 
BALB/c 40 2 Intranasally 3 days 
(-3, -2 & -1) 
+2 
AmB-PMA (18 kDa) 
+ HC + FK-506  
+ infection 
BALB/c 40 4 Intranasally 3 days 
(-3, -2 & -1) 
+2 
       
AmB-PMA (3.1 kDa)  
+ HC + FK-506  
+ infection 
BALB/c 15 3 Intranasally 3 days 
(-3, -2 & -1) 
+2 
AmB-PMA (3.1 kDa)  
+ HC + FK-506  
+ infection 
BALB/c 40 4 Intranasally 3 days 
(-3, -2 & -1) 
+2 
Table 5: AmB-PMA intranasal administration in BALB/c mice 
N/A=not applicable 
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2.1.2.12.2 AmB-PMA aerosol administration in BALB/c mice 
The aim of this experiment was to determine the feasibility of AmB-PMA prophylaxis 
via nebulisation.  
In this experiment, the same dose of AmB-PMA that was administrated intranasally 
was nebulised into the chamber. 40 µg AmB was administered via nebulisation into 
the chamber. The number of administrations was similar to the intranasal 
experiments. Mice were immuno-suppressed with HC and FK-506. HC was given on 
days -3 and -1. FK-506 was injected every day starting on day -3 and continued until 
day +1. AmB-PMA was administrated for 3 days before-infection (-3, -2 & -1). This 
pilot experiment was performed on 4 mice. Table 6 below shows the summary of 
these two experiments. 
Treated  
with… 
Mouse 
strain 
Dose 
(µg/ml) 
Mice 
(n) 
Nebulisation Days of 
prophylaxis 
End of 
expt 
(day) 
HC+ FK-506 +  
infection (control) 
BALB/c None 5 None N/A +2 
       
AmB-PMA (3.1 kDa) 
+ HC+ FK-506  
+ infection 
BALB/c 40 6 Nebulisation 3 days 
(-3, -2 & -1) 
+2 
Table 6: AmB-PMA aerosol administration in BALB/c mice 
N/A=not applicable 
2.1.2.13 Determining the dosing regimens in BALB/c mice 
The aim of this experiment was to determine the most effective dose of AmB-PMA 
for nebulisation.  
As no benefit and no significant differences between treated and untreated groups 
were seen after nebulisation of 40 µg AmB in AmB-PMA, I decided to increase the 
dose. In this experiment, the dose-ranging study was performed based on 4 different 
doses in BALB/c mice (i.e., 200, 250, 300 & 400 µg AmB). This animal study was 
performed to determine the most effective dose of AmB-PMA. 
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The dose and number of AmB-PMA administrations was changed in this experiment 
as compared to the previous experiment. In this experiment, AmB-PMA prophylaxis 
was performed at days -3, -2, -1 & 0. Mice were given prophylaxis for three days 
before infection and on the day of infection. On the day of infection, mice were given 
AmB-PMA prophylaxis 5 h prior to being infected. Mice were immuno-suppressed 
with HC and FK-506. HC was given on days -3 and -1. FK-506 was injected every 
day starting on day -3 and continuing until day +1. This experiment is summarised in 
the Table 7 below.  
Treated  
with… 
Mouse 
strain 
Dose 
(µg/ml) 
Mice 
(n) 
Nebulisation Days of 
prophylaxis 
End of 
expt 
(day) 
Healthy mice 
(control) 
BALB/c None 4 None N/A +2 
HC + FK-506 
(control) 
BALB/c None 4 None N/A +2 
HC + FK-506 +  
infection (control) 
BALB/c None 6 None N/A +2 
       
AmB-PMA (3.1 kDa)  
+ HC + FK-506  
+ infection 
BALB/c 200 6 Nebulisation 4 days  
(-3, -2, -1 & 0) 
+2 
AmB-PMA (3.1 kDa)  
+ HC + FK-506 
+ infection 
BALB/c 250 4 Nebulisation  4 days  
(-3, -2, -1 & 0) 
+2 
AmB-PMA (3.1 kDa)  
+ HC + FK-506 
+ infection 
BALB/c 300 4 Nebulisation 4 days  
(-3 , -2, -1 & 0) 
+2 
AmB-PMA (3.1 kDa)  
+ HC + FK-506 
+ infection 
BALB/c 400 4 Nebulisation 4 days 
(-3, -2 & -1, 0) 
+2 
Table 7: Determining the AmB-PMA dosing regimens in BALB/c mice 
N/A= not applicable 
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2.1.2.14 Determination of the efficacy of AmB-PMA administration 
in BALB/c mice after extending the time post-infection 
The aim of this experiment was to extend the time post-infection in order to 
determine how long the treated BALB/c mice could survive. 300 µg AmB was 
administered via nebulisation for 4 days before infection. The mice with AmB-PMA 
prophylaxis were culled at different time points; at days 0, +1, +2, +4 & +8. The 
untreated mice were sacrificed at days 0, +1 & +2.  It was reasoned that AmB-PMA 
nebulisation on the same day as the infection (day 0) may kill the fungi before it 
reached and infected the lungs. Therefore, the days of AmB-PMA administration 
were changed to days (-4, -3, -2 & -1) instead of days (-3, -2, -1 & 0). Mice were 
immuno-suppressed with HC and FK-506. HC was given on days -3, -1, +2 & +5. 
FK-506 was injected every day starting on day -3 and continued until day +7. The 
details of this experiment are summarised in Table 8 below.    
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Treated 
with… 
Mouse 
strain 
Dose 
(µg/ml) 
Mice 
(n) 
Nebulisation Days of 
prophylaxis 
End of 
expt 
(day) 
HC + FK-506 +  
infection (control) 
BALB/c  None 4 None N/A 0 
HC + FK-506 +  
infection (control) 
BALB/c  None 4 None N/A +1 
HC + FK-506 +  
infection (control) 
BALB/c  None 4 None N/A +2 
       
AmB-PMA (3.1 kDa) 
+ HC + FK-506  
+ infection 
BALB/c 300 4 Nebulisation 4 days 
(-4, -3 ,-2 & -1) 
0 
AmB-PMA (3.1 kDa) 
+ HC + FK-506  
+ infection 
BALB/c 300 4 Nebulisation  4 days 
(-4 ,-3 ,-2 & -1) 
+1 
AmB-PMA (3.1 kDa) 
+ HC + FK-506  
+ infection 
BALB/c 300 4 Nebulisation 4 days 
(-4, -3, -2 & -1) 
+2 
AmB-PMA (3.1 kDa) 
+ HC + FK-506  
+ infection 
BALB/c 300 4 Nebulisation  4 days 
(-4 ,-3, -2 & -1) 
+4 
AmB-PMA (3.1 kDa) 
+ HC + FK-506  
+ infection 
BALB/c 300 4 Nebulisation  4 days 
(-4 ,-3, -2 & -1) 
+8 
Table 8: Determination of the efficacy of AmB-PMA administration in BALB/c 
mice after extending the time to killing of the mice post-infection 
N/A=not applicable 
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2.1.2.15 Confirm the efficacy of AmB-PMA administration (300 µg 
AmB) and increase in the n-number in BALB/c mice 
The aim of this experiment was to increase the number of AmB-PMA treated mice. 
Due to the significant differences in IFN-γ expression of some AmB-PMA treated 
mice at day +2, the number of AmB-PMA treated and untreated mice was increased. 
The mice were aerosolised with 300 µg/ml of AmB-PMA for 4 days before infection. 
Mice were immuno-suppressed with HC and FK-506. HC was given on days -3 and -
1. FK-506 was injected every day starting on day -3 and continued until day +1. The 
results from this experiment were pooled with data from the previous experiment at a 
dose 300 µg AmB in AmB-PMA. This experiment is summarised in Table 9 below. 
Treated 
with… 
Mouse 
strain 
Dose 
(µg/ml) 
Mice 
(n) 
Nebulisation Days of 
prophylaxis 
End of 
expt 
(day) 
HC + FK-506 +  
infection (control) 
BALB/c None 4 None N/A +2 
       
AmB-PMA (3.1 kDa) 
+ HC + FK-506  
+ infection 
BALB/c 300 8 Nebulisation 4 days 
(-4 ,-3, -2 & -1) 
+2 
Table 9: Confirm the efficacy of AmB-PMA administration (300 µg AmB) and 
increase the number in BALB/c mice 
N/A=not applicable 
 
 
 
 
 
135 
 
2.1.2.16 Determination of the efficacy of AmB-PMA administration 
as both prophylaxis and treatment in BALB/c mice 
Due to the presence of some focal inflammation and some focal aspergillosis in 
BALB/c mice at days +4 and +8, this experiment aimed to administer AmB-PMA as 
both prophylaxis and treatment to decrease the incidence of these focal lesions. 300 
µg AmB-PMA was administrated for 4 days before infection and at days +1 & +2 
after infection. AmB-PMA treated mice were culled at day +4. Mice were immuno-
suppressed with HC and FK-506. HC was given on days -3, -1 & +2. FK-506 was 
injected every day starting on day -3 and continued until day +3. The details for this 
experiment are summarised in Table 10 below.  
Treated 
with… 
Mouse 
strain 
Dose 
(µg/ml) 
Mice 
(n) 
Nebulisation Days of 
prophylaxis & 
treatment 
End of 
expt 
(day) 
Infection only 
(control) 
BALB/c None 2 None N/A +2 
HC + FK-506 +  
infection (control) 
BALB/c None 2 None N/A +2 
       
AmB-PMA (3.1 kDa)  
+ HC + FK-506  
+ infection 
BALB/c 300 8 Nebulisation 6 days 
(-4 ,-3, -2 & -1) 
& +1 & +2 
+4 
Table 10: Determination of the efficacy of AmB-PMA administration as both 
prophylaxis and treatment in BALB/c mice 
N/A=not applicable 
C57BL/6 mice 
2.1.2.17 Determination of the efficacy of AmB-PMA administration 
in C57BL/6 mice 
After determination of the efficacy of AmB-PMA in BALB/c mice, I decided to confirm 
the results by also defining the response to AmB-PMA administration in a second 
species of mouse, the C57BL/6 mice. The intention was to define the efficacy of 
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AmB-PMA prophylaxis against IA and to also determine the impact of AmB-PMA 
administration on IFN-γ expression in C57BL/6 mice. In this experiment, the AmB-
PMA treated C57BL/6 mice lungs were monitored at different time points (+2, +3 & 
+4). C57BL/6 mice were given prophylaxis (600 μg AmB) for 4 days before infection. 
Immuno-suppressive treatment continued up to day +4. HC was given on days -3, -1 
& +2. FK-506 was injected every day starting on day -3 and continued until the day 
of death. Untreated C57BL/6 mice were all killed on day +2 and AmB-PMA treated 
mice were killed on days +2, +3 & +4. This experiment is summarised in Table 11 
below. 
Treated 
with… 
Mouse 
strain 
Dose 
(µg/ml) 
Mice 
(n) 
Nebulisation Days of 
prophylaxis 
End of  
expt 
(day) 
Healthy mice 
(control) 
C57BL/6 None 4 None N/A +2 
HC + FK-506 
(control) 
C57BL/6 None 4 None N/A +2 
Infection only 
(control) 
C57BL/6 None 4 None N/A +2 
HC + FK-506 +  
infection (control) 
C57BL/6 None 6 None N/A +2 
       
AmB-PMA (3.1 kDa)  
+ HC + FK-506  
+ infection 
C57BL/6 600 8 Nebulisation 4 days 
(-4 ,-3, -2 & -1) 
+2 
AmB-PMA (3.1 kDa)  
+ HC + FK-506 
+ infection 
C57BL/6 600 4 Nebulisation 4 days 
(-4 ,-3, -2 & -1) 
+3 
AmB-PMA (3.1 kDa)  
+ HC + FK-506  
+ infection 
C57BL/6 600 4 Nebulisation 4 days 
(-4 ,-3, -2 & -1) 
+4 
Table 11: Determination of the efficacy of AmB-PMA administration in C57BL/6 
mice 
N/A=not applicable 
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2.1.2.18 Analysis of mouse samples (in-vitro) 
2.1.2.18.1 Weight measurements during the course of the 
experiment 
During the in-vivo studies, the weight of the mice was monitored daily. Loss of weight 
is indicative of an immuno-suppression related side-effect or infection progression 
and could also be due to AmB-related toxicity. None of the AmB-PMA doses that 
were tested in isolation resulted in weight loss. 
2.1.2.18.2 Animal harvest and tissue sample collection 
Animals were killed by cervical dislocation and their chest area sterilized with 70% 
ethanol. Lungs were then removed from animals and placed in a sterile Petri dish 
(Fisher Scientiﬁc) and washed with 1 ml PBS. The lungs were then chopped into 
small parts and these were divided into 4 parts for 4 different analyses: histological 
studies, CFU, qPCR fungal burden, and measurement of chemokine and cytokine 
responses by qPCR. Samples designated for fungal burden using qPCR analysis 
were frozen at -80°C until use. Samples for determination of chemokine and cytokine 
responses were put into 1 ml RNA-later (Sigma-Aldrich) and kept overnight at 4°C 
and then stored at -80°C until the assay was done. RNA-later preserves the 
structural integrity of RNA in tissues. 
The left lung was chosen for the histology studies. Three small incisions were made 
into the left lung and it was then transferred to the 10% neutral buffered formalin 
solution (Sigma-Aldrich) for fixation.    
2.1.2.18.3 Fungal burden assessment 
Fungal burden in the mouse lung was determined by CFU counting and qPCR by 
killing mice at defined time points (i.e. 1, 2, 4 and 8 days) post-infection to monitor 
the development and spread of the infection. 
For CFU determinations, 1 ml of saline or PBS was added to lung tissue and it was 
mechanically disrupted by vigorous agitation in a homogenizer for 30 sec (Biospec). 
This procedure released the fungal spores and hyphae from tissue. Then, aliquots 
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were serially diluted and spread onto SDA plates with a sterile L-shaped spreader 
(VWR) followed by incubation at 37°C for 24 h before the A. fumigatus colonies were 
counted. 
2.1.2.18.3.1 Fungal burden by quantitative PCR 
2.1.2.18.3.1.1 DNA extraction from mouse lungs 
The tissue for fungal burden qPCR analysis was homogenised in 250 µl of PBS and 
DNA extracted using a DNeasy Blood and Tissue kit (Qiagen) according to the 
manufacturer’s instructions. 180 µl of buffer ATL and 20 µl of proteinase K solution 
(included in the kit) were added to 250 µl of homogenate lung and incubated 
overnight at 56°C. Proteinase K-digested samples were processed according to the 
manufacturer’s instructions and applied to DNeasy columns, and the DNA was then 
diluted in 200 µl elution buffer and stored at -20°C until analysis.  
 
2.1.2.18.3.1.2 Quantitative PCR analysis 
A. fumigatus fungal burden was determined by quantitative RT-PCR after 
normalisation with murine β-actin as described by White et al., 2006. 
Quantitative PCR was performed on the extracted tissue DNA. An Aspergillus 
TaqMan probe (ASP28P florescence probe) was employed to bind to the A. 
fumigatus specific region of the 28s rRNA gene. This assay uses ADR1 and ASF1 
primers to amplify the fungal 28S rRNA gene, with detection of A. fumigatus based 
on hybridisation and cleavage of the ASP28P TaqMan probe.  
Purified DNA (2 µl) was added to the PCR reaction containing Master Mix (18 µl, 
Sigma-Aldrich), oligonucleotide ampliﬁcation primers (5 µM), and oligonucleotide 
hybridization probe complementary to the sequence from the A. fumigatus 28S rRNA 
gene (5 µM, Sigma-Aldrich). The sequences of these oligonucleotides are listed in 
Table 12 below. All three oligonucleotides were synthesized by Sigma-Aldrich. 
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 Sequences 
ASP28P probe [6 FAM] CATTCGTGCCGGTGTACTTCCCCG [TAM] 
ADR1 primer  CAGGCTGGCCGCATTG.... 
ASF1 primer  GCACGTGAAATTGTTGAAAGG  
β-actin Rev CCCATGGTGTCCGTTCTGA 
β-actin For CGAGCACAGCTTCTTTGCAG 
Table 12: Sequences of the specific ASP28P probe, fungal primers ADR1 & 
ASF1 and mouse β-actin primers 
 
The PCR comprised 45-cycles of denaturation for 5 sec at 95°C and elongation at 30 
sec at 60°C. The PCR for β-actin comprised 45-cycles of denaturation for 5 sec at 
95°C, annealing for 5 sec at 56°C, and extension for 15 sec at 72°C. Known 
quantities of purified genomic DNA from A. fumigatus were added to PCRs to 
generate a standard curve. The amount of A. fumigatus DNA was assessed by 
comparing the amplification threshold cycle of the unknown sample with the 
threshold cycle values of the standards. The plasmid was cloned by (Herbst et al., 
2013). All samples were run in triplicate with the mean result reported. Statistical 
significance was determined using Graphpad Prism software. 
 
2.1.2.18.4 Measurement of chemokine and cytokine mRNAs from 
harvested mouse lung 
2.1.2.18.4.1 Mouse Plasmid Standards 
Target nucleic acid was quantified by relative quantification or absolute qPCR. Whilst 
the former is most commonly used  and gives rise to a ratio between the quantities of 
target relative to the house keeping gene HPRT, where possible, I have used cloned 
plasmid standards to generate absolute copy numbers as this provides real and 
more  accurate  values. 
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2.1.2.18.4.2 The generation of nominal copy numbers of mRNA  
A mouse multi-gene quantification plasmid (pCCy17) containing two housekeeping 
genes (β-actin & HPRT), 12 chemokines and 3 cytokines was created by Dr Ian Teo 
in our laboratory (see Figure 29). Another mouse gene plasmid (pCCY5) containing 
5 cloned cytokines was created by Dr Ian Teo & Dr Karina Corware and it was also 
used in my assays . 
 
Figure 29: Murine multigene plasmid pCCy17 
 
2.1.2.18.4.3 Propagation of mouse plasmids pCCy17 and pCCY5 for 
in-vivo studies 
To create a plasmid, the desired target sequences were amplified and then purified 
through gel electrophoresis on 2.5% agarose gel. The target sequence was cloned 
into a vector by Karina Corware, and the rest of the plasmid was synthesised by me 
as part of this PhD. 
Competent DH5α or TOP10 cells were thawed on ice prior to being transformed with 
aliquots of plasmid as follows; 25 μl of competent cells were added to reaction tubes 
containing 2 μl of plasmid (50-100 ng). The reaction mixture was incubated on ice for 
30 min and then heat-shocked for 30 sec at 42°C without shaking. The tube was 
then immediately transferred on to ice.  S.O.C medium or Luria Base (LB) broth (250 
μl, Sigma-Aldrich) was added and the cells incubated at 37°C for 1 h with shaking at 
200 rpm. After a 1 h incubation, the solution was transferred into 5 ml LB broth 
containing ampicillin (100 μg/ml) and shaken for 1 h to allow expression of the 
antibiotic resistance genes. An aliquot of this mixture was then plated onto prepared 
LB agar plates containing ampicillin (100 μg/ml). Plates were incubated overnight at 
37°C and the following day 10 colonies were selected to ascertain both positive and 
negative transformation. Colonies were inoculated into LB broth containing ampicillin 
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(100 μg/ml) in a 96-well plate and incubated at 37°C for at least 8 h followed by 
centrifugation at 13,000 rpm for 5 min. The supernatant was removed and the pellet 
resuspended in water and heated to 95°C for 5 min to lyse the cells. After 
centrifugation at 13,000 rpm for 5 min in a microfuge, the PCR was carried out with 2 
µl of the supernatant using the appropriate primers. Colonies that were thus 
confirmed to contain the plasmid were subsequently cultured in larger volumes. The 
plasmid was isolated by a GeneElute Plasmid mini-preparation kit (Sigma-Aldrich). 
Known amounts of the plasmids were linearised using restriction enzymes Sac1 and 
Not1 for pCCy17 and pCCY5, respectively. The plasmids were then diluted in 
nuclease-free water to a final stock concentration of 108 copies/μl and the standard 
curve prepared as described previously. For IRF-1 and iNOS, which were not 
cloned, PCR amplifications of the target were done using iNOS and IRF-1 primers, 
but an artificial quantification standard curve was generated using the HPRT cloned 
standard. This gives rise to “nominal copy numbers”. A Mann-Whitney U test was 
used to determine the statistical significance of the results obtained. 
Mouse 
Gene 
Forward primer (5’to 3’) Reverse primer (3’ to 5’) 
HPRT GTAATGATCAGTCAACGGGGGAC GCAAGCTTGCAACCTTAACCA 
MIP-1β CCTCTCTCTCCTCTTGCTCGT GCAAAGACTGCTGGTCTCATAG 
TNF-α CACCACGCTCTTCTGTCTACTG TGAGAAGATGATCTGAGTGTGA 
IFN-γ TCAAGTTCAAGTGGCATAGATGTGGAAGAA TGGCTCTGCAGGATTTTCATG 
IL-6 ACCGCTATGAAGTTCCTCTCTG AATTAAGCCTCCGACTTGTGAA 
IL-10 GGTTGCCAAGCCTTATCGGA ACCTGCTCCACTGCCTTGCT 
IL-4 TCAACCCCCAGCTAGTTGTC TGTTCTTCGTTGCTGTGAGG 
iNOS GTTCTCAGCCCAACAATACAAGA GTGGACG GGTCGATGTCAC 
IRF-1 CAGAGGAAAGAGAGAAAGTCC CACACGGTGACAGTGCTGG 
Table 13: Mouse primer sequences 
Forward and reverses mouse primer sequences. The chemokine and cytokines studied 
using qPCR. 
 
 
 
 
142 
 
2.1.2.18.5 Histopathology 
Processing the tissue in paraffin blocks and also cutting were performed in 
collaboration with Mahrokh Nohadani and members of the histopathology lab at 
Imperial College Healthcare NHS Trust, Hammersmith Hospital. 
 
2.1.2.18.5.1 Preparation of paraffin blocks 
2.1.2.18.5.1.1 Fixation of tissue 
Lungs were extracted and cut into 4 pieces and either the left lung or both lungs 
were used for these histology studies. The sections were fixed in 10% neutral 
buffered formalin (Sigma-Aldrich) for at least 24 h before processing. 
 
2.1.2.18.5.1.2 Embedding tissue into paraffin blocks 
Paraffin wax was used for embedding tissue as it is safe to use, cheap, and is easily 
used when cutting a wide range of tissue types. Embedding tissue protects samples 
that are to be studied at a later time. The water present in the tissue after fixation 
with formalin was removed using a Vacuum Impregnation Processor series 5 (VIP, 
Tissue-Tek VIP, model 5E-F2) which employs mild heat and pressure to the tissue 
and replaces the water firstly with alcohol (spirit methylated industrial 90%, VWR) 
and then with wax. The tissue was embedded into paraffin wax blocks using the 
Tissue-Tek-Sakura embedding apparatus. The mould was placed on a hot 
embedding plate and then filled with paraffin wax. Then, the tissue was placed into 
the mould. There should be a space of at least 1 mm around the tissue in the mould. 
The mould was cooled on the cold plate and the tissue orientated and firmed into the 
wax to maintain its position. Then, more paraffin wax was added to the mould 
without the introduction of air bubbles. The blocks were cooled by placing them on a 
cold plate for 30 min. The blocks were then removed from the mould and labelled (K. 
Corware PhD thesis, 2010). 
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2.1.2.18.5.2 Cutting of sections 
The surface of the paraffin blocks was kept on ice for a few minutes. Then, 1 micron 
thickness sections from the paraffin block were cut using a rotary microtome 
Olympus America inc. cut 4060. Before being attached to microscope slides (VWR), 
the sections were flattened by floating them on warm water in a water bath. The 
water bath was kept at a temperature (4-6°C) below the melting point of wax. The 
sections were picked up on slides and kept in an upright position to dry. 
 
2.1.2.18.5.3 Staining 
2.1.2.18.5.3.1 Pre-treatment (deparaffinization and hydration)  
The paraffin wax was removed from the slides by incubating the slides in an oven at 
65°C prior to staining. Before the stain was applied, the sections were treated twice 
in 100% xylene and then taken to water via a decreasing percentage of ethanol 
(100%, 90% & 70%, each) for 3 min.  
2.1.2.18.5.3.2 Periodic Acid-Schiff’s stain (PAS) 
Periodic acid-Schiff (PAS) is a staining method for detection of polysaccharides such 
as glycogen and other macromolecules like glycolipids, glycoproteins and mucins in 
tissues. PAS stain contains periodic acid which breaks the bonds between carbon-
carbon in 1, 2-glycols to create a pair of aldehydes. These aldehydes are then able 
to react with Schiff’s reagent to form a magenta-coloured compound.  
After hydration with alcohol, the sections were oxidized in 0.5% periodic acid for 5 
min. Then, the slides were washed with distilled water before the addition of stains to 
remove residual solvent. The slides were placed in Schiff reagent for 15 min in the 
fume hood. They were then washed with tap water for 5 min followed by addition of 
hematoxylin counterstain for 20 sec. The slides were then rinsed under running tap 
water. 
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2.1.2.18.5.3.3 Dehydration of stained sections 
The slides were then dehydrated to prevent tissue degradation. The slides were 
dehydrated sequentially with 70% ethanol, 90% ethanol and absolute ethanol for 30 
sec followed by twice rinsing in xylene. This effectively removes some of the stain 
and water from the section and enables them to be mounted.   
 
2.1.2.18.5.4 Mounting of sections 
A drop of mountant was placed in the centre of the section. Then, the slide was 
inverted over a cover slip. Firm pressure was applied to the cover slip to get rid of air 
bubbles. The slides were stored long-term at room temperature.  
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2.1.2.18.6 Determination of percentage of inflammation 
ImageJ is a public domain Java image processing program. It is a downloadable 
application on any computer with Java. It can display, edit, analyse, process, save 
and print 8-bit, 16-bit and 32-bit images. It can calculate area and pixel value 
statistics of user-defined selections. It can also measure distances and angles.  
 
The amount of inflammation was quantified in histopathological mouse lung tissue 
using ImageJ software. Inflammation was determined by threshold particle analysis 
using this software. Herbst et al., (2013) reported that: “analysis of lung 
histopathological inflammation was performed using ImageJ software 
(rsb.info.nih.gov/ij/). Quantitative analysis of total lung area was performed by 
threshold particle analysis in ImageJ (http://rsbweb.nih.gov/ij/). Further thresholding 
procedures were performed within selective areas of inflammation that were visually 
identified and a subsequent percentage affected proportion calculated”. 
Mice lungs were fixed and 3 PAS stained histology sections from each mouse were 
recorded with ImageJ software.  
The ImageJ window contains a menu bar (black arrow), tool bar (blue arrow) and 
status bar (red arrow). The below pictures show how the software works 
 
Figure 30: The picture represents the ImageJ window 
It contains the menu bar (black arrow), tool bar (blue arrow) and status bar (red arrow). 
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2.1.2.18.6.1 Selecting of 8-bit for the type of image 
The histological image was opened via selection of the file from tool bar. File → 
Open Samples → Histological Image. Then, the colour histology image was 
converted to grayscale by following method: Image → Type → 8-bit. 
The below pictures show the procedure of how to set the type of image:  
 
Figure 31: Image types  
 
Figure 32: 8-bit grayscale of lung tissue image 
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2.1.2.18.6.2 Determining the threshold 
The threshold was adjusted by moving the sliders to include all of image in red. 
Image → Adjust →Threshold and then click ‘Apply’. The pictures below show the 
procedure of threshold analysis in histological lung tissue. 
 
Figure 33: Threshold analysis of histological image 
 
Figure 34: Adjusted threshold 
 
 
148 
 
2.1.2.18.6.3 Threshold particle analysis  
Quantitative analysis of total lung area was determined by threshold particle analysis 
in software. This software was used to determine the amount of inflammation in each 
focal lesion in the lung tissue image. The measurement results are shown in the 
"summary" window. This analysis shows the total area and average size of the entire 
lung section area.  Edit → Selection →Select All and then Analyse → Analyse 
Particles. The pictures below show the procedure for threshold particle analysis: 
 
Figure 35: The threshold analysis of the entire area of the image  
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After determination of the threshold of the entire lung tissue, the threshold for the 
lesion within an image was determined. A line was drawn around the lesion area and 
then the length of the selection was measured using Analyse → Analyse Particle. 
Only one selection can be active at a time.  
The percentage inflammation was determined by calculating the threshold of the 
lesions divided by the threshold of the total lung area multiplied by 100. 
 
2.1.2.18.7 Statistical Analysis 
All data was analysed using GraphPad Prism vs5 software and is shown as mean ± 
SEM (standard error of mean). p values were determined using a Mann-Whitney 
test.  
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Chapter 3 
3.1 Results -Part A: Chemical Synthesis & Characterisation 
3.1.1 Biological Activities of Polymers 
I chose to work with PMA because recent years have witnessed the emergence of 
PMA hydrogel capsules that are very safe in animals and their progressive 
development into a mature biomedical platform for oral medicines. Mixtures of 
oppositely charged polyelectrolytes can be used to form discrete, stable and water 
soluble macromolecules (Sajeesh et al., 2010; Singh et al., 2001; Nakamura et al., 
1999). To promote the properties of a drug requires the careful characterisation of 
the biological activity of the polymer. The toxicity of PMA was tested in-vitro before 
use in the synthesis of AmB-PMA. Several in-vitro methods can be used to 
determine this activity using different human cell types.  
3.1.1.1 Haemolysis assay 
In order to define the toxicity of the PMA-Na polymer itself to mammalian cells, 
haemolysis assay was used. It defined the toxic properties of the polymer by 
quantification of the degree of RBC lysis. Fresh washed RBCs were incubated for 1 
h with each polymer (1.2, 1.7, 3.1, 8 & 18 kDa). From the results of these 
experiments, I concluded that all of the PMA-Na polymers with different molecular 
weights (MWs) tested were found to cause a negligible degree of RBCs lysis after a 
1 h incubation at a concentration of up to 2.5 mg/ml. 
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Figure 38: Haemolytic potential of PMA-Na (1.2 to 18 kDa)   
PMA-Na (1.2 to 18 kDa) were incubated with a 2% v/v RBC solution at concentrations up to 
2500 µg/ml for 1 h. RBC haemolysis were measured in triplicate relative to untreated cells 
(0% haemolysis) or Triton-X treated cells (100% haemolysis). PMA-Na polymers of different 
MWs did not lyse RBCs up to a concentration of 2.5 mg/ml. Representative data from each 
experiment is shown in triplicate (n=3).  
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3.1.1.2 Toxicity of polymers for human primary cells 
 
It was also necessary to assess whether these polymers were toxic when incubated 
with human primary white blood cells. The viability of these cells in the presence of 
PMA-Na was tested with an MTT assay. MTT is a tetrazolium salt that is oxidized by 
mitochondrial dehydrogenase to insoluble formazan in the presence of living cells, 
resulting in a purple color. Dead cells do not have mitochondrial dehydrogenase 
enzyme and therefore do not produce a purple color. This assay was performed on 
three separate occasions and in triplicate. From these experiments, I concluded that 
the PMA-Na polymers with different MWs were not toxic to primary human MDMs 
when tested up to 500 µg/ml. 
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Figure 39: Viability of MDMs stimulated with PMA-Na (1.2 to 18 kDa)  
1×106 cells/well were seeded in triplicate with each polymer for 3 h. The cells were then 
incubated with MTT for a further 3 h. Cell viabilities were measured in triplicate relative to 
untreated cells (100% viability) or Triton-X treated cells (0% viability). Representative data 
from experiment performed in triplicate is shown (n=3).  
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3.1.1.3 Activity of PMA-Na against A. fumigatus 
 
The antifungal activity of PMA-Na was also determined. Antifungal activity testing 
was performed using MIC testing for all sizes of PMA-Na polymer on 11 isolates of 
A. fumigatus. 100% growth rates of A. fumigatus was observed in the presence of 
256 µg/ml of PMA-Na. The PMA-Na had no toxic effect on A. fumigatus. 
 
 
3.1.1.4 The pro-inflammatory effect of PMA-Na on MDMs 
It was essential to evaluate the pro-inflammatory activity of PMA-Na on primary 
human MDMs. Any activation of cytokines by the polymer itself could conflict with the 
advantages of using the polymer in a biomedical application. In this assay, cells were 
stimulated with endotoxin-free PMA-Na at concentrations of 25 µg/ml for 3 h. The 
cells were then harvested and chemokine and cytokine mRNA levels were measured 
using qPCR. 
Lipopolysaccharide (LPS) was used as a positive control. LPS is an effective 
activator of a pro-inflammatory innate immune response with production of cytokines 
and chemokines. Results were expressed as mRNA expression levels with respect 
to HPRT. Each PCR run was performed in triplicate.  
        
157 
 
TNF-
U
ns
tim
ul
at
ed
 
LP
S
P
M
A
0
1.0105
2.0105
3.0105
2.0106
2.5106
3.0106
3.5106
C
o
p
ie
s
 o
f 
T
N
F
-

 m
R
N
A
/1
0
5
H
P
R
T
IFN-
U
ns
tim
ul
at
ed
LP
S
P
M
A
0
4.0103
8.0103
1.2104
4.0104
5.0104
6.0104
7.0104
C
o
p
ie
s
 o
f 
IF
N
- 
 m
R
N
A
/1
0
5
H
P
R
T
MIP-1
U
ns
tim
ul
at
ed
 
LP
S
P
M
A
0
2.0105
4.0105
6.0105
8.0105
4.0107
5.0107
6.0107
7.0107
C
o
p
ie
s
 o
f 
M
IP
-1

 m
R
N
A
/1
0
5
H
P
R
T
Figure 40: Lack of a pro-inflammatory effect of PMA-Na on MDMs 
Adhered MDMs were incubated for 3 h with PMA at a concentration of 25 µg/ml. The cells 
were then harvested and treated with Tri Reagent for RNA extraction and qPCR. There was 
no significant difference in the expression of the pro-inflammatory cytokines IFN-γ & TNF-α 
and the chemokine MIP-1β between the unstimulated cells and the cells stimulated with 
PMA (3.5 kDa) at 25 μg/ml. Pooled data from three experiments performed in triplicate 
(n=3).  
 
3.1.1.5 Polymer summary 
 
As shown in the experiments detailed in this section, there are no distinguishable 
biological characteristics between the different sizes of PMA-Na polymer. 
There was also in-vitro biological similarity between the different sizes of PMA-Na. 
No toxicity was observed using human MDMs and human RBCs after incubation with 
different sizes of PMA-Na. It did not demonstrate any antifungal activity against A. 
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fumigatus. In summary, the different sizes of PMA-Na polymer tested were 
biologically inactive. 
 
3.1.2 Part B: Critical factors during AmB-PMA synthesis 
 
3.1.2.1 Establish the optimum pH for dialysis of AmB-PMA 
The AmB-PMA was synthesized as described in the Materials and Methods section. 
A batch of AmB-PMA was first dialysed against sterile water for irrigation at room 
temperature for 4 h. After 4 h dialysis, the water was changed and the dialysis 
continued for a further 20 h dialysis. After 24 h dialysis, the pH of the dialysate 
solution was checked. The dialysate solution was turbid due to the release of free 
AmB at pH 6-6.5. The solubility state of AmB is pH-dependent and the addition of 
NaOH to the dialysate solution ensured an alkaline environment at pH 12. This shifts 
AmB to a monomeric state. But it does not affect the AmB trapped within the 
polymer’s matrix. Altering the pH ensures that the free AmB within the dialysate 
solution is in a monomeric state and can pass easily through the dialysis membrane 
and into the dialysis solution. 
This suggested that by maintaining the pH of the dialysate solution at a alkaline pH 
during dialysis, all free AmB could be removed. For maintaining the pH at alkaline 
pH, 100 µl of NaOH was added to the chamber containing the water for dialysis (1 L) 
after 4 h of dialysis. Then, after 24 h of dialysis the pH was recorded. I found that, 
the pH again dropped down to the acidic pH of 6-6.5 and that AmB was released 
from the AmB-PMA to give a turbid solution. The free AmB was pelleted after 
centrifugation at 13,000 rpm for 10 min. The addition of NaoH to the pellet turned the 
solution clear. This showed that the pellet was free AmB. 
I decided to record the pH from the beginning to the end of the synthesis and 
readjust the pH to an alkaline pH before it had a chance to drop down. As discussed 
in the Materials and Methods section, the pH of the AmB-PMA solution was recorded 
before starting dialysis and after 4 h of dialysis.  
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The pH was tested again after 24 h dialysis. It was found that the pH had dropped 
down to 6-6.5 and gave a turbid solution. As I explained earlier, in acidic conditions, 
the AmB-PMA dissociates and AmB is released. This free AmB causes toxicity and 
RBC haemolysis. To minimize any such toxicity and haemolysis, I readjusted the pH 
to 7.5 with 1N NaOH after an overnight dialysis. Several drops of 1N NaOH were 
added to the dialysis solution. The AmB-PMA turned back to a yellow solution. The 
AmB went back to the solution, but this does not mean that the AmB was bound to 
the PMA into a complex, because the haemolysis and MTT assay showed that AmB-
PMA is still toxic to RBC and monocytes. Due to this, the pH of AmB-PMA was 
tested before starting the dialysis. It was 12-12.5 and then tested again after 4 h of 
dialysis. After 4 h dialysis, the pH was adjusted to the same pH as at the beginning 
of the dialysis (pH=12) and it kept at this for another 20 h of dialysis. Next day, the 
pH was recorded and I found that the pH was alkaline pH at 7-7.5. Therefore, it 
became clear that the pH needed to be maintained at an alkaline pH throughout the 
course of the synthesis and the dialysis. The solution was then clear and not turbid. 
This means that there was no free AmB in the dialysate solution. Taken together, 
this shows that the pH of the complex has to be kept at an alkaline pH during the 
synthesis and dialysis. 
 
3.1.2.2 Molecular weight cut off of the dialysis cassettes 
Dialysis membranes are made up of cross-linked polymers which have different pore 
sizes (Molecular Weight Cut-off (MWCO)) and this determines the size of the 
molecule that can be retained. It is recommended that the MWCO should be at least 
half the size of the molecule that needs to be retained. In addition to the MWCO, 
other factors such as molecular polarity, shape and ionic charge can also have an 
effect on the permeability of the molecule through the membrane.  
The purification of AmB-PMA was achieved using the Slide-a-Lyzer dialysis cassette 
with a molecular cut off 2,000 Da (2 kDa). The molecular weight of AmB is 920 Da; 
therefore this membrane cut-off should allow removal of free AmB but not of the 
AmB that was in a complex with AmB-PMA via electrostatic interactions. In the 
beginning, some of AmB-PMA synthesised batches such as AmB-PMA (3.1 kDa) 
and (8 kDa & 18 kDa) were dialysed with 3.5 kDa and 7 kDa Slide-a-Lyzer cassette 
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respectively. No difference was observed in percentage loading of AmB between 
these batches compared to batches dialysed with 2 kDa cut-off. Therefore, the Slide-
a-Lyzer cassettes with a molecular cut-off of 2 kDa were used for the dialysis of all 
subsequent AmB-PMA batches (3.1 kDa, 8 kDa, 18 kDa) and Float-a-Lyzer (1,000 
Da) cassettes were used for the dialysis of AmB-PMA (1.2 kDa) and (1.7 kDa).  
 
3.1.2.3 Dialysis 
It was concluded that all synthesis should be purified using 2,000 Da (2 kDa) dialysis 
cassettes with dialysis for 24 h at cold room (4°C). They were dialysed in endotoxin-
free water (water for irrigation) and protected from light. The pH was maintained at 
an alkaline pH during the dialysis. All AmB-PMA batches were freeze dried and 
dissolved at 1 mg/ml AmB to determine the percentage AmB loading. They were 
then incubated with RBCs for 1 h to assess their haemolytic potential. 
 
3.1.2.4 Concentration of PMA-Na 
PMA-Na is a commercially sourced polymer which is purchased in a variety of 
molecular weights by Polymer Standards Services (PSS) and Sigma-Aldrich. PMA-
Na was used at a concentration of 5 mg/ml in the reaction. This was the same 
concentration of PMA-Na (18 kDa) as used by Corware et al., 2011. They reported 
that PMA-Na (18 kDa) at 5 mg/ml consistently yielded soluble AmB-PMA. AmB-PMA 
(1.2 kDa) and PMA-Na (18 kDa) were synthesised with the polymer at a 
concentration of 5 mg/ml and I found them to be indistinguishable in their 
characteristics in terms of both appearance and AmB loading. Therefore, all batches 
of AmB-PMA with different sizes of polymer were synthesised using a concentration 
of 5 mg/ml of PMA-Na.  
The AmB-PMA reactions were performed using a concentration of 5 mg/ml in a 1:1 
volume ratio with AmB. This was found to be a suitable concentration for the AmB in 
the reaction mixture and was important for permitting electrostatic bonds to form 
between PMA-Na and AmB.  
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3.1.2.5 The ratio of organic solvent and water 
Free AmB has restricted solubility and is soluble in organic solvents like DMSO only. 
PMA-Na is much less soluble in organic solvents. PMA-Na is a salt and soluble in 
water. The AmB-PMA was initially synthesised by addition of AmB and PMA-Na in 
water. But this did not yield a soluble product. The addition of NaOH to the mixture 
enabled the PMA-Na to be hydrolysed and enabled association with AmB. Also, 
double the reaction volume of the reaction mixture endotoxin free water was added. 
It was believed that the addition of water increases the solubility of the final product. 
AmB was first solubilised in DMSO and then added to the PMA-Na dissolved in 
water. This produced a water-soluble AmB-PMA after lyophilisation.  
 
There are other factors which are critical during the synthesis and they required 
more investigation, as some of AmB-PMA batches showed variable AmB loadings 
and increased toxicity despite keeping all of the synthetic conditions constant. The 
characterisation of AmB-PMA properties was required when the AmB-PMA was 
synthesized. For this purpose, the AmB-PMA compounds were characterized by UV 
spectrophotometry, haemolysis assay, antifungal MIC and a cellular toxicity assay. 
 
 
3.1.3 Part C: Characterisation of AmB within the AmB-PMA 
complex 
The AmB-PMA compounds synthesised were characterized by UV 
spectrophotometry, haemolysis assay, antifungal MIC and a cellular toxicity assay. 
 
 
3.1.3.1 Quantitation of AmB loading (by UV spectrophotometry) 
The loading of AmB within AmB-PMA was determined using a Fungizone standard 
curve. The aggregation of AmB is dependent upon both solute and concentration. At 
high concentrations, AmB is in an aggregated form that absorbs light at 328 nm. As 
the concentration of AmB decreases, the monomeric proportion of AmB increases. 
Monomeric AmB absorbs light at 409 nm. In addition, AmB tends to aggregate even 
at low concentrations in water as compared to organic solvents such as DMSO 
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(Balakrishnan & Easwaran, 1993). From the experiments performed, I found that the 
standard curve of Fungizone in water showed a linear association between 
absorbance and AmB concentration. This is because AmB is monomeric at low 
concentrations. AmB is soluble and monomeric in DMSO and in 50% methanol. AmB 
in 50% methanol is completely monomeric. A representative standard curve of 
Fungizone in 50% methanol is shown in Figure 41. 
It was found by Corware et al., (2011) that AmB in 50% methanol is also in a 
completely monomeric form with a peak at 409 nm. This allows for the production of 
a standard curve using Fungizone with which the percentage of AmB within AmB-
PMA can be determined. A new standard curve was prepared each time a new batch 
of AmB-PMA was evaluated.  
A representative standard curve is shown in Figure 41. It demonstrates a direct 
linear correlation between concentration and absorbance (r2 = 0.98). 
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Figure 41: Linear regression line for Fungizone 
Fungizone dissolved in 50% methanol. The UV measurements were performed at 409 nm. 
Pooled data from 12 different readings is shown (r2 = 0.989). 
 
Because Fungizone and AmB-PMA are not fully solubilised in methanol, it was first 
necessary to dissolve all of the AmB-PMA samples in water for injection at a 
concentration of 1 mg/ml and then serially dilute them in 50% methanol. To limit any 
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AmB degradation, the UV measurements were performed within 60 min of dissolving 
AmB-PMA in water. 
 
 
3.1.3.2 UV spectra of AmB-PMA (1.2, 1.7, 3.1, 8 & 18 kDa) and 
Fungizone 
AmB is present in solution in different states. After the quantitation of AmB loading, 
the absorbance of AmB-PMA was visualised over 300-450 nm and compared with 
Fungizone. The figures below demonstrate the spectra of different sizes of AmB-
PMA and of Fungizone. The spectra show that all of the batches of AmB-PMA have 
a large peak at 328 nm and a small peak at 409 nm. In contrast, Fungizone has a 
single large peak at 328 nm. This demonstrates that most of the AmB in Fungizone 
is present in an aggregated state. In contrast, the AmB in AmB-PMA is present in a 
monomeric state. This shift in spectra is due to the interaction of AmB with PMA 
because PMA does not absorb light in the 300-450 nm wavelength region. There 
was no significant difference in the spectra of AmB-PMA with different sizes of PMA-
Na. The AmB present in all of the batches of AmB-PMA was monomeric.  
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Figure 42: UV spectra of AmB-PMA & Fungizone  
Spectra for 1.2 kDa (brown, Figure 43), 1.7 kDa (light blue, Figure 44), 3.1 kDa (purple, 
Figure 45), 8 kDa (green, Figure 46) & 18 kDa (dark blue, Figure 47) and Fungizone is 
shown in red (Figure 48). AmB-PMA was reconstituted at a final concentration of 10 µg/ml 
AmB in water for injection. UV measurements were recorded at 409 nm. The UV spectra 
were performed for each compound on three separate occasions.  
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Figure 43: AmB-PMA (1.2 kDa) 
 
Figure 44: AmB-PMA (1.7 kDa) 
                                           Figure 45: AmB-PMA (3.1 kDa) 
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Figure 46: AmB-PMA (8 kDa) 
 
Figure 47: AmB-PMA (18 kDa) 
 
Figure 48: Fungizone 
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                                                               Absorbance  
Drugs 328 nm 365 nm 385 nm 409 nm 
AMB-PMA (1.2 kDa) 0.726  0.273 0.238 0.159 
AMB-PMA (1.7 kDa) 0.759 0.286 0.278 0.213 
AMB-PMA (3.1 kDa) 0.649 0.215 0.215 0.161 
AMB-PMA (8 kDa) 0.659 0.273 0.302 0.245 
AMB-PMA (18 kDa) 0.704 0.252 0.238 0.166 
Fungizone 1.294 0.333 0.275 0.188 
 
Table 14: Absorbance of different batches of AmB-PMA and Fungizone at 328, 
365, 385 & 409 nm 
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3.1.3.3 The pH related solubility of AmB-PMA in water 
It was necessary to determine the effect of pH on the state of the AmB in AmB-PMA 
after reconstituting it in water for injection. The stability of AmB in AmB-PMA was pH-
dependent. At an alkaline pH (e.g., pH=8), PMA’s carboxylic acid groups are ionized 
and the PMA hydrogel swells. This leads to AmB becoming trapped within the 
polymer’s matrix. However, at an acidic pH (e.g., pH=5), the carboxylic acid groups 
are not ionized and the PMA hydrogel collapses; AmB is released from PMA into 
solution (Corware et al., 2011) (Figure 49). 
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Figure 49: The effect of pH on solubility of AmB-PMA in water 
AmB-PMA was reconstituted in water at a concentration of 1 mg/ml AmB at pH=7. The pH 
was then adjusted to 6 and then 5 and the sample centrifuged at 1,800 rpm for 5 min. The 
OD of the supernatant was measured at 409 nm.   
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3.1.3.4 Endotoxin assay on AmB-PMA (1.2, 1.7, 3.1, 8 & 18 kDa) 
batches 
Before performing any in-vitro or in-vivo studies, an endotoxin assay was performed. 
The presence of endotoxin in all compound samples was determined using a limulus 
amebocyte assay. All samples had to have an endotoxin level of <0.06 EU/ml before 
being used. This is the EU standard for water for injection. Most of the AmB-PMA 
batches used were confirmed to be endotoxin-free (Figure 50). 
 
 
Figure 50: Endotoxin assay 
Presence of endotoxin in batches of AmB-PMA (A1-C2). LPS and endotoxin-free water were 
used as positive and negative controls respectively. All of the AmB-PMA batches were 
confirmed to be endotoxin-free.  
 
3.1.3.5 Screening 
After determining the percentage of AmB loading in AmB-PMA, the analysis of its 
biological properties was performed. This involved an MTT assay and a haemolysis 
assay which both reflect the degree of toxicity of AmB-PMA on human primary cells 
and RBCs respectively. In addition, the anti-fungal activity of AmB-PMA was 
determined using an MIC assay (EUCAST).  
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3.1.3.5.1 Haemolytic potential of AmB-PMA (1.2, 1.7, 3.1, 8 & 18 kDa) 
and Fungizone 
Haemolysis is the most serious side-effect of AmB-PMA treatment. Toxicity was 
therefore evaluated using freshly obtained RBCs. This assay illustrates the low 
haemolytic activity of AmB-PMA as compared to Fungizone. The percentage of 
RBCs haemolysis for each size of AmB-PMA at a concentration of 12.5 µg/ml of 
AmB is listed in Table 15. AmB-PMA (1.2 kDa) and AmB-PMA (3.1 kDa) showed the 
least haemolytic activity as compared to all other sizes. AmB-PMA (1.2 kDa) and 
AmB-PMA (3.1 kDa) had a 1.8 ± 0.6 % and 2.8 ± 0.4 % haemolytic potential. This 
was almost 4 times less haemolysis than Fungizone.  The results are summarised in 
Table 15. 
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Figure 51: Haemolytic potential of AmB-PMA (1.2, 1.7, 3.1, 8 & 18 kDa) and 
Fungizone 
AmB-PMA and Fungizone were incubated with 2% v/v RBC for 1 h at a concentration of 30 
µg/ml. The OD of the supernatant was used to measure the RBCs lysis by AmB-PMA. 
Representative data from an experiment performed in triplicate is shown. The results are 
summarised in Table 15 at a concentration of 12.5 µg/ml of AmB. 
 
172 
 
3.1.3.5.2 Toxicity of AmB-PMA (1.2, 1.7, 3.1, 8 & 18 kDa) and 
Fungizone on MDMs 
This assay illustrates the cytotoxic activity of each size of AmB-PMA as compared to 
Fungizone which was used as the positive control in this experiment. It has well 
established toxicity properties (Latge, 1999). It was found that there was a dose-
dependent effect on cell viability after exposure of cells to Fungizone and that it was 
more toxic than AmB-PMA. There was not a significant difference in cell viabilities 
observed with AmB-PMA (1.7 kDa) & AmB-PMA (8 kDa) as compared to Fungizone. 
The major difference that was observed was in the cell viability with AmB-PMA (3.1 
kDa) as compared to Fungizone. MDMs treated with AmB-PMA (3.1 kDa) had a 
LD50=362 µg/ml and Fungizone had a LD50=200 µg/ml (LD50=lethal dose 50%). The 
results are summarised in Table 15. 
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Figure 52: Viability of MDMs stimulated with AmB-PMA (1.2 & 1.7 kDa) and 
Fungizone 
1×106 cells/well were seeded and cultured for 3 h with AmB-PMA and Fungizone at a 
concentration of 400 µg/ml.  MTT was then added and incubated for further 3 h. All 
experiments were performed in triplicate. 
 
174 
 
                  
0 50 100 150 200 250 300 350 400
0
20
40
60
80
100
120
n=4
AmB-PMA (3.1 kDa) & Fungizone
n=11
Fungizone
AmB-PMA (3.1 kDa)
AmB concentration (µg/ml)
%
 C
e
ll 
vi
a
b
ili
ty
0 50 100 150 200 250 300 350 400
0
20
40
60
80
100
120
n=6
AmB-PMA (8 kDa) & Fungizone
n=11
AmB-PMA (8 kDa)
Fungizone
AmB concentration (µg/ml)
%
 C
e
ll 
vi
a
b
ili
ty
0 50 100 150 200 250 300
0
20
40
60
80
100
120
n=4
AmB-PMA (18 kDa) & Fungizone
n=11
AmB-PMA (18 kDa)
Fungizone
AmB concentration (µg/ml)
%
 C
e
ll 
vi
a
b
ili
ty
 
Figure 53: Viability of MDMs stimulated with AmB-PMA (3.1, 8 & 18 kDa) and 
Fungizone 
1×106 cells/well were seeded and cultured for 3 h with AmB-PMA and Fungizone at a 
concentration of 400 µg/ml.  MTT was then added and incubated for a further 3 h. All 
experiments were performed in triplicate. The summarised results are shown in Table 15. 
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Table 15 shows the summary characteristics of different sizes of AmB-PMA as 
compared to Fungizone.  
 
Table15: Summary characteristics for the AmB-PMA compounds 
Syntheses % AmB loading 
            (n=3) 
%RBC haemolysis 
(at 12.5 µg/ml) 
of AmB 
 LD50 
(µg/ml) of AmB 
AmB-PMA (1.2 kDa) 20 ± 3       1.8 ± 0.6      252 
AmB-PMA (1.7 kDa) 25 ± 3 4.6 ± 1.3 212 
AmB-PMA (3.1 kDa) 20 ± 2 2.8 ± 0.4 362  
AmB-PMA (8 kDa) 25 ± 3 3.1 ± 0.5 226  
AmB-PMA (18 kDa) 30 ± 3 1.7 ± 0.3 276  
    
Fungizone  8.1 ± 1.1 200  
 
3.1.3.5.3 The pro-inflammatory effect of AmB-PMA (1.2, 1.7, 3.1, 8 & 
18 kDa) and Fungizone on MDMs 
As described previously, the different MWs of PMA-Na did not stimulate pro-
inflammatory cytokine expression of TNF-α, IFN-γ or MIP-1β when added to MDMs. 
For the AmB-PMA, it was essential to evaluate its pro-inflammatory potential too. 
The expression of IFN-γ, TNF-α & IL-6 and MIP-1β were evaluated using RT-PCR. 
The following data is expressed as absolute copies of mRNA levels normalised for 
HPRT. The data is representative of quantitative RT-PCR runs performed in 
triplicate.   
The pro-inflammatory responses were measured in MDMs after stimulation with 
AmB-PMA (1.2, 1.7, 3.1, 8 & 18 kDa) and Fungizone (positive control). MDMs were 
stimulated with 50 and 100 µg/ml of AmB-PMA. MIP-1β, TNF-α & IL-6 up-regulation 
was observed in the presence of AmB-PMA and Fungizone at a concentration of 50 
& 100 μg/ml AmB. There was no up-regulation of the chemokine MIP-1β and 
cytokine IL-6 in the presence of AmB-PMA (1.2 kDa and 1.7 kDa).  
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Figure 54: Pro-inflammatory responses for MDMs stimulated with AmB-PMA 
and Fungizone at a concentration of 50 μg/ml AmB 
MDMs were seeded and incubated for 3 h with AmB-PMA and Fungizone. Cells were 
harvested and RNA extracted before performing PCR. The mRNA level of TNF-α, IFN-γ, IL-
6 and MIP-1β were shown in the presence of AmB-PMA at a concentration of 50 μg/ml AmB 
(Figure 54.a, 54.b, 54.c & 54.d). Fungizone was used as a comparison. The TNF-α, IL-6 and 
MIP-1β expression were significantly up-regulated in the presence of AmB-PMA (3.1, 8 & 18 
kDa) and Fungizone (Figure 54.a, 54.c & 54.d). There was no change in cytokine expression 
between cells treated with AmB-PMA (1.2 & 1.7 kDa) and untreated cell. There was a 
significant increase in IFN-γ mRNA levels in the presence of AmB-PMA (3.1 kDa & 18 kDa) 
as compared to unstimulated cells (Figure 54.b). In contrast, this cytokine level decreased in 
the presence of AmB-PMA (1.2 kDa & 1.7 kDa). No difference was observed in IFN-γ mRNA 
levels between unstimulated and stimulated cells with Fungizone (Figure 54.b). This is a 
representative data set from of an experiment performed in triplicate. The mean ± sem of 
these experiments are listed below in Table 16-19. 
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TNF-α mean ± sem n-number 
Unstimulated cells 658,894 ± 29,439 6 
LPS 4.61 x 106 ± 241,296 6 
AmB-PMA (1.2 kDa) 2.64 x 106 ± 46,004 3 
AmB-PMA (1.7 kDa) 5.11 x 106 ± 41,906 3 
AmB-PMA (3.1 kDa)  1.02 x 108 ± 813,218 3 
AmB-PMA (8 kDa) 1.08 x 108 ± 364,481 3 
AmB-PMA (18 kDa) 7.63 x 107 ± 3,075,862 3 
Fungizone 7.01 x 107 ± 2,324,712 3 
                                                                  Table 16 
IFN-γ mean ± sem n-number 
Unstimulated cells 37,512 ± 460 6 
LPS 52,438 ± 605 6 
AmB-PMA (1.2 kDa) 2,844 ± 262 3 
AmB-PMA (1.7 kDa)  5,594 ± 190  3 
AmB-PMA (3.1 kDa)  60,988 ± 3337 3 
AmB-PMA (18 kDa) 55,865 ± 3328 3 
                                                                        Table 17 
IL-6 mean ± sem n-number 
Unstimulated cells 134,240 ± 5506 6 
LPS 2.83 x 107 ± 106 6 
AmB-PMA (3.1 kDa) 3.96 x 106 ± 13,756 3 
AmB-PMA (8 kDa) 3.55 x 106 ± 6,233 3 
AmB-PMA (18 kDa)  1.32 x 106 ± 10,343 3 
Fungizone 5.83 x 106 ± 457,368 3 
                                                                       Table 18 
MIP-1β mean ± sem n-number 
Unstimulated cells 9.07 x 106  ± 283,817 6 
LPS 1.61 x 108 ± 1,971,428 6 
AmB-PMA (3.1 kDa) 1.79 x 108 ± 7,632,183 3 
AmB-PMA (8 kDa) 1.57 x 108 ± 1,466,091 3 
AmB-PMA (18 kDa)  1.21 x 108 ± 1,226,436 3 
Fungizone 2.05 x 108 ± 3,104,022 3 
                                                               Table 19 
Table 16-19: Summary of mean ± sem for MDMs treated cell with AmB-PMA 
with an AmB concentration of 50 μg/ml 
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Figure 55: Pro-inflammatory responses for MDMs stimulated with AmB-PMA 
and Fungizone at a concentration of 100 μg/ml AmB 
MDMs were seeded and incubated for 3 h with AmB-PMA and Fungizone. Cells were 
harvested and RNA extracted before performing PCR.  The mRNA level of TNF-α, IFN-γ, IL-
6 & MIP-1β are shown in the presence of AmB-PMA at a concentration of 100 μg/ml AmB 
(Figure 55.a, 55.b, 55.c & 55.d). Fungizone was used as a comparison. The TNF-α, IL-6 and 
MIP-1β expression were significantly up-regulated in the presence of AmB-PMA (3.1, 8 & 18 
kDa) and Fungizone (Figure 55.a, 55.c & 55.d). No change was observed in cytokine 
expression between cells treated with AmB-PMA (1.2 & 1.7 kDa) compared to untreated cell. 
There was an increase in IFN-γ mRNA levels in the presence of AmB-PMA (3.1, 8 & 18 kDa) 
as compared to un-stimulated cells. However, this difference was not significant (Figure 
55.b). This is a representative data set from an experiment performed in triplicate. The mean 
± sem of these experiments are listed below in Table 20-23. 
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TNF-α mean ± sem n-number 
Unstimulated cells 658,894 ± 29,439 6 
LPS 4.61 x 106 ± 241, 296 6 
AmB-PMA (1.2 kDa) 144,141 ± 1,474 3 
AmB-PMA (1.7 kDa) 270,466 ± 872 3 
AmB-PMA (3.1 kDa)  3.46 x 107 ± 530,447 3 
AmB-PMA (8 kDa) 1.99 x 107 ± 661,494 3 
AmB-PMA (18 kDa) 3.57 x 107 ± 460,056 3 
Fungizone 2.66 x 107 ± 778,160 3 
      Table 20 
IFN-γ mean ± sem n-number 
Unstimulated cells 37,512 ± 460 6 
LPS 52,438 ± 605 6 
AmB-PMA (1.2 kDa) 910 ± 152 3 
AmB-PMA (1.7 kDa) 669 ± 26 3 
Fungizone 17,394 ± 1,560 3 
                                                                       Table 21 
IL-6 mean ± sem n-number 
Unstimulated cells 134,240 ± 5506 6 
LPS 2.83 x 107 ± 106 6 
AmB-PMA (1.2 kDa) 38,064 ± 720 3 
AmB-PMA (1.7 kDa) 83,864 ± 2035 3 
AmB-PMA (3.1 kDa) 4.01 x 106 ± 47,378 3 
AmB-PMA (8 kDa) 2.89 x 106 ± 141,463 3 
AmB-PMA (18 kDa) 2.16 x 106 ± 19,798 3 
Fungizone 3.15 x 106 ± 191,689 3 
                                                                Table 22 
MIP-1β mean ± sem n-number 
Unstimulated cells 9.07 x 106 ± 283,817 6 
LPS 1.61 x 108 ± 197,1428 6 
AmB-PMA (1.2 kDa) 10,232 ± 530 3 
AmB-PMA (1.7 kDa) 2.48 x 106 ± 33,155 3 
AmB-PMA (3.1 kDa) 9.98 x 107 ± 4,214,450 3 
AmB-PMA (8 kDa) 6.9 x 107 ± 2,945,664 3 
AmB-PMA (18 kDa) 1.13 x 108 ± 5,384,393 3 
Fungizone 1.9 x 108 ± 11,445,714 3 
                                                                    Table 23 
Table 20-23: Summary of mean ± sem for MDMs treated cell with AmB-PMA 
with an AmB concentration of 100 μg/ml 
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Figure 56: TNF-α, IFN-γ, MIP-1β and IL-6 expression from MDMs stimulated 
with AmB-PMA (3.1 kDa) at a concentration of 50 and 100 µg AmB 
TNF-α, IFN-γ and MIP-1β expression decreased at 100 µg AmB as compared to 50 µg AmB. 
The same level of IL-6 mRNA level was seen between 50 µg AmB and 100 µg AmB. There 
was no significant difference between mRNA levels at a concentration of 50 µg AmB as 
compared to 100 µg AmB (n=3).  
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3.1.3.5.4 Antifungal activity of AmB-PMA (1.2, 1.7, 3.1, 8 & 18 kDa) 
and Fungizone 
It was necessary to evaluate whether, by forming an AmB-based drug, the antifungal 
activity of AmB was reduced. The antifungal activity of AmB-PMA was determined by 
MIC testing using 11 isolates of A. fumigatus. Fungizone was used as the positive 
control. The table below demonstrates the antifungal activity of all of the different 
sizes of AmB-PMA as compared to Fungizone. From the MIC tests, it was concluded 
that the antifungal activity of AmB in AmB-PMA was not reduced. The summarised 
MIC test results are shown in Table 25. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
186 
 
Isolate Name AmB-
PMA 
 
(1.2 kDa) 
AmB-
PMA 
 
(1.7 kDa) 
AmB-
PMA 
 
(3.1 kDa) 
AmB-
PMA 
 
(8 kDa) 
AmB-
PMA 
 
(18 kDa) 
 
Fungizone 
  
MIC 
(g/ml) 
 
 
MIC 
(g/ml) 
 
MIC 
(g/ml) 
 
MIC 
(g/ml) 
 
MIC 
(g/ml) 
 
MIC 
(g/ml) 
 
J1 A. fumigatus 0.25 0.25 0.125 0.125 0.5 0.125 
J2 A. fumigatus 0.25 0.25 0.125 0.125 0.25-0.5 0.25 
J3 A. fumigatus 0.125 0.125 0.0625 0.0625 0.25 0.0625 
J4 A. fumigatus 0.25 1.0 0.125 0.125 0.5 0.125-0.25 
J5 A. fumigatus 0.25 1.0 0.125 0.125 0.5 0.125-0.25 
HH-7 A. fumigatus 1.0 0.25 0.5 0.5 2.0 0.5 
HH-12 A. fumigatus 0.5 0.25 0.25 0.25 1.0 0.25-0.5 
HH-23 A. fumigatus 0.25 0.5 0.125 0.125 0.5 0.125-0.25 
HH-24 A. fumigatus 0.5 0.5 0.25 0.25 1.0 0.25 
HH-55 A. fumigatus 0.25 0.0625 0.125 0.125 0.25 0.125 
CEA10 A. fumigatus 0.0625 0.25 0.0312 0.0312 0.125 0.0312 
 
Table 24: Antifungal activity of AmB-PMA and Fungizone 
Antifungal activity was determined against 11 isolates of A. fumigatus at a final concentration 
of 16 µg/ml. AMB-PMA (1.2 kDa & 1.7 kDa) had the same MIC as Fungizone (0.25 µg/ml). 
However AMB-PMA (3.1 & 8 kDa) had better antifungal activity at 0.125 µg/ml as compared 
to Fungizone. The AMB-PMA (18 kDa) had reduced activity (MIC 0.5-1 µg/ml).  
 
Table 25: Summary of MIC test 
Drugs Range of MIC (µg/ml) Mean of MIC 
(µg/ml) 
AMB-PMA (1.2 kDa) 0.0625 - 1 0.25 
AMB-PMA (1.7 kDa) 0.0625 - 1 0.25 
AMB-PMA (3.1 kDa) 0.0312 - 0.5 0.125 
AMB-PMA (8 kDa) 0.0312 - 0.5 0.125 
AMB-PMA (18 kDa) 0.125 - 2 0.5-1 
   
Fungizone 0.0312 - 0.5 0.25 
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3.1.3.6 Summary of the biological characterisation of the different 
sizes of the AmB-PMA batches made 
From these data, it was concluded that Fungizone is more toxic than AmB-PMA. It 
was found that AmB-PMA (3.1 kDa) was less toxic to human monocytes and had 
more antifungal activity than Fungizone and all of the other AmB-PMA compounds 
synthesized. Taken together, my results suggested that AmB-PMA (3.1 kDa) was the 
best candidate of all of the compounds that I have synthesised to be studied further 
in a mouse model of Aspergillus infection. 
 
 
 
3.1.4 Part D: Comparison of AmB-PMA (3.1 kDa) batches 
synthesised using AmB from Fungizone or AmB from 
Sigma 
The AmB-PMA was synthesised as described in the Materials and Methods. Firstly, 
the Fungizone was used as a source of AmB for synthesise of the AmB-PMA.  But, 
due to the high toxicity and haemolytic activity of this AmB-PMA complex, it was 
decided to synthesise new AmB-PMA batches using pure AmB (Sigma-Aldrich) 
without deoxycholate as found in Fungizone. The following two batches were 
therefore synthesised and their biological characterisation compared with each other 
as shown below. 
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3.1.4.1 AmB-PMA (3.1 kDa) synthesised with Fungizone from 
Bristol-Myers Squibb 
  
Initially, Fungizone was used as the source of the AmB for the synthesis of the AmB-
PMA. Because it is endotoxin-free, a vial of Fungizone (containing 50 mg AmB) was 
solubilised in DMSO for 1 h and then added to the PMA-Na. After biological 
characterisation of the AmB-PMA, I found that these batches were highly toxic and 
haemolytic to RBCs. It was concluded that, this could be due to the poor solubility of 
Fungizone. Therefore, in the next synthesis, a vial of Fungizone was split into 3 parts 
and added to DMSO to solubilise it for 1 h. Then, another 20 mg of Fungizone was 
added to the DMSO solution and this was allowed to solubilise for a second hour. 
Another 20 mg of Fungizone was added to the DMSO solution again (to which 30 mg 
of AmB had now been added) and allowed to solubilise for a further 1 h, making a 
total of 3 h. The biological characterisation of this batch of AmB-PMA was 
determined in-vitro and no significant differences were observed as compared to 
batches with only 1 h of Fungizone solubilisation. It was found that the toxicity of 
AmB-PMA was due to the presence of the de-oxycholate in Fungizone.   
 
3.1.4.2 AmB-PMA (3.1 kDa) synthesised with AmB from Sigma-
Aldrich 
The AmB from Sigma-Aldrich was used as the source of the AmB for the synthesis 
of AmB-PMA. It was endotoxin positive in a limulus assay. After the synthesis, the 
presence of endotoxin was tested for all batches of AmB-PMA. Some batches were 
endotoxin-free because this endotoxin could be removed during dialysis. AmB (50 
mg) was added to DMSO and allowed to solubilise for 1 h and 3 h. The solution of 
AmB was visualised under a microscope after 1 h and 3 h. I found that there was no 
difference in the solubility of AmB after 1 h and 3 h. The solution was clear and no 
AmB particles were observed under the microscope. The biological characterisation 
of each batch was determined separately. The toxicity and haemolytic activity of 
batches synthesised with Fungizone and AmB-Sigma was determined in-vitro. There 
was a significant difference in the toxicity of batches synthesised from Fungizone 
compared to batches synthesised with AmB (Sigma). The batches containing 
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Fungizone showed more toxicity and haemolytic potential as compared to batches 
synthesised with AmB (Sigma). I then decided to synthesise all of the batches of 
AmB-PMA with AmB (Sigma) and to stop synthesising AmB-PMA using Squibb 
Fungizone.  
 
3.1.4.3 Comparison of the toxicity of AmB-PMA (3.1 kDa) batches 
synthesised with AmB from Sigma or AmB from Fungizone 
  
AmB-PMA (3.1 kDa) synthesised with AmB from Sigma or Fungizone and the toxicity 
of these batches was determined against RBCs and U937 & A549 cell lines. 
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3.1.4.4 Toxicity of (AmB-PMA (3.1 kDa)-from Fungizone) and (AmB-
PMA (3.1 kDa)-AmB (Sigma)) 
 
3.1.4.4.1 U937 (human monocyte lymphoma) 
The viability of U937 was determined after stimulation with (AmB-PMA (3.1 kDa)-
from Fungizone) or (AmB-PMA (3.1 kDa)-AmB (Sigma)) at a concentration of 300 
µg/ml. It was found that batches synthesised with Fungizone were slightly more toxic 
than the AmB (Sigma) batches. LD50=300 µg/ml and LD50=240 µg/ml for batches 
synthesised with AmB (Sigma) and Fungizone, respectively. Fungizone was used as 
the positive control. The viability of U937 cells incubated with Fungizone was very 
low at LD50=75 µg/ml (shown in red).   
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Figure 57: Viability of U937 cells after stimulation with AmB-PMA (3.1 kDa) 
synthesised with AmB from Fungizone or AmB from (Sigma) at a 
concentration of 300 µg/ml AmB 
106 (cells/well) were seeded and stimulated with (AmB-PMA (3.1 kDa)-from Fungizone) or 
(AmB-PMA (3.1 kDa)-AmB (Sigma)) at a concentration of 300 µg/ml. Fungizone was used 
as the positive control (n=3). 
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3.1.4.4.2 A549 cell line 
In addition to U937 cells, the toxicity of AmB-PMA was tested on the A549 
respiratory epithelium cell line. A549 cells were stimulated with (AmB-PMA (3.1 
kDa)-from Fungizone) or (AmB-PMA (3.1 kDa)-AmB (Sigma)) at a concentration of 
100 µg/ml. It was found that there was no difference in cell viability after stimulation 
with up to 50 µg/ml of both batches. However, the viability of cells stimulated with 
batches synthesised using AmB from Fungizone decreased dramatically and 
showed only 35% survival at a concentration of 100 µg/ml AmB. However, there was 
a good cell survival after stimulation with (AmB-PMA (3.1 kDa)-AmB (Sigma)) at a 
concentration of 100 µg/ml AmB. Fungizone was used as a positive control.  
Fungizone showed an LD50=40 µg/ml and only 30% survival at a concentration of 
100 µg/ml AmB.
Viability of A549
0 20 40 60 80 100
0
20
40
60
80
100
120
AmB-PMA (3.1 kDa)-AmB (Sigma)
AmB-PMA(3.1 kDa)-Fungizone
Fungizone
AmB concentration (µg/ml)
%
 C
e
ll 
vi
a
b
ili
ty
 
Figure 58: Viability of A549 cells after stimulation with AmB-PMA (3.1 kDa) 
synthesised with AmB from Fungizone or AmB from (Sigma) at a concentration 
of 100 µg/ml AmB 
106 (cells/well) were seeded and stimulated separately with (AmB-PMA (3.1 kDa)-from 
Fungizone) and (AmB-PMA (3.1 kDa)-AmB (Sigma)) batches at a concentration of 100 
µg/ml. Fungizone was used as the positive control. No significant difference was observed 
between two batches at a concentration of 50 µg/ml. However, the viability of cells 
stimulated with (AmB-PMA (3.1 kDa)-from Fungizone) reduced considerably at a 
concentration of 100 µg/ml.  Both AmB-PMA batches were less toxic than Fungizone (n=3). 
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3.1.4.5 Haemolytic potential of (AmB-PMA (3.1 kDa)-from 
Fungizone) and (AmB-PMA (3.1 kDa)-AmB (Sigma)) 
This assay illustrated the low haemolytic activity of (AmB-PMA (3.1 kDa)-AmB 
(Sigma)) as compared to (AmB-PMA (3.1 kDa)-from Fungizone). Batches 
synthesised from AmB (Sigma) were approximately eight times less haemolytic than 
batches synthesised with AmB from Fungizone (5% & 40%, respectively). However, 
these batches were less haemolytic than Fungizone. 
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Figure 59: Haemolytic activity of AmB-PMA (3.1 kDa) synthesised with AmB 
from Fungizone or AmB from (Sigma) at a concentration of 30 µg/ml AmB 
Both batches of AmB-PMA were separately incubated with 2% v/v RBC for 1 h. After 1 h, the 
percentage of RBCs haemolysis was measured using the OD measurement at 507 nm to 
determine the amount of haemoglobin released into the supernatant. Batches synthesised 
with Fungizone were more haemolytic than batches synthesised with AmB (n=12). 
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3.1.4.6 Summary of comparison of AmB-PMA (3.1 kDa) batches 
synthesised with AmB (Sigma) or AmB derived from Fungizone 
In these experiments, it was found that AmB-PMA (3.1 kDa)-AmB (Sigma)) was less 
toxic than AmB-PMA synthesised with AmB from Fungizone. It was concluded that 
the most efficient AmB-PMA batches could be synthesised with AmB (Sigma) and 
with a 3.1 kDa PMA-Na polymer. Therefore, all the in-vivo animal studies were 
performed with pooled batches of AmB-PMA (3.1 kDa) synthesised with AmB 
(Sigma). 
  
3.1.5 Part E: The synthesis and optimisation of AmB-PMA 
The following demonstrates the chemical characteristics of AmB-PMA batches using 
the optimised protocol as compared to Fungizone. 
 
3.1.5.1 Chemical characterisation of the AmB-PMA 
The size of AmB-PMA was determined using Dynamic Light Scattering (DLS). This 
study of AmB-PMA particle size hypothesized that AmB-PMA is at a nanometer size 
and it can penetrate deep into the alveoli where the spores are located. This study of 
AmB-PMA showed that the requirement for creating a chemically stable and non-
haemolytic batch was more important than the requirement for making AmB in a 
monomeric form. DLS was therefore performed on the optimised batches. 
 
3.1.5.2 Dynamic light scattering (DLS) 
DLS is a technique that can be used to determine the size and shape of a particle in 
solution. DLS evaluates the intensity of light and also the polarization of the light that 
is scattered when a molecule passes through the solution. The figures below show 
the effective diameters and polydispersities for AmB-PMA (18 kDa) and AmB-PMA 
(3.1 kDa) synthesised with AmB from Fungizone (AmB-PMA (3.1 kDa)-from 
Fungizone) as compared to another batch of AmB-PMA that was synthesised with 
AmB from Sigma. Fungizone was used for the comparison. Batches of AmB-PMA 
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and Fungizone were dissolved in water for injection at a concentration of 1.5 mg/ml 
and a total of 10 runs were performed to measure their mean diameter. 
(AmB-PMA (3.1 kDa)-from Fungizone) and Fungizone were similar in size having an 
average diameter of 78.9 nm (Figure 61) and 75.6 nm (Figure 63), respectively. The 
size of (AmB-PMA (3.1 kDa)-from Fungizone) and (AmB-PMA (3.1 kDa)-AmB 
(Sigma)) were also determined. (AmB-PMA (3.1 kDa)-AmB (Sigma)) is almost 
double the size of (AmB-PMA (3.1 kDa)-from Fungizone). I have found that the 
batches synthesised with AmB from Sigma were larger than the batches synthesised 
with AmB from Fungizone.   
AmB-PMA (18 kDa) and AmB-PMA (3.1 kDa) showed a small difference in their size. 
This small difference may be due to a difference in the size of the polymer. AmB-
PMA batches with the PMA-Na (18 kDa) had an average diameter of 94.1 nm 
(Figure 60) and with 3.1 kDa had an average diameter of 78.9 nm (Figure 61).  
Therefore, the size of each batch depends firstly on the source of AmB used for the 
synthesis and secondly, it depends upon the size of the polymer. The summarised 
results for DLS are shown in Table 26 below. 
 
 
Batches Average of Diameter (nm) 
(AmB-PMA (3.1 kDa)-AmB (Sigma)) 174.9 
(AmB-PMA (3.1 kDa)-from Fungizone) 78.9 
(AmB-PMA (18 kDa)-from Fungizone) 94.1 
  
Fungizone 75.6 
 
Table 26: Summary of DLS of AmB-PMA and Fungizone 
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Figure 60: DLS of AmB-PMA (18 kDa) synthesised with Fungizone 
 
AmB-PMA (18 kDa) was dissolved in water for injection at a concentration of 1.5 mg/ml and 
a total of 10 runs performed to measure its diameter.  
Figure (A) shows the lognormal distribution, allowing the user to visualize the size 
distribution and to display cumulative and differential results at 5% intervals. The Std. Error 
of the Effective (or Average) Diameter is less than 1% of the mean of the 10 repeated runs; 
the duration of the 10 runs was only five minutes. 
Figure (B) shows the average diameter of AmB-PMA (18 kDa). The average diameter of 
AmB-PMA (18 kDa) was 94.1 nm. It had a distribution width (polydispersity) of 0.255.   
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Figure 61: DLS of AmB-PMA (3.1 kDa) synthesised with Fungizone 
 
AmB-PMA (3.1 kDa) was dissolved in water for injection at a concentration of 1.5 mg/ml and 
a total of 10 runs performed to measure its diameter.  
Figure (A) shows the lognormal distribution, allowing the user to visualize the size 
distribution and to display cumulative and differential results at 5% intervals. The Std. Error 
of the Effective (or Average) Diameter is less than 1% of the mean of the 10 repeated runs; 
the duration of the 10 runs was only five minutes. 
Figure (B) shows the average diameter of AmB-PMA (3.1 kDa). The average diameter of 
AmB-PMA (3.1 kDa) was 78.9 nm. It had a distribution width (polydispersity) of 0.257.   
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Figure 62: DLS of AmB-PMA (3.1 kDa) synthesised with AmB 
 
AmB-PMA (3.1 kDa) was dissolved in water for injection at a concentration of 1.5 mg/ml and 
a total of 10 runs performed to measure its diameter.  
Figure (A) shows the lognormal distribution, allowing the user to visualize the size 
distribution and to display cumulative and differential results at 5% intervals. The Std. Error 
of the Effective (or Average) Diameter is less than 1% of the mean of the 10 repeated runs; 
the duration of the 10 runs was only five minutes. 
Figure (B) shows the average diameter of AmB-PMA (3.1 kDa). The average diameter of 
AmB-PMA (3.1 kDa) was 174.9 nm. It had a distribution width (polydispersity) of 0.336.   
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Figure 63: DLS of Fungizone 
Fungizone was dissolved in water for injection at a concentration of 1.5 mg/ml and a total of 
10 runs performed to measure its diameter.  
Figure (A) shows the lognormal distribution, allowing the user to visualize the size 
distribution and to display cumulative and differential results at 5% intervals. The Std. Error 
of the Effective (or Average) Diameter is less than 1% of the mean of the 10 repeated runs; 
the duration of the 10 runs was only five minutes. 
Figure (B) shows the average diameter of Fungizone. The average diameter of Fungizone 
was 75.6 nm. It had a distribution width (polydispersity) of 0.265.   
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3.1.6 Part F: Biological characterisation of new batches of 
AmB-PMA (3.1 kDa) synthesised with a new protocol 
After establishing the new synthesis protocol by adjusting the pH to an alkaline pH 
before the overnight dialysis, it was essential to re-assess the toxicity of the 
improved synthesis protocol for AmB-PMA as compared to the AmB-PMA batches 
made previously. The following toxicity experiments were performed on RBCs and 
human monocytes, A549 & U937 cells. Each experiment was performed on at least 
5 separate occasions. The results for all these experiments were pooled and are 
shown below. 
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3.1.6.1 Haemolytic potential of AmB-PMA (3.1 kDa) synthesised 
with the new protocol 
The AmB-PMA with AmB loadings ranging from 25-40% was incubated with RBCs 
for 1 h at 37°C. Only 5% RBCs haemolysis was seen after incubation with AmB-PMA 
(3.1 kDa) at a concentration of 30 µg/ml AmB (Figure 64). The positive control 
(Fungizone) displayed 55% haemolysis at this AmB concentration. AmB-PMA was 
therefore almost 10 times less haemolytic than Fungizone. In contrast, this difference 
in haemolytic activity of AmB-PMA and Fungizone before adjusting the pH to alkaline 
pH was only 20% (Figure 51). The results for all the experiments pooled are shown 
below. 
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Figure 64: Haemolytic potential of AmB-PMA (3.1 kDa) and Fungizone 
AmB-PMA or Fungizone were incubated with 2% v/v RBC for 1 h. After 1 h, the percentage 
of RBCs haemolysis was measured using the OD measurement at 507 nm to determine the 
amount of haemoglobin released into the supernatant. The data showed that significantly 
less RBCs haemolysis occurred with AmB-PMA than with Fungizone. This result is 
representative of pooled data from 12 different experiments (n=25). 
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3.1.6.2 Toxicity of AmB-PMA (3.1 kDa) synthesised with the new 
protocol against different cell types 
The toxicity of AmB-PMA was determined on human monocytes and the cells A549 
& U937 after optimising the synthesis protocol. Fungizone was used as the positive 
control. The results for all the experiments were pooled and are shown below. 
  
3.1.6.2.1 A549 cell line 
The figure below shows that AmB-PMA was not toxic to respiratory epithelial A549 
cells after 3 h. There was a slight decrease in cell viability (5-10%) after stimulation 
with AmB-PMA at a concentration of 100 μg/ml AmB. At this concentration, 
Fungizone noticeably caused a 70% loss of cell viability. 
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Figure 65: Viability of A549 cells stimulated with AmB-PMA (3.1 kDa) & 
Fungizone 
Adherent A549 cells (106 cells/well) were added to the plate and left to attach before the 
addition of AmB-PMA and Fungizone at a concentration of 100 μg/ml for 3 h. The cells were 
then incubated with MTT for a further 3 h before the addition of DMSO. The OD was 
measured at 507 nm. No significant toxicity was observed after stimulation of A549 cells with 
AmB-PMA. Fungizone was used as a positive control (n=5). 
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3.1.6.2.2 U937 cell line 
The figure below shows the toxicity of AmB-PMA and Fungizone on U937 cells after 
a 3 h incubation at a concentration of 300 µg/ml AmB. There was only 50% cell 
viability at a concentration of 300 µg/ml AmB (LD50=300 µg/ml). In contrast, at this 
concentration, Fungizone showed a 90% reduction in cell viability. Fungizone had 
LD50=75 µg/ml. 
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Figure 66: Viability of U937 cells stimulated with AmB-PMA (3.1 kDa) & 
Fungizone 
106 cells/well were seeded and cultured for 3 h with AmB-PMA and Fungizone at a 
concentration of 300 μg/ml. The cells were then incubated with MTT for a further 3 h before 
the addition of DMSO. The OD was measured at 507 nm. 50% U937 cells viability was 
observed after stimulation with AmB-PMA. Fungizone was used as a positive control. 
Fungizone showed a significantly greater reduction in cell viability at a concentration of 300 
µg/ml AmB (n=3). 
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3.1.6.2.3 Monocytes 
AmB-PMA was found not to be toxic to human monocytes. It was found that 
monocytes showed 70-75% survival after stimulation with AmB-PMA at a 
concentration of 300 µg/ml. In comparison, Fungizone displayed high toxicity with 
only 15% survival of monocytes at the same concentration (red line). 
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Figure 67: Viability of monocytes after stimulation with AmB-PMA (3.1 kDa) & 
Fungizone   
106 cells/well were seeded and cultured for 3 h with AmB-PMA or Fungizone at a 
concentration of 300 µg/ml. MTT was then added and incubated for a further 3 h. All 
experiments were performed in triplicate. There was a marked reduction in monocyte 
viability after stimulation with Fungizone as compared to AmB-PMA (n=25). 
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3.1.6.3 The pro-inflammatory effect of AmB-PMA (3.1 kDa) 
synthesised with new protocol on human monocytes 
As described previously, no immuno-modulatory responses were seen with PMA-Na 
polymer alone in terms of up-regulation of cytokines and chemokines when exposed 
to human monocytes. After optimisation of the synthesis protocol, it was again 
essential to determine the pro-inflammatory effect of new batches of AmB-PMA (3.1 
kDa) after adjusting the dialysis pH to an alkaline pH. The effect of AmB-PMA on the 
release of the monocyte pro-inflammatory chemokine MIP-1β and cytokines IFN-γ & 
TNF-α was determined by quantitative real-time RT-PCR. As described in the 
Materials and Methods section, the PCR was run in triplicate and the results were 
expressed as copies of mRNA normalised to 105 copies of the house keeping 
reference gene HPRT.  The data are pooled from at least 3 separate experiments 
and are shown below. 
Monocytes were stimulated with AmB-PMA (3.1 kDa) or Fungizone at a 
concentration of 25 µg/ml for 3 h. LPS was used as a positive control. It was found 
that the MIP-1β mRNA copy number increased in the presence of AmB-PMA as 
compared to unstimulated cells. No significant difference was observed between 
stimulated cells with AmB-PMA or Fungizone. TNF-α was also increased after 
stimulation with AmB-PMA and Fungizone as was IFN-γ as compared to 
unstimulated cells. The expression of IFN-γ increased in the presence of AmB-PMA 
as compared to Fungizone and control cells. In contrast, no significant difference 
was seen between IFN-γ mRNA copy numbers between Fungizone and 
unstimulated cells. 
The results showed that TNF-α and MIP-1β were stimulated to a greater degree in 
the presence of Fungizone than by AmB-PMA. However, IFN-γ mRNA expression 
was upregulated significantly in the presence of AmB-PMA. This increase did not 
occur after Fungizone stimulation.  
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Figure 68: Pro-inflammatory response of AmB-PMA and Fungizone stimulated 
MDMs at 25 μg/ml of AmB in AmB-PMA 
106 cells/well were seeded and cultured for 3 h with AmB-PMA and Fungizone. Cells were 
harvested, RNA extracted and reverse transcribed to cDNA before performing the PCR. The 
release of the monocyte pro-inflammatory chemokine MIP-1β and the cytokines IFN-γ & 
TNF-α were measured at a concentration of 25 µg/ml of AmB-PMA. LPS was the positive 
control. These data are pooled from at least 3 separate experiments (n=3).  
  
 
3.1.6.4 The pro-inflammatory effect of immuno-suppression and 
AmB-PMA on MDMs in-vitro 
Before a determination of the efficacy of AmB-PMA and its immuno-modulatory 
activity in-vivo, the effect of FK-506 & Hydrocortisone (HC) immuno-suppression on 
MDMs was tested. Pro-inflammatory responses were determined in MDMs after 
incubation with AmB-PMA and HC & FK-506. The effect of immuno-suppression was 
tested by measuring TNF-α & IFN-γ expression in MDMs. The effect of a 
combination of HC and FK-506 was compared with the effect of HC or FK-506 tested 
alone.  
It was found that TNF-α & IFN-γ mRNA levels increased significantly after stimulation 
with AmB-PMA. In contrast, the mRNA levels of TNF-α and IFN-γ decreased after 
exposure to HC and FK-506. 
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Figure 69: TNF-α & IFN-γ expression in MDMs after stimulation with AmB-PMA 
and HC & FK-506 
MDMs cells were stimulated with AmB-PMA or (HC + FK-506). Cells were also stimulated 
with a combination of AmB-PMA and (HC + FK-506). TNF-α & IFN-γ expression increased 
significantly after incubation with AmB-PMA. However, the mRNA expression decreased 
after exposure to HC & FK-506. It was found that cells stimulated with AmB-PMA + (HC & 
FK-506) showed a greater decrease in TNF-α & IFN-γ expression as compared to cells 
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stimulated with HC or FK-506 alone (n=4). The mean ± sem of these experiments are listed 
below in Table 27-28. 
 
 
IFN-γ mean ± sem n-number 
Control 10,080 ± 237 3 
LPS 97,734 ± 562 3 
HC + FK-506 7,281 ± 153 3 
AmB-PMA (3.1 kDa) 19,279 ± 172 24 
AmB-PMA (3.1 kDa) + HC + FK-506 17,512 ± 267 3 
AmB-PMA (3.1 kDa)+ HC 240.8 ± 754.5 6 
AmB-PMA (3.1 kDa)+ FK-506 26,945 ± 202 6 
                                                             Table 27 
TNF-α  mean ±  sem n-number 
Control 203,591 ± 2,032 3 
LPS 1.11 x107 ± 75,532 3 
HC + FK-506 79,332 ± 545 3 
AmB-PMA (3.1 kDa) 6.3 x106 ± 77,285 24 
AmB-PMA (3.1 kDa) + HC + FK-506 3.86 x106 ± 99,504 6 
AmB-PMA (3.1 kDa)+ HC 5.56 x106 ± 119,786 6 
AmB-PMA (3.1 kDa)+ FK-506 7.13 x106 ± 35,535 4 
                                                            Table 28 
Table 27-28: Summary of mean ± sem for stimulated MDMs with AmB-PMA and 
HC & FK-506 in-vitro 
 
 
 
3.1.7 Part G: The relationship between the presence of 
endotoxin and its pro-inflammatory potential 
It is known there is a relationship between the presence of endotoxin and pro-
inflammatory cytokine responses. The pro-inflammatory responses were measured 
in some of the AmB-PMA batches synthesised with AmB from Fungizone and AmB 
from Sigma. I have found that, there is a correlation between the batches with 
endotoxin and an increased immuno-modulatory response.    
The presence of endotoxin was observed in some of the AmB-PMA batches 
synthesised with AmB (Sigma) rather than with Fungizone.  
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(a) AmB-PMA batches synthesised with AmB from Sigma
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Figure 70: The relationship between the presence of endotoxin and its pro-
inflammatory potential 
The white bars show the endotoxin-free batches (batches 1-7) and the gray bars show the 
endotoxin positive batches (batches A-C).   
(a) AmB-PMA batches synthesised with AmB from Sigma. (b) AmB-PMA batches 
synthesised with AmB from Fungizone. The presence of endotoxin and chemokine MIP-1β 
expression was evaluated with quantitative real time PCR. It was found that MIP-1β 
expression increased in the batches containing endotoxin as compared to the endotoxin-free 
batches. In addition, the batches synthesised using Fungizone were usually endotoxin-free 
as compared to the batches synthesised with AmB (Sigma) which is not supplied as an 
endotoxin-free product (n=3). 
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Figure 71: The relationship between the presence of endotoxin and its pro-
inflammatory potential 
The white bars show the endotoxin-free batches (batches 1-7) and the gray bars show the 
endotoxin positive batches (batches A-C).   
(a) AmB-PMA batches synthesised with AmB from Sigma. (b) AmB-PMA batches 
synthesised with AmB from Fungizone. The presence of endotoxin and cytokine IL-6 
expression was evaluated with quantitative real time PCR. It was found that IL-6 expression 
increased in the batches containing endotoxin as compared to the endotoxin-free batches. In 
addition, the batches synthesised using Fungizone were usually endotoxin-free as compared 
to the batches synthesised with AmB (Sigma) which is not supplied as an endotoxin-free 
product (n=3). 
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Chapter 4 
 
4.1 Results - Part B: In-vivo experiments 
 
Each in-vivo study was carried out after reconstitution and administration of the 
AmB-PMA either intranasally or by aerosolisation followed by infection. Different 
routes of administration, different doses and different times of drug administration 
were all tested. AmB-PMA was administered intranasally and also by nebulisation 
before and after infection. AmB-PMA prophylaxis was used to determine the 
therapeutic potential of AmB-PMA against A. fumigatus in an infected host, and to 
optimise the treatment regimen. Thereafter, the efficacy of the AmB-PMA to resolve 
established IA in immuno-suppressed mice was also tested by administration of the 
AmB-PMA for 4 days before infection. This was to evaluate AmB-PMA’s potential as 
a treatment for IA. 
 
4.2 BALB/c  
4.2.1 Different routes of administration 
After biological characterisation of AmB-PMA in-vitro, its efficacy was determined in-
vivo in a murine model of aspergillosis. The effect of AmB-PMA was first tested on 
BALB/c mice. These mice were immuno-suppressed with FK-506 combined with HC. 
125 mg/kg HC was given subcutaneously at day -3 & -1 before infection and, at days 
+2 after infection. 5 mg/kg FK-506 was given intraperitoneally every day from day -3 
(Herbst et al., 2013). 
Treatment of IA in my experimental mouse model was either intranasally or by 
nebulisation. The route of choice was dependent upon the effective distribution of 
AmB-PMA in the lungs in order to maximally decrease fungal growth. Both routes 
were tested to assess which route of AmB-PMA administration was the most 
effective. The dosing schedule and time of administration that was established in 
these experiments then remained unchanged to limit experimental variability. Both 
routes of AmB-PMA administration were found to be effective against fungal growth 
as compared to untreated mice.  Importantly, the group receiving the AmB-PMA by 
aerosolisation had no visible focal hyphae in the lung up to day +2. This indicated 
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that the treatment was successful because AmB-PMA had reached the site of 
infection.  
The mice receiving the drug intranasally showed a few focal hyphae in the lung at 
day +2. This suggested that AmB-PMA may have been poorly distributed into the 
deepest parts of the lung as compared to its distribution by the nebulisation route.  
The AmB-PMA was not toxic on administration with a nebuliser or intranasally. It was 
evident that treatment by both routes resulted in less fungal growth as compared to 
untreated mice. There was a significant difference in CFU and fungal burden 
between untreated and AmB-PMA treated mice via both routes. The results indicated 
that the infected mice, after AmB-PMA nebulisation, showed a reduction in their lung 
fungal burden as compared to infected mice after intranasal AmB-PMA 
administration. Both groups of mice were infected with 5x106 A. fumigatus CEA10 at 
day 0 and their lungs harvested at day +2. These findings indicated that nebulisation 
was the most effective route of administration of AmB-PMA.  
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Figure 72: Optimisation of routes of AmB-PMA administration in immuno-
suppressed and A. fumigatus infected BALB/c mice 
(a) CFU in the mouse lungs after the intranasal and nebulisation routes of AmB-PMA 
administration. BALB/c mice were infected with A. fumigatus CEA10. Mice lungs were 
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harvested and the viable counts of colony forming units (CFU) of Aspergillus quantiﬁed by 
plating. 
(b) Fungal burden in the mouse lungs after intranasal administration or nebulisation of AmB-
PMA. Lung was homogenised in PBS and total DNA extracted from the homogenate and 
fungal burden quantified by qPCR. Bars represent mean CFU and fungal 28S rRNA copies 
adjusted for murine β-actin (mean ± sem). A Mann Whitney U statistical test was used to 
compare the intranasal and nebulisation administration methods (n=4 mice /group). 
 
 
4.2.2 Intranasal administration 
 
4.2.2.1 AmB-PMA prophylaxis-intranasal administration 
AmB-PMA was administrated at doses of 40 µg/ml and 15 µg/ml for 3 days before 
infection. AmB-PMA was administrated to the mice intranasally. FK-506 was given 
daily and HC given at days -3 & -1 before infection. As the mice were culled at day 
+2, the HC was not given at day +2. On the day of infection, mice were inoculated 
intranasally with 5x106 spores of A. fumigatus CEA10. 
Disease progression in A. fumigatus-infected BALB/c mice was monitored by 
histology, qPCR analysis of the chemokine and cytokine response in the mouse 
lung, colony forming units (CFU) and qPCR for Aspergillus ribosomal 28S rRNA. 
Figure 73 shows a summary of this experiment. 
 
 
Figure 73: This diagram shows the summary of an experiment designed for 
intranasal administration of AmB-PMA  
The stars show the days of AmB-PMA administration. 
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4.2.2.1.1 Determination of percentage weight loss in immuno-
suppressed and A. fumigatus infected BALB/c mice after intranasal 
administration of AmB-PMA 
The percentage weight loss was determined for both untreated and AmB-PMA 
treated mice. AmB-PMA treated mice lost less weight than the untreated group. In 
fact, AmB-PMA treated mice gained weight after infection. Control mice were culled 
at day +2 due to a >20% weight loss (n=4 mice/ group).  
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Figure 74: Percentage weight loss in immuno-suppressed and infected BALB/c 
mice after AmB-PMA by intranasal administration 
AmB-PMA treated mice lost less weight than non-treated group. AmB-PMA treated mice 
gained weight after infection. Control mice were culled at day +2 because of a >20% weight 
loss (n=4 mice/ group). 
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4.2.2.1.2 Fungal burden in mouse lung after intranasal 
administration of AmB-PMA (15 µg AmB) 
Disease progression in immuno-suppressed A. fumigatus-infected BALB/c mice was 
monitored by CFU and qPCR for Aspergillus ribosomal 28S rRNA. Mice were culled 
and their lungs harvested. Viable counts (CFU) were quantiﬁed by plating serial 
dilutions of lung homogenates. The CFU of AmB-PMA treated mice lungs were 
significantly less than those of untreated mice at 48 h after infection. Because the 
CFU method suffers from limited sensitivity, I also used a qPCR assay to monitor 
disease progression and to measure drug efficacy. DNA extracted from 
homogenised lungs and their fungal burden was then also quantified by qPCR. The 
qPCR assay detected a decrease in fungal DNA load in AmB-PMA treated mice as 
compared to untreated mice. However, this reduction in fungal DNA load was not 
significant (Figure 75).  
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Figure 75: Quantitation of A. fumigatus conidia or mycelium in BALB/c mice 
lungs by the CFU and qPCR methods 
BALB/c mice were infected with A. fumigatus CEA10. At day +2 post-infection, mice were 
culled and lungs CFU were quantiﬁed by plating (a). Fungal burden was also quantified by 
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the qPCR method (b). AmB-PMA treated mice showed a decrease in their fungal burden as 
compared to untreated mice. There was no significant difference in fungal burden between 
treated & untreated mice as determined by qPCR. But there was a significant difference in 
CFU of AmB-PMA treated lungs compared to untreated mice lungs. Bars represent mean 
CFU & 28S rRNA fungi copy number values (mean ± sem). The data from AmB-PMA treated 
mice is shown in green bars and the untreated mice data is shown in red bars. A Mann-
Whitney U test was used for the statistical analysis (n=4 mice / group). 
 
 
4.2.2.1.3 Measurement of chemokine and cytokines responses from 
mouse lung after intranasal administration of AmB-PMA 
My results showed that TNF-α and MIP-1β expression did not change after exposure 
to AmB-PMA. There was no significant difference in TNF-α and MIP-1β expression 
between untreated and AmB-PMA treated mice. IFN-γ expression decreased 
significantly in AmB-PMA treated mice as compared to untreated mice. Prophylaxis 
with AmB-PMA reduced iNOS and IL-10 mRNA expression.  
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Figure 76: MIP-1β and TNF-α expression in immuno-suppressed and infected 
BALB/c mice after intranasal administration of AmB-PMA 
MIP-1β and TNF-α expression increased after intranasal exposure of AmB-PMA 3 days 
before infection. No significant difference was observed between these two groups. A Mann-
Whitney U test was used for the statistical analysis (n=4 mice / group). 
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Figure 77: IFN-γ expression in immuno-suppressed and infected BALB/c mice 
after intranasal administration of AmB-PMA 
IFN-γ expression decreased significantly after intranasal administration of AmB-PMA. A 
Mann-Whitney U test was used for statistical analysis to compare the AmB-PMA treated with 
untreated mice (n=4 mice / group). 
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Figure 78: iNOS and IL-10 expression in immuno-suppressed and infected 
BALB/c mice after intranasal administration of AmB-PMA 
iNOS and IL-10 expression decreased after exposure to AmB-PMA. iNOS expression was 
reduced in AmB-PMA treated mice as compared to untreated mice. The difference between 
these two groups was significant for iNOS expression. A Mann-Whitney U test was used for 
the statistical analysis (n=4 mice / group). 
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The mean ± sem of these experiments are listed below in Table 29-33. 
TNF-α  mean ± sem n-number 
Untreated 32,465 ± 1,284 4 
AmB-PMA- 15 µg  36,155 ± 2,504 4 
                                                                Table 29 
MIP-1β  mean ± sem n-number 
Untreated 133,429 ± 8,738 4 
AmB-PMA- 15 µg 244,843 ± 19,770 4 
                                                                      Table 30 
IFN-γ mean ± sem n-number 
Untreated 3,704 ± 295 4 
AmB-PMA- 15 µg 1,159 ± 35 4 
                                                                      Table 31 
iNOS mean ± sem n-number 
Untreated 15,710 ± 1,698 4 
AmB-PMA- 15 µg 2,612 ± 206 4 
                                                                     Table 32 
 IL-10   mean ± sem n-number 
Untreated 2,375 ± 343 4 
AmB-PMA- 15 µg 784 ± 42 4 
                                                                     Table 33 
Table 29-33: Table represents the mean ± sem for chemokine and cytokines 
responses after intranasal administration of AmB-PMA 
There was a significant difference in iNOS and IFN-γ expression between AmB-PMA treated 
and untreated mice. No significant difference was observed in TNF-α, MIP-1β & IL-10 
expression between treated and untreated mice. 
  
 
4.2.2.1.4 Histology of immuno-suppressed and infected BALB/c 
mice after intranasal administration of AmB-PMA 
A noticeable difference was seen in the histology of BALB/c mice lung sections 
between untreated and AmB-PMA treated mice. There were hyphal invasion in 
untreated mice, but only one focal lesion was observed in AmB-PMA treated mice. 
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Figure 79: PAS stain lung tissue of immuno-suppressed and A. fumigatus 
infected BALB/c mice 
This photo shows the untreated infected lung tissue. Photo taken at x10 magnification and 
represents the hyphal invasion and inflammation in immuno-suppressed infected mice. A. 
fumigatus hyphae are visualised in red. The average percentage inflammation was 
calculated as 73 ± 1.25% for six mice. The percentage of inflammation was determined by 
Fiji software (as explained in the Materials & Methods section) (PAS stain-original 
magnification x10). 
 
 
Figure 80: PAS stain of immuno-suppressed and A. fumigatus infected BALB/c 
mice lung after intranasal administration of AmB-PMA 
Hyphal invasion and massive inflammation 
Focal lesion-with 
germinated fungi 
Immuno-suppressed + 
infection 
73 ± 1.25% inflammation 
 
Immuno-suppressed + 
infection + AmB-PMA 
12.5% inflammation 
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Mice were given AmB-PMA prophylaxis for 3 days before infection. AmB-PMA was 
administrated intranasally (15 µg AmB). A few focal hyphae and less inflammation were 
seen in the AmB-PMA treated mice. In contrast, disseminated hyphae were seen in the 
untreated mouse lung. The percentage inflammation was calculated as 12.5%. The 
percentage of inflammation was determined by Fiji software (as explained in the Materials & 
Methods section) (PAS stain-original magnification x10). 
 
 
4.2.2.1.5 Summary of AmB-PMA prophylaxis with intranasal 
administration  
 
AmB-PMA-treated mice gained weight but untreated lost weight after infection. 
Multiple foci of IA were seen in untreated mice, but very few foci were seen in AmB-
PMA treated mice. There was no significant change in expression of chemokines 
and cytokines responses between treated and untreated mice. There was no 
significant change in fungal burden between treated & untreated mice by qPCR, but 
the CFU were reduced. It was found that intranasal application works for upper lobe 
infection, but there may be issues of drug distribution into the lower lobes of both 
lungs. 
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4.2.3 Aerosol administration 
4.2.3.1 Aims of in-vivo nebulised AmB-PMA studies 
Due to AmB-PMA distribution in the lung via intranasal administration being 
restricted to the upper lobes, I set out to develop a method to deliver nebulised AmB-
PMA to mice. Nebulised AmB has been used clinically with widespread distribution in 
the lung (Monforte et al 2001).  The aims were:  
A) Develop a time-dose treatment protocol that has anti-fungal activity. 
B) Evaluate the prophylactic dose of aerosolized AmB-PMA in the murine model of 
aspergillosis.  
C) Determine the pharmacokinetic behaviour of nebulised AmB-PMA that protects 
mice from infection. 
There were some issues that I had to overcome. They are listed below: 
A) There were very few published studies on delivering nebulised drugs to mice. 
(e.g. Manunta et al., 2011 gene delivery to lung by nebuliser).  
B) It was necessary to construct a new chamber for nebulising 4 mice at a time.  
C) It was essential to determine the effective dose required for prophylaxis from in-
vitro infection experiments using fungal plates.  
D) Devise a simple dosing regimen. 
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4.2.3.2 Testing the efficacy of AeroEclipse II & Aeroneb Pro in 
nebulising 
As mentioned in the Materials & Methods, AeroEclipse II and Aeroneb Pro are two 
types of nebulisers with different advantages and disadvantages (listed in section 
2.1.2.2). The effectiveness of these nebulisers was tested in-vitro. Each nebuliser 
was connected to the perspex box and used to nebulise the AmB-PMA for 30 min 
into the box containing an SDA agar. It was found that the AeroEclipse II nebuliser 
could nebulise AmB-PMA very well. The aerosol spread easily and evenly through 
the box and also onto the surface of the agar plate. Therefore, no fungal growth was 
observed after incubation of the plate at 37°C. 
Aeroneb Pro was also connected to the box and used to nebulise AmB-PMA into the 
box. It was observed that with this nebuliser, the drug was not evenly nebulised 
throughout the box, and that some A. fumigatus colonies were seen on the plate at 
the end of the experiment (Figure 81).    
 
                 
 
 
Figure 81: Aerosolisation of AmB-PMA using an Aeroneb Pro nebuliser 
AmB-PMA nebulised for 30 min inside the box and then A. fumigatus was cultured on the 
plate and incubated overnight at 37°C.   
 
    SAB plate 
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4.2.3.3 Determining the effective dose for AmB-PMA for 
nebulisation 
The effective dose for nebulisation was determined based upon inhibition of growth 
on fungal plates. The experiment was performed in-vitro by nebulising different 
doses of AmB-PMA on the fungal plate. In order to determine whether the intranasal 
dose (40 µg AmB) was also a suitable dose for nebulisation, 40 µg AmB was 
nebulised into the mouse lung. In contrast to intranasal administration, nebulisation 
of 40 µg AmB was not efficient. No difference was observed between AmB-PMA 
treated and untreated mice after nebulisation of 40 µg AmB. 
Therefore, the dose was increased to 400 µg AmB which was 10 times more than 
the initial dose.  400 µg AmB were nebulised onto the plate inside the chamber. No 
fungi growth was observed with this dose after nebulisation.  
In addition to this, 200 µg, 250 µg and 300 µg were also tested based upon inhibition 
of fungi growth. No fungi growth was observed at a dose of 400 µg and 300 µg of 
AmB whereas a few colonies were observed at a dose of 200 and 250 µg of AmB. 
Figure 82 shows a summary of this experiment. 
 
 
 
Figure 82: The diagram shows an experiment designed for the aerosol 
administration of AmB-PMA 
The stars show the days of AmB-PMA nebulisation. 
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4.2.3.4 Percentage weight loss in immuno-suppressed and infected 
BALB/c mice after nebulisation of 40 µg AmB-PMA 
No difference was observed in percentage weight loss between immuno-suppressed 
infected and AmB-PMA treated mice (40 µg) as compared to immuno-suppressed 
infected untreated mice. Both groups of mice lost almost 20% of their body weight by 
day +2. 
 
 
         
-3 -2 -1 0 1 2
70
80
90
100
Untreated
AmB-PMA- 40 µg
days
%
 w
e
ig
h
t
 
Figure 83: Percentage weight loss in immuno-suppressed and infected BALB/c 
mice after nebulisation of AmB-PMA at 40 µg AmB  
A similar pattern observed in weight loss between immuno-suppressed AmB-PMA treated 
and untreated mice. Mice were treated with 40 µg AmB-PMA. There was no difference in the 
percentage of weight loss between immuno-suppressed AmB-PMA treated and untreated 
mice. Both immuno-suppressed AmB-PMA treated and untreated mice were culled at day +2 
due to average 20% weight loss (n=6 mice/group). 
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4.2.3.5 Fungal burden in immuno-suppressed and infected BALB/c 
mice lung after nebulisation of 40 µg AmB-PMA 
Fungal burden was performed on immuno-suppressed and infected mouse lung after 
nebulisation of 40 µg AmB-PMA. There was no significant difference in fungal 
burden between untreated and AmB-PMA treated mice. 
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Figure 84: Fungal burden measurement in immuno-suppressed and infected 
BALB/c mouse lung by qPCR method after administration of 40 µg AmB-PMA 
There was no significant difference in DNA fungal load between untreated (immuno-
suppressed + infected) and AmB-PMA treated mice (40 µg AmB). A Mann-Whitney U test 
was used for statistical analysis (n=6 mice/group). 
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4.2.3.6 Histology of immuno-suppressed and infected BALB/c 
mouse lung after AmB-PMA prophylaxis at 40 µg AmB 
The pictures below show the histological slides of mice lungs that were given AmB-
PMA prophylaxis for 3 days before infection (Figure 85). The pictures below show 
the difference in the histological sections after prophylaxis of 40 µg AmB with both 
intranasal and nebulisation routes of administration. 
 
a) Immuno-suppressed and A. fumigatus infected BALB/c mouse lung 
The arrows illustrate fungal hyphae. 
 
 
b) Mouse prophylaxis with 40 µg AmB- AmB-PMA given intranasally 
 
 
      Disseminated hyphae 
 
Immuno-suppressed + 
infection 
73 ± 1.25% inflammation 
 
Immuno-suppressed + 
infection + AmB-PMA 
4% inflammation 
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c) Mouse prophylaxis with 40 µg AmB- by nebulisation 
The arrows illustrate some focal lesions with fungal hyphae.  
 
Figure 85: PAS stain of immuno-suppressed and infected BALB/c mouse lung 
after AmB-PMA prophylaxis at 40 µg AmB with both intranasal and 
nebulisation routes of administration 
a) The disseminated hyphae and inflammation observed in immuno-suppressed and 
infected BALB/c mice. A. fumigatus hyphae are visualised in pink (PAS stain-original 
magnification x10). The average percentage inflammation was calculated as 73 ± 1.25% for 
six mice.  
 
b) The lung was almost clear and no germinated fungi were seen. Only a few spores were 
seen in BALB/c mouse lung section after intranasal administration of AmB-PMA (40 µg 
AmB). The inflammation percentage was calculated as 4% in three mice (PAS stain-original 
magnification x10). 
 
c) In contrast, multiple focal lesions and inflammation observed throughout the lung after 
nebulisation of AmB-PMA (40 µg AmB). The inflammation percentage was measured as 
46% in three mice. The percentage of inflammation was determined by Fiji software (as 
explained in the Materials & Methods section) (PAS stain-original magnification x10). 
 
 
 
 
Multiple focal lesions 
within a lung 
Immuno-suppressed + 
infection + AmB-PMA 
46% inflammation 
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4.2.4 Determine the dosing regimens 
Different types of AmB-PMA were synthesised and also both routes of administration 
were evaluated. This allowed me to focus on the optimal dosing schedule for AmB-
PMA. On investigating a drug containing the toxic molecule AmB, it is ideal to have 
as little AmB as possible within the AmB-PMA complex to ensure low toxicity and 
good efficiency in-vivo. On evaluating the results of the treatment of IA in-vivo, a total 
concentration of 200 μg, 250 μg, 300 μg and 400 μg AmB was used for prophylaxis 
against IA. Efficacy of aerosolisation of AmB-PMA was determined in-vivo in a 
mouse model of aspergillosis. Again, BALB/c mice were immuno-suppressed with 
FK-506 in combination with HC. FK-506 was given daily (from day -3) and HC was 
given at days -3 and -1 before infection. Prophylaxis was given with 4 different doses 
(200 μg, 250 μg, 300 μg & 400 μg AmB/ml) at 24 h, 48 h & 72 h before infection and 
at day 0 before infection. 3.5 ml of AmB-PMA was administered by nebulisation 
(AeroEclipse II nebuliser) over a 45 min period in 1 min bursts followed by 1 min 
“standing” time in a specially constructed nebulising chamber. Four mice were 
treated per nebulisation cycle. On the day of infection, mice were inoculated 
intranasally with 5x106 spores from A. fumigatus CEA10.  
Disease progression in A. fumigatus-infected BALB/c mice was monitored by 
histology, CFU, qPCR for Aspergillus ribosomal 28S rRNA and qPCR analysis of 
chemokine and cytokine responses in the mouse lung.  
From the data, it was observed that a total dose of 400 μg & 300 μg AmB resulted in 
a very large reduction in a fungal growth as compared to the untreated animals; 
however a total dose of 200 μg & 250 μg AmB gave rise to only some fungal growth 
reduction as compared to a dose of 300 μg and 400 μg AmB (Figure 88-b). It was 
found that, the reduction in a fungal growth at dose 300 μg AmB was the same as at 
the dose of 400 μg AmB. Therefore, the optimum total dose was found to be 300 μg 
AmB for the rest of animal studies in the BALB/c mice. Figure 86 is a summary of 
this experiment. 
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Figure 86: The diagram shows an experiment designed to determine the 
dosing regimens of AmB-PMA 
The stars show the days of AmB-PMA nebulisation. 
 
 
4.2.4.1 Weight loss percentage in immuno-suppressed and infected 
BALB/c mice after nebulisation of 200 µg, 250 µg, 300 µg & 400 µg 
of AmB-PMA 
There was the same pattern of reduction in percentage weight loss in AmB-PMA 
treated mice at dose 200 µg & 250 µg AmB. The same pattern was observed at dose 
300 µg & 400 µg of AmB-PMA administration. 
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Figure 87: Percentage weight loss in immuno-suppressed infected BALB/c 
mice after nebulisation of AmB-PMA at 200 µg, 250 µg, 300 µg & 400 µg AmB 
A notable difference was observed in the percentage weight loss between AmB-PMA treated 
and untreated mice. The immuno-suppressed and AmB-PMA treated mice lost less weight 
than untreated group. Mice treated with 400 µg & 300 µg AmB showed less weight loss as 
compared to mice treated with 200 µg & 250 µg AmB. 400 µg & 300 µg AmB treated mice 
lost only 5% of weight after infection whereas, immuno-suppressed untreated mice lost 
almost 20% weight (n=4 mice/group).  
 
4.2.4.2 Fungal burden in immuno-suppressed and infected and 
AmB-PMA treated BALB/c mice lungs by CFU and qPCR methods 
Fungal burden decreased in AmB-PMA treated mice as compared to untreated mice. 
CFU decreased significantly in AmB-PMA treated mice at 200 µg, 250 µg & 300 µg 
AmB doses as compared to untreated mice. There was a significant reduction in 
CFU of mice treated with 300 µg AmB as compared to mice treated with 200 µg 
AmB (Figure 88-a).  
I also used a qPCR assay to monitor disease progression. The same pattern of 
fungal burden was found with this method. It was found that there was a significant 
difference between untreated (immuno-suppressed + infected) and AmB-PMA 
treated mice. Fungal burden decreased significantly in all immuno-suppressed and 
AmB-PMA treated mice as compared to immuno-suppressed untreated mice (Figure 
88-b).  
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Figure 88: Quantitation of A. fumigatus conidia and hyphae in immuno-
suppressed and infected BALB/c mice lungs by CFU and qPCR methods 
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BALB/c mice were aerosol infected with A. fumigatus CEA10 (5x106 per mouse). At +2 days 
post-infection, all mice were killed and lungs harvested. CFU were quantiﬁed by plating (a). 
Fungal burden was also quantified by the qPCR method (b). Bars represent mean CFU & 
28S rRNA fungi copy number (mean ± sem). The data from AmB-PMA treated mice is 
shown in green and the untreated group shown in red. There was a significant difference in 
fungal burden between all AmB-PMA treated mice as compared to untreated mice 
(p<0.0001). A Mann-Whitney U test was used for statistical analysis (n=4 mice/group). 
 
 
4.2.4.3 Measurement of chemokines and cytokines responses in the 
mouse lung after nebulisation of different doses of AmB-PMA 
AmB-PMA prophylaxis was given to the mice at 4 different doses for 3 days before 
infection and also at day 0 (before infection). At day +2 post-infection, mice were 
culled and lungs harvested for measurement of cytokine and chemokine responses 
by qPCR. In immuno-suppressed and Aspergillus-infected mice, MIP-1β, TNF-α, IL-
10 and iNOS levels all increased. In the presence of AmB-PMA, they were reduced 
to near normal levels. There was a significant difference in TNF-α, MIP-1β, IFN-γ, IL-
10 and iNOS expression between AmB-PMA treated and untreated mice. The 
chemokines and cytokines responses suppressed after immuno-suppressive 
treatment and then increased dramatically after infection. IFN-γ level increased with 
nebulisation of 300 µg AmB (Figure 90). Healthy (immuno-competent mice) showed 
a normal level of chemokine and cytokine expression. But the level of cytokines 
expression increased after infection with A. fumigatus (except expression of IL-10) 
(Figure 91). However, the level of expression of these cytokines and chemokine 
were still lower than that in immuno-suppressed infected mice. There was a 
significant difference in expression of MIP-1β, IFN-γ and IL-10 in immuno-
suppressed + infected mice compared to immuno-competent + infected mice. 
Figures below show the chemokines and cytokines expression with 3 doses 200 µg, 
250 µg and 300 µg AmB.  
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Figure 89: MIP-1β and TNF-α expression in immuno-suppressed and A. 
fumigatus infected BALB/c mice after nebulisation of 200 µg, 250 µg & 300 µg 
AmB  
There was a large dose-related reduction in TNF-α and MIP-1β mRNA expression as 
compared to untreated mice. TNF-α and MIP-1β levels in treated mice (300 µg AmB) were 
almost the same as those in healthy mice. There was a significant difference in expression 
of MIP-1β in immuno-suppressed + infected mice as compared to immuno-competent + 
infected mice. No significant difference was observed in TNF-α expression between these 
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two groups. PCR was performed in triplicate. A Mann Whitney U test was used for statistical 
analysis of AmB-PMA treated mice as compared to the immuno-suppressed and infected 
mice (n=4 mice/group). 
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Figure 90: IFN-γ expression in immuno-suppressed and A. fumigatus infected 
BALB/c mice after nebulisation of 200 µg, 250 µg & 300 µg AmB 
Treated mice (dose 300 µg of AmB) showed increased expression of IFN-γ as compared to 
healthy and untreated mice. There was an increase in IFN-γ expression by increasing the 
dose of AmB-PMA. Note the inverse dose response as compared to TNF-α. Immuno-
suppressed + infected mice showed the least expression of IFN-γ. Increase in IFN-γ 
expression was seen in only half of the mice with 300 µg AmB (2 mice had high copies 
number and 2 mice had low copies number). The big error bar in the treated group with 300 
µg AmB is due to this variation between mice. A Mann Whitney U test was used for 
statistical analysis of AmB-PMA treated mice as compared to immuno-suppressed and 
infected mice (n=4 mice/group). 
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Figure 91: iNOS and IL-10 expression in immuno-suppressed and A. fumigatus 
infected BALB/c mice after nebulisation of 200 µg, 250 µg & 300 µg AmB 
IL-10 & iNOS expression decreased significantly in all different doses of treated group after 
AmB-PMA administration. iNOS and IL-10 expression decreased after immuno-suppressive 
regimens. iNOS expression increased in healthy mice after infection (immuno-competent + 
infection). In contrast, IL-10 expression decreased after infection. There was a significant 
difference in expression of IL-10 in immuno-suppressed + infected mice as compared to 
immuno-competent + infected mice. A Mann Whitney U test was used for statistical analysis 
238 
 
of AmB-PMA treated mice compared to the immuno-suppressed and infected mice (n=4 
mice/group). 
 
The mean ± sem of these experiments are listed below in Table 34-38. 
MIP-1β mean ± sem n-number 
Immunosupp + infect 146,939 ± 8,038 4 
AmB-PMA-200 µg 24,971 ± 1,162 4 
AmB-PMA-250 µg 13,716 ± 1,041 4 
AmB-PMA-300 µg 3,821 ± 290 4 
                                                            Table 34 
TNF-α mean ± sem n-number 
Immunosupp + infect 46,917 ± 3,032 4 
AmB-PMA-200 µg 9,555 ± 478 4 
AmB-PMA-250 µg 4,326 ± 300 4 
AmB-PMA-300 µg 1,880 ± 95 4 
                                                            Table 35 
IFN-γ mean ± sem n-number 
Immunosupp + infect 188 ± 16 4 
AmB-PMA-200 µg                          196 ± 9 4 
AmB-PMA-250 µg                          353 ± 10 4 
AmB-PMA-300 µg 1,754 ± 145 4 
                                                           Table 36 
iNOS mean ± sem n-number 
Immunosupp + infect 3,975 ± 412 4 
AmB-PMA-200 µg 596 ± 51.5 4 
AmB-PMA-250 µg 562 ± 55 4 
AmB-PMA-300 µg 467 ± 29 4 
                                                           Table 37 
IL-10 mean ± sem n-number 
Immunosupp + infect 1,799 ± 182 4 
AmB-PMA-200 µg 189 ± 14 4 
AmB-PMA-250 µg 155 ± 9 4 
AmB-PMA-300 µg 485 ± 35 4 
                                                           Table 38 
Table 34-38: Table represents the mean ± sem of chemokine and cytokines 
responses after administration of 200 µg, 250 µg, 300 µg & 400 µg AmB  
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4.2.4.4 Histology of immuno-suppressed and infected BALB/c mice 
lungs after prophylaxis with different doses 200 µg, 250 µg, 300 µg 
& 400 µg AmB 
BALB/c mice treated for 4 days before infection with different doses of AmB-PMA. 
Then, all mice were killed at day +2 and lungs harvested for histology studies. From 
the histology slides, I found that 400 µg & 300 µg AmB were the most effective 
doses for prevention from IA. Lungs were clear after prophylaxis with both of the 
doses of 400 and 300 µg AmB. The pictures below show the PAS stained mouse 
lung sections after prophylaxis with different doses of AmB-PMA (Figures 95-98). 
The photos for healthy and immuno-competent and infected mice are also shown 
below (Figures 92 & 93).  
 
   
Figure 92: PAS stain of lung tissue of healthy BALB/c mouse 
Picture represents the healthy BALB/c mouse lung. The slide of healthy BALB/c mouse lung 
showed a clear and normal structure of lung tissue (PAS staining-original magnification x10). 
 
Healthy mouse  
No inflammation 
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Figure 93: PAS stain of lung tissue of immuno-competent and infected BALB/c 
mouse  
Immuno-competent infected BALB/c mouse lung was harvested on day +2 and PAS stained. 
Lung tissue of mouse was challenged by A. fumigatus at day 0. Histological examination 
revealed that most of fungi were destroyed by immuno-competent host. The average 
percentage inflammation was 6.5 ± 1.2% in four mice (Figure 99). The percentage of 
inflammation was determined by Fiji software (as explained in the Materials & Methods 
section) (PAS stain- original magnification x10).  
 
 
Figure 94: PAS stain of lung tissue of immuno-suppressed and A. fumigatus 
infected BALB/c mouse  
BALB/c mice were immuno-suppressed and infected with A. fumigatus. Hyphal invasion 
were observed in untreated mice. A. fumigatus hyphae are seen in pink. The average 
percentage of inflammation was calculated as 73 ± 1.25% in six mice (Figure 99). The 
 Hyphal invasion 
 
Immuno-competent + 
infection 
6.5 ± 1.2% inflammation 
Immuno-suppressed + 
infection 
73 ± 1.25% inflammation 
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percentage of inflammation was determined by Fiji software (as explained in the Materials & 
Methods section) (PAS stain-original magnification x10).   
 
 
Figure 95: PAS stain of lung tissue of immuno-suppressed and A. fumigatus 
infected BALB/c mouse after nebulisation of 200 µg AmB 
BALB/c mice were immuno-suppressed and infected with A. fumigatus. They were given 
prophylaxis with 200 µg of AmB for 4 days before infection. A few focal hyphae and 
inflammation is seen in this group of mice as compared to untreated mice. A. fumigatus 
hyphae are seen in dark purple. The average percentage of inflammation was calculated as 
20 ± 2.75% in four mice (Figure 99). The percentage of inflammation was determined by Fiji 
software (as explained in the Materials & Methods section) (PAS stain-original magnification 
x10).  
 
 
Figure 96: PAS stain of lung tissue of immuno-suppressed and A. fumigatus 
infected BALB/c mouse after nebulisation of 250 µg AmB  
Focal hyphae 
Immuno-suppressed + 
infection + AmB-PMA 
(200 µg AmB) 
20 ± 2.75% inflammation 
 
Immuno-suppressed + 
infection + AmB-PMA 
(250 µg AmB) 
19 ± 0.6% inflammation 
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BALB/c mice were immuno-suppressed and infected with A. fumigatus. They were given 
prophylaxis with 250 µg of AmB for 4 days before infection. A few focal hyphae and 
inflammation were seen in the mice treated with 250 µg AmB as compared to untreated 
mice. Less inflammation and less focal hyphae were seen in this group of mice as compared 
to a group of mice treated with 200 µg AmB. A. fumigatus were seen in lungs as a mixture 
of hyphal and non-germinated conidial form. Non-germinated forms were observed more 
often than hyphal forms. The average percentage of inflammation was calculated as 19 ± 
0.6% in four mice (Figure 99). The percentage of inflammation was determined by Fiji 
software (as explained in the Materials & Methods section) (PAS stain-original magnification 
x10). 
 
 
Figure 97: PAS stain lung tissue of immuno-suppressed and A. fumigatus 
infected BALB/c mouse after nebulisation of 300 µg AmB 
BALB/c mice were immuno-suppressed and infected with A. fumigatus. They were given 
prophylaxis with 300 µg AmB. No fungal hyphae were seen in this group of mice whereas 
some germinated hyphae were seen with lower doses of AmB-PMA. A. fumigatus was seen 
in the conidial form only. Most of the spores are engulfed by alveolar macrophages. The 
average percentage of inflammation was calculated as 14 ± 1.19% in six mice after 
prophylaxis with 300 µg AmB (Figure 99). The percentage of inflammation was determined 
by Fiji software (as explained in the Materials & Methods section) (PAS stain-original 
magnification x40). 
 
 
Spores engulfed 
by macrophages 
Immuno-suppressed + 
infection + AmB-PMA 
(300 µg AmB) 
14 ± 1.19% inflammation 
 
243 
 
 
Figure 98: PAS stain lung tissue of immuno-suppressed and A. fumigatus 
infected BALB/c mouse after nebulisation of 400 µg AmB  
BALB/c mice were immuno-suppressed and infected with A. fumigatus. They got prophylaxis 
with 400 µg AmB. Lungs were clear at 400 µg AmB nebulisation. No fungal hyphae and 
inflammation was seen in this group, whereas some germinated hyphae were seen at doses 
of 200 µg & 250 µg AmB. A. fumigatus was in a conidial form only and 10 ± 1.16% 
inflammation was seen (Figure 99). The percentage of inflammation was determined by Fiji 
software (as explained in the Materials & Methods section) (PAS stain-original magnification 
x10). 
 
 
4.2.4.5 Determine the inflammation percentage in immuno-
suppressed and infected BALB/c mice lungs after nebulisation of 
different doses of AmB-PMA 
The percentage of inflammation was determined in BALB/c mice lungs after 
administration of 200 µg, 250 µg, 300 µg & 400 µg AmB. The percentage of 
inflammation was increased by increasing the AmB-PMA dose. No significant 
difference was observed in percentage inflammation between AmB-PMA treated 
mice at different doses. There was a significant difference in percentage 
inflammation between untreated and AmB-PMA treated mice at dose 300 µg AmB. 
There was no significant difference between immuno-competent and infected mice 
as compared to AmB-PMA treated mice at dose 300 µg AmB. 
 
Immuno-suppressed + 
infection + AmB-PMA 
(400 µg AmB) 
10 ± 1.16% inflammation 
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Figure 99: Percentage inflammation in immuno-suppressed and A. fumigatus 
infected BALB/c mice after administration of 3 different doses of AmB-PMA 
The percentage of inflammation was determined by Fiji software (as explained in the 
Materials & Methods section). The data showed that, there was a relation between the 
percentages of inflammation and the dose of AmB-PMA. The emergence of germinated 
hyphae was decreased by increasing the AmB-PMA dose. This results in reduction in the 
inflammation percentage. The inflammation percentage was determined on 4 slides for each 
dose (n=3).  
 
4.2.4.6 Summary of determination of effective dosing regimens   
My results show that AmB-PMA can be administered by AeroEclipse II nebuliser and 
that it induces protection in immuno-suppressed BALB/c mice. These are two 
advantages of using AmB as an aerosol. First, remarkably high concentrations of 
AmB can be achieved in the lower respiratory tree, as compared to intravenous 
delivery which results in toxic accumulation of AmB in the liver and spleen. Second, 
the AmB-PMA complex will be suitable for formulation into a simple inhaler which 
would enable patients to self-medicate with the drug daily (Christiansen et al., 1985). 
The results show a dose-dependent effect of treatment with increasing amounts of 
AmB-PMA. Mice treated with a dose of 300 µg AmB showed high expression of IFN-
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γ. There was reduced expression of TNF-α, MIP-1β and iNOS as compared to the 
other doses of 200 µg & 250 µg AmB.  
 
4.2.5 Determine the efficacy of AmB-PMA nebulisation in immuno-
suppressed and infected BALB/c mice at different time points 
BALB/c mice were immuno-suppressed with FK-506 and HC. FK-506 was given 
daily and HC was given at days -3 & -1. Prophylaxis was given with 300 μg AmB for 
4 days before infection (-4, -3, -2 & -1). On the day of infection, mice were inoculated 
intranasally with 5x106 spores from A. fumigatus CEA10. AmB-PMA treated and 
untreated mice were culled at days 0, +1 and +2. Mice were culled at day 0 before 
infection and at days +1 and +2 after infection. Then, lungs were harvested to 
determine the disease progression in A. fumigatus-infected BALB/c mice. The 
picture 100 shows a summary of this experiment.  
        
 
Figure 100: This diagram shows an experiment designed for determining the 
efficacy of 300 μg AmB-PMA nebulisation in BALB/c mice at different time 
points (0, +1 & +2) 
The stars show the days of AmB-PMA nebulisation. 
 
 
 
 
 
Days 
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4.2.5.1 Percentage weight loss in AmB-PMA treated and untreated 
mice after prophylaxis with 300 µg AmB at days 0, +1 & +2 
 
AmB-PMA prophylaxis was given for 4 days before infection and then the 
percentage weight loss was calculated in AmB-PMA treated and untreated mice. 
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Figure 101: Percentage weight loss in immuno-suppressed and infected 
BALB/c mice at days 0, +1 & +2 after 300 µg AmB-PMA by nebulisation  
Weight loss was not seen in AmB-PMA treated mice as compared to untreated animals.  
Untreated mice lost 20-25% of weight by day +2, but AmB-PMA treated mice lost less than 
5% weight (n=4 mice/group).  
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4.2.5.2 Fungal burden in immuno-suppressed and infected BALB/c 
mice lungs at days 0, +1 & +2 after 300 µg AmB-PMA nebulisation 
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Figure 102: Quantitation of A. fumigatus spores and mycelium in immuno-
suppressed and infected BALB/c mice lungs at days 0, +1 & +2 after 300 µg 
AmB-PMA nebulisation 
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There was a significant difference in fungal burden between untreated and AmB-PMA 
treated mice. Fungal burden decreased in both groups at day +2 compared to day +1. A 
Mann Whitney U test was used for statistical analysis of AmB-PMA treated mice as 
compared to the untreated (immuno-suppressed + infected) mice (n=4 mice/time point). 
 
4.2.5.3 Measurement of pro-inflammatory responses in immuno-
suppressed and infected BALB/c mice lungs at days 0, +1 & +2 
after 300 µg AmB-PMA nebulisation 
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Figure 103: MIP-1β and TNF-α expression in immuno-suppressed and infected 
BALB/c mice lungs at days 0, +1 & +2 after 300 µg AmB-PMA nebulisation 
There was a time-related increase in MIP-1β and TNF-α expression in AmB-PMA treated 
and untreated mice. MIP-1β and TNF-α mRNA levels increased significantly by days +1 and 
+2 as compared to day 0. The difference in MIP-1β and TNF-α expression between AmB-
PMA treated mice and untreated mice was significant at days +1 and +2, but this difference 
was not significant at day 0. A Mann Whitney U test was used for statistical analysis of AmB-
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PMA treated mice compared to the untreated (immuno-suppressed + infected) mice (n=4 
mice/time point). 
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Figure 104: IFN-γ expression in immuno-suppressed and infected BALB/c mice 
lungs at days 0, +1 & +2 after 300 µg AmB-PMA nebulisation 
No significant difference was observed in IFN-γ expression between AmB-PMA treated and 
untreated at days 0, +1 and +2. IFN-γ expression was slightly higher in AmB-PMA treated 
mice as compared to untreated mice at day 0. A Mann Whitney U test was used for 
statistical analysis of AmB-PMA treated mice compared to the untreated (immuno-
suppressed + infected) mice (n=4 mice/time point). 
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Figure 105: iNOS and IL-10 expression in immuno-suppressed and infected 
BALB/c mice lungs at days 0, +1 & +2 after 300 µg AmB-PMA nebulisation 
iNOS and IL-10 mRNA levels increased in immuno-suppressed infected mice over 2 days. 
After AmB-PMA administration these levels decreased significantly as compared to 
untreated mice. iNOS and IL-10 expression stayed almost constant in AmB-PMA treated 
252 
 
mice over 2 days. iNOS level decreased slightly by day +2 as compared to day 0. A Mann 
Whitney U test was used for statistical analysis of AmB-PMA treated mice as compared to 
the immuno-suppressed and infected mice (n=4 mice/time point). 
 
The mean ± sem of these experiments are listed below in Table 39-43. 
MIP-1β mean ± sem n-number 
Untreated (Day 0)                            242 ± 17 4 
Untreated (Day +1) 327,637 ± 9,659 4 
Untreated (Day +2) 624,875 ± 19,608 4 
AmB-PMA (Day 0)                           175.8 ± 10 4 
AmB-PMA (Day +1) 3,823 ± 146 4 
AmB-PMA (Day +2) 15,766 ± 1,328 4 
                                                              Table 39 
TNF-α mean ± sem n-number 
Untreated (Day 0)                            512 ± 11 4 
Untreated (Day +1) 127,414 ± 9,568 4 
Untreated (Day +2) 437,910 ± 40,037 4 
AmB-PMA (Day 0)                           531 ± 24 4 
AmB-PMA (Day +1) 2,883 ± 172 4 
AmB-PMA (Day +2) 14,947 ± 768 4 
                                                             Table 40 
IFN-γ mean ± sem n-number 
Untreated (Day 0)                          227 ± 19 4 
Untreated (Day +1)                        282 ± 12 4 
Untreated (Day +2)                        209 ± 22 4 
AmB-PMA (Day 0)                         248 ± 21 4 
AmB-PMA (Day +1)                       239 ± 11 4 
AmB-PMA (Day +2)                       93 ± 6 4 
                                                            Table 41 
iNOS mean ± sem n-number 
Untreated (Day 0)                            2,273 ± 99 4 
Untreated (Day +1) 7,343 ± 348 4 
Untreated (Day +2) 21,910 ± 532 4 
AmB-PMA (Day 0)                           2,300 ± 124 4 
AmB-PMA (Day +1) 1,989 ± 76 4 
AmB-PMA (Day +2) 1,343 ± 83 4 
                                                            Table 42 
IL-10 mean ± sem n-number 
Untreated (Day 0)                            85 ± 7 4 
Untreated (Day +1) 579 ± 27 4 
Untreated (Day +2) 17,334 ± 2,186 4 
AmB-PMA (Day 0)                           72.8 ± 5 4 
AmB-PMA (Day +1) 106 ± 17 4 
AmB-PMA (Day +2) 97.8 ± 4 4 
                                                           Table 43 
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Tables 39-43: Table represents the mean ± sem for chemokine and cytokine 
mRNA expression in immuno-suppressed and infected BALB/c mice at days 0, 
+1 & +2 after 300 µg AmB-PMA nebulisation 
There was no significant difference between untreated and AmB-PMA treated at day 0. No 
significant data was seen in IFN-γ expression between untreated and AmB-PMA treated at 
days, 0, +1 & +2.  
 
 
4.2.5.4 Histology of immuno-suppressed and infected BALB/c mice 
lungs at days 0, +1 & +2 after 300 µg AmB-PMA nebulisation 
AmB-PMA treated and untreated BALB/c mice culled at different time points. A 
quarter of the lung was kept in 10% formalin overnight and then a PAS stain 
performed. Histological pictures for each lung are shown below: 
 
 
Figure 106: PAS stain of immuno-suppressed non-infected BALB/c mice lungs 
after 300 µg AmB-PMA nebulisation- lungs harvested at day 0 
BALB/c mice were immuno-suppressed and given AmB-PMA prophylaxis for 4 days before 
infection.  This group of mice were culled at day 0 (before infection) and the lung harvested 
for histology studies. No inflammation was seen in mice lungs after 4 days of AmB-PMA 
administration. The inflammation was calculated as 12.6 ± 1.4% in six mice (Figure 110). 
The percentage of inflammation was determined by Fiji software (as explained in the 
Materials & Methods section) (PAS stain-original magnification x20). 
 
 
Immuno-suppressed + 
AmB-PMA 
(Day 0) 
 
12.6 ± 1.4% inflammation 
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Figure 107: PAS stain of immuno-suppressed and A. fumigatus infected 
BALB/c mice lungs after 300 µg AmB-PMA nebulisation- lungs harvested at 
day +1 
BALB/c mice were immuno-suppressed and given AmB-PMA prophylaxis for 4 days before 
infection. Mice were infected at day 0 and their lungs harvested at day +1 for histological 
studies. No germinated hyphae were seen in mouse lung at day +1. A. fumigatus was seen 
in the conidial form only (red) at day +1. The black arrows show where the spores are 
deposited in the lungs. Some inflammation was seen in mice lungs at day +1 after infection. 
The amount of inflammation was calculated as 16.5 ± 5.4% in three mice lung sections 
(Figure 110). The percentage of inflammation was determined by Fiji software (as explained 
in the Materials & Methods section) (PAS stain-original magnification x20). 
 
 
 
 
 
 
 
 
A. fumigatus spores 
(non-germinated) 
Immuno-suppressed + 
infection + AmB-PMA 
(Day +1) 
 
16.5 ± 5.4% inflammation 
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Figure 108: PAS stain of immuno-suppressed non-infected BALB/c mice-lungs 
harvested at day 0 
BALB/c mice were immuno-suppressed and lungs harvested at day 0 (before infection). This 
group of mice were immuno-suppressed, had no AmB-PMA prophylaxis and no infection. 
Lungs were clear without the presence of significant inflammation (6 ± 0.7% inflammation) 
(Figure 110). The percentage of inflammation was determined by Fiji software (as explained 
in the Materials & Methods section) (PAS stain-original magnification x10).  
 
Figure 109: PAS stain of immuno-suppressed and infected BALB/c mice-lungs 
harvested at day +1 
BALB/c mice were immuno-suppressed and infected, and the lungs harvested after 1 day of 
infection (day +1). Some focal lesions and inflammation was seen in mice lungs at day +1. 
4 focal invasive 
hyphae 
Only immuno-suppressed 
(Day 0) 
 
6 ± 0.7% inflammation 
Immuno-suppressed +      
infection 
(Day +1) 
 
36 ± 3.1% inflammation 
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There was a noticeable difference in the lungs of AmB-PMA treated mice (Figure 107) as 
compared to untreated mice at day +1. This group of mice had focal hyphae, and no 
disseminated disease was seen in these mice lungs. The black arrows show some focal 
hyphae in the lung. The inflammation was measured as 36 ± 3.1% in four mice (Figure 110). 
The percentage of inflammation was determined by Fiji software (as explained in the 
Materials & Methods section) (PAS stain-original magnification x10). 
4.2.5.5 Determine the inflammation percentage in immuno-
suppressed and infected BALB/c mice lungs at days 0 and +1 
The inflammation percentage was determined in mouse lung at days 0 and +1. The 
percentage of inflammation increased after infection by day +1 compared to day 0. 
Inflammation was also increased in immuno-suppressed and AmB-PMA treated mice 
as compared to immuno-suppressed mice at days 0. However, the inflammation 
percentage decreased after infection in AmB-PMA treated mice as compared to 
untreated mice at day +1. 
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Figure 110: Percentage inflammation in immuno-suppressed infected AmB-
PMA treated and untreated BALB/c mice lung at days 0 & +1 
The percentage of inflammation was determined by Fiji software (as explained in the 
Materials & Methods section). The inflammation increased in BALB/c mice lungs in both 
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AmB-PMA treated and untreated after infection. The percentage of Inflammation also 
increased in immuno-suppressed mice lungs after AmB-PMA treatment. More inflammation 
was seen in AmB-PMA treated mice as compared to untreated mice at days 0 and +1. 
Untreated mice are shown in (red bar) and AmB-PMA treated mice are shown in (blue bar). 
The inflammation percentage was determined on 3 different mice (n=3).  
 
4.2.6 Prophylaxis in immuno-suppressed and infected BALB/c mice 
with nebulised AmB-PMA at 300 µg AmB-confirmation of the 
results and increasing the “n”-number 
Due to the variability seen in IFN-γ expression in AmB-PMA treated mice, I decided 
to increase the number of mice. In the next animal study, 15 mice were treated with 
300 µg AmB. Data for all the mice treated with 300 µg AmB was then pooled 
together. 
In this experiment, mice were given AmB-PMA prophylaxis with 300 µg AmB for 4 
days before infection and were then infected at day 0. Immuno-suppressive 
treatment was performed as per the previous experiments. The experiment started at 
day -4 but FK-506 injections started at day -3 and were performed daily. HC was 
given at days -3 and -1 (Figure 111). 
                  
Figure 111: This diagram shows an experiment designed for confirming the 
results obtained with a dose of 300 µg AmB 
The stars show the days of AmB-PMA nebulisation. 
 
Days 
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4.2.6.1 Percentage weight loss in immuno-suppressed and infected 
BALB/c mice after nebulisation with 300 µg AmB-PMA-confirmed 
the results and increased the “n”-number 
The immuno-suppressed and infected mice weight was decreased by 20% by day 
+2. In contrast, the immuno-suppressed infected and AmB-PMA treated mice 
decreased slightly by day 0 and then increased after infection. A constant weight 
was observed in healthy and immuno-suppressed mice over 6 days. 
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Figure 112: Percentage weight loss in immuno-suppressed and infected 
BALB/c mice after nebulisation of AmB-PMA at 300 µg AmB  
Healthy mice had a constant weight and did not lose weight as compared to all other groups. 
The immuno-suppressed group lost 5% of weight. AmB-PMA treated mice lost less weight 
than non-treated group. Mice treated with 300 µg AmB-PMA showed 5-10% of weight loss 
before infection, but after infection the mice gained weight. 300 µg AmB-PMA treated mice 
lost only 5% weight after infection whereas, control mice lost 20% weight by day +2. Healthy 
mice are shown in (red), and immuno-suppressed are shown in (orange) (n=15 mice/group). 
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4.2.6.2 Fungal burden in immuno-suppressed and infected BALB/c 
mice after 300 µg AmB-PMA nebulisation-confirmed the results and 
increased the “n”-number 
Fungal burden was measured in the mouse lung with CFU and qPCR methods. CFU 
was decreased significantly in AmB-PMA treated mice and also in immuno-
competent infected mice (Figure 113-a). The same pattern was found with the qPCR 
method. A significant difference was seen in DNA fungal load between AmB-PMA 
treated + infected mice and immuno-competent infected mice (p<0.0001) (Figure 
113-b). There was no significant difference in CFU of immuno-competent infected 
mice and AmB-PMA treated + infected mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
260 
 
(a) 
                                  
Im
m
un
oc
om
pe
t +
 in
fe
ct
Im
m
un
os
up
p 
+ 
in
fe
ct g 
A
M
B
-P
M
A
-3
00
 
0
100,000
200,000
300,000
400,000
p<0.0001
p<0.0001
C
F
U
 
(b) 
                             
Im
m
un
oc
om
pe
t +
 in
fe
ct
Im
m
un
os
up
p 
+ 
in
fe
ct g 
A
m
B
-P
M
A
-3
00
 
0
2,500
5,000
7,500
10,000
p<0.0001
p<0.0001
p<0.0001
2
8
S
 r
R
N
A
 c
o
p
ie
s
 /
 2
5
0
0
 m
u
ri
n
e

-a
c
ti
n
 c
o
p
ie
s
 
Figure 113: Quantitation of A. fumigatus conidia and hyphae in immuno-
suppressed and infected BALB/c mice lungs by CFU and qPCR methods 
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BALB/c mice were aerosol infected with A. fumigatus CEA10. At day +2, groups of mice 
were killed and lungs harvested. CFU were quantiﬁed by plating (a) Fungal burden was also 
quantified by qPCR (b). Fungal burden was measured on mouse lung after 300 µg AmB-
PMA nebulisation. Fungal burden decreased significantly when mice were given AmB-PMA 
prophylaxis. But the DNA fungal load in AmB-PMA treated mice was significantly higher than 
that in immuno-competent infected mice. PCR was performed in triplicate. A Mann Whitney 
U test was used for statistical analysis (n=15 mice/group). 
 
 
4.2.6.3 Measurement of chemokines and cytokines responses in 
immuno-suppressed and infected BALB/c mice after prophylaxis 
with 300 µg AmB-PMA-confirmed the results and increased the “n”-
number 
The chemokines and cytokines responses were measured after increasing the 
number of mice to determine IFN-γ production. IFN-γ expression in a group of mice 
which got AmB-PMA prophylaxis increased as compared to untreated, healthy and 
immuno-suppressed group. However, this difference was not significant. In addition, 
the level of IFN-γ expression in immuno-competent + infection group was higher than 
that in AmB-PMA treated group (Figure 115). 
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Figure 114: MIP-1β and TNF-α expression in BALB/c mice lungs after 
nebulisation of 300 µg AmB-PMA  
There was a reduction in TNF-α and MIP-1β mRNA expression after treatment with 300 µg 
AmB-PMA. There was a significant difference in TNF-α and MIP-1β mRNA expression in 
AmB-PMA treated mice compared to untreated mice. There was a significant difference in 
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expression of MIP-1β in immuno-suppressed + infected mice compared to immuno-
competent + infected mice. No significant difference was observed in TNF-α expression 
between these two groups. MIP-1β and TNF-α expression increased in AmB-PMA treated 
group (almost 10 times) when the number of mice increased to 15 mice and data was 
pooled. The MIP-1β and TNF-α level increased almost 2 & 4 times respectively in the 
untreated group when the data pooled. There was a significant difference in expression of 
TNF-α in immuno-competent + infected mice as compared to AmB-PMA treated mice. PCR 
was performed in triplicate. Data from all the AmB-PMA treated mice (300 µg AmB) was 
pooled together. A Mann Whitney U test was used for statistical analysis of AmB-PMA 
treated mice compared to the immuno-suppressed and infected mice (n=15 mice/group). 
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 Figure 115: IFN-γ expression in BALB/c mice lungs after nebulisation of 300 
µg of AmB-PMA 
There was a reduction in IFN-γ expression compared to the previous experiment (small 
number of mice n=4), after prophylaxis with 300 µg of AmB-PMA. IFN-γ level was almost 
double than healthy mice. Immuno-suppressed + infected mice showed the least expression 
of IFN-γ. There was a difference in IFN-γ mRNA expression in AmB-PMA treated mice 
compared to untreated mice. But this difference was not significant in a large group of mice. 
There was a significant difference in expression of IFN-γ in immuno-suppressed + infected 
mice compared to immuno-competent + infected mice. There was also a significant 
difference in expression of IFN-γ in immuno-competent + infected mice as compared to 
AmB-PMA treated mice. PCR was performed in triplicate. Data from all the AmB-PMA 
treated mice (300 µg AmB) pooled together. A Mann Whitney U test was used for statistical 
analysis of AmB-PMA treated mice compared to the immuno-suppressed infected mice 
(n=31 mice/group).  
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Figure 116: iNOS and IL-10 expression in BALB/c mice lungs after nebulisation 
of 300 µg AmB-PMA 
IL-10 & iNOS mRNA decreased significantly in AmB-PMA treated group at day+2 post-
infection compared to untreated. iNOS and IL-10 expression decreased after the immuno-
suppressive regimen. There was a significant difference in expression of IL-10 in immuno-
suppressed + infected mice as compared to immuno-competent + infected mice. There was 
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a significant difference in expression of iNOS and IL-10 in immuno-competent + infected 
mice as compared to AmB-PMA treated mice. The average iNOS expression increased 
almost 5 times as compared to the previous experiment after increasing the n-number. A 
Mann Whitney U test was used for statistical analysis of AmB-PMA treated mice as 
compared to the immuno-suppressed and infected mice. Data from all the AmB-PMA treated 
mice (300 µg AmB) was pooled together (n=15 mice/group). 
 
The mean ± sem of these experiments are listed below in Table 44-48. 
MIP-1β mean ± sem n-number 
Immunosupp + Infect 327,677 ± 8,775 11 
AmB-PMA-300 µg 42,966 ± 1,087 15 
Immunocompet + infect 26,975 ± 1,398 6 
                                                                 Table 44 
TNF-α mean ± sem n-number 
Immunosupp + Infect 187,801 ± 10,884 11 
AmB-PMA-300 µg 19,085 ± 402 15 
Immunocompet + infect                   43,445 ± 1,265 6 
                                                                Table 45 
IFN-γ mean ± sem n-number 
Immunosupp + Infect 127 ± 1.7 25 
AmB-PMA-300 µg                          516 ± 12 31 
Immunocompet + infect 1,313 ± 52 6 
                                                                Table 46 
iNOS  mean ± sem n-number 
Immunosupp + Infect 14,724 ± 347 11 
AmB-PMA-300 µg 2,889 ± 60 15 
Immunocompet + infect                 7,128 ± 502 6 
                                                                Table 47 
IL-10 mean ± sem n-number 
Immunosupp + Infect 6,101 ± 472 11 
AmB-PMA-300 µg 298 ± 8 15 
Immunocompet + infect 74 ± 3.7 6 
                                                                Table 48 
Table 44-48: Table represents the mean ± sem of chemokine and cytokines in 
BALB/c mice lungs after nebulisation of 300 µg AmB-PMA 
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4.2.6.4 Histology of immuno-suppressed and infected BALB/c 
mouse lung at days +2 after 300 µg AmB-PMA nebulisation              
 
Figure 117: PAS stain of immuno-suppressed and A. fumigatus infected 
BALB/c mice after nebulisation of 300 µg AmB-lungs harvested at day +2 
BALB/C mice were immuno-suppressed and infected, and then they culled at day +2 after 
infection. AmB-PMA was administrated through nebulisation. No invasive fungal hyphae and 
inflammation were seen in AmB-PMA treated mice. A. fumigatus were seen in conidial form 
and most of them were engulfed by alveolar macrophages which inhibited their germination. 
Both Figure 117 & Figure 97 are the same pictures and they represent the histology of 
BALB/c mouse lung after prophylaxis with 300 µg AmB. The percentage of inflammation was 
determined by Fiji software (as explained in the Materials & Methods section) (PAS stain-
original x40).   
 
4.2.6.5 Summary of 300 µg AmB-PMA nebulisation after increasing 
the number 
 
According to the above data, 300 µg/ml AmB nebulisation was defined as the best 
dose for prophylaxis against aspergillosis. The time of post-infection was then 
extended from 2 days to 8 days to see how long AmB-PMA mice given prophylaxis, 
could survive. 
 
 
Spores engulfed by 
macrophages 
Immuno-suppressed + 
infection + AmB-PMA 
(300 µg AmB) 
14 ± 1.19% inflammation 
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4.2.7 Extending time post-infection to 4 days 
 
Efficacy of aerosolisation of AmB-PMA was also determined in-vivo in a mouse 
model after extending time post-infection. Again, BALB/c mice were immuno-
suppressed with FK-506 in combination with HC. FK-506 was given daily and HC 
was given at days -3 & -1 before infection and at day 2 after infection. Prophylaxis 
was given with 300 μg AmB /ml for 4 days before infection. On the day of infection, 
mice were inoculated intra-nasally with 5x106 spores from A. fumigatus CEA10. Mice 
were culled at day +4 and lungs harvested to determine disease progression in A. 
fumigatus-infected BALB/c mice. The disease progression was monitored by 
histology, CFU, qPCR for Aspergillus ribosomal 28S rRNA and analysis of 
chemokine and cytokine response in mouse lung. The Figure 118 represents the 
summary of this experiment. 
 
 
 
Figure 118: This diagram represents the summary of an experiment designed 
for extending time post infection to 4 days  
The stars show the days of AmB-PMA nebulisation. 
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4.2.7.1 Percentage weight loss in immuno-suppressed and A. 
fumigatus infected BALB/c mice after extending time to 4 days 
post-infection 
 
    
-4 -3 -2 -1 0 1 2 3 4
70
80
90
100
110
Untreated
AmB-PMA-300 µg
days
%
 w
e
ig
h
t
 
       
Figure 119: Analysis the weight loss percentage in BALB/c mice after 
extending time post-infection to 4 days 
Mice got AmB-PMA prophylaxis for 4 days before infection and were then infected at day 0. 
Untreated mice were culled at day +2 due to 20-25% loss weight. The AmB-PMA treated 
mice were well at day 4 with only 5% weight loss (n=4 mice/group).  
 
 
4.2.7.2 Measurement of chemokine and cytokines responses after 
extending time post infection to 4 days 
The chemokines and cytokines expression from mouse lungs were measured after 
extending time post-infection to 4 days. Mice got prophylaxis with 300 µg AmB-PMA 
and then at days +2 and +4 each group of mice were culled and their lungs 
harvested for qPCR analysis. RNA was reverse transcribed to cDNA with the Qiagen 
QuantiTect. My results showed that MIP-1β expression increased with extending 
time post-infection (Figure 120). IFN-γ expression decreased by day 4 and there was 
a significant difference in IFN-γ expression at day +4 as compared to day +2 (Figure 
121). IL-10 and iNOS mRNA levels also increased significantly with increasing time 
post-infection from day +2 to day +4 (Figure 122). A Mann Whitney U test was used 
for statistical analysis to compare the mRNA copies number at day +2 and day +4. 
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Figure 120: MIP-1β and TNF-α expression in immuno-suppressed and A. 
fumigatus infected BALB/c mice at days +2 and +4 post-infection 
MIP-1β mRNA level increased at day +4 compared to day +2 (n=4 mice/group).  
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Figure 121: IFN-γ expression in immuno-suppressed and A. fumigatus infected 
BALB/c mice at days +2 and +4 post-infection 
IFN-γ mRNA level decreased in mice with AmB-PMA prophylaxis. IFN-γ expression 
decreased significantly by day +4 compared to day +2 (n=4 mice/group).  
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Figure 122: iNOS and IL-10 expression in immuno-suppressed and A. 
fumigatus infected BALB/c mice at days +2 and +4 post-infection 
iNOS and IL-10 expression were measured after AmB-PMA treatment. iNOS and IL-10 
expression increased significantly over 4 days (n=4 mice/group).  
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4.2.7.3 Histology of BALB/c mice lungs at day +2 and +4 post-
infection 
The pictures below represent the AmB-PMA treated mice lungs at day +2 compared 
with mice at day +4. Only spores were seen in the lungs of AmB-PMA treated mice 
culled at day +2. No hyphae or inflammation were seen in this group of mice. A few 
focal hyphae were observed in AmB-PMA treated mice culled at day +4 post-
infection. 
 
 
 
Figure 123: PAS stain of immuno-suppressed and A. fumigatus infected 
BALB/c mouse lung after nebulisation of 300 µg AmB-PMA-lungs harvested at 
day +2 
BALB/C mice were immuno-suppressed and AmB-PMA was given for 4 days. Mice lungs 
harvested at day +2 p.i. No hyphae were seen in the mouse lungs. Only some spores were 
seen in the lungs. Some inflammation was also seen. The average percentage of 
inflammation was calculated as 14 ± 1.2% in six mice (Figure 132). Inflammation was 
measured by Fiji software (as explained in the Materials & Methods section) (PAS stain-
original magnification x10).  
 
Immuno-suppressed + 
infection + AmB-PMA   
(Day +2) 
14 ± 1.2% inflammation 
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Figure 124: PAS stain of immuno-suppressed and A. fumigatus infected 
BALB/c mouse lung after nebulisation of 300 µg AmB-PMA-lungs harvested at 
day +4 
BALB/C mice were immuno-suppressed and AmB-PMA was given for only 4 days. No 
addition AmB-PMA was given. Mice lungs were harvested at day +4 p.i. By extending the 
period of time after infection, germinated fungi became obvious. Few focal hyphae were 
seen in the lungs. However, the number of focal hyphae was still less than untreated mice at 
day +2 (Figure 79 & Figure 85-a). The disease had not disseminated at day +4 post-
infection. The black arrows show a big lesion of hyphae with germinated fungi. The average 
percentage of inflammation increased to 43 ± 6.8% at day +4 (Figure 132). Figure 124 
shows one of the lung sections with 30 ± 1.1% inflammation. Inflammation was measured by 
Fiji software (as explained in the Materials & Methods section) (PAS stain-original 
magnification x10). 
 
 
 
 
 
 
 
 
 
 
Invasive focal hyphae with 
germinated conidia (Pink) 
Immuno-suppressed + 
infection + AmB-PMA   
(Day +4) 
30 ± 1.1% inflammation 
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4.2.8 Extending time post-infection to 8 days 
BALB/c mice were immuno-suppressed with FK-506 and HC. FK-506 was given 
daily and HC was given at days -3, -1 and at days +2 and +5 after infection. 
Prophylaxis was given with 300 μg AmB /ml for 4 days before infection (-4, -3, -2 & -
1). On the day of infection, mice were inoculated intra-nasally with 5x106 spores from 
A. fumigatus CEA10. Mice were culled at day +8 and the lungs harvested to 
determine disease progression in A. fumigatus-infected BALB/c mice. Figure 125 
shows the summary of this experiment.  
 
 
 
Figure 125: Diagram represents the summary of experiment designed for 
extending time post-infection to 8 days  
The stars show the days of AmB-PMA nebulisation. 
 
 
 
 
 
 
 
 
275 
 
4.2.8.1 Percentage weight loss in immuno-suppressed and A. 
fumigatus infected BALB/c mice after extending time to 8 days 
post-infection 
A noticeable difference was observed in the percentage weight loss between 
untreated and AmB-PMA treated mice. Untreated mice were culled at day +2 due to 
25% loss weight, but AmB-PMA treated mice lost only 5% and 10% of weight by 
days +2 & +8 respectively. 
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Figure 126: Analysis the percentage weight loss in immuno-suppressed and A. 
fumigatus infected BALB/c mice after extending time post-infection to 8 days 
Untreated mice lost 20-25% of weight by day 2 after infection, but AmB-PMA treated mice 
survived up to 8 days with only 10% weight loss (n=4 mice/ group).  
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4.2.8.2 Pulmonary fungal burden after extending time post-infection 
to 4 and 8 days 
(a)                                                           
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Figure 127: Quantitation of A. fumigatus conidia and mycelium in immuno-
suppressed and infected BALB/c mice lungs by the CFU and qPCR methods 
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BALB/c mice were aerosol infected with A. fumigatus CEA10 (5x106 per mouse). At 2, 4 & 8 
days post-infection, groups of mice were killed and lungs harvested. Viable counts (CFU) 
were quantiﬁed from lung homogenate (a). A quarter of the lung was homogenised in PBS 
and DNA extracted for qPCR analysis (b). Bars represent mean CFU & 28S rRNA fungi 
copies number values (mean ± sem). A Mann Whitney U test was used for statistical 
analysis to compare the DNA fungal load in untreated mice with AmB-PMA treated mice at 
days +2, +4 & +8 (n=4 mice /time point).  
 
4.2.8.3 Measurement of chemokine and cytokines responses after 
extending time post infection to 4 and 8 days 
The chemokines and cytokines expression from mouse lungs were measured after 
extending time post-infection to 4 and 8 days. Mice got prophylaxis with 300µg AmB-
PMA and then at three different time points (day +2, +4 & +8) each group of mice 
were culled and their lungs harvested for qPCR analysis. My results showed that 
MIP-1β and TNF-α expression increased with increasing time post-infection (Figure 
128). IFN-γ expression decreased at day +4 and day +8, and this decrease was 
significant (Figure 129). IL-10 and iNOS mRNA levels also increased significantly 
with increasing time post-infection from day +2 to day +8 (Figure 130). A Mann 
Whitney U test was used for statistical analysis to compare the mRNA copies 
number at different time points.  
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Figure 128: MIP-1β and TNF-α expression in immuno-suppressed and A. 
fumigatus infected BALB/c mice lungs at days +2, +4 and +8 post-infection 
The chemokine and cytokine expression were measured after extending time post-infection 
to 4 and 8 days. MIP-1β and TNF-α mRNA level increased over 8 days. There was a 
significant difference in MIP-1β and TNF-α expression between AmB-PMA (Day +2) and 
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AmB-PMA (Day +8). However, this difference was not significant between AmB-PMA (Day 
+4) and AmB-PMA (Day +8) (n=4 mice/group).  
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Figure 129: IFN-γ expression in immuno-suppressed and A. fumigatus infected 
BALB/c mice lungs at days +2, +4 and +8 post-infection 
The chemokine and cytokine expression were measured after extending time post-infection 
to 4 and 8 days. IFN-γ mRNA level was decreased by day 8. There was a significant 
difference in IFN-γ expression between AmB-PMA (Day +2) and AmB-PMA (Day +4) and 
also between AmB-PMA (Day +2) and AmB-PMA (Day +8). However, there was no 
significant difference between AmB-PMA treated groups at days +4 & +8 (n=4 mice/group).  
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Figure 130: iNOS and IL-10 expression in immuno-suppressed and A. 
fumigatus infected BALB/c mice lungs at days +2, +4 and +8 post-infection 
The chemokine and cytokine expression were measured after extending time post-infection 
to 4 and 8 days. iNOS and IL-10 expression increased significantly by day +8. There was a 
significant difference in iNOS and IL-10 expression between AmB-PMA treated mice at day 
+4 as compared to day +8 (n=4 mice/group).  
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The mean ± sem of these experiments are listed below in Table 49-53. 
MIP1β mean ± sem n-number 
AmB-PMA (D+2) 42,966 ± 1,087 15 
AmB-PMA (D+4) 60,059 ± 1,210 4 
AmB-PMA (D+8) 71,513 ± 2,015 4 
                                                             Table 49 
TNF-α mean ± sem n-number 
AmB-PMA (D+2) 19,085 ± 402 15 
AmB-PMA (D+4)                                  25,649 ± 761 4 
AmB-PMA (D+8)                            38,624 ± 2,183 4 
                                                             Table 50 
IFN-γ mean ± sem n-number 
AmB-PMA (D+2) 510 ± 12 31 
AmB-PMA (D+4) 402 ± 28 4 
AmB-PMA (D+8) 413 ± 32 4 
                                                             Table 51 
iNOS  mean ± sem n-number 
AmB-PMA (D+2) 2,889 ± 60 15 
AmB-PMA (D+4) 10,292 ± 643 4 
AmB-PMA (D+8) 30,346 ± 1,984 4 
                                                            Table 52 
IL-10 mean ± sem n-number 
AmB-PMA (D+2) 298.6 ± 8 15 
AmB-PMA (D+4) 567 ± 12 4 
AmB-PMA (D+8) 1,450 ± 62 4 
                                                            Table 53 
Table 49-53: Table represents the mean ± sem of chemokine and cytokine 
expression after extending time post-infection to +4 and +8 days 
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4.2.8.4 Histology of immuno-suppressed and A. fumigatus infected 
BALB/c mouse at day +8 post-infection 
 
 
 
Figure 131: PAS stain of immuno-suppressed and A. fumigatus infected 
BALB/c mouse lung section at day +8 post-infection 
Picture represents the AmB-PMA treated BALB/c mouse lung at day +8 post-infection. Some 
focal hyphae and inflammation were seen in lungs at day 8. More focal hyphae were seen in 
the lungs at day +8 as compared to day +4. The average percentage of inflammation at day 
+8 increased to 65 ± 2.1% in four mice (Figure 132). Inflammation was measured by Fiji 
software (as explained in the Materials & Methods section) (PAS stain-original magnification 
x10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Big focal invasive 
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Immuno-suppressed + 
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(Day +8) 
65 ± 2.1% inflammation 
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4.2.8.5 Determination the amount of inflammation in immuno-
suppressed and A. fumigatus infected BALB/c mice at days +2, +4 
& +8 post-infection 
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Figure 132: Percentage of inflammation in immuno-suppressed A. fumigatus 
infected and AmB-PMA treated BALB/c mice at days +2, +4 and +8 
Inflammation was measured by Fiji software (as explained in the Materials & Methods 
section). The inflammation percentage was increased by extending the time post-infection. 
The amount of inflammation increased significantly at day +8 as compared to day +2. The 
data showed that the amount of inflammation increased the mass of focal pulmonary hyphae 
and necrosis in the lung. The inflammation percentage was determined on at least 4 different 
lung sections at each time point (n=4).  
 
4.2.8.6 Summary of extending time of post-infection 
 
Few focal hyphae and inflammation were seen at days +4 and +8 post-infection. In 
contrast, no hyphae and inflammation were seen at day +2. Only spores were seen 
at day +2 after infection. It was found that there was an increase in the number of 
focal hyphae with extending time post-infection. It was concluded that administration 
of AmB-PMA after infection could decrease the emergence of focal hyphae. The next 
animal experiment was aimed to determine the effect of AmB-PMA administration 
post-infection.  
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4.2.9 Determine the effect of AmB-PMA administration as treatment 
after infection in BALB/c mice 
Due to little infection and inflammation after extending the time post-infection, 
another experiment was done whose aim was to increase the total amount of AmB 
by altering the number of nebulisation rather than increasing the dose of AmB. In this 
experiment, BALB/c mice were immuno-suppressed with FK-506 and HC. FK-506 
and HC were given like above experiment. AmB-PMA prophylaxis was given with 
300 μg AmB /ml for 4 days before infection (-4, -3, -2 & -1) and 2 days after infection 
(+1 & +2). Mice were inoculated intranasally with 5x106 A. fumigatus spores at day 0. 
The mice were culled at day +4 after infection. Immuno-suppressed and immuno-
competent infected mice were sacrificed at day +2. Figure 133 shows the summary 
of this experiment.  
 
 
 
Figure 133: This diagram shows the summary of an experiment designed for 
determining the effect of AmB-PMA administration in BALB/c mice as 
prophylaxis and treatment after infection 
The stars show the days of AmB-PMA nebulisation. 
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4.2.9.1 Percentage weight loss in immuno-suppressed and infected 
BALB/c mice after AmB-PMA administration as prophylaxis and 
treatment            
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Figure 134: Percentage weight loss in immuno-suppressed and infected 
BALB/c mice after AmB-PMA administration as both prophylaxis and treatment 
No weight loss was seen in immuno-competent + infected mice. 10% weight loss was 
observed from day -4 to day 0. Then, mice gained weight from day 0 to day +2 and followed 
by loss weight from day +2 to +4 (15-20%). Immuno-suppressed + infected mice lost 25% of 
weight by day +2.  
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4.2.9.2 Fungal burden measurement after administration of AmB-
PMA post-infection 
Fungal burden was measured in BALB/c mice after AmB-PMA administration before 
and after infection. Fungal burden decreased significantly in AmB-PMA treated mice 
as compared to immuno-suppressed and infected mice. There was also a significant 
difference in the fungal burden between immuno-suppressed and immuno-
competent infected mice.    
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Figure 135: Fungal burden measurement in BALB/c mice lungs by CFU and 
qPCR methods after administration of AmB-PMA post-infection 
There was a significant difference in CFU of untreated (immuno-suppressed + infected) 
compared to AmB-PMA treated mice. Fungal burden was decreased significantly in immuno-
competent and infected mice and there was a noticeable difference between immuno-
competent and immuno-suppressed infected mice. A Mann Whitney U test was used for 
statistical analysis (n=8 mice/group). 
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4.2.9.3 Chemokine and cytokines measurement in immuno-
suppressed and infected BALB/c mice after AmB-PMA 
administration as both prophylaxis and treatment  
Chemokines and cytokines responses were measured in BALB/c mice after 
administration of AmB-PMA before and after infection. All AmB-PMA treated mice 
were culled at day +4. Immuno-suppressed and immuno-competent infected mice 
were sacrificed at day +2 because of a 20% weight loss in the immuno-suppressed 
infected mice. There was a significant difference in MIP-1β, IFN-γ, iNOS and IL-10 
expression between 2 days AmB-PMA treated mice as compared to immuno-
suppressed and infected mice (Figure 137 & Figure 138). There was a significant 
difference in expression of all cytokines except TNF-α between immuno-suppressed 
and immuno-competent infected mice (Figure 136). A Mann Whitney U test was 
used for statistical analysis. 
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Figure 136: MIP-1β and TNF-α expression in immuno-suppressed and A. 
fumigatus infected BALB/c mice after administration of AmB-PMA post-
infection  
MIP-1β and TNF-α were suppressed by immuno-suppressive treatment.  MIP-1β and TNF-α 
were increased in immuno-suppressed + infected mice. These responses decreased after 
AmB-PMA administration (n=8 mice/group).  
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Figure 137: IFN-γ expression in immuno-suppressed and A. fumigatus infected 
BALB/c mice after administration of AmB-PMA post-infection 
IFN-γ increased in healthy mice after infection. There was a significant difference in IFN-γ 
between immuno-competent infected and immuno-suppressed infected mice. IFN-γ  
decreased significantly in AmB-PMA treated mice (2 days post-infection) as compared to 
immuno-suppressed and infected mice (n=8 mice/group).  
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Figure 138: iNOS and IL-10 expression in immuno-suppressed and A. 
fumigatus infected BALB/c mice after administration of AmB-PMA post-
infection 
iNOS and IL-10 were suppressed by immuno-suppressive treatment. After infection, their 
levels increased significantly. iNOS and IL-10 levels decreased significantly after AmB-PMA 
treatment (n=8 mice/group).  
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The mean ± sem of these experiments are listed below in Table 54-58. 
 
MIP1β mean ± sem n-number 
Immuno-competent + infection (Day+2) 26,975 ± 1,392 3 
Immuno-suppressed + infection (Day+2) 314,312 ± 6,920 12 
AmB-PMA (2 days p.i) (Day+4) 112,437 ± 1,438 8 
                                                                 Table 54 
TNF-α mean ± sem n-number 
Immuno-competent + infection (Day+2) 43,445 ± 1,265 3 
Immuno-suppressed + infection (Day+2) 191,297 ± 8,395 12 
AmB-PMA (2 days p.i) (Day+4) 51,211 ± 885 8 
                                                                Table 55 
IFN-γ mean ± sem n-number 
Immuno-competent + infection (Day+2) 1,313 ± 52 3 
Immuno-suppressed + infection (Day+2) 144 ± 2.3 25 
AmB-PMA (2 days p.i) (Day+4) 35 ± 0.9 8 
                                                                 Table 56 
iNOS mean ± sem n-number 
Immuno-competent + infection (Day+2) 7,128 ± 500 3 
Immuno-suppressed + infection (Day+2) 37,395 ± 500 12 
AmB-PMA (2 days p.i) (Day+4) 31,405 ± 560 8 
                                                                Table 57 
IL-10 mean ± sem n-number 
Immuno-competent + infection (Day+2) 63 ± 5  3 
Immuno-suppressed + infection (Day+2) 5,589 ± 358 12 
AmB-PMA (2 days p.i) (Day+4) 860 ± 16 8 
                                                                Table 58 
Table 54-58: Table shows the mean ± sem of chemokine and cytokine 
expression after administration of AmB-PMA as prophylaxis and treatment 
 
4.2.9.4 Histological analysis of the lung tissue sections of immuno-
suppressed infected and AmB-PMA treated BALB/c mice 
BALB/c mice were given AmB-PMA for 4 days before infection and also for 2 days 
after infection. AmB-PMA treated mice were culled on day +4 and immuno-
suppressed and immuno-competent infected mice were culled on day +2. No 
significant difference was seen in the lung histology of BALB/c mice given AmB-PMA 
prophylaxis and treatment with AmB-PMA as compared to mice given AmB-PMA as 
prophylaxis only (Figure 124). 
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(A) 
 
 
(B) 
 
 
Figure 139: PAS stain of BALB/c mouse lung section after administration of 
AmB-PMA as both prophylaxis and treatment 
(A and B) represent two views of two different lung sections. A) Lung section from a group of 
mice treated for 4 days before infection and 2 days after infection and the lungs harvested at 
day +4. Invasive focal hyphae and inflammation is seen in the treated lung tissue post-
infection. Necrosis was also seen around hyphae. The inflammation percentage was 
calculated as 41 ± 4% (Figure 139-A).  This is very similar to inflammation percentage in the 
mice given AmB-PMA as prophylaxis only (43 ± 6.8%, Figure 124) (PAS stain-original 
magnification x10). 
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B) Lung section from immuno-suppressed and infected mouse without any AmB-PMA 
treatment. Lungs were harvested at day +2. The slides of A. fumigatus infected BALB/c mice 
showed clear-cut invasive aspergillosis and necrosis. The average percentage of 
inflammation was calculated as 73 ± 1.25% in six mice. Inflammation was measured by Fiji 
software (as explained in the Materials & Methods section) (PAS stain-original magnification 
x10). 
  
 
4.2.9.5 Summary of AmB-PMA administration as both prophylaxis 
and treatment post-infection 
It was concluded that there was no effect of AmB-PMA administration as treatment 
post-infection. The next experiment aimed to test the efficacy of AmB-PMA 
administration in C57BL/6 mice. 
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C57BL/6 mice 
 
4.2.10 Test the efficacy of AmB-PMA administration in immuno-
suppressed and A. fumigatus infected C57BL/6 mice 
C57BL/6 mice were immuno-suppressed with FK-506 and HC. FK-506 and HC were 
given as previously. AmB-PMA prophylaxis was given with 600 μg AmB /ml for 4 
days before infection (-4, -3, -2 and -1). Mice were inoculated intranasally with 5x106 
spores from A. fumigatus at day 0. AmB-PMA treated mice were culled at different 
time points (days +2, +3 & +4). Immuno-suppressed and immuno-competent infected 
mice were killed at day +2. The plan was to kill mice at days +4 and +8. But this 
experiment had to be shortened because of vestibulitis in the ear. The mice started 
somersaulting because of inner ear infection with Aspergillus. Figure 140 is a 
summary of this experiment. 
 
 
Figure 140: This diagram shows an experiment designed for determining the 
efficacy of AmB-PMA prophylaxis in C57BL/6 mice  
The stars show the days of AmB-PMA nebulisation. 
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4.2.10.1 Weight loss percentage in immuno-suppressed and A. 
fumigatus infected C57BL/6 mice after extending time post-
infection 
AmB-PMA treated C57BL/6 mice were culled at different time points (days +2, +3 & 
+4). No weight loss was observed by extending the time post-infection. Immuno-
suppressed and infected mice were sacrificed at day +2 due to 15-20% weight loss. 
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Figure 141: Percentage weight loss in immuno-suppressed and infected 
C57BL/6 mice after extending time post-infection 
No weight loss was seen in immuno-competent infected and immuno-suppressed mice. 15-
20% weight loss was seen in immuno-suppressed and infected mice. Little weight loss was 
seen with AmB-PMA administration, but weight loss increased after infection.  
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4.2.10.2 Fungal burden measurement in immuno-suppressed and 
infected C57BL/6 mice after extending time post-infection 
Fungal burden was decreased significantly after AmB-PMA treatment. DNA fungal 
load was similar in AmB-PMA treated and immuno-competent infected mice. There 
was a significant difference in CFU and DNA fungal load between immuno-
suppressed and immuno-competent infected groups.   
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Figure 142: Quantitation of A. fumigatus spores and hyphae in immuno-
suppressed and infected C57BL/6 mice lungs by CFU & qPCR methods after 
extending time post-infection 
There was a significant difference in fungal burden between untreated (immuno-suppressed 
+ infected) mice and AmB-PMA treated mice (n=4 mice/group).  
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4.2.10.3 Chemokine and cytokines released from immuno-
suppressed and infected C57BL/6 mice lungs after extending time 
post-infection 
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Figure 143: MIP-1β and TNF-α in immuno-suppressed and infected C57BL/6 
mice lungs after extending time post-infection 
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C57BL/6 mice could not survive up to 8 days because of vestibulitis in the ear. Therefore, 
mice were killed at different time points. There was no significant difference between 
immuno-suppressed and immuno-competent infected mice (n=4 mice/group).  
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Figure 144: IFN-γ in immuno-suppressed and infected C57BL/6 mice lungs 
after extending time post-infection 
No significant difference was seen in IFN-γ between AmB-PMA treated and immuno-
suppressed infected group (n=4 mice/group).  
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Figure 145: iNOS and IL-10 expression in immuno-suppressed and infected 
C57BL/6 mice lungs after extending time post-infection 
iNOS and IL-10 increased up to day +3 and then fell at day +4. The levels were significantly 
less than those in untreated mice (n=4 mice/group).  
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Figure 146: IRF-1 expression in immuno-suppressed and infected C57BL/6 
mice lungs after extending time post-infection 
IRF-1 increased significantly after AmB-PMA treatment at days +2 and +4 as compared to 
untreated infected mice. No decrease in IRF-1 expression was seen in immuno-suppressed 
only mice after HC and FK-506 injection (n=4 mice/group).  
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MIP1β    mean ± sem n-number 
Immuno-competent + infection (Day+2) 29,577 ± 440 3 
Immuno-suppressed + infection (Day+2) 59,364 ± 2,681 6 
AmB-PMA (D+2) 1,063 ± 30 9 
AmB-PMA (D+3) 5,378 ± 741 3 
AmB-PMA (D+4) 893 ± 61 4 
                                                                  Table 59 
TNF-α          mean ± sem n-number 
Immuno-competent + infection (Day+2) 14,244 ± 554 3 
Immuno-suppressed + infection (Day+2) 22,687 ± 853 6 
AmB-PMA (D+2) 920 ± 15.8 9 
AmB-PMA (D+3) 2,563 ± 309 3 
AmB-PMA (D+4) 1,075 ± 52 4 
                                                                  Table 60 
IFN-γ    mean ± sem n-number 
Immuno-competent + infection (Day+2)    1,112 ± 51 3 
Immuno-suppressed + infection (Day+2) 37 ± 1.7 6 
AmB-PMA (D+2) 37 ± 1.6 9 
AmB-PMA (D+3) 23 ± 1.5 3 
AmB-PMA (D+4) 39.5 ± 1.6 4 
                                                                 Table 61 
iNOS    mean ± sem n-number 
Immuno-competent + infection (Day+2)  2,347 ± 87.7 3 
Immuno-suppressed + infection (Day+2) 2,134 ± 238 6 
AmB-PMA (D+2) 476 ± 8.8 9 
AmB-PMA (D+3) 653 ± 78 3 
AmB-PMA (D+4) 333 ± 11 4 
                                                                 Table 62 
IL-10    mean ± sem n-number 
Immuno-competent + infection (Day+2)   25 ± 2 3 
Immuno-suppressed + infection (Day+2) 348 ± 15.5 6 
AmB-PMA (D+2) 25 ± 0.8 9 
AmB-PMA (D+3) 189 ± 17 3 
AmB-PMA (D+4) 84 ± 6 4 
                                                                Table 63 
IRF-1    mean ± sem n-number 
Immuno-competent + infection (Day+2)    231,309 ± 14,528 3 
Immuno-suppressed + infection (Day+2) 157,334 ± 3,817 6 
AmB-PMA (D+2) 220,011 ± 2,882 9 
AmB-PMA (D+3) 165,527± 2,449 3 
AmB-PMA (D+4)  261,217 ± 5,293 4 
                                                               Table 64 
Table 59-64: Table shows the mean ± sem of chemokine and cytokine 
expression in C57BL/6 mice after extending time post-infection  
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4.2.10.4 Histology of immuno-suppressed and infected C57BL/6 
mice lungs after extending time post-infection 
 
C57BL/6 mice could not survive up to 8 days. They were culled at days +2, +3 and 
+4 because of vestibulitis in the ear.  
 
 
Figure 147: PAS stain of immuno-competent infected C57BL/6 mouse lung-
lungs harvested at day +2 
Immuno-competent C57BL/6 mice were infected and culled at day +2. No AmB-PMA was 
given. C57BL/6 mice lungs were the same as immuno-competent infected BALB/c mice 
lungs. The mouse lung was clear. No hyphae and no spores were observed in the lung. No 
inflammation was seen in the lung (PAS stain-original magnification x10).  
 
 
 
 
 
 
 
 
 
 
 
Immuno-competent + 
infection (Day +2) 
No inflammation 
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Figure 148: PAS stain of immuno-suppressed and infected C57BL/6 mouse 
lung-lungs harvested at day +2 
C57BL/6 mice were immuno-suppressed and infected. No AmB-PMA was given. These 
C57BL/6 mice lungs were almost the same as untreated BALB/c mice lungs at day +2. The 
inflammation was measured as 60 ± 1.6% in three mice (Figure 152). The inflammation was 
measured using Fiji software (as explained in the Materials & Methods section) (PAS stain-
original magnification x10).  
 
 
 
 
 
 
 
 
Invasive hyphae- Necrosis around 
the hyphae 
 
Immuno-suppressed + 
infection (Day +2) 
60 ± 1.6% inflammation 
306 
 
 
Figure 149: PAS stain of immuno-suppressed and infected C57BL/6 mouse 
lung after AmB-PMA administration-lungs harvested at day +2 
C57BL/6 mice were immuno-suppressed and infected. AmB-PMA was given for 4 days 
before infection. There was no significant difference between histology slides of AmB-PMA 
treated C57BL/6 mouse lung as compared to BALB/c mouse lung at day +2. Only spores 
were seen in both C57BL/6 and BALB/c mice lungs at day +2. The inflammation was 
reduced to 18.5 ± 3.9% after AmB-PMA administration as compared to 60 ± 1.6% in the 
control (Figure 148). The inflammation was measured using Fiji software (as explained in the 
Materials & Methods section) (PAS stain-original magnification x10). 
 
 
 
Figure 150: PAS stain of immuno-suppressed and infected C57BL/6 mouse 
lung after AmB-PMA administration-lungs harvested at day +3 
 Non-germinated spores 
Immuno-suppressed + 
infection + AmB-PMA 
(Day +2) 
18.5 ± 3.9% 
inflammation 
Immuno-suppressed + 
infection + AmB-PMA 
(Day +3) 
20 ± 1.9% 
inflammation 
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Some of the mice were culled at day +3 because of infection in the brain. The germinated 
fungi and inflammation had increased by extending the time post-infection (+3) as compared 
to day +2 (Figure 152). The inflammation was increased to 20 ± 1.9% after AmB-PMA 
administration at day +3 as compared to 18.5 ± 3.9% at day +2 (Figure 149). The 
inflammation was measured using Fiji software (as explained in the Materials & Methods 
section) (PAS stain-original magnification x10).  
 
 
 
 
Figure 151: PAS stain of immuno-suppressed and infected C57BL/6 mouse 
lung after AmB-PMA administration-lungs harvested at day +4 
Another group of mice were culled at day +4 due to vestibulitis in the ear. The inflammation 
expanded by day +4 as compared to day +3 and day +2. There was a correlation between 
the emergence of inflammation and extending time post-infection (Figure 152). The amount 
of inflammation increased to 25 ± 4% after AmB-PMA administration at day +4 as compared 
to day +3 when it was 20 ± 1.9% (Figure 150). The inflammation was measured using Fiji 
software (as explained in the Materials & Methods section) (PAS stain-original magnification 
x4).  
 
 
 
 
 
 
 
 
Non-germinated spores & inflammation 
Immuno-suppressed + 
infection + AmB-PMA 
(Day +4) 
25 ± 4% inflammation 
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4.2.10.5 Determination of the inflammation percentage in immuno-
suppressed infected and AmB-PMA treated C57BL/6 mice after 
extending time post-infection 
 
The percentage inflammation was determined in immuno-suppressed infected and 
AmB-PMA treated C57BL/6 mice at days +2, +3 & +4. The percentage inflammation 
increased with extending the day post-infection. The inflammation percentage 
increased by 10% every day as compared to the previous day.  
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Figure 152: Inflammation percentage in immuno-suppressed infected and 
AmB-PMA treated C57BL/6 mice at days +2, +3 and +4 
The inflammation was measured using Fiji software (as explained in the Materials & 
Methods section). The percentage inflammation increased gradually with extended time 
post-infection. The same pattern of increase in inflammation was seen in BALB/c and 
C57BL/6 mice by extending the time after infection.  More inflammation was seen in 
C57BL/6 mice as compared to BALB/c mice at day +2. The percentage inflammation was 
determined on 3 different mice at each time point (n=3). 
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4.2.11 Comparison of the difference in amount of inflammation in 
BALB/c and C57BL/6 mice  
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Figure 153: Difference in percentage inflammation in immuno-suppressed and 
infected BALB/c and C57BL/6 mouse lung 
The same pattern of inflammation was seen in BALB/c and C57BL/6 mice. The percentage 
inflammation in C57BL/6 mice was less than BALB/c mice. There was no noticeable 
difference in the inflammation between BALB/c and C57BL/6 mice. The percentage 
inflammation was determined on 3 different mice (n=3). 
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4.2.12 Comparison of the chemokine and cytokine responses in 
BALB/c and C57BL/6 mice lungs 
The chemokine and cytokine responses were measured in C57BL/6 and BALB/c 
mice separately and then compared with each other. Both immuno-suppressed and 
immuno-competent infected BALB/c mice produced more chemokine and cytokine 
when compared to C57BL/6 mice. Chemokine and cytokine expression was higher in 
C57BL/6 healthy mice as compared to healthy BALB/c mice. Chemokine and 
cytokine responses were suppressed in C57BL/6 and BALB/c mice after immuno-
suppressive treatment. No comparison was performed between AmB-PMA treated 
BALB/c and AmB-PMA treated C57BL/6 mice, due to different dose of AmB-PMA 
administration. 
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Figure 154: Comparison of the MIP-1β and TNF-α expression in BALB/c and 
C57BL/6 mice lungs 
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MIP-1β and TNF-α were measured in each strain of mice and compared. There was a 
significant difference in MIP-1β in healthy, immuno-suppressed and immuno-suppressed 
infected C57BL/6 mice as compared to BALB/c mice. No significant difference was seen in 
MIP-1β expression of immuno-competent infected C57BL/6 mice as compared to BALB/c 
mice. In contrast, a significant difference was seen in TNF-α expression of immuno-
competent infected C57BL/6 mice when compared with BALB/c mice. All mice were culled at 
day +2 (n=4 mice/group).  
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Figure 155: Comparison of the IFN-γ expression in BALB/c and C57BL/6 mice 
lungs 
IFN-γ expression in C57BL/6 mice compared with BALB/c mice. There was a significant 
difference in IFN-γ expression in healthy, immuno-suppressed and immuno-suppressed 
infected C57BL/6 mice as compared to BALB/c. No significant difference was seen in IFN-γ 
between BALB/c and C57BL/6 immuno-competent infected mice. All mice were culled at day 
+2 (n=4 mice/group).  
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Figure 156: Comparison the iNOS and IL-10 expression in BALB/c and C57BL/6 
mice lungs 
iNOS and IL-10 expression in C57BL/6 mice as compared to BALB/c mice. There was a 
significant difference in iNOS and IL-10 expression in C57BL/6 healthy mice as compared to 
314 
 
BALB/c healthy mice. There was no noticeable difference in iNOS and IL-10 mRNA levels in 
(immuno-suppressed only) and immuno-competent infected C57BL/6 and BALB/c mice. IL-
10 expression in immuno-suppressed infected BALB/c mice was almost 5 times more than 
IL-10 expression in C57BL/6 mice. All mice were culled at day +2 (n=4 mice/group).  
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Figure 157: Comparison of the IRF-1 expression in BALB/c and C57BL/6 mice 
lungs 
No significant difference was observed in IRF-1 expression between both BALB/c and 
C57BL/6 healthy mice. Both immuno-competent infected BALB/c and C57BL/6 mice had the 
same level of IRF-1. Immuno-suppressed and (immuno-suppressed + infected) BALB/c and 
C57BL/6 mice also had the same levels of IRF-1. All mice were culled at day +2 (n=4 
mice/group).  
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Chapter 5 
5.1 Discussion 
5.1.1 In-vitro studies 
Invasive aspergillosis (IA) has become the most serious infection in transplant 
patients on immuno-suppressive therapy and Aspergillus fumigatus is responsible for 
most of the invasive fungal infections. The data from the US TRANSNET registry 
shows that, patients with solid organ transplantation have an overall risk of 3.1% per 
annum for invasive fungal infections, and this risk continues for at least 3 years after 
transplantation (Pappas et al., 2010). To overcome the problems of poor responses 
to antifungal therapy, effective prophylactic strategies are being developed. Atkins & 
Crowder (2004) reported that: ‘‘because of insufficient drug diffusion into pulmonary 
tissue and dose-limiting toxicities, pulmonary infections do not always respond well 
to systemic therapy’’ (Atkins & Crowder, 2004). In the last few decades, aerosol 
delivery of antifungal drugs has been of increasing interest. Avoiding the systemic 
side-effects by direct deposition of antifungal drugs in the lungs is the main 
advantage of inhalation of antifungal agents. Amphotericin B (AmB) is a membrane 
active polyene antifungal drug which has been used as an effective drug against 
several systemic fungal infections. It is the only antifungal drug which has been used 
for many years without the appearance of fungal resistance. It acts by binding to the 
ergosterol of fungal membranes (Kasai et al., 2008). However, it also binds to 
cholesterol and this property increases its toxicity when it is given intravenously to 
patients (Kawabata et al., 2001). Due to its unusual and amphipathic structure, AmB 
aggregates in water and it has low water solubility. These problems have meant that 
a lot of suitable formulations of AmB has formed on which minimize its side effects 
in-vivo.  
The existing formulations of AmB include Abelcet, Ambisome and Amphotec. Their 
utility as cost-effective medicine is limited by the high dose requirements and high 
cost. 
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The use of polymers has gained special attention as a cost-effective alternative 
method for the delivery of AmB (Liu et al., 2009). In my research, poly-methacrylic 
acid sodium salt (PMA-Na) has been used as a suitable vehicle for pulmonary 
delivery of AmB. It improved the water solubility and decreased the aggregation state 
of AmB to considerable effect. 
There are other biodegradable polymers such as poly (lactic acid) (PLA) and poly 
(glycolic acid). Both of these polymers are used in medical applications such as 
medical dressings and orthopaedic implants. However, their long biological half-life 
limited their use in pulmonary delivery (Labiris & Dolovich, 2003). 
I chose to work with PMA-Na because recent years have witnessed the emergence 
of PMA-Na hydrogel capsules that have been shown to be safe in animals, and their 
development into a mature biomedical platform. PMA-Na is already widely and safely 
used in inhalers. It is available in high purity and low polydispersity. Mixtures of 
oppositely charged polyelectrolytes can be used to form discrete, stable and water-
soluble macromolecules (Sajeesh et al., 2010; Singh et al., 2001; Nakamura et al., 
1999). This relies upon the self-assembling ability of polycarboxylic acids with the 
hydrogen bonds formed acting co-operatively to create strong oligomeric structures 
that have a water-soluble coat in water. In the case of PMA, there is the added 
advantage that its hydrogel swelling behaviour is pH dependent as I have also 
shown in Figure 49 (Sanchez-Brunete et al., 2004; Corware et al., 2011).  These are 
the main advantages of using PMA-Na as a drug carrier for the pulmonary delivery of 
AmB. 
At alkaline pH (e.g., pH 8), the carboxylic acid groups of AmB are ionized and they 
repel each other; this means that the PMA hydrogel swells and AmB becomes 
trapped within the PMA matrix. However, at acid pH (e.g., pH 5), the carboxylic acid 
groups are not ionized and the PMA hydrogel collapses to release AmB. This makes 
these pH responsive polymers, with their rapid and reversible switching between 
well-defined size based conformations, into useful candidates for miniaturized drug 
delivery for certain tissue micro-environments such as inhalation based 
administration to the lung.  
There are already examples of antifungal drug delivery by PMA-Na. For example, 
the antifungal drugs miconazole and chlorhexidine bind to PMA-Na through an ionic 
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interaction. They have been developed as anti-conidial drugs to treat conidia-
associated denture stomatitis (Cao et al., 2010).  
I chose to work with the AmB polyene antifungal drug because it is the only 
antifungal drug to which fungal resistance has not emerged, and it is low cost (Kasai 
et al., 2008). Previous work by Harris (2006) and Corware (2011) in Professor 
Shaunak's laboratory had demonstrated that AmB could be efficiently and effectively 
packaged into PMA-Na. AmB-PMA showed less cell toxicity and less RBC lysis in-
vitro than AmB alone. It was also highly effective at killing leishmania.  
In my PhD thesis, I have shown that the previous work undertaken by Harris (2006) 
and Corware (2011) with AmB and PMA-Na could be extended to create several 
new compounds that are suitable for aerosol based delivery. These new AmB-PMA 
compounds have an optimised AmB loading of between 25% and 40%, having been 
made with PMA-Na molecules whose MWt ranges from 1.2 kDa to 18 kDa. 
Optimisation of the chemical synthetic process, as previously described by both 
Harris and Corware, was required to achieve reliable, reproducible and consistent 
synthesis of these new compounds. This has meant that a major chemical synthesis 
milestone has now been achieved and that these compounds are now suitable for 
detailed biological studies. My aim was to develop a new and safe alternative AmB 
therapy for prophylaxis against IA.  
 
5.1.1.1 Biological properties of PMA-Na 
The biological properties of the different sizes of PMA-Na were determined in-vitro. 
Monocytes, U937 and A549 cell lines were used for these biological studies. In 
addition to these cell lines, the effect of PMA-Na was also tested on RBCs. Toxicity 
was assessed using both a haemolysis assay and an MTT assay. No toxicity was 
seen to both RBCs and monocytes after incubation with different sizes of PMA-Na. 
The pro-inflammatory properties of PMA-Na were also determined. 
The main aim of testing the pro-inflammatory effects of PMA-Na in-vitro was to 
ensure that it had no endogenous or detrimental immune effects in-vivo. There was 
no increase in mRNA level of cytokines after stimulation with PMA-Na as compared 
to untreated cells. PMA-Na did not induce MIP-1β, TNF-α and IFN-γ expression after 
stimulation of MDMs with 25 µg/ml PMA-Na.   
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The absence of a pro-inflammatory effect means that PMA-Na did not increase 
expression of cytokines in human primary cells. Nakamura et al. reported that PMA-
Na was suitable for use in blood and it has been accepted for use in therapeutics for 
asthma (Nakamura et al., 1999). In addition, recent studies by Sajeesh and Sharma 
have shown that PMA-Na can be used to encapsulate insulin for its oral therapeutics 
delivery (Sajeesh & Sharma, 2004). This makes PMA-Na safe for use as a drug 
carrier in humans.  
 
5.1.1.2 AmB-PMA synthesis reaction 
All the AmB-PMA reaction mixtures were performed in endotoxin-free conditions. 
Some modifications were necessary to the synthesis protocol as compared to the 
previous protocol as developed by Dr Karina Corware and Dr Debbis Harris. These 
modifications included addition of NaOH, increasing the duration of AmB 
solubilisation, overnight pH recording, pH re-adjustment during the dialysis phase, 
and different sources of AmB.  
NaOH was added to the synthesis protocol in the presence of PMA-Na and AmB. 
NaOH forced the AmB into a monomeric state and before its interactions with PMA-
Na. Addition of NaOH to the reaction mixture at any other time did not improve the 
non-covalent association of AmB with PMA-Na and often led to the aggregation of 
the AmB.  
Simply mixing AmB and PMA-Na together did not give a soluble AmB-PMA product. 
AmB and PMA-Na were stabilized by solubilising them in DMSO and water 
respectively.  For AmB-PMA to be formed, NaOH was added to the AmB to force it 
into a monomeric state. When aqueous PMA-Na was then added to this monomeric 
AmB, it allowed the AmB to associate non-covalently with the PMA-Na. Zeghal 
(1999) reported that PMA-Na can form strong hydrogen bonds and oligomeric 
structures with a polyanionic coat in water in the presence of oppositely charged 
polyelectrolytes (Zeghal, 1999; Corware et al., 2011). This was important for the 
formation of my AmB-PMA. 
In the previous synthesis protocol, AmB was solubilised for 1 h. But in my synthesis 
protocol, the solubilisation was extended to 3 h. 50 mg of AmB powder was divided 
equally into 3 parts and each one solubilised for 1 h before use. This limited the 
aggregation of the AmB. 
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Different studies have reported that variability in pH can also affect the stability of the 
AmB. Poor stability contributes to the toxicity of AmB. In my synthesis method, the 
pH was recorded regularly for 24 h.  
Another change which was made to the synthesis protocol was maintaining the pH at 
an alkaline pH at all times. In addition to pH recording, the pH of AmB-PMA was also 
re-adjusted to an alkaline pH before the overnight dialysis; i.e. pH re-adjusted to pH 
12 (the pH of solution before starting the dialysis) and maintained at pH 7-7.5 at the 
end of the dialysis. In contrast, in the previous protocol, the pH of AmB-PMA 
dropped down to the acidic pH range at the end of dialysis.  
Another difference between this synthesis and the previous synthesis was the 
source of AmB. This chemical synthesis was performed with 2 sources of AmB: 
Fungizone (Squibb) and AmB from Sigma; the previous protocol used Fungizone as 
source of AmB.   
Once the AmB-PMA was synthesised, it needed to be purified. Dialysis was used to 
purify the AmB-PMA. Dialysis was optimised by studying the effect of pH, membrane 
pore size, temperature and time on the physico-chemical and biological 
characteristics of the AmB-PMA. Due to the different MWts of the PMA-Na, different 
dialysis membrane pore sizes of cassettes were used in this study. Cassette 2 kDa 
dialysis membrane was found to be the best molecular cut-off for dialysis of the 
reaction mixture. It removed free-AmB without removing the AmB-PMA. In addition 
to the 2 kDa dialysis membranes, 3.5 kDa and 7 kDa were also used for dialysis of 
the AmB-PMA (8 kDa) and the AmB-PMA (18 kDa). 
Temperature was controlled throughout the synthesis at 4°C. The prevented re-
aggregation of the AmB which can occur with increasing temperature due to the heat 
produced during the synthesis. 
pH was also strictly controlled throughout the synthesis reaction. The pH of the AmB-
PMA complex was kept at an alkaline pH during the synthesis and the dialysis. The 
careful definition of each of these conditions during the synthesis of the AmB-PMA 
was critical for the optimum production of batches with minimal variation from batch-
to-batch. 
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5.1.1.3 Chemical properties of AmB-PMA 
The chemical characterisations of the AmB-PMA were then determined. AmB from 
Sigma-Aldrich and Fungizone (Squibb) were used as the sources of AmB for the 
AmB-PMA synthesis. The toxicity of each batch synthesised with AmB from both 
sources was determined in-vitro. From the comparison of these batches, I concluded 
that the batches synthesised with AmB from Sigma showed less toxicity to RBCs 
and A549 & U937 cell lines than the AmB derived from the Fungizone from Squibb. 
This is likely due to the presence of deoxycholate acid in Fungizone becoming 
trapped in the AmB-PMA.  
The percentage of AmB loading was determined using a UV spectrophotometer. 
Dynamic Light Scattering (DLS) was also used to determine the size of the AmB-
PMA. The size of AmB-PMA (3.1 kDa) synthesised with AmB from Fungizone and 
AmB from Sigma were measured and compared with Fungizone. The median 
diameter of AmB-PMA synthesised with AmB from Sigma was 174.9 nm as 
compared to 78.9 nm for AmB-PMA using AmB from Fungizone. The median 
diameter of AmB-PMA (18 kDa) and AmB-PMA (3.1 kDa) with both synthesised with 
AmB from Fungizone was 94.1 nm and 78.9 nm, respectively. The batches 
synthesised with Fungizone had a smaller median diameter as compared to the 
batches synthesised with AmB from Sigma. Fungizone has an average diameter of 
75.6 nm (Figure 63). 
The sizes of the AmB-PMA batches also varied slightly depending upon the size of 
the PMA-Na used.  For example, AmB-PMA with an 18 kDa PMA-Na polymer had 
slightly bigger median diameter (Figure 60) as compared to 3.1 kDa PMA-Na 
polymer (Figure 61). 
Stuart et al. have recently suggested that an ideal drug delivery system for inhalation 
of drugs should have a diameter of 25-100 nm. If the average diameter of each 
particle exceeds 200 nm, then it will be too large to be engulfed by alveolar 
macrophages. This would make it unsuitable for delivery to the lungs (Stuart et al., 
2010). DLS showed that the physico-chemical characteristics of AmB-PMA and 
Fungizone were similar. 
This meant that a major chemical synthesis milestone and also the physico-chemical 
properties of AmB-PMA were found to be suitable for testing these compounds in my 
in-vitro biological systems. 
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5.1.1.4 Biological characterisation of AmB-PMA 
The biological characterisation of AmB-PMA was determined using RBCs and 
primary human cells in-vitro. 
Toxicity was assessed using both a haemolysis assay and an MTT assay. The 
haemolysis assay showed that all of the AmB-PMA compounds synthesised were 
less haemolytic than Fungizone (8.1 ± 1.1% at 12.5 μg/ml). The AmB-PMA (18 kDa) 
that I synthesised had the same haemolytic activity as reported by Dr Harris and Dr 
Corware at 1.7 ± 0.3% at 12.5 μg/ml. Amongst the other compounds synthesised, 
the lowest haemolytic activity was seen in AmB-PMA (1.2 kDa) at 1.8 ± 0.6% at 12.5 
μg/ml and for AmB-PMA (3.1 kDa) at 2.8 ± 0.4% at 12.5 μg/ml (Table 15, Page 175). 
The cytotoxicity assay showed that all of the AmB-PMA compounds were less toxic 
than Fungizone (LD50=200 μg/ml). AmB-PMA (3.1 kDa) was the least cytotoxic of the 
new compounds synthesised with an LD50=362 μg/ml (Table 15, Page 175). This 
reduced toxicity of AmB-PMA (3.1 kDa) might be because of the different structure of 
PMA-Na (3.1 kDa) which promotes its high binding with AmB and leads to less cell 
toxicity as compared with the other sizes of PMA-Na. 
A comparison was performed between the toxicity of the AmB-PMA batches 
synthesised with AmB from Sigma and AmB from Fungizone. Less cell toxicity and 
haemolytic activity were observed in AmB-PMA batches synthesised with AmB from 
Sigma as compared to batches with AmB from Fungizone. The reduction in toxicity 
that was observed in batches synthesised with AmB from Sigma as compared to 
AmB from Fungizone means that more AmB can be administered to patients. 
Currently, the long treatment regimen required is the main disadvantage of available 
antifungal drugs. For example, Fungizone cannot be given to patients for more than 
20 days due to its toxicity (Kleinberg, 2006). Additional hospital monitoring is 
required for the side effects. This results in an increase in total treatment cost per 
patient. Although, Ambisome (Liposomal AmB) is practical, can be given in a higher 
dose and has a short-term regimen, its utility is limited by its high cost (Amato et al., 
2007). 
All of the AmB-PMA compounds synthesised also showed in-vitro activity against 11 
isolates of A. fumigatus. The best MIC was seen with AmB-PMA (3.1 kDa) at 0.125 
μg/ml and with AmB-PMA (8 kDa) at 0.125 μg/ml. Notably, the poorest activity was 
seen with AmB-PMA (18 kDa) at 0.5-1 μg/ml.  
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The immuno-modulatory activity of all of the compounds was also determined using 
human MDMs as previously determined for the polymer. The pro-inflammatory 
measurements showed that all batches of AmB-PMA did not stimulate a pro-
inflammatory response in MDMs at a concentration of 25 µg/ml AmB. In this assay, 
the results with the AmB-PMA (3.1 kDa) compound were almost identical to those 
that have been previously been reported for AmB-PMA (18 kDa) by Corware et al., 
2011.  
There was no immuno-modulatory response after stimulation of MDMs with 25 µg/ml 
AmB in AmB-PMA (3.1 kDa). However, at a concentration of more than 25 µg/ml 
AmB the TNF-α, IFN-γ, MIP-1β and IL-6 expression were increased. Interestingly, 
unlike TNF-α, MIP-1β and IL-6, IFN-γ expression was increased to levels seen in 
LPS stimulated MDMs. This observation is important because elevated levels of IFN-
γ are necessary for fungal clearance, and a drug carrier that also elevates IFN-γ and 
kills Aspergillus has great therapeutic potential; it could be used as an 
immunotherapeutic adjuvant for treating IA. 
However, the IFN-γ expression was less in MDMs cells in-vitro when HC + FK-506 
were present.  
 
5.1.1.5 Summary of in-vitro studies 
I have determined the biological characterisation of low MWts PMA-Na. Then, I have 
developed a novel low MWt and non-toxic AmB-PMA molecule which has the 
potential for use for prophylaxis against pulmonary aspergillosis in a new solid organ 
transplant immunosuppressed mouse model. My studies show that established, 
scalable and low cost synthetic methods can be used to make a water soluble AmB-
PMA that is both safe and stable. It is non-toxic to human cells and could be used as 
an effective antifungal drug for killing A. fumigatus. Toxicity was assessed using both 
haemolysis and MTT assays. My studies showed that all of the AmB-PMA 
compounds synthesised were less toxic than Fungizone. Taken together, AmB-PMA 
(3.1 kDa) was far less haemolytic and far less toxic than Fungizone, and it was 
therefore taken forward for further in-vivo studies. In addition to this, the data in this 
thesis also shows that AmB-PMA can stimulate the production of IFN-γ in MDMs 
which, in turn, could lead to a more favourable immune response for treating A. 
fumigatus in-vivo. 
323 
 
5.1.2 In-vivo studies 
Invasive fungal infections are an important cause of morbidity and mortality in solid 
organ transplant patients who are immuno-suppressed with calcineurin inhibitors and 
steroids (Pappas et al., 2010). I have used an animal model which was developed by 
Herbst et al and published in 2013. This animal model used both FK-506 & HC as 
immuno-suppression and it enabled me to evaluate the efficacy of the AmB-PMA. 
The association of FK-506 and steroid drug regimens contribute to increased 
susceptibility to invasive fungal infections in organ transplant recipients (Herbst et al., 
2013). 
The aim of the second part of this thesis was to determine the efficacy of AmB-PMA 
in-vivo. Combating A. fumigatus infections is dependent on the development of a 
sufficient Th1 immune response. This involves the production of IFN-γ which 
augments innate and Th1 dependent immunity (Elenkov, 2004). Immuno-suppressed 
BALB/c and C57BL/6 mice are susceptible to pulmonary fungal infections and they 
cannot eliminate or control fungal growth. This is believed to be due to down-
regulation of the Th1 immune response after steroid treatment. In addition, the 
presence of a Th2 response that involves the up-regulation of IL-10 inhibits fungal 
clearance in the lung. The optimised AmB-PMA was tested for its efficacy as 
prophylaxis against pulmonary aspergillosis in this new solid organ transplant 
immuno-suppression mouse model.   
Specifically, it was evaluated for its prophylaxis properties in reducing the fungal load 
and inhibiting the invasion of hyphae into lung tissue. The different routes of 
administration, dosing regimens and treatment frequency were also determined in 
BALB/c mice. The efficacy of AmB-PMA administration on disease progression was 
assessed by CFU, DNA fungal load and qPCR analysis of chemokine and cytokine 
responses in the mouse lung. QPCR analysis was used to measure the differences 
in chemokine and cytokine responses in immuno-suppressed infected, untreated and 
AmB-PMA treated BALB/c and C57BL/6 mice.  
Due to the increased occurrence of IA in high-risk populations, prophylaxis against 
IA is important. There are three potential antifungal prophylactic strategies. One 
strategy is administration of nonabsorbable antifungal drugs to decrease the 
colonization of the patient‘s gastrointestinal tract. The second is to give systemic 
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antifungal agents to recipients at the time of surgery or after organ transplantation. 
The third is to aerosolize antifungal drugs directly into the lung (Perfect et al., 2004). 
Inhaled AmB is a useful option for prevention of IA and it has been reported to 
decrease the incidence of IA in solid organ transplant populations and neutropenic 
patients (Arthur et al., 2004). Additional data supports the use of inhaled AmB for 
prophylaxis against IA while minimizing the drug interactions and toxicities 
associated with other intravenous formulations of AmB. For example, Fungizone is 
highly toxic to RBCs and renal tubules and accumulates primarily in the 
reticuloendothelial system when given intravenously (Mohammad & Klein, 2006). 
When AmB is given by nebuliser, no AmB was detected in blood or other organs 
(Ruijgrok et al., 2006). The lack of adverse effects and good tolerability are big 
benefits of using inhaled AmB for prophylaxis against IA, as are the absence of any 
known acquired resistance mechanisms (Mohammad & Klein, 2006). 
There was a limitation in the animal model based studies of using free AmB, 
Fungizone or AmBisome for the following toxicity related reasons. Firstly, free AmB 
is insoluble in water and not absorbed through the lung epithelium and will only 
dissolve in an organic solvent such as DMSO. However, DMSO has known 
significant side effects and it was found to be toxic to epithelial cells. Secondly, 
Fungizone is made up of 66% deoxycholic acid and only 33% AmB. Deoxycholic 
acid is a detergent and causes swelling, pain, acute inﬂammatory inﬁltration, fat 
necrosis, and necrosis of small blood vessels (Odo et al., 2007; Schuller-Petrovic et 
al., 2008; Corware et al., 2011). Ambisome nebulisation is not nephrotoxic and can 
be introduced as an alternative option treatment against IA, although its very high 
cost limits its usage. 
Current IA treatment involves intravenously, oral and aerosol administration of 
antifungal drugs (Ruijgrok et al., 2000). Disseminated fungal infections used to be 
treated by intravenous administration of AmB formulations, but recently, aerosol 
delivery of AmB is gaining more attention (Panagiotis et al., 2010). 
Therefore, I assessed the efficacy of AmB-PMA to treat immuno-suppressed and 
infected BALB/c and C57BL/6 using different delivery routes. Both aerosol and 
intranasal delivery of AmB-PMA administration were tested in mice. Both routes of 
AmB-PMA administration decreased the emergence of focal hyphae as compared to 
the infected untreated mice. 
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The non-toxic transport of AmB into the airways and tissues in the form of AmB-PMA 
is therapeutically very useful. However, when taken up into the acidic micro-
environment of the endosomal-lysosomal compartment (pH 5-5.5) in which the 
fungus will survive and persist, the carboxylic acids will no longer be ionized, the 
hydrogen bonds will disappear, and the hydrogel’s matrix will collapse. As a result, 
the AmB will be released. This should rapidly kill A. fumigatus. 
My studies have shown that the aerosol administration of AmB-PMA was more 
effective than intranasal administration. I found that there were a few focal hyphae in 
AmB-PMA treated group after intranasal administration of AmB-PMA at day +2. 
However, no focal disease was seen after AmB-PMA nebulisation. Some spores 
were seen within alveolar macrophages.  
Due to poor distribution of AmB-PMA in the lung after intranasal administration, I 
subsequently developed aerosol delivery of AmB-PMA using a nebuliser.  
Before determining the efficacy of nebulised AmB-PMA in an immuno-suppressed 
animal model of invasive aspergillosis, it was important to find a suitable nebuliser 
for aerosol delivery. Different nebulizers have been used in the several published 
reports. I have tested two different nebulizers to determine the most suitable 
nebulizer for delivery of AmB-PMA. The parameters such as design, operating 
conditions and ancillary equipment are pivotal for final delivered dose and product 
stability delivered by nebuliser (Drew, 2006). AmB-PMA (3.1 kDa) was administrated 
to the mouse lung using an AeroEclipse II nebuliser. 
My results show that AmB-PMA can be administered by nebuliser and that it protects 
immuno-suppressed BALB/c mice against IA. There are two advantages of using 
AmB as an aerosol. First, remarkably high concentrations of AmB can be achieved in 
the lower respiratory tree as compared to intravenous delivery which results in toxic 
accumulation of AmB in the liver and spleen. Second, the AmB-PMA complex will be 
suitable for formulation into a simple inhaler which would enable patients to self-
medicate the drug daily (Christiansen et al., 1985). 
Aerosolised antifungal prophylaxis has been shown to be a safe and effective 
alternative approach to preventing IA. It was found that it is free from drug 
interactions and there are no undesirable side-effects that result.   
The correct administration is an important factor in determining the efficacy of AmB-
PMA by inhalation. Therefore, the following need to be taken into account: 
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1) Type of nebuliser and compressor: a suitable nebuliser producing aerosol 
particles that are 2-5 µm in diameter. 
2) The drug solution and volume: the solution must be isotonic.  
The prophylaxis with antifungal drugs also requires consideration of the conditions 
below:  
Drew (2006) reported that: “ the ideal prophylactic agent would possess the following 
characteristics: (1) efficacy established by randomized, controlled clinical trials; (2) 
acceptable safety profile; (3) sufficiently broad-spectrum antifungal activity to prevent 
the most prevalent aetiologies of IFIs; (4) easy to administer (e.g. oral rather than 
intravenous) and (5) free of significant drug interactions”. 
This efficient mode of administration was observed for delivery of other antifungal 
drugs such as itraconazole (Alvarez et al., 2007) caspofungin (Kurtz et al., 1995) and   
voriconazole (Tolman et al., 2009). However, still more in-vivo studies are required to 
evaluate the aerosolisation of these antifungal drugs.  
Although aerosolisation is a useful route of drug delivery, the aerosolisation of 
Fungizone is a problem due to the following reasons: 
1) Fungizone inhibited surfactant function in the lung due to the presence of 
deoxycholate which acts as a detergent (Ruijgrok et al., 2001).  
2) It cannot be administered at much longer intervals. 
 
5.1.2.1 Dosing schedule  
As explained earlier, a suitable therapeutic antifungal drug for treating IA would have 
no toxicity and require a simple method of administration. After optimisation of the 
AmB-PMA synthesis protocol and determination of both nasal and pulmonary routes 
of administration, the optimal dosing and frequency of AmB-PMA administration 
were defined. The dosing regimens were tested by trying a range of different doses 
in-vitro by nebulising the AmB-PMA onto a SAB agar plate in a chamber. The initial 
dose of aerosolisation was based on the dose that was used for intranasal 
administration of AmB-PMA. This dose of AmB-PMA was 40 µg AmB. There was a 
significant difference in the histology of AmB-PMA treated mice lungs as compared 
to infected and untreated mice after intranasal administration of this dose of AmB-
PMA. 
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No difference was seen between AmB-PMA treated and untreated mice after 
nebulisation of 40 µg AmB. This suggested that the nebulisation dose needed to be 
higher than the intranasal dose. As explained earlier, one of the disadvantages of 
nebulisation with AeroEclipse II nebuliser is the waste of drug during nebulisation. In 
the next animal experiment, I decided to increase the nebulisation dose of AmB-PMA 
to 400 µg AmB. The results from that study showed a major reduction in fungal 
burden in immuno-suppressed and AmB-PMA treated mice as compared to infected 
and untreated mice. Histological lung sections showed disseminated fungal hyphae 
in immuno-suppressed and infected BALB/c mice as compared to immuno-
suppressed and AmB-PMA treated BALB/c mice (400 µg AmB). However, some 
inflammation was still seen (10 ± 1.16%, Figure 98). This compared favourably with 
the 6.5 ± 1.2% inflammation seen in immuno-competent and infected BALB/c mice. 
Therefore, it was decided to decrease the total amount of AmB from 400 µg to 200 
µg AmB. The total amount of AmB was decreased by reducing the dose of AmB per 
nebulisation, and by increasing the period and number of nebulisations administered.  
Three different doses 200 µg, 250 µg and 300 µg AmB were then tested and 
compared with each other. This study showed that 300 µg AmB led to the rapid 
control of the fungal load and CFU in immuno-suppressed and infected BALB/c 
mice. At a total dose of 200 µg AmB the fungal load and inflammation were reduced. 
Moreover more inflammation was observed after 200 µg AmB nebulisation (20 ± 
2.75%, Figure 95, Page 241) as compared to 300 µg AmB (14 ± 1.19%, Figure 97, 
Page 242). These data suggest that AmB-PMA administration of less than a total 
dose of 200 µg AmB is insufficient to kill the A. fumigatus fungi in this immuno-
suppressed mouse model. 
It was concluded that nebulisation of AmB-PMA containing 300 μg AmB prevented 
the germination of Aspergillus spores into mycelia. Therefore, it could be a safe and 
effective prophylactic dose that gives rise to good efficacy in-vivo with no 
inflammation and no side-effects. 
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5.1.2.2 AmB-PMA prophylaxis studies  
When the optimal dosage had been determined, then the frequency of AmB-PMA 
administration was defined. To evaluate the therapeutic properties of AmB-PMA 
against IA, prophylaxis started by administration of AmB-PMA for 3 days before 
infection. It was found that the AmB-PMA had a significant potential to reduce both 
the fungal burden and lung inflammation in AmB-PMA treated mouse lung as 
compared to the infected untreated mouse lung. The success of these initial 
experiments and also experiments into different routes of administration encouraged 
me to progress with defining a precise treatment schedule. Administration of AmB-
PMA for 3 days before A. fumigatus infection resulted in a large reduction in the 
fungal load. I also investigated whether increasing the number of AmB-PMA doses 
given could be more effective than increasing the total amount of AmB given per 
nebulisation. Therefore, the effect of increasing the number of doses administered 
from 3 days to 4 days was determined. AmB-PMA was administrated for 4 days in 
two different schedules. They were:  
(a) AmB-PMA was administrated for 4 days before infection as (-3,-2,-1 and 0) and (-
4,-3, -2 and -1) schedules. For both 4 day courses of AmB-PMA nebulisation, there 
was no significant difference in either fungal killing or lung inflammation. In addition, 
no difference was seen in the reduction of fungal load in AmB-PMA treated mice 
after 4 days administration at days (-3,-2, -1 and 0) as compared to administration at 
days (-4,-3, -2 and -1). The chemokine and cytokine responses were also similar 
with both schedules of AmB-PMA administration by nebulisation.  
In addition to evaluation of the effect of AmB-PMA administration before infection, 
the effect of AmB-PMA administration was also determined after infection. As shown 
in the results section on pages 273 and 282, the focal hyphae developed after 4 and 
8 days of infection. This data showed that the focal hyphae appeared at day +4 and 
that they increased in number by day +8 in AmB-PMA treated mice (Figure 131, 
Page 282). Extending the time post-infection without continuing with the daily dose of 
nebulised AmB-PMA leads to widespread lung disease with multiple foci of hyphae 
and tissue necrosis in the immuno-suppressed and A. fumigatus infected BALB/c 
mice. 
Immuno-suppressed and infected BALB/c mice receiving 300 µg nebulised AmB for 
four days before infection lived for longer than the control animals; the untreated 
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immuno-suppressed mice died at 48 h after infection. In contrast, the AmB-PMA 
treated mice were still alive 8 days after being infected and with less than 10% 
weight loss. However, there was an increase in fungal burden in AmB-PMA treated 
group 8 days after infection (Figure 127, Page 276). At day +8 post-infection, an 
increase in the cytokine responses was also observed. TNF-α, MIP-1β, iNOS and IL-
10 were increased by extending time post-infection from day +2 to day +8. In 
contrast, IFN-γ decreased from day +2 to day +8 (Figure 129, Page 279). These 
data suggest that the high fungal load and CFU at days +4 and +8, as compared to 
day +2, is likely due to a loss of AmB activity in the lung followed by focal 
germination of the persistent Aspergillus spores present in the alveolar macrophages 
(Figure 131, Page 282). 
Therefore, to tackle this problem, I decided to nebulise AmB-PMA both before and 
after exposure to A. fumigatus conidia. This would mean that the aerosolised AmB-
PMA would be most effective as prophylaxis but also needed to be given after 
infection to prevent the persisting Aspergillus spores in the lungs from germinating. 
Therefore, AmB-PMA was nebulised for 4 days before infection and for 2 days after 
infection with the mice kept for 4 days after infection.  
These studies showed that there was no difference in CFU, fungal load and number 
of focal hyphae in AmB-PMA treated mice at day +4 as compared to mice which 
were only given prophylaxis. One explanation could be the incomplete distribution of 
AmB-PMA throughout the both periphery of lung fields. This meant that the spores in 
the alveolar macrophages in the peripheral lung could germinate into tissue invasive-
hyphae because they had not been exposed to an adequate dose of AmB-PMA. 
 
5.1.2.3 Immunological studies 
The in-vivo studies of AmB-PMA against IA also addressed the question of whether 
it modulated host immune responses. Chemokine and cytokine levels in infected and 
untreated animals were compared to infected and AmB-PMA treated mice using RT-
PCR analysis of lung tissue homogenates at different time points post-infection.  
Phagocytosis of bacteria and fungi by AMs as part of the innate immune response 
protects the immuno-competent host. AMs and recruited monocytes play a major 
role in this host defence against A. fumigatus infections. The innate immunity 
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response against A. fumigatus is primarily mediated by production of cytokines and 
chemokines by phagocytic cells (Cortez et al., 2006). IFN-γ and TNF-α are the most 
important cytokines responsible for host resistance against A. fumigatus 
infection. Damage to lung tissue is secondary to the recruitment of inflammatory 
cells to the site of infection in the lung. 
As previously described in my introduction, exposure of the host to A. 
fumigatus spores leads to the development of CD4 T cells including; Th1, Th2 and 
Th17 (Bozza et al., 2009; Cramer et al., 2011). CD4 T cells are important effector 
cells in the protection of the host against IA. It was reported that Th1 responses also 
benefit the host by neutralizing Th2 cytokines and that this improves the disease 
outcome in immuno-suppressed (in the case of the references given here, 
neutropenic) hosts (Cenci et al., 1997; Cramer et al., 2011).  
During the AmB-PMA prophylaxis studies, mRNA expression of chemokine and 
cytokine was measured. As Th1 or Th2 immune responses play a critical role in the 
resolution of IA, it was important for me to define the cytokine profiles that have been 
reported to be important in Th cell subset differentiation. The cytokine IFN-γ drives 
and upregulates a Th1 immune response with the aid of TNF-α & IL-12 (Liew et al., 
1990; Corware et al., 2011). I determined the role of TNF-α, IFN-γ, IL-10, iNOS and 
MIP-1β in mouse lung in response to A. fumigatus hyphae and with administration of 
AmB-PMA.  
As shown in the results chapter, AmB-PMA stimulates the expression of IFN-γ from 
MDMs in-vitro (Figure 68, Page 206). It was expected that IFN-γ would also 
stimulate IFN-γ production from immuno-suppressed and infected and AmB-PMA 
treated mouse lung. My results show that immuno-suppressed mice have a markedly 
decreased production of IFN-γ cytokine after exposure to A. fumigatus. 
Administration of AmB-PMA had no effect on IFN-γ mRNA expression when 
compared to immuno-suppressed and infected mice. It is likely that the steroid 
treatment required to make the mouse susceptible and suppresses IFN-γ production 
from mouse alveolar macrophages. Steroids suppress IRF-1 production and AmB-
PMA administration could not reverse that (Figure 146, Page 302). 
Sau et al reported that, AmB induces the expression of inflammatory cytokines from 
cells expressing TLR-2 receptor. It was suggested that this receptor may be 
necessary for AmB-dependent inflammatory stimulation of innate cells (Sau et al., 
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2003; Netea et al., 2003). During A. fumigatus infection and AmB-PMA treatment, 
IFN-γ augments and activates macrophages and this results in NO production via 
iNOS. The result is rapid killing of the Aspergillus in macrophage endosomes. 
However, this process is inhibited by corticosteroids by suppression of IRF-1 
(Granger et al., 1988). My data showed a reduction in IRF-1 and in iNOS after 
steroids and AmB-PMA respectively (Figure 138, Page 291).  
In my initial experiments, there was a significant increase in IFN-γ with AmB-PMA 
containing 300 µg AmB as compared to AmB-PMA doses containing 200 and 250 µg 
AmB (Figure 90, Page 236). In contrast, the decrease in TNF-α was dose dependent 
(Figure 89, Page 235). Therefore, it was decided to repeat the experiment with a 
larger group of mice to confirm the IFN-γ result because of its importance. The 
results from this larger experiment did not show a significant increase in IFN-γ after 
administration of AmB-PMA containing 300 µg AmB as compared to untreated mice 
(Figure 115, Page 263). The IFN-γ level remained lower than that seen in immuno-
competent and infected mice (Figure 115, Page 263). 
RT-PCR analysis further analysed IFN-γ at the time points of 0, +1, +2, +4 & +8. 
IFN-γ decreased in infected and AmB-PMA treated mice by day +2 as compared to 
non-infected and AmB-PMA treated mice at day 0 (Figure 104, Page 250). These 
data showed that in addition to the immuno-suppressive treatment, the exposure to 
A. fumigatus could also be reducing IFN-γ in lung tissue. During these studies, it 
became apparent that the combination of immuno-suppressive treatment (steroids + 
tacrolimus) and exposure to A. fumigatus spores could reduce IFN-γ in the lung 
significantly.   
After extending the time post-infection, IFN-γ was measured at days +4 & +8 and 
compared to day +2. IFN-γ had decreased by day +8 as compared to day +2 (Figure 
129, Page 279). In contrast, levels for other cytokines and chemokine such as MIP-
1β, TNF-α, IL-10 and iNOS increased over 8 days (Figure 128 & Figure 130, Page 
280). Reduction in IFN-γ level was associated with an impaired ability to Kill A. 
fumigatus spores even though the Aspergillus hyphae were killed. Therefore, the 
spores that persisted germinated into fungal hyphae and cause new disease in the 
lung (Armstrong-James et al., 2009).  
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In further studies, I tried to increase IFN-γ and prevent foci of hyphae appearing in 
the day +8 experiments. As explained in the materials and methods, the AmB-PMA 
administration was extended for a further 2 days after infection. Despite this, IFN-γ 
was still significantly lower in infected and AmB-PMA treated mice at day +4 as 
compared to immuno-suppressed and infected BALB/c mice at day +2. There was a 
reduction in MIP-1β, TNF-α and IL-10 levels in immuno-suppressed and AmB-PMA 
treated mice at day +4 as compared to immuno-suppressed and untreated mice at 
day +2. Interestingly, the iNOS expression increased after extending the time of 
post-infection for which AmB-PMA was given (Figure 130, Page 280). 
Reeves et al. reported that AmB increases the synthesis and release of the immuno-
suppressive agent gliotoxin from A. fumigatus (Reeves et al., 2004). Wichmann et al. 
also reported that gliotoxin impairs IFN-γ production (Wichmann et al., 2002). 
Therefore, these finding could explain the hypothesis that the increase in the number 
of AmB-PMA doses given enhanced the release of gliotoxin. This reduces IFN-γ and 
increases the susceptibility of mice to Aspergillus infection.  
IL-10 is an anti-inflammatory cytokine which is responsible for down-regulating the 
Th1 response. IL-10 was down-regulated in response to A. fumigatus and AmB-PMA 
treatment as compared to untreated mice. It has been shown that IL-10 increases 
the susceptibility of the host to IA and acts as a key regulator of inflammatory 
response (Chai et al., 2011). The secretion of IL-10 by activated macrophages is a 
key early host defence mechanism against invasive fungal infections (Bhatia et al., 
2011). IL-10 inhibits the production of pro-inflammatory cytokines such as IFN-γ, 
TNF-α and NO (Fiorentino et al., 1991). Previous studies have also shown that IL-10 
plays a key role in suppressing the TNF-α required for generating an IFN-γ Th1 
response (Armstrong-James et al., 2009). My data showed that there was a 
correlation between IL-10 and IFN-γ expression in AmB-PMA treated mice. IL-10 
increased with increasing time post-infection and it had increased significantly by day 
+8 as compared to day +2 (Figure 130, Page 280). This contrasted with IFN-γ which 
decreased over the 8 days of the experiments.  
As mentioned previously, MIP-1β is an early inflammatory chemokine that is 
released to recruit inflammatory cells to the site of infection. Sallusto et al. reported 
that MIP-1β is produced to recruit circulating immature dendritic cells and neutrophils 
to the site of inflammation (Sallusto et al., 2000). MIP-1β was present at low levels in 
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infected and AmB-PMA treated mice as compared to immuno-suppressed and 
infected untreated mice. However, this level was still higher than that seen in 
immuno-competent and infected mice. Thus, I concluded that the AmB-PMA 
treatment could reduce the recruitment of inflammatory infiltrate to the site of 
infection by MIP-1β expression. This is because macrophage recruitment is 
dependent upon the release of MIP-1β from activated neutrophils. Mehrad et al. 
showed that impaired fungal clearance is also associated with a low level of MIP-1β 
which results in reduced recruitment of neutrophils to the lungs (Mehrad et al., 1999). 
The effect of AmB-PMA treatment and the progress of the disease was also studied 
using tissue histology. It is an essential tool to further demonstrate the impact of 
AmB-PMA on pathology and fungal load. This method is commonly used to 
recognize the differences in tissue morphology of experimental animal models after 
infection with A. fumigatus (Franquet et al., 2001). Histological slides of immuno-
suppressed infected and untreated mouse lung showed extensive necrosis and 
invasive fungal hyphae. In contrast, no necrosis and invasive fungal hyphae were 
seen in AmB-PMA treated slides at day +2. Macrophages containing A. fumigatus 
spores were seen in the AmB-PMA treated histology lung slides (at a dose of 300 µg 
AmB) (Figure 117, Page 266). PAS stained lung tissue sections were also very 
useful in visualising the differences between AmB-PMA treated and untreated mice. 
The AmB-PMA treated BALB/c mice lung sections showed no hyphae at day +2 with 
a few focal hyphae seen at day +4 and day +8. These focal areas of hyphae did not 
disappear even after extension of the AmB-MA administration into the period after 
infection. This suggested that the AmB-PMA does not persist and accumulate in the 
lung tissues because of rapid lung based clearance mechanisms. It also suggests 
that the AmB-PMA has to be given on a daily basis if it is to remain effective up to 
day +8. Such experiments were not performed and should be the subject of future 
work. 
 
5.1.2.4 Inflammation in the mouse lung 
The effect of AmB-PMA treatment and progress of the disease was also studied 
using tissue inflammation as the readout. The same amount of inflammation was 
seen in BALB/c mouse lung at day +2 with both routes (i.e. nasal versus nebuliser) 
of AmB-PMA administration. The percentage inflammation was increased almost 6 
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times in immuno-suppressed and infected BALB/c mice (73 ± 1.25%, Figure 85 a, 
Page 228) as compared to immuno-suppressed + infected and AmB-PMA treated 
mice with 300 µg AmB (14 ± 1.2%, Figure 117, Page 266). However, this amount of 
inflammation was still higher than that seen in immuno-competent and infected 
BALB/c mice (6.5 ± 1.2%). 
Inflammation increased as a consequence of time in AmB-PMA treated BALB/c 
mice. The percentage inflammation had increased to 65 ± 2.1% at day +8 as 
compared to 14 ± 1.2% at day +2 (Figure 132, Page 283).  
There was no significant difference in the inflammation between immuno-competent 
and infected BALB/c mice as compared to immuno-competent and infected C57BL/6 
mice (Figure 153, Page 309). No significant difference was seen between immuno-
suppressed and infected BALB/c mice in comparison with immuno-suppressed and 
infected C57BL/6 mice (Figure 153, Page 309).  
 
5.1.2.5 The comparison of AmB-PMA treated mice and immuno-
suppressed + infected BALB/c mice at day +2 
The difference in chemokine and cytokine responses between AmB-PMA treated 
mice and immuno-suppressed and infected BALB/c mice was determined as below:   
1) IFN-γ does not change in immuno-suppressed + infected and AmB-PMA 
treated mice as compared to immuno-suppressed and infected BALB/c mice 
(Figure 115, Page 263).  
2) TNF-α has gone down in immuno-suppressed + infected and AmB-PMA 
treated mice as compared to immuno-suppressed and infected BALB/c mice 
(p<0.0001) (Figure 114, Page 262).  
3) IL-10 and iNOS have also gone down in immuno-suppressed + infected and 
AmB-PMA treated mice as compared to immuno-suppressed and infected 
BALB/c mice (p<0.0001) (Figure 116, Page 264). 
 
 
 
 
335 
 
5.1.2.6 The comparison of AmB-PMA treated mice and immuno-
competent + infected BALB/c mice at day +2 
1) There was a major failure to mount an IFN-γ response. There was a 
significant difference in IFN-γ level between immuno-competent and infected 
mice as compared to immuno-suppressed + infected and AmB-PMA treated 
BALB/c mice (p=0.004) (Figure 115, Page 263). 
2) The AmB-PMA administration results in reduced TNF-α level. The TNF-α level 
decreased significantly after AmB-PMA nebulisation as compared to immuno-
competent and infected BALB/c mice (p=0.004) (Figure 114, Page 262). 
3)  IL-10 increased slightly in immuno-suppressed + infected and AmB-PMA 
treated mice in comparison with immuno-competent and infected BALB/c 
mice (p=0.02). It reached the same level of healthy mice (Figure 116, Page 
264).  
4) AmB-PMA administration results in reduced iNOS expression as compared to 
immuno-competent and infected BALB/c mice (p=0.003) (Figure 116, Page 
264). 
 
5.1.2.7 Findings in BALB/c mice versus C57BL/6 mice 
Lung sections from C57BL/6 mice also demonstrated focal hyphae and inflammation 
at days +2, +3 and +4 after infection (Figures 149, 150 & 151 respectively). Only a 
few spores were seen in both C57BL/6 and BALB/c mice lungs at day +2. No 
germinated hyphae were seen at day +2 in both BALB/c and C57BL/6 mice. Bonnett 
et al. have seen similar results in BALB/c and C57BL/6 mice at +2 days after 
infection. They reported that PMNs can be recruited to the lungs and form oxidase-
active aggregates with conidia which prevent germination in BALB/c mice. In 
C57BL/6 mice the slow recruitment of PMN means that they germinate faster than in 
BALB/c mice at 6 h and 12 h after infection. Bonnett et al. reported that the lung 
sections taken from C57BL/6 mice showed germinating conidia at 6 h but not at 48 
h. Lung sections from BALB/c mice showed no germinating conidia (Bonnett et al., 
2006). 
IFN-γ in normal C57BL/6 mouse lung was much higher than in normal BALB/c 
mouse lung. IFN-γ was depressed in immuno-suppressed BALB/c and C57BL/6 
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mouse lung infected with A. fumigatus at day +2 post-infection.  Normal IFN-γ for 
BALB/c mouse = 310 ± 56 copies/105 copies HPRT; Normal IFN-γ for C57BL/6 
mouse = 8,230 ± 395 copies/105 copies HPRT. 
My data showed much lower levels of IFN-γ production in immuno-suppressed + 
infected, immuno-competent + infected and only immuno-suppressed C57BL/6 mice 
as compared to BALB/c mice (Figure 155). The histological data supports the 
effectiveness of the AmB-PMA in the control of invasive aspergillosis. This was seen 
as a reduction in fungal load, inflammation and cellular infiltrate in AmB-PMA treated 
mice lungs. These observations suggested that IFN-γ is not highly induced in 
immuno-suppressed BABL/c and C57BL/6 mice. FK-506 and HC immuno-
suppression were the key drivers for both mouse strains and their increased 
susceptibility to IA.  
My data also showed that MIP-1β, TNF-α, IFN-γ, IL-10 and iNOS increased 
significantly in healthy C57BL/6 mice as compared to healthy BALB/c mice. But, no 
significant difference was seen in cytokine expression between BALB/c and C57BL/6 
healthy mice after infection with A. fumigatus except for TNF-α (Figure 154). BALB/c 
mice produced higher level of TNF-α than C57BL/6 mice.  
There was no significant difference in cytokine expression between immuno-
suppressed BALB/c and C57BL/6 mice except for IFN-γ (Figure 155). IFN-γ went 
down significantly in C57BL/6 mice after immuno-suppression as compared to 
BALB/c mice. C57BL/6 mice also showed less expression of IFN-γ after infection. 
Interestingly, MIP-1β, TNF-α, IFN-γ, IL-10 and iNOS decreased significantly in 
immuno-suppressed + infected C57BL/6 mice as compared to BALB/c mice (Figures 
154, 155 & 156).  
In conclusion, my thesis showed that IFN-γ, TNF-α and iNOS were induced less in 
BALB/c mice exposed to A. fumigatus and treated with AmB-PMA as compared to 
immuno-competent BALB/c mice exposed to A. fumigatus only. In contrast, immuno-
suppressed infected and AmB-PMA treated mice produced higher levels of IL-10 
than immuno-competent BALB/c mice when exposed to only A. fumigatus (p=0.02). 
Understanding the complex relationships between phagocytes cells, AmB-PMA and 
A. fumigatus is necessary to provide additional insights into IA. Such experiments 
should be the subject of future work. 
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Chapter 6 
6.1 Conclusion 
 
 
My results have shown that AmB can bind to a range of small MWts of PMA-Na 
polymer in the range of 1.2 to 18 kDa. The low MWts AmB-PMA (3.1 kDa) in 
comparison to other marketed AmB-formulations such as Fungizone, had less 
toxicity and haemolytic activity in-vitro. The results also showed that AmB-PMA 
batches can be synthesised at low cost and administered with less toxicity both in-
vitro and in-vivo.  
It was also observed that the AmB-PMA batches synthesised with AmB from Sigma 
were less toxic than AmB-PMA batches synthesised with AmB from Fungizone 
(Squibb). Monocytes could induce the expression of IFN-γ after incubation with 
AmB-PMA (3.1 kDa) in-vitro.  
The aim of my thesis was to develop a cost-effective formulation of AmB that could 
be competitively priced in order to prevent invasive aspergillosis. My studies have 
shown that established, scalable and low cost synthetics PMA-Na polymer can be 
used to make a water soluble AmB-PMA that is both safe and stable. The overall 
polymer size reduction of this drug enabled its safe and reliable administration using 
a nebuliser. The efficacy of AmB-PMA prophylaxis was determined against 
pulmonary aspergillosis in a new solid organ transplant immuno-suppressed mouse 
model. The efficacy of AmB-PMA nebulisation was tested in both BALB/c and 
C57BL/6 mice in-vivo. 
I determined the optimal AmB-PMA dosing regimens by nebulisation. I monitored the 
disease progression by determining lung fungal burden, measurement of chemokine 
& cytokine responses and histopathology of mouse lung. The results showed that 
AmB-PMA nebulisation was very effective. AmB-PMA decreased the chemokine and 
cytokine expression in immuno-suppressed and A. fumigatus infected mice as 
compared to infected untreated mice. IFN-γ levels did not change in infected and 
AmB-PMA treated mice as compared to immuno-suppressed and infected BALB/c 
mice. This reflected a major failure to increase IFN-γ when compared to immuno-
competent and infected mice. The AmB-PMA results in reduced TNF-α level as 
compared to immuno-suppressed + infected and immuno-competent + infected 
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mice. IL-10 decreased in infected and AmB-PMA treated mice as compared to 
immuno-suppressed and infected untreated mice. 
The number of focal hyphae and chemokine and cytokine responses except for IFN-
γ were increased as a consequence of time. The efficacy of AmB-PMA was also 
tested as prophylaxis in combination with treatment in BALB/c mice to reduce the 
number of hyphae at days +4 and +8. There was a reduction in fungal burden (CFU 
and DNA fungal load) and histological analysis showed no significant difference 
between mice given prophylaxis and treatment as compared to the mice given 
prophylaxis only.  
In addition, AmB-PMA prophylaxis prevented invasive aspergillosis in C56BL/6 mice. 
My data showed that MIP-1β, TNF-α, IFN-γ, IL-10 and iNOS increased significantly 
in normal C57BL/6 mice as compared to normal BALB/c mice. But, no significant 
difference was seen in cytokine expression between BALB/c and C57BL/6 healthy 
mice after infection with A. fumigatus. 
Taken together, my thesis has shown that it is possible to generate an AmB-PMA to 
kill A. fumigatus infections in a mouse model with immuno-therapeutic manipulation 
of host immunity in highly susceptible BALB/c and C57BL/6 mice. 
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6.1.1 Future studies 
 
In this thesis, quantification of the CFU and DNA fungal load have been directly 
evaluated using ex-vivo counting of the number of colonies. Disease progression 
was assessed indirectly by measuring percentage of weight loss. However, recent 
developments in fluorescence imaging have made it possible to visualize the precise 
progression of invasive aspergillosis. The development in in-vivo and ex-vivo 
bioluminescent imaging can be used to monitor the progress of IA (Brock, 2011). 
This involves using a bioluminescent A. fumigatus strain that produces luciferase to 
monitor its localization, fungal burden within tissues, and dissemination of infections. 
Therefore, the real-time monitoring of infection can be achieved in a single animal 
and without the need to sacrifice the animal (Hutchens & Luker, 2007 cited by Brock 
et al., 2008). In addition to successful in-vivo monitoring of clearance of fungal 
infections, it may also help to determine the effectiveness of antifungal drugs in-vivo. 
Furthermore, the recent development of fluorescently-labelled AmB and PMA 
provides for the opportunity of create a labelled AmB-PMA. Then, by development of 
labelled AmB-PMA and bioluminescent A. fumigatus, it would be possible to follow 
the intracellular trafficking of the AmB-PMA into the AMs and identify the precise 
mode of action by AmB-PMA and AMs in fungal killing.  
Hence, further characterisation of the role of IFN-γ up-regulation in protecting the 
lung against aspergillosis could be determined. Additional attempts to increase IFN-γ 
could involve the administration of AmB-PMA prophylaxis in combination with 
recombinant IFN-γ therapy.  
In future, another aim would be determination of the maximum pulmonary 
concentration of AmB in lung homogenates after a 30-45 min nebulisation. 
Radiolabelling of AmB may also play an important role in the determination of the 
exact AmB concentration in the lungs. Developments in radiolabelling could also 
increase the likelihood of determining the pulmonary deposition of aerosol AmB-PMA 
in the lungs. This would be achieved by nebulising radiolabelled AmB-PMA in the 
lungs and then measuring the radioactivity present in lung tissue.  
 
 
 
 
340 
 
Bibliography 
 
Websites 
 
http://aspergillusproject11.wordpress.com/2013/04/18/life-cycle/ 
http://www.doctorfungus.org/thedrugs/antif_pharm.php 
http://www.life-worldwide.org/fungal-diseases/invasive-aspergillosis/ 
www.doctorfungus.org 
http://rsbweb.nih.gov/ij/ 
 
  References 
 
1.   Adams, M.L., & Kwon, G.S. (2003) Relative aggregation state and hemolytic 
activity of amphotericin B encapsulated by poly (ethylene oxide)-block-poly (N-
hexyl-L-aspartamide)-acyl conjugate micelles: effects of acyl chain length. J 
Control Release, 87, 23-32. 
2.   Adediran, S.A., Day, T.P., Sil, D., Kimbrell, M.R., Warshakoon, H.J., Malladi, 
S.S., & David, S.A. (2009) Synthesis of a highly water-soluble derivative of 
amphotericin B with attenuated pro-inflammatory activity. Molecular 
Pharmaceutics, 6 (5), 1582-1590.  
3.   Adler-Moore, J. & Proffitt, R.T. (2002) AmBisome: liposomal formulation, 
structure, mechanism of action and pre-clinical experience. J. Antimicrob. 
Chemother., 49 (1), 21-30. 
 
4. Aimanianda, V., Bayry, J., Bozza, S. et al. (2009) Surface hydrophobin prevents 
immune recognition of airborne fungal spores. Nature, 460 (7259), 1117–1121.  
5.   Akira, S., Uematsu, S., & Takeuchi, O. (2006) Pathogen recognition and innate 
immunity. Cell, 124 (4), 783-801. 
6.    Allen, M. J., Harbeck, R., Smith, B., Voelker, D.R., & Mason, R.J. (1999) 
Binding of rat and human surfactant proteins A and D to Aspergillus fumigatus 
conidia. Infect. Immun., 67, 4563-4569. 
7.    Allen, M. J., Voelker, D. R., & Mason. R. J. (2001) Interactions of surfactant a 
341 
 
proteins A and D with Saccharomyces cerevisiae and Aspergillus fumigatus. 
Infect. Immun., 69, 2037-2044. 
8.    Alles, V. V., Bottazzi, B., Peri, G., Golay, J., Introna, M., & Mantovani, A. (1994) 
Inducible expression of PTX3, a new member of the pentraxin family, in human 
mononuclear phagocytes. Blood, 84, 3483–3493. 
9.    Alvarez, C.A., Wiederhold, N.P., McConville, J.T., et al. (2007) Aerosolized 
nanostructured itraconazole as prophylaxis against invasive pulmonary 
aspergillosis. J Infect, 55, 68–74. 
10.    Amato, V.S., Tuon, F.F., Siqueira, A.M., Nicodemo, A.C., & Neto, V.A. (2007) 
Treatment of mucosal leishmaniasis in Latin America: systematic review.   Am. J. 
Trop. Med. Hyg., 77 (2), 266-274. 
11.    Amitani, R., Taylor, G., Elezis, E.N., Llewellyn-Jones, C., Mitchell, J., Kuze, F., 
Cole, P.J., & Wilson, R., (1995) Puriﬁcation and Characterization of Factors 
Produced by Aspergillus fumigatus Which Affect Human Ciliated Respiratory 
Epithelium. Infection And Immunity, 63 (9), 3266–3271. 
12.   Andrews, C.P. & Weiner, M.H., (1981) Immunodiagnosis of invasive pulmonary 
aspergillosis in rabbits. Fungal antigen detected by radioimmunoassay in 
bronchoalveolar lavage ﬂuid. Am. Rev. Respir. Dis., 124, 60–64. 
13.    Andriole, V. T. (1993) Infections with Aspergillus species. Clin. Infect. Dis.,17, 
S481-S486. 
14.     Annaix, V., Bouchara, J. P., Larcher, G., Chabasse, D., & Tronchin, G. (1992) 
Specific binding of human fibrinogen fragment D to Aspergillus fumigatus conidia. 
Infect. Immun., 60, 1747-1755. 
15.     Ansorg, R., Von Heinegg, E. H., & Rath. P. M. (1994) Aspergillus antigenuria 
compared to antigenemia in bone marrow transplant recipients. Eur. J. Clin. 
Microbiol. Infect. Dis., 13, 582-589. 
16.     Archer, D.B. & Gale, E.F. (1975) Antagonism by sterols of the action of 
amphotericin and filipin on the release of potassium ions from Candida albicans 
and Mycoplasma mycoides subsp. capri. J. Gen. Microbiol., 90 (1), 187-190. 
17.     Armstrong-James, D., Teo, I.A., Shrivastava, S., et al. (2010) Exogenous 
interferon-gamma immunotherapy for invasive fungal infections in kidney 
transplant patients. Am J Transplant, 10, 1796–1803. 
18.    Armstrong-James, D.P.H., Turnbull, S.A., Teo, I., Stark, J., Rogers, N.J.,  
342 
 
Rogers, T.R.F., Bignell, E., & Haynes, K., (2009) Impaired Interferon-g 
Responses, Increased Interleukin-17 Expression, and a Tumor Necrosis Factor–
a Transcriptional Program in Invasive Aspergillosis. J. Infect. Dis., 200 (8), 1341-
1351. 
19.     Arthur, R.R., Drew, R.H., & Perfect, J.R. (2004) Novel modes of antifungal 
drug administration. Expert Opin Investig Drugs, 13 (8), 903-932. 
20.     Atkins, P.J. & Crowder, T.M. (2004) The design and development of inhalation 
drug delivery systems. In: Hickey A. Pharmaceutical inhalation aerosol 
technology, 2nd ed. New York: Dekker. 
21.     Baginski, M., Gariboldi, P., Bruni, P., & Borowski, E. (1997) Conformational 
analysis of Amphotericin B. Biophys. Chem., 65, (2-3), 91-100.  
22.     Baginski, M., Resat, H., & Borowski, E. (2002) Comparative molecular 
dynamics simulations of amphotericin B-cholesterol/ergosterol membrane 
channels. Biochim. Biophys. Acta, 1567, (1-2) 63-78.  
23.    Baginski, M.,Tempczyk, A. & Borowski, E. (1989) comparative conformational 
analysis of cholestrol and ergosterol by molecular mechanics. European 
Biophysics Journal, 17, 159-166. 
24.     Baker, R. (1987) Controlled Release of Biologically Active Agents; Academic 
Press: New York. 
25.     Balakrishnan, A.R. & Easwaran, K.R. (1993) CD and NMR studies on the 
aggregation of amphotericin-B in solution. Biochim.Biophys.Acta, 1148, (2) 269-
277. 
26.     Balloy, V. & Chignard, M. (2009) The innate immune response to Aspergillus 
fumigatus. Microbes and Infection, 11, 919-927. 
27.     Balloy, V., Huerre, M., Latgé, J.P., & Chignard, M. (2005) Differences in 
patterns of infection and inflammation for corticosteroid treatment and 
chemotherapy in experimental invasive pulmonary aspergillosis. Infect. Immun., 
73, 494–503. 
28.     Balloy, V., Sallenave, J. M., Wu, Y., Touqui, L., Latge, J. P., Si-Tahar, M., & 
Chignard, M. (2008) Aspergillus fumigatus-induced interleukin-8 synthesis by 
respiratory epithelial cells is controlled by the phosphatidylinositol 3-kinase, p38 
MAPK, and ERK1/2 pathways and not by the Toll-like receptor- MyD88 pathway. 
J. Biol. Chem. 283, 30513–30521. 
343 
 
29.      Balloy, V., Si-Tahar, M., Takeuchi, O., Philippe, B.,  Nahori, M. A.,  Tanguy, M. 
, Huerre, M., Akira, S.,  Latge, J. P., & Chignard, M. (2005) Involvement of Toll-
like receptor 2 in experimental invasive pulmonary aspergillosis. Infect. Immun., 
73, 5420–5425. 
30.      Bals, R., & Hiemstra, P. S. (2004) Innate immunity in the lung: how epithelial 
cells fight against respiratory pathogens. Eur. Respir. J., 23, 327-333. 
31.      Bandoh, S., Fujita, J., Fukunaga, Y., et al. (1999) Cavitary lung cancer with an 
aspergilloma-like shadow. Lung Cancer, 26, 195-8. 
32.      Baran, M. & Mazerski, J. (2002) Molecular modelling of amphotericin B-
ergosterol primary complex in water. Biophysical Chemistry, 95 (2), 125-133.  
33.      Bartnicki-Garcia, S. (1968) Cell wall chemistry morphogenesis and taxonomy 
of fungi. Annu Rev Microbiol., 22, 87-108. 
34.      Barton, R.C. (2013) Laboratory Diagnosis of Invasive Aspergillosis: From 
Diagnosis to Prediction of Outcome. Hindawi Publishing Corporation Scientica, 
2013, 1-29. 
35.      Bayat, M. & Cook, A.M. (2004) Intrapulmonary administration of medications. 
J Neurosci Nurs, 36, 231–235. 
36.      Becker, M.J., de Marie, S., Fens, M. H. A. M., Verbrugh, H.A. & Bakker-
Woudenberg, I. A. J. M.  (2003) Effect of amphotericin B treatment on kinetics of 
cytokines and parameters of fungal load in neutropenic rats with invasive 
pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy, 52, 428–434. 
37.      Bellanger, A. P., Millon, L., Khoufache, K., Rivollet, D., Bieche, I., Laurendeau, 
I., Vidaud, M., Botterel, F., & Bretagne, S. (2009). Aspergillus fumigatus germ 
tube growth and not conidia ingestion induces expression of inflammatory 
mediator genes in the human lung epithelial cell line A549. J. Med. Microbiol., 
58,174-179. 
38.      Bellocchio, S., Gaziano, R., Bozza, S., Rossi, G., Montagnoli, C., Perruccio, 
K., Calvitti, M., Pitzurra, L., & Romani, L. (2005) Liposomal amphotericin B 
activates antifungal resistance with reduced toxicity by diverting Toll-like receptor 
signalling from TLR-2 to TLR-4. J. Antimicrob. Chemother., 55, 214–222. 
39.      Bellocchio, S., Moretti, S., Perruccio, K., Fallarino, F., Bozza, S., Montagnoli, 
C., Mosci, P., Lipford, G. B., Pitzurra, L. & Romani. L., (2004) TLRs govern 
neutrophil activity in aspergillosis. J. Immunol., 173, 7406–7415. 
344 
 
40.     Bennett, J. E., Dismukes, W. E., Duma, R. J. & 12 other authors (1979). A 
comparison of amphotericin B alone and combined with flucytosine in the 
treatment of cryptoccal meningitis. N Engl J Med, 301, 126-131. 
41.     Berenguer, J., Allende, M. C., Lee, J., Garret, K., Lyman, C., Ali, N. M., 
Bacher, J., Pizzo, P. A., & Walsh. T. J. (1995) Pathogenesis of pulmonary 
aspergillosis-granulocytopenia versus cyclosporine and methylprednisolone 
induced immunosuppression. Am. J. Respir. Crit. Care Med., 152, 1079–1086. 
42.     Bernard, M., & Latge, J.P. (2001) Aspergillus fumigatus cell wall: composition 
and biosynthesis. Med Mycol., 39 (1), 9–17.  
43.     Bertout, S., Badoc, C., Mallie, M., Giamimis, J. & Bastide, J. M. (2002) Spore 
diffusate isolated from some strains of Aspergillus fumigatus inhibits 
phagocytosis by murine alveolar macrophages. FEMS Immunol Med Microbiol, 
33, 101–106. 
44.     Beyer, J., Schwartz, S., Barzen, G., et al (1994) Use of amphotericin B 
aerosols for the prevention of pulmonary aspergillosis. Infection, 22, 143–148. 
45.     Bhatia, S., Fei, M., Yarlagadda, M., et al. (2011) Rapid host defence against 
Aspergillus fumigatus involves alveolar macrophages with a predominance of 
alternatively activated phenotype. Plos One, 6 (1), 1-15. 
46.      Bodey, G. P. & Vartivarian, S. (1989) Aspergillosis. Eur. J. Clin. Microbiol. 
Infect. Dis., 8, 413–437. 
47.      Bonnett, C.R., Cornish, E.J., Harmsen, A.G., & Burritt, J.B. (2006) Early 
Neutrophil Recruitment and Aggregation in the Murine Lung Inhibit Germination 
of Aspergillus fumigatus Conidia. Infection and Immunity, 74 (12), 6528–6539. 
48.      Borro, J.M., Solé, A., Torre, M., Pastor, A. , Fernandez, R., Saura, A., 
Delgado, M., Monte, E. & Gonzalez, D. (2008) Efficiency and Safety of Inhaled 
Amphotericin B Lipid Complex (Abelcet) in the Prophylaxis of Invasive Fungal 
Infections Following Lung Transplantation. Transplantation Proceedings, 40, 
3090–3093.  
49.     Botterel, F., Gross, K., Ibrahim-Granet, O., Khoufache, K., Escabasse, V., 
Coste, A., Cordonnier, C., Escudier, E. & Bretagne, S. (2008) Phagocytosis of 
Aspergillus fumigatus conidia by primary nasal epithelial cells in vitro. BMC 
Microbiology, 8, 97. 
50.      Bouchara, J. P., Sanchez, M., Chevailler, A., Marot-Leblond, A., Lissitzky, 
345 
 
J.C., Tronchin, G., & Chabasse, D. (1997) Sialic acid-dependent recognition of 
laminin and fibrinogen by Aspergillus fumigatus conidia. Infect. Immun., 65, 
2717–2724. 
51.     Bouzani, M., Ok, M., McCormick, A., Ebel, F.,  Kurzai, O., Morton, C.O., 
Einsele, H. & Loeffler, J (2011) Human NK Cells Display Important Antifungal 
Activity against Aspergillus fumigatus, Which Is Directly Mediated by IFN-γ 
Release. The Journal of Immunology, 187 (3), 1369-1376. 
52.     Bowman, S.M. & Free, S.J. (2006) The structure and synthesis of the fungal 
cell wall. Bioessays, 28, 799-808. 
53.     Bowman, S.M., Piwowar, A., Al Dabbous, M., Vierula, J., & Free, S.J. (2006) 
Mutational analysis of the GPI anchor pathway demonstrates that GPIanchored 
Proteins are required for cell wall biogenesis and normal hyphal growth in 
Neurospora crassa. Eukaryotic Cell, 5, 187–200. 
54.      Bozza, S., Clavaud, C., Giovannini, G., et al. (2009) Immune sensing 
of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the 
impact on Th immunity and vaccination. J Immunol., 183, 2407–2414. 
55.     Brajtburg, J., Powderly, W.G., Kobayashi, G.S., & Medoff, G. (1990) 
Amphotericin B: current understanding of mechanisms of action. Antimicrobial 
Agents and Chemotherapy, 34 (2), 183-188. 
56.     Brem, H., Piantadosi, S., Burger, P.C., Walker, M., Selker, R., Vick, N.A., 
Black, K., Sisti, M., Brem, S., Mohr, G. (1995) Placebo-controlled trial of safety 
and efficacy of intraoperative controlled delivery by biodegradable polymers of 
chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. 
Lancet, 345, 1008-1012. 
57.    Breviario, F., d’Aniello, E. M., Golay, J., Peri, G., Bottazzi, B., Bairoch, A., 
Saccone, S., Marzella, R., Predazzi, V., Rocchi, M.,  Vallell, G. D.,  Dejana, E., 
Mantovani, A., & Introna, M. (1992) Interleukin-1-inducible genes in endothelial 
cells. Cloning of a new gene related to C-reactive protein and serum amyloid P 
component. J. Biol. Chem., 267, 22190–22197. 
58.  Brock, M (2011) Application of Bioluminescence Imaging for In Vivo Monitoring 
of Fungal Infections. International Journal of Microbiology, 2012, 1-9. 
59.      Brock, M., Jouvion, G., Droin-Bergère, S., Dussurget, O., Nicola, M.A., 
& Ibrahim-Granet, O. (2008) Bioluminescent Aspergillus fumigatus, a New Tool 
346 
 
for Drug Efficiency Testing and In Vivo Monitoring of Invasive Aspergillosis. Appl 
Environ Microbiol, 74 (22), 7023-7035. 
60.     Brown, G. D. & Gordon, S. (2001) Immune recognition: a new receptor for 
beta-glucans. Nature, 413, 36–37. 
61.     Brown, G. D., Herre, J., Williams, D. L., Willment, J. A., Marshall, A. S. & 
Gordon. S. (2003) Dectin-1 mediates the biological effects of beta-glucans. J. 
Exp. Med., 197, 1119–1124. 
62.     Brown, G. D., Taylor, P. R. , Reid, D. M., Willment, J. A. , Williams, D. L., 
Martinez-Pomares, L., Wong, S. Y. C., & Gordon, S. (2002) Dectin-1 is a major 
beta-glucan receptor on macrophages. J. Exp. Med., 196, 407–412. 
63.     Brown, J.A. & Catley, B.J. (1992) Monitoring polysaccharide synthesis in 
Candida albicans. Carbohydr Res, 227, 195–202. 
64.     Brown, G.D., & Gordon, S. (2005) Immune recognition of fungal β-
glucans. Cell Microbiol., 7, 471-479. 
65.     Brunton, L., Lazo, J., Parker, K. (2006) Goodman and Gilman’s The 
Pharmacological Basis of Therapeutics. 11th ed. San Francisco: McGraw-Hill. 
66.     Cao, Z., Sun, X., Yeh, C.K. & Sun, Y. (2010) Rechargeable Infection 
responsive Antifungal Denture Materials. J Dent Res, 89 (12), 1517-1521. 
67.     Cenci, E., Mencacci, A., Casagrande, A., Mosci, P., Bistoni, F., & Romani, L. 
(2001) Impaired antifungal effector activity but not inflammatory cell recruitment in 
interleukin-6-deficient mice with invasive pulmonary aspergillosis. J. Infect. Dis. 
184, 610–617. 
68.     Cenci, E., Mencacci, A., d’Ostiani, C. F., Montagnoli, C. ,Bacci, A.,  Sero, G. 
D., Perito S., Bistoni, F., & Romani. L. (1998) Cytokine- and T-helper-dependent 
immunity in murine aspergillosis. Res. Immunol., 149, 445–453. 
69.     Cenci, E., Perito, S., Enssle, K.H., et al. (1997) Th1 and Th2 cytokines in mice 
with invasive aspergillosis. Infect. Immun., 65, 564–570. 
70.     Chai, L.Y., Kullberg, B.J., Vonk, A.G. et al. (2009) Modulation of Toll-like 
receptor 2 (TLR2) and TLR4 responses by Aspergillus fumigatus. Infect. 
Immun., 77 (5), 2184-2192.  
71.      Chai, L.Y.A., Vonk, A.G., Kullberg, B, J. & Netea, M, G. (2011) Immune 
Response to Aspergillus fumigatus in Compromised Hosts: From Bedside to 
Bench. Future Microbiol., 6 (1), 73-83. 
347 
 
72.      Chandrasekar, P.H., & Sobel, J.D. (2006) Micafangin: a new echinocandin. 
Clinical Infectious Diseases, 42, 1171-1178. 
73.      Chignard, M., Balloy, V., Sallenave, J.M. & Si-Tahar, M. (2007) Role of Toll-
like receptors in lung innate defense against invasive aspergillosis. Distinct 
impact in immunocompetent and immunocompromized hosts. Clin. Immunol., 
124, 238-243. 
74.      Choi, J. K., Mauger, J. & McGowan, K. L. (2004) Immunohistochemical 
detection of Aspergillus species in pediatric tissue samples. American Journal of 
Clinical Pathology, 121(1), 18-25. 
75.      Choi, J.H., Kwon, E.Y., Park, C.M., Choi, S.M., Lee, D.G., Yoo, J.H., Shin, 
W.S., & Stevens, D.A. (2010) Immunomodulatory effects of antifungal agents on 
the response of human monocytic cells to Aspergillus fumigatus conidia. 
Med.Mycol., 48, 704-709. 
76.      Christiansen, K. J., Bernard, E. M., Gold, J. W. and Armstrong, D. (1985) 
Distribution and activity of amphotericin B in humans. J. Infect. Dis., 152, 1037-
1043.  
77.      Christin, L., Wysong, D.R., Meshulam, T., Hastey, R., Simons, E.R., Diamond, 
R.D. (1998) Human platelets damage Aspergillus fumigatus hyphae and may 
supplement killing by neutrophils. Infect. Immun., 66(3), 1181–1189.  
78.      Cleary, J.D., Weisdorf, D., & Fletcher, C.V. (1988) Effect of infusion rate on 
amphotericin B-associated febrile reactions. Drug Intell. Clin. Pharm., 22 (10), 
769-772. 
79.     Clemons, K.V., Grunig, G., Sobel, R. A., Mirels, L. F., Rennick, D. M. & 
Stevens, D. A., (2000) Role of IL-10 in invasive aspergillosis: increased 
resistance of IL-10 gene knockout mice to lethal systemic aspergillosis. Clin Exp 
Immunol, 122, 186-191. 
80.      Como, J.A. & Dismukes, W.E. (1994) Oral azole drugs as systemic antifungal 
therapy. N Engl J Med, 330, 263-72. 
81.      Corcoran, T.E., Venkataramanan, R., Mihelc, K.M., et al. (2006) Aerosol 
deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. 
Am J Transplant, 6, 2765–2773. 
82.      Cortez,  K.J.,  A. Lyman, C.,  Kottilil, S.,  Kim, H.S., Roilides , E.,  Yang, 
J.,  Fullmer, B.,   Lempicki, R., & Walsh, T.J. (2006) Functional Genomics of 
348 
 
Innate Host Defense Molecules in Normal Human Monocytes in Response 
to Aspergillus fumigatus. Infect. Immun., 74 (4), 2353-2365. 
83.      Corware, K. (2010) Modifying amphotericin B for the treatment of cutaneous 
leishmaniasis. PhD thesis. Faculty of Medicine, University of London. 
84.      Corware, K., Harris, D., Teo, I., Rogers, M., Naresh, K., Müller, I., Shaunak, S. 
(2011) Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c 
mice using water soluble amphotericin B-polymethacrylic acid. Biomaterials, 1-
11. 
85.      Covarrubias, M.B., & Milstone, A.B. (2005) An overview of fungal prophylaxis 
in lung transplantation. Curr Opin Organ Transplant, 10, 272. 
86.      Cramer, R.A., Rivera, A. & Hohl, T.M (2011) Immune responses against 
Aspergillus fumigatus: what have we learned? Curr Opin Infect Dis., 24 (4), 315-
322. 
87.      Dagenais, T.R.T., & Keller, N.P. (2009) Pathogenesis of Aspergillus fumigatus 
in Invasive Aspergillosis. Clinical Microbiology Reviews, 22(3), 447–465. 
88.      Daly, P. & Kavanagh, K. (2001) Pulmonary aspergillosis: clinical presentation, 
diagnosis and therapy. Br J Biomed Sci., 58 (3), 197-205. 
89.      De Beule, K., & Van Gestel, J., (2001) Pharmacology of itraconazole. Drugs, 
61 (1), 27-37. 
90.      De Nobel, H., van Den Ende, H., & Klis, F.M. (2000) Cell wall maintenance in   
fungi. Trends Microbiol., 8, 344-345. 
91.      De Waal Malefyt, R., Haanen, J., Spits, H., Roncarolo, M.G., te Velde, A., 
Figdor, C., Johnson, K., Kastelein, R., Yssel, H., & de Vries, J.E. (1991) 
Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T 
cell proliferation by diminishing the antigen-presenting capacity of monocytes via 
downregulation of class II major histocompatibility complex expression. The 
Journal of Experimental Medicine, 174, (4) 915-924. 
92.      De, P. B., Walsh, T. J., Donnelly, J. P.  et al., (2008) Revised denitions of 
invasive fungal disease from the European Organization for Research and 
Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the 
National Institute of Allergy and Infectious Diseases Mycoses Study Group 
(EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 46, 1813–1821. 
93.      Delmas, G., Park, S., Chen, Z.W., Tan, F., Kashiwazaki, R., et al. (2002) 
349 
 
Efficacy of orally delivered cochleates containing amphotericin B in a murine 
model of aspergillosis. Antimicrob Agents Chemother, 46, 2704–2707. 
94.      Denning, D. W. (1998) Invasive aspergillosis. Clin. Infect. Dis., 26, 781–803. 
95.      Denning, D. W., Ward, P. N., Fenelon, L. E. & Benbow, E. W. (1992) Lack of 
vessel wall elastolysis in human invasive pulmonary aspergillosis. Infect. Immun., 
60, 5153-5156. 
96.     Denning, D.W., Lee, J.Y., Hostetler, J.S., et al. (1994) NIAID Mycoses Study 
Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am 
J Med, 97, 135-44. 
97.      Denning, D.W. (2001) Chronic forms of pulmonary aspergillosis. Clin. 
Microbiol. Infect., 7 (2), 25-31. 
98.      Denning, D.W., Venkateswarlu, K., Oakley, K.L., Anderson, M.J., Manning, 
N.J., Stevens, D.A., et al. (1997) Itraconazole resistance in Aspergillus fumigatus. 
Antimicrob Agents Chemother, 41, 1364–8. 
99.      Deray, G. (2002) Amphotericin B nephrotoxicity. J. Antimicrob. Chemother., 
49 (1), 37-41. 
100.      Diamond, R.D. & Clark, R.A. (1982) Damage to Aspergillus 
fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative 
microbicidal products of human neutrophils in vitro. Infect. Immun., 38 (2), 487–
495.  
101.      Diamond, R.D. (1983) Inhibition of monocyte-mediated damage to fungal 
hyphae by steroid hormones. J. Infect. Dis., 147 (1), 160.  
102. Diot, P., Dequin, P.F., Rivoire, B., Gagnadoux, F., Faurisson, F., Diot, E., et 
al. (2001) Aerosols and anti-infectious agents. J Aerosol Med.,14, 55-64. 
103. Diot, P., Rivoire, B. L. e., Pape, A., et al (1995) Deposition of amphotericin B 
aerosols in pulmonary aspergilloma. Eur Respir J, 8, 1263–1268. 
104. Drew, R (2006) Potential role of aerosolized amphotericin B formulations in 
the prevention and adjunctive treatment of invasive fungal infections. 
International Journal of Antimicrobial Agents, 27S, S36-S44. 
105. Dufresne, M.H., Gauthier, M.A., Leroux, J.C. (2005) Thiol-functionalized 
polymeric micelles: from molecular recognition to improved mucoadhesion. 
Bioconjug Chem.,16, 1027-33. 
106. Elenkov, I.J. (2004) Glucocorticoids and the Th1/Th2 balance. Ann N Y Acad Sci., 
350 
 
1024, 138-46. 
 
 
107.   Elvira, C., Gallardo, A., Roman, J.S.  & Cifuentes, A. (2005) Covalent 
Polymer-Drug Conjugates. Molecules, 10, 114-125. 
108.  Enoch, D. A., Ludlam, H. A. & Brown, N. M. (2006) Invasive fungal infections: 
a review of epidemiology and management options. Journal of Medical 
Microbiology, 55, 809–818. 
109.  Eskdale, J., Kube, D., Tesch, H., & Gallagher, G (1997) Mapping of the 
human IL10 gene and further characterization of the 5' flanking 
sequence. Immunogenetics, 46 (2), 120–8. 
110. Falvey, D. G. & Streifel, A. J. (2007) Ten-year air sample analysis of 
Aspergillus prevalence in a university hospital. J. Hosp. Infect, 67, 35-41. 
111. Faurisson, F., Dessanges, J.F., Grimfeld, A., Beaulieu, R., Kitzis, M.D., 
Peytavin, G., et al. (1996) Comparative study of the performance and ergonomics 
of nebulizers in cystic fibrosis. Rev Mal Respir .,13,155-62. 
112. Feldmesser, M. (2006) Role of Neutrophils in Invasive Aspergillosis. Infect. 
Immun., 6514-6516. 
113. Filler, S. G., & Sheppard, D. C.  (2006) Fungal invasion of normally 
nonphagocytic host cells. PLoS Pathog., 2, e129. 
114. Fiorentino, D.F., Zlotnik, A., Vieira, P., Mosmann, T.R., Howard, M., Moore, 
K.W., & O'Garra, A. (1991) IL-10 acts on the antigen-presenting cell to inhibit 
cytokine production by Th1 cells. The Journal of Immunology, 146 (10), 3444-
3451. 
115. Fleet, G.H. (1991) Cell walls. In Rose AH, Harrison, J.S. ed; The Yeasts. 2nd 
edn. London: Academic Press. 4, 199-277. 
116. Flume, P., Klepser, M.E. (2002) The rationale for aerosolized antibiotics. 
Pharmacotherapy, 22 (3 Pt 2), 71S-79S. 
117. Fox, D.S. & Heitman, J. (2002) Good fungi gone bad: the corruption of 
calcineurin. Bioessays, 24, 894-903. 
118. Franquet, T.,  Müller, N.L., Giménez, A., Guembe, P., de la Torre, J., 
& Bagué, S. (2001) Spectrum of Pulmonary Aspergillosis: Histologic, Clinical, and 
Radiologic Findings. Education Exhibit, 21 (4), 825-837. 
351 
 
119. Fukuda, T., Boeckh, M., Carter, R.A., et al. (2003) Risks and outcomes of 
invasive fungal infections in recipients of allogeneic hematopoietic stem cell 
transplants after nonmyeloablative conditioning. Blood, 102, 827-33. 
120. Gallin, J.I. (1991) Interferon-gamma in the management of chronic 
granulomatous disease. Rev Infect Dis., 13, 973-8. 
121. Garlanda, C., Hirsch, E., Bozza, S., Salustri, A., De Acetis, M., Nota, R., 
Maccagno, A., Riva, F., Bottazzi, B., Peri, G., Doni, A., Vago, L.  Botto, M., De 
Santis, R., Carminati, P., Siracusa, G., Altruda, F., Vecchi, A., Romani, L., & 
Mantovani, A. (2002) Non-redundant role of the long pentraxin PTX3 in antifungal 
innate immune response. Nature, 420, 182–186. 
122. Gefter, W.B. (1992) The spectrum of pulmonary aspergillosis. J Thorac 
Imaging, 7, 56-74. 
123. Geller D.E. and Kesser, K.C. (2005) Efficient delivery of albuterol with a new 
vibrating mesh nebulizer (eFlow) (abstract). Am J Respir Crit Care Med, 2, A376. 
124. George, D., Kordick, D., Miniter, P., Patterson, T.F., & Andriole, V.T. (1993) 
Combination Therapy in Experimental Invasive Aspergillosis, The Journal of 
Infectious Diseases, 168, 692-698. 
125. Gersuk, G. M., Underhill, D. M., Zhu, L. & Marr. K. A. (2006) Dectin-1 and 
TLRs permit macrophages to distinguish between different Aspergillus fumigatus 
cellular states. J. Immunol., 176, 3717–3724. 
126. Golenser, J. & Domb, A. (2006) New formulations and derivatives of 
amphotericin B for treatment of leishmaniasis. Mini Rev Med Chem, 6 (2), 153-
62. 
127. Granger, D. L., Hibbs, J. B., Perfect, J. R., & Durack. D. T. (1988) Speciﬁc 
amino acid (L -arginine) requirement for the microbiostatic activity of murine 
macrophages. J. Clin. Invest., 81,1129-1136. 
128. Grant, S.M., & Clissold, S.P. (1989) Itraconazole, a review of its 
pharmacodynamic and pharmacokinetic properties, and therapeutic use in 
superficial and systemic mycoses. Drugs, 37, 310. 
129. Gray, K.C., Palacios, D.S., Dailey, I., Endo, M.M., Uno, B.E., Wilcock, B.C. & 
Burke, M.D. (2012) Amphotericin primarily kills yeast by simply binding 
ergosterol, Proceedings of the National Academy of Sciences, 109 (7), 2234-
2239. 
352 
 
130. Greenblatt, M.B., Aliprantis, A., Hu, B., & Glimcher, L.H. (2010) Calcineurin 
regulates innate antifungal immunity in neutrophils. J Exp Med, 207, 923-931. 
131. Gross, N. T., Nessa, K., Camner, P., & Jarstrand, C.  (1999) Production of 
nitric oxide by rat alveolar macrophages stimulated by Cryptococcus neoformans 
or Aspergillus fumigates. Medical Mycology, 37, 151-157. 
132. Grunig, G., Corry, D.B., Leach, M.W., Seymour, B.W., Kurup, V.P., Rennick, 
D.M. (1997) Interleukin-10 is a natural suppressor of cytokine production and 
inflammation in a murine model of allergic bronchopulmonary aspergillosis. J Exp 
Med, 185, 1089-99. 
133. Gubbins, P.O., & Anaissie, E.J. (2009) Antifungal therapy. 2nd edition. [on 
line], Churchill Livingstone Elsevier. Available from: http://www 
books.google.co.uk/books?isbn=1416056807. 
134.  Harris, D.L. (2006) A homopolymer complex of amphotericin B for the 
pharamcological treatment and immunotherapy of leishmaniasis. PhD thesis. 
Faculty of Science, University of London. 
135. Hatziagorou, E., Walsh, T.J. Tsanakas, J.N., Roilides, E. (2009) Aspergillus 
and the Paediatric Lung. Paediatric Respiratory Reviews, 10 (4), 178-185. 
 
136. Herbrecht, R., Natarajan-Ame, S., Nivoix, Y., Letscher-Bru, V. (2003) The lipid 
formulations of Amphotericine B. Expert Opinion Pharmacother, 4, 1277-1287.  
137. Herbst, S., Shah, A., Carby, M., Chusney,G., Kikkery, N., Dorling, A., Bignell, 
E., Shaunak, S. & Armstron-james, D., (2013) A new and clinically relevant 
murine model of solid organ transplant aspergillosis. Disease Models & 
Mechanisms, 6 (3), 643-651. 
138. Herve, M., Bebouzy, J. C., Borowski, E., Cybulska, B., & Gary-Bobo, C. M. 
(1989) The role of the carboxyl and amino groups of polyene macrolides in their 
interactions with sterols and their selective toxicity. A P-NMR study. Biochim. 
Biophys. Acta., 980, 261-272. 
139. Hess, D., Fisher, D., Williams, P., et al. (1996) Medication nebulizer 
performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. 
Chest, 110, 498–505. 
140. Hoeben, B.J., Burgess, D.S., McConville, J.T., et al. (2006) In vivo efficacy of 
aerosolized nanostructured itraconazole formulations for prevention of invasive 
pulmonary aspergillosis. Antimicrob Agents Chemother, 50, 1552–1554. 
353 
 
141. Hohl, T. M., Van Epps, H. L.,  Rivera, A.,  Morgan, L. A., Chen, P. L., 
Feldmesser, M., & Pamer, E. G., (2005) Aspergillus fumigatus triggers 
inﬂammatory responses by stage-speciﬁc beta-glucan display. PLoS Pathog. 
1:e30. 
142. Hohl, T.M., & Feldmesser, M (2007) Aspergillus fumigatus: Principles of 
Pathogenesis and Host Defence. Eukaryotic Cell, 6 (11), 1953-1963. 
143. Hope, W.W., Walsh, T. J. & Denning, D.W. (2005) Laboratory diagnosis of 
invasive aspergillosis. Lancet Infect Dis, 5, 609-22. 
144. Howard, S.J., Cerar, D., Anderson, M.J., Albarrag, A., Fisher, M.C., 
Pasqualotto, A.C.,  Laverdiere, M., Arendrup, M.C., Perlin, D.S., & Denning, D.W. 
(2009) Frequency and Evolution of Azole Resistance in Aspergillus fumigates 
Associated with Treatment Failure. Emerging Infectious Diseases, 15 (7), 1068-
1076. 
145. Husain, S., Paterson, D.K.L., & Studerd, S., et al (2006) Voriconazole 
prophylaxis in lung transplant recipients. Am J Transplant, 6, 3008. 
146. Hutchens, M. & Luker, G.D. (2007) Applications of bioluminescence imaging 
to the study of infectious diseases. Cell Microbiol., 9 (10), 2315-22.  
147. Ibrahim-Granet, O., Jouvion, G., Hohl, T.M. et al. (2010) In 
vivo bioluminescence imaging and histopathopathologic analysis reveal distinct 
roles for resident and recruited immune effector cells in defence against invasive 
aspergillosis. BMC Microbiol., 10 (105), 1-22. 
148. Ibrahim-Granet, O., Philippe, B., Boleti, H., Boisvieux-Ulrich, E., Grenet, D., 
Stern, M., & Latge, J.P. (2003) Phagocytosis and Intracellular Fate of Aspergillus 
fumigatus Conidia in Alveolar Macrophages. Infection and Immunity, 71 (2), 891–
903. 
149. Inoue, S.B., Qadota, H., Arisawa, M., et al. (1996) Signaling toward yeast 1, 
3-beta-glucan synthesis. Cell Struct Funct, 21, 395-402. 
 
150. Jaillon, S., Peri, G., Delneste, Y., Frémaux, I., Doni, A., Moalli, F., et al. (2007) 
The humoral pattern recognition receptor PTX3 is stored in neutrophil granules 
and localizes in extracellular traps. The Journal of experimental medicine, 204 
(4), 793-804.  
151. Jambor, W.P., Steinberg, B.A. & Suydam, L.O. (1955-1956) Amphotericins A 
354 
 
and B: two new antifungal antibiotics possessing high activity against deep-
seated and superficial mycoses.  Antibiot Annu, 3, 574-8.  
152. Janeway, C.A., Travers, P., Walport, M., & Murphy, K.P. (2008) Janeway's 
Immunobiology, seventh edition ed. Garland Science. 
153. Jeong, B. & Gutowska, A. (2002) Lessons from nature: stimuli-responsive 
polymers and their biomedical applications. Trends Biotechnol., 20, (7) 305-311. 
154. Jørgensen, K.A., Koefoed-Nielsen, P.B., & Karamperis, N., (2003) Calcineurin 
phosphatase activity and immunosuppression. A review on the role of calcineurin 
phosphatase activity and the immunosuppressive effect of cyclosporin A and 
tacrolimus. Scand J Immunol., 57(2), 93-8. 
155. Kapteyn, J.C., Van Den Ende, H. & Klis, F.M. (1999) The contribution of cell 
wall proteins to the organization of the yeast cell wall. Biochim Biophys Acta., 
1426, 373-383. 
156. Kasai, Y., Matsumori, N., Umegawa,Y., Matsuoka, S.,Ueno, H., Ikeuchi, H., 
Oishi,T. & Murata, M.(2008) Self-Assembled Amphotericin B Is Probably 
Surrounded by Ergosterol:Bimolecular Interactions as Evidenced by Solid-State 
NMR and CD Spectra. Chem. Eur. J., 14, 1178 -1185. 
157. Kaur, S., Gupta, V. K., Thiel, S., Sarma, P. U. & Madan, T. (2007) Protective 
role of mannan-binding lectin in a murine model of invasive pulmonary 
aspergillosis. Clin. Exp. Immunol., 148, 382-389. 
158. Kawabata, M., Onda, M. & Mita, T. (2001) Effect of aggregation of 
amphotericin B on lysophosphatidylcholine micelles as related to its complex 
formation with cholesterol or ergosterol. J. Biochem., 129 (5), 725-732. 
159. Kawazu, M., Kanda, Y., Nannya, Y. et al. (2004) Prospective comparison of 
the diagnostic potential of real-time PCR, double sandwich enzyme-linked 
immuno-sorbent assay for galactomannan, and a (1 ﬁ 3)-beta-D-glucan test in 
weekly screening for invasive aspergillosis in patients with hematological 
disorders. J Clin Microbiol, 42, 2733-2741. 
160. Kayser, O., Olbrich, C., Yardley, V., et al. (2003) Formulation of amphotericin 
B as nanosuspension for oral administration. Int J Pharm, 254 (1), 73-5. 
161. Kesser, K.C. & Geller D.E. (2009) New Aerosol Delivery Devices for Cystic 
Fibrosis. Piratory Care, 54 (6), 754-768. 
162. Kim, S.Y., Lee, K.S., Han, J., et al. (2000) Semi invasive pulmonary 
355 
 
aspergillosis: CT and pathologic findings in six patients. AJR Am J Roentgenol, 
174, 795-8. 
163. Kino, T., Hatanaka, H., Miyata, S., et al. (1987) FK-506, a novel 
immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect 
of FK-506 in vitro. J Antibiot (Tokyo), 40, 1256–1265. 
164. Kleinberg, M. (2006) What is the current and future status of conventional 
amphotericin B? International Journal of Antimicrobial Agents, 27, 12-16. 
165. Knoch, M. & Finlay, W.H. (2002) "Ch. 71 Nebuliser Technologies". In 
Rathbone, Hadgraft, Roberts. Modified-Release Drug Delivery Technology. 
Marcel Dekker. pp. 849–856. 
166. Knoch, M. & Keller, M. (2005) The customised electronic nebuliser: a new 
category of liquid aerosol drug delivery systems. Expert Opin Drug Deliv, 2 (2), 
377-390. 
167. Koch, S., Hohne, F.M. & Tietz, H.J. (2004) Incidence of systemic mycoses in 
autopsy material. Mycoses, 47, 40-6. 
168. Korn, T., Bettelli, E., Gao, W., et al. (2007) IL-21 initiates an alternative 
pathway to induce proinflammatory T(H)17 cells. Nature, 448, 484–487.  
169. Kousha, M., Tadi, R. & Soubani, A.O. (2011) Pulmonary aspergillosis: a 
clinical review. Eur Respir Rev., 20 (121), 156–174. 
170. Kravetz, H.M., Andriole, V.T., Huber, M.A. & Utz, J.P. (1961) Oral 
administration of solubilized amphotericin B. N Engl J Med, 265, 183-4. 
171. Kröncke, K.D., Fehsel, K., & Kolb-Bachofen, V., (1998) Inducible Nitric Oxide 
Synthase In Human Diseases. Clin Exp Immunol., 113 (2), 147–156.  
172. Kropf, P., Freudenberg, M.A., Modolell, M., Price, H.P., Herath, S., Antoniazi, 
S., Galanos, C., Smith, D.F., & Muller, I. (2004) Toll-like receptor 4 contributes to 
efficient  control of infection with the protozoan parasite Leishmania major. 
Infection and Immunity, 72 (4), 1920-1928. 
173. Kuhn, R.J. (2002) Pharmaceutical considerations in aerosol drug delivery. 
Pharmacotherapy, 22 (3 Pt 2), 80S–85S. 
174. Kullberg, B.J., van t’Wout, J.W., Hoogstraten, C., & von Furth, R. (1993) 
Recombinant interferon-g enhances resistance to acute disseminated Candida 
albicans infections in mice. J Infect Dis, 168, 436-43. 
175. Kurtz, M.B., Bernard, E.M., Edwards, F.F., et al. (1995) Aerosol and 
356 
 
parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. 
Antimicrob Agents Chemother, 39, 1784–1789. 
176. Kydonieus, A. (1992) Treatise on Controlled Drug Delivery. Marcel Dekker: 
New York. 
177. Labiris, N. R.  & Dolovich, M. B. (2003) Pulmonary drug delivery. Part II: The 
role of inhalant delivery devices and drug formulations in therapeutic 
effectiveness of aerosolized medications. Br J Clin Pharmacol, 56, 600–612. 
178. Lass-Florl, C. (2009) The changing face of epidemiology of invasive fungal 
disease in Europe. Mycoses, 52, 197–205. 
179. Latge, J.P. (2003) Aspergillus fumigatus, a saprotrophic pathogenic fungus. 
Mycologist, 17, 56-61. 
180. Latge, J.P., (1999) Aspergillus fumigatus and Aspergillosis. Clinical 
Microbiology Reviews, 12 (2), 310–350. 
181. Latge, J.P., Kobayashi, H., & Debeaupuis, J.P. (1994) Chemical and 
immunological characterization of the galactomannan secreted by Aspergillus 
fumigatus. Infect Immun., 62, 5424–5433. 
182. Laube, B.L., Jashnani, R., Dalby, R.N. & Zeitlin, P.L. (2000) Targeting aerosol 
deposition in patients with cystic fibrosis: effects of alterations in particle size and 
inspiratory flow rate. Chest, 118, 1069-76. 
183. Le Gros, G., Ben-Sasson, S.Z., Seder, R., Finkelman, F.D., & Paul, W.E. 
(1990) Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 
and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp 
Med., 172, 921-929. 
184. Le Thi Huong, D., Wechsler, B., Chamuzeau, J.P., Bisson, A. & Godeau, P. 
(1995) Pulmonary aspergilloma complicating Wegener’s granulomatosis. Scand J 
Rheumatol, 24, 260. 
185. Le, J., & Schiller, D.S., (2010) Aerosolized Delivery of Antifungal Agents. Curr 
Fungal Infect Rep, 4, 96–102.  
186. Letourneau, S., van Leeuwen, E.M., Krieg, C., Martin, C., Pantaleo, G., 
Sprent, J., Surh, C.D., & Boyman, O. (2010) IL-2/anti-IL-2 antibody complexes 
show strong biological activity by avoiding interaction with IL-2 receptor alpha 
subunit CD25. Proc. Natl. Acad. Sci. U.S.A, 107 (5), 2171-2176. 
187. Levitz, S.M. & Diamond, R.D (1985) Mechanisms of resistance of Aspergillus 
357 
 
fumigatus conidia to killing by neutrophils in vitro. J. Infect. Dis., 152 (1), 33–42. 
188. Lewis, J.H., Zimmerman, H.J., Benson, G.D. & Ishak, K.G. (1984) Hepatic 
injury associated with ketoconazole therapy. Analysis of 33 cases. 
Gastroenterology, 86 (3), 503–513. 
189. Liew, F.Y., Li, Y., & Millott, S. (1990) Tumor necrosis factor-alpha synergizes 
with IFN-gamma in mediating killing of Leishmania major through the induction of 
nitric oxide. The Journal of Immunology, 145(12), 4306-4310. 
190. Lin, S. J., Schranz, J., & Teutsch, S. M. (2001) Aspergillosis case-fatality rate: 
systematic review of the literature. Clin. Infect. Dis., 32, 358–366. 
191. Littman, M.L., Horowitz, P.L. & Swadey, J.G. (1958) Coccidioidomycosis and 
its treatment  with amphotericin B. Am J Med , 24 (4), 568-92. 
192. Lopes Bezerra, L.M. & Filler, S. G. (2004) Interactions of Aspergillus 
fumigatus with endothelial cells: internalization, injury, and stimulation of tissue 
factor activity. Blood, 103, (6), 2143-2149. 
193. Lovchik, J., Lipscomb, M., & Lyons, C. R. (1997) Expression of lung inducible 
nitric oxide synthase protein does not correlate with nitric oxide production in vivo 
in a pulmonary immune response against Cryptococcus neoformans. J. 
Immunol., 158, 1772–1778. 
 
194. Madan, T., Eggleton, P., Kishore, U., Strong, P., Aggrawal, S. S., Sarma, P. 
U., & Reid, K. B. (1997) Binding of pulmonary surfactant proteins A and D to 
Aspergillus fumigatus conidia enhances phagocytosis and killing by human 
neutrophils and alveolar macrophages. Infection and Immunity, 65, 3171–3179. 
195. Madan, T., Kishore, U., Singh, M., Strong, P., Hussain, M., Reid, K. B. M., & 
Sarma, P.U. (2001) Protective Role of Lung Surfactant Protein D in a Murine 
Model of Invasive Pulmonary Aspergillosis. Infection and Immunity, 69 (4), 2728-
2731. 
196. Madan, T., Reid, K. B., Singh, M., Sarma, P. U., & Kishore, U. (2005) 
Susceptibility of mice genetically deficient in the surfactant protein (SP)-A or SP-
D gene to pulmonary hypersensitivity induced by antigens and allergens of 
Aspergillus fumigatus. J. Immunol., 174, 6943-6954. 
197. Magill, S.S. (2006) Antifungal prophylaxis in transplant recipients: where do 
we go from here? Transplant Infectious Disease, 8,187-189. 
358 
 
198. Manunta, M.D.I., McAnulty, R.J., Tagalakis, A.D., Bottoms, S.E., Campbell, 
F., Hailes, H.C., Tabor, A.B., Laurent, G.J., O’Callaghan, C., Hart, S.L. (2011) 
Nebulisation of Receptor-Targeted Nanocomplexes for Gene Delivery to the 
Airway Epithelium. PLOS ONE, 6 (10), 1-13. 
199. Mathiowitz, E. (1999) Encyclopedia of Controlled Drug Delivery. Wiley-
Interscience: New York. 
200. Mayer, J., Doubek, M., Doubek, J., Horky, D., Scheer, P., & Stepanek, M. 
(2002) Reduced nephrotoxicity of conventional amphotericin B therapy after 
minimal nephroprotective measures: animal experiments and clinical study. J. 
Infect. Dis., 186 (3), 379-388. 
201. McConville, J.T., Overhoff, K.A., Sinswat, P., et al. (2006) Targeted high lung 
concentrations of itraconazole using nebulized dispersions in a murine model. 
Pharm Res, 23, 901-911. 
202. Mehrad, B., Strieter, R.M., & Standiford, T.J (1999) Role of TNF-a in 
pulmonary host defense in murine invasive aspergillosis. The American 
Association of Immunologists. 1633-1640. 
203. Menichetti, F., Del Favero, A., Martino, P., et al. (1999) Itraconazole oral 
solution as prophylaxis for fungal infections in neutropenic patients with 
hematologic malignancies; a randomized, placebo-controlled, double-blind, 
multicentre trail. Clin Infect Dis, 28, 250. 
204. Mesa-Arango, A.C., Scorzoni, L., & Zaragoza, O. (2012) It only takes one to 
do many jobs: Amphotericin B as antifungal and immunomodulatory drug. 
Frontiers in microbiology, 3, 1-10. 
205. Mezger, M., Kneitz, S., Wozniok, I., Kurzai, O., Einsele, H., & Loefﬂer, J. 
(2008) Proinﬂammatory response of immature human dendritic cells is mediated 
by dectin-1 after exposure to Aspergillus fumigatus germ tubes. J. Infect. Dis., 
197, 924-931. 
206. Michaliszyn, E., Senechal, S., Martel, P., & Repentigny, L., (1995) Lack of 
Involvement of Nitric Oxide in Killing of Aspergillus fumigatus Conidia by 
Pulmonary Alveolar Macrophages. Infection And Immunity, 63 (5), 2075-2078. 
207. Minami, Y., Kono, T., Miyazaki, T., & Taniguchi, T. (1993) The IL-2 Receptor 
Complex: Its Structure, Function, and Target Genes. Annual Review of 
Immunology, 11(1), 245-268. 
359 
 
208. Mircescu, M.M., Lipuma, L., van Rooijen, N., Pamer, E.G., Hohl, T.M. (2009) 
Essential role for neutrophils but not alveolar macrophages at early time points 
following Aspergillus fumigatus infection. J. Infect. Dis., 200 (4), 647-656.  
209. Modolell, M., Corraliza, I. M., Link, F., Soler, G.  & Eichmann. K., (1995) 
Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse 
bone marrow-derived macrophages by T H 1 and T H 2 cytokines. Eur. J. 
Immunol., 25, 1101-1104. 
210. Mohammad, R.A. & Klein, K.C. (2006) Inhaled Amphotericin B for Prophylaxis 
Against Invasive Aspergillus Infections. The Annals of Pharmacotherapy, 40, 
2148-2154. 
211. Monforte, V., Roman, A., Gavalda, J., et al. (2003) Nebulized amphotericin B 
concentration and distribution in the respiratory tract of lung transplanted 
patients. Transplantation, 759, 1571-1574. 
212. Moore, K.W., de Waal, M.R., Coffman, R.L. & O'Garra, A. (2001) Interleukin-
10 and the interleukin-10 receptor. Annu. Rev. Immunol., 19, 683-765. 
213. Moore, R., Lord, R., & Collins, R.H. (1994) Tacrolimus (FK506) versus 
cyclosporin in prevention of liver allograft rejection. Lancet, 344, 948-949. 
214. Morris, G., Kokki, M. H., Anderson, K. & Richardson, M. D.  (2000) Sampling 
of Aspergillus spores in air. J. Hosp. Infect., 44, 81–92. 
215. Morrison, B. E., Park, S. J. Mooney, J. M.  & Mehrad, B. (2003) Chemokine- 
mediated recruitment of NK cells is a critical host defense mechanism in invasive 
aspergillosis. J. Clin. Investig., 112, 1862–1870. 
216. Mosmann, T.R., & Coffman, R.L. (1989) TH1 and TH2 cells: different patterns 
of lymphokine secretion lead to different functional properties. Annu Rev 
Immunol, 7,145-173. 
217. Mozaffarian, N., Berman, J. W., & Casadevall, A. (1997) Enhancement of 
nitric oxide synthesis by macrophages represents an additional mechanism of 
action for amphotericin B.  Antimicrob. Agents Chemother., 41,1825–1829. 
218. Muers, M. F. (1997) Overview of nebuliser treatment. Thorax, 52 (Suppl 2), 
S25-S30. 
 
219. Munder, M., Mallo, M., Eichmann, K., & Modolell, M. (1998) Murine 
macrophages secrete interferon gamma upon combined stimulation with 
360 
 
interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage 
activation. J Exp.Med, 187 (12), 2103-2108. 
220. Munoz, P., Guinea, J., & Bouza, E.  (2006) Update on invasive aspergillosis: 
clinical and diagnostic aspects. Clin Microbiol Infect., 12, (7), 24-39. 
221. Nakamura, K., Maitani, Y., Lowman, A.M., Takayama, K., Peppas, N.A. & 
Nagai, T. (1999) Uptake and release of budesonide from mucoadhesive, pH-
sensitive copolymers and their application to nasal delivery. Journal of Controlled 
Release, 61, 329-335. 
222. Netea, M. G., Warris, A., Van der Meer, J. W., Fenton, M. J., Verver-Janssen, 
T. J., Jacobs,  L. E., Andresen, T., Verweij, P. E. & Kullberg, B. J. (2003). 
Aspergillus fumigatus evades immune recognition during germination through 
loss of Toll-like receptor-4-mediated signal transduction. J. Infect. Dis., 188, 320-
326. 
223. Neth, O., Jack, D.L., Dodds, A.W., Holzel, H., Klein, N.J. & Turner, M.W. 
(2000) Mannose-Binding Lectin Binds to a Range of Clinically Relevant 
Microorganisms and Promotes Complement Deposition. Infect. Immun., 68 (2), 
688-693. 
224. Newman, K.C. & Riley, E.M. (2007) Whatever turns you on: accessory cell-
dependent activation of NK cells by pathogens. Nat Rev Immunol, 7, 279-91. 
225. Ng, T. T. C., Robson, G. D., & Denning. D. W. (1994) Hydrocortisone 
enhanced growth of Aspergillus spp: implication for pathogenesis. Microbiology, 
140, 2475-2479. 
226. Oakley, K.L., Morrissey, G., Denning, D.W. (1997) Efficacy of SCH-56592 in a 
temporarily neutropenic murine model of invasive aspergillosis with an 
itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus 
fumigatus. Antimicrob Agents Chemother, 41, 1504-7. 
227. Odo, M. E. Y., Cuce, L. C., Odo, L. M. & Natrielli, A. (2007) Action of sodium 
deoxycholate on subcutaneous human tissue: local and systemic effects. 
Dermatol Surg, 33,178-189. 
228. Paquet, M.J., Fournier, I., Barwicz, J., Tancrede, P., & Auger, M. (2002) The 
effects of amphotericin B on pure and ergosterol- or cholesterol-containing 
dipalmitoylphosphatidylcholine bilayers as viewed by 2H NMR. Chem. Phys. 
Lipids., 119 (1-2), 1-11.  
361 
 
229. Paris, S., Boisvieux-Ulrich, E., Crestani, B., Houcine, O., Taramelli, D., 
Lombardi, L., & Latge, J. P. (1997) Internalization of Aspergillus fumigatus 
conidia by epithelial and endothelial cells. Infect. Immun., 65, 1510-1514. 
230. Park, S.J., & Mehrad, B (2009) Innate Immunity to Aspergillus Species. 
Clinical Microbiology Reviews, 22 (4), 535-551. 
231. Pasqualotto, A. (2008) Differences in pathogenicity and clinical syndromes 
due to Aspergillus fumigatus and Aspergillus flavus, Medical Mycology, 1-10. 
232. Paterson, N. S. (2005) Aspergillus Infections in Transplant Recipients. Clinical 
Microbiology Review, 44-69. 
233. Paugam, A., Baixench, M.T, Lebuisson, A. & Dupouy-Camet, J. (2010) 
Diagnosis of invasive pulmonary aspergillosis: value of bronchoalveolar lavage 
galactomannan for immuno-compromised patients. Pathologie Biologie, 58 (1), 
100-103. 
234. Paul, W.E., & Seder, R.A. (1994) Lymphocyte responses and cytokines. Cell, 
76, 241-251. 
235. Pazos, C., Pontón, J., & Del Palacio, A. (2005) Contribution of (1,3)-beta-D-
glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive 
aspergillosis in neutropenic adult patients: A comparison with serial screening for 
circulating galactomannan. J Clin Microbiol., 43, 299-305. 
236. Peppas, N.A. & Sahlin, J.J. (1996) Hydrogels as mucoadhesive and 
bioadhesive materials: a review. Biomaterials, 17, 1553-1561. 
237. Pappas, P. G.,  Alexander, B. D.,  Andes, D. R.,  Hadley, S., Kauffman, C. 
A.,  Freifeld, A.,  Anaissie, E. J.,  Brumble, L. M.,  Herwaldt, L., Ito, J., et al. 
(2010) Invasive fungal infections among organ transplant recipients: results of the 
Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. 
Dis., 50, 1101-1111. 
238. Perfect, J.R., Ashley, E.D. & Drew, R. (2004) Design of Aerosolized 
Amphotericin B Formulations for Prophylaxis Trials among Lung Transplant 
Recipients. Clinical Infectious Diseases, 39, S207-10. 
239. Perfect, J.R., Cox, G.M., Lee, J.Y. et al. (2001) The impact of culture isolation 
of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis, 
33, 1824-1833. 
240. Perkhofer, S., Kehrel, B.E., Dierich, M.P. et al. (2008) Human platelets 
362 
 
attenuate Aspergillus species via granule-dependent mechanisms. J. Infect. 
Dis., 198 (8), 1243-1246. 
241. Pfaller, M.A., Boyken, L., Hollis, R.J., Messer, S.A., Tendolkar, S. & Diekema, 
D. J. (2006) Global surveillance of in vitro activity of micafungin against Candida: 
a comparison with caspofungin by CLSI-recommended methods. J Clin Microbiol; 
44 (10), 3533-3538. 
242. Pfaller, M.A., Messer, S.A., Hollis, R.J., Jones, R.N. (2002) SENTRY 
Participants Group. (2002) Antifungal activities of posaconazole, ravuconazole, 
and voriconazole compared to those of itraconazole and amphotericin B against 
239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from 
SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother, 46 
(4), 1032-7. 
243. Phadke, A.P. & Mehrad, B. (2005) Role of cytokines in innate host defence 
against Aspergillus: recent advances. Med Mycology, 423, S173-S176. 
244. Philippe, B., Ibrahim-Granet, O., Prevost, M.C., Gougerot-Pocidalo, M.A., 
Sanchez Perez, M., Van der Meeren, A., & Latge, J.P. (2003) Killing of 
Aspergillus fumigatus by alveolar macrophages is mediated by reactive oxidant 
intermediates. Infect. Immun., 71, 3034-3042. 
245. Puccetti, P., Romani, L. & Bistoni, F. (1995) A TH1-TH2-like switch in 
candidiasis: new perspectives for therapy. Trends Microbiol., 3, 237-240. 
246. Rafferty, P., Biggs, B.A., Crompton, G.K. & Grant, I.W. (1983) What happens 
to patients with pulmonary aspergilloma? Analysis of 23 cases. Thorax, 38, 579-
83. 
247. Readio, J.D. & Bittman, R. (1982) Equilibrium binding of amphotericin B and 
its methyl ester and borate complex to sterols. Biochim. Biophys. Acta, 685 (2), 
219-224. 
248. Reeves, E.P., Murphy, T., Daly, P., & Kavanagh, K. (2004) Amphotericin B 
enhances the synthesis and release of the immunosuppressive agent gliotoxin 
from the pulmonary pathogen Aspergillus fumigates. Journal of Medical 
Microbiology, 53, 1-7. 
249. Rivera, A., Van Epps, H.L., Hohl, T.M., Rizzuto, G. & Pamer, E.G. (2005) 
Distinct CD4+-T-cell responses to live and heat-inactivated Aspergillus fumigatus 
conidia. Infect. Immun., 73, 7170-7179. 
363 
 
250. Rodland, E.K., Ueland, T., Pedersen, T.M. et al. (2010) Activation of platelets 
by Aspergillus fumigatus and potential role of platelets in the 
immunopathogenesis of Aspergillosis. Infect. Immun., 78 (3), 1269-1275.  
251. Rodrigues, A.G., Araujo, R., & Pina-Vaz, C. (2005) Human albumin promotes 
germination, hyphal growth and antifungal resistance by Aspergillus fumigatus. 
Med Mycol., 43, 711-717. 
252. Roilides, E., Dimitriadou, A., Kadiltsoglou, I., Sein, T., Karpouzas, J., Pizzo, 
P.A., & Walsh, T.J., (1997) IL-10 exerts suppressive and enhancing effects on 
antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J 
Immunol, 158, 322 - 9. 
253. Roilides, E., Robinson, T., Sein, T., Pizzo, P. A. & Walsh, T. J. (1994) In vitro 
and ex vivo effects of cyclosporin A on phagocytic host defences against 
Aspergillus fumigatus. Antimicrob. Agents Chemother, 38, 2883-2888. 
254. Roilides, E., Uhlig, K., Venzon, D., Pizzo, P. A., & Walsh, T. J. (1993) 
Prevention of corticosteroid-induced suppression of human polymorphonuclear 
leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte 
colony-stimulating factor and g-interferon. Infect. Immun., 61, 4870-4877. 
255. Roilides, E., Uhlig, K., Venzon, D., Pizzo, P. A., & Walsh. T. J. (1993) 
Enhancement of oxidative response and damage caused by human neutrophils 
to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and 
gamma interferon. Infect. Immun., 61, 1185-1193. 
256. Roilides, E., Lyman C.A., Filioti J., Akpogheneta O., Sein T., Lamaignere 
C.G., Petraitiene R. & Walsh T.J. (2002) Amphotericin B formulations exert 
additive antifungal activity in combination with pulmonary alveolar macrophages 
and polymorphonuclear leukocytes against Aspergillus fumigatus. Antimicrob. 
Agents Chemother., 46, 1974-1976. 
257. Roilides, E., Dimitriadou-Georgiadou, A., Sein, T., Kadiltsoglou, I. & Walsh, T. 
(1998) Tumor necrosis factor alpha enhances antifungal activities of 
polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. 
Infection and Immunity, 66, 5999. 
258. Romani, L. (2004) Immunity to fungal infections. Nat. Rev. Immunol., 4 (1), 1-
23.  
259. Roos, D (1994) The genetic basis of chronic granulomatous disease. 
364 
 
Immunological Reviews, (138), 121-157.  
260. Rousset, F., Garcia, E., Defrance, T., Peronne, C., Vezzio, N., Hsu, D.H., 
Kastelein, R., Moore, K.W., & Banchereau, J. (1992) Interleukin 10 is a potent 
growth and differentiation factor for activated human B lymphocytes. Proc. Natl. 
Acad Sci. U.S.A, 89 (5), 1890-1893. 
261. Ruijgrok, E.J., Vulto, A.G. & van Etten, E.W.M. (2000) Aerosol delivery of 
amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B 
(AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in 
rats. Journal of Pharmacy and Pharmacology, 52, 619-27. 
262. Ruijgrok, E.J., Vulto, A.G. & Van Etten, E.W.M. (2001) Efficacy of aerosolized 
amphotericin B deoxycholate and liposomal amphotericin B in the treatment of 
invasive pulmonary aspergillosis in severely immunocompromised rats. Journal 
of Antimicrobial Chemotherapy, 48, 89-95. 
263. Ruijgrok, E.J., Fens, M. H. A. M., Bakker-Woudenberg, I. A. J. M., van Etten, 
E. W. M. & Vulto, A.G. (2006) Nebulized Amphotericin B Combined with 
Intravenous Amphotericin B in Rats with Severe Invasive Pulmonary 
Aspergillosis. Antimicrobial Agents and Chemotherapy, 50 (5), 1852-1854. 
264. Sabra, R., Takahashi, K., Branch, R.A., & Badr, K.F. (1990) Mechanisms of 
amphotericin B-induced reduction of the glomerular filtration rate: a 
micropuncture study. J. Pharmacol. Exp. Ther., 253 (1), 34-37. 
265. Sajeesh, S. & Sharma, C.P. (2004) Poly methacrylic acid-alginate semi-IPN 
microparticles for oral delivery of insulin: a preliminary investigation. J Biomater. 
Appl., 19 (1), 35-45. 
266. Sajeesh, S., Vauthier, C., Gueutin, C., Ponchel, G., & Sharma, C.P. (2010). 
Thiol functionalized polymethacrylic acid-based hydrogel microparticles for oral 
insulin delivery. Acta Biomater., 6, (8), 3072-3080. 
267. Salah, A., El-Mashad, N., El-Deeb, D. & Mansour, M. (2010) antifungal drug 
resistance in pathogenic fungi (review article). 21(1), 31-41. 
268. Sallusto, F., Mackay, C.R., & Lanzavecchia, A. (2000) The role of chemokine 
receptors in primary, effector, and memory immune responses. Annu. Rev. 
Immunol., 18, 593-620. 
269. Sanchez-Brunete, J.A., Dea, M.A., Rama, S., Bolas, F., Alunda, J.M., 
Torrado-Santiago, S., & Torrado, J.J. (2004) Amphotericin B molecular 
365 
 
organization as an essential factor to improve activity/toxicity ratio in the 
treatment of visceral leishmaniasis. J. Drug Target, 12, (7) 453-460. 
270. Santangelo, R., Paderu, P., Delmas, G., Chen, Z.W., Mannino, R., Zarif, L. & 
Perlin, D.S. (2000) Efficacy of Oral Cochleate-Amphotericin B in a Mouse Model 
of Systemic Candidiasis. Antimicrob Agents Chemother., 44 (9), 2356–2360. 
271. Sarfati, J., Diaquin, M., Debeaupuis, J. P., Paris, S., & Latge, J. P.  
Unpublished data. 
272. Sau, K., Mambula, S.S., Latz, E.,  Henneke, P.,  Golenbock, D.T. & Levitz, 
S.M. (2003) The Antifungal Drug Amphotericin B Promotes Inflammatory 
Cytokine Release by a Toll-like Receptor- and CD14-dependent Mechanism. The 
Journal of Biological Chemistry. 278 (39), 37561-37568. 
273. Schaffner, A. (1985) Therapeutic concentrations of glucocorticoids suppress 
the antimicrobial activity of human macrophages without impairing their 
responsiveness to g-interferon. J. Clin. Investig., 76, 1755-1764. 
 
274. Schaffner, A., Douglas, H., Braude, A. (1982) Selective protection against 
conidia by mononuclear and against mycelia by polymorphonuclear phagocytes 
in resistance to Aspergillus. Observations on these two lines of defence in-vivo 
and in-vitro with human and mouse phagocytes. J. Clin. Invest, 69 (3), 617-631. 
275. Schmidt, S., Tramsen, L., Hanisch, M., Latgé, J.P., Huenecke, S., Koehl, U. & 
Lehrnbecher, T. (2011) Human Natural Killer Cells Exhibit Direct Activity Against 
Aspergillus fumigatus Hyphae, But Not Against Resting Conidia. J Infect Dis., 203 
(3), 430-435. 
276. Schuller-Petrovic, S., Wolkart, G., Hoﬂer, G., Neuhold, N., Freisinger, F., 
Brunner, F. (2008) Tissue toxic effects of phosphatidylcholine/deoxycholate after 
subcutaneous injection for fat dissolution in rats and a human volunteer. 
Dermatol Surg, 34, 529-43. 
277. Scott, E. (2011-09-22). "Cortisol and Stress: How to Stay Healthy". 
About.com. Retrieved 2011-11-29.  
 
278. Segal, B.H., Kwon-Chung, J., Walsh, T.J., Klein, B.S., Battiwalla, M., 
Almyroudis, N.G., Holland, S.M., & Romani, L. (2006) Immunotherapy for Fungal 
Infections. Immunotherapy for Fungal Infections, 42, 507-515. 
366 
 
 
279. Serbina, N.V., Cherny, M., Shi, C. et al. (2009) Distinct responses of human 
monocyte subsets to Aspergillus fumigatus conidia. J. Immunol., 183 (4), 2678-
2687.  
280. Serra, L., Domenech, J. & Peppas, N.A. (2006) Design of poly (ethylene 
glycol)-tethered copolymers as novel mucoadhesive drug delivery systems. 
European Journal of Pharmaceutics and Biopharmaceutics, 63 (1), 11-18. 
281. Serrano-Gomez, D., Dominguez-Soto, A., Ancochea, J., Jimenez-Heffernan, 
J. A., Leal, J. A. & Corbi, A. L. (2004) Dendritic cell-speciﬁc intercellular adhesion 
molecule 3-grabbing nonintegrin mediates binding and internalization of 
Aspergillus fumigatus conidia by dendritic cells and macrophages. J. Immunol., 
173, 5635-5643. 
282. Shapiro, R.S., Robbins, N. & Cowen, L.E. (2011) Regulatory Circuitry 
Governing Fungal Development, Drug Resistance and Disease. Microbiology and 
Molecular Biology Reviews, 75 (2), 213-267. 
283. Shaunak, S., Gooderham, N.J., Edwards, R.J., Payvandi, N., Javan, C.M., 
Baggett, N., MacDermot, J., Weber, J.N. & Davies, D.S. (1994) Infection by HIV-1 
blocked by binding of dextrin 2-sulphate to the cell surface of activated human 
peripheral blood mononuclear cells and cultured T-cells. Br. J. Pharmacol., 113 
(1), 151-158. 
284. Sheehan, D.J., Hitchcock, C.A. & Sibley, C.M. (1999) Current and emerging 
azole antifungal agents. Clinl. Microbiol. Rev., 12, 40-79. 
285. Shirk, M.B., Donahue, K.R., & Shirvani, J. (2006) Unlabeled uses of nebulized 
medications. Am J Health-Syst Pharm, 63, 1704-1716. 
286. Simitsopoulou, M., Roilides, E., Paliogianni, F. et al. (2008) 
Immunomodulatory effects of voriconazole on monocytes challenged 
with Aspergillus fumigatus: differential role of Toll-like receptors. Antimicrob. 
Agents Chemother, 52 (9), 3301-3306.  
287. Singh, N.,  Paterson, D.L., Gayowski, T., Wagener, M.M. & Marino, I.R. 
(2001) Preemptive prophylaxis with a lipid preparation of amphotericin b for 
invasive fungal infections in liver transplant recipients requiring renal replacement 
therapy. Transplantation, 71, 910-913. 
288. Steele, C., Rapaka, R. R.,  Metz, A., Pop, S. M., Williams, D. L., Gordon, S., 
367 
 
Kolls, J. K., & Brown, G. D. (2005) The beta-glucan receptor dectin-1 recognizes 
speciﬁc morphologies of Aspergillus fumigatus. PLoS Pathog.,1, e42. 
289. Steinbach, W.J. (2010) Invasive aspergillosis in pediatric patients. Current 
Medical Research & Opinion, 26 (7), 1779-1787. 
290. Stepkowski, S.M. (2000) Molecular targets for existing and novel 
immunosuppressive drugs. Expert Reviews in Molecular Medicine, 1-23. 
291. Stevens, D.A., Kan, V.L., Judson, M.A., et al. (2000) Practice guidelines for 
diseases caused by Aspergillus. Infectious Diseases Society of America. Clin 
Infect Dis, 30, 696-709. 
292. Stevens, D.A., Schwartz, H.J., Lee, J.Y., et al. (2000) A randomized trial of 
itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med, 342, 756-
62. 
293. Stuart, M.A.C, Huck, W.T.S., Genzer, J., Muller, M., Ober, C., Stamm, M., et 
al. (2010) Emerging applications of stimuli-responsive polymer materials. Nat 
Mater, 9, 101-113. 
294. Sundar, S., Chakravarty, J., Agarwal, D., Rai, M., & Murray, H.W. (2010) 
Singledose liposomal amphotericin B for visceral leishmaniasis in India. N. Engl. 
J. Med., 362, (6), 504-512. 
295. Surarit, R., & Shepherd, M.G. (1987) The effects of azole and polyene 
antifungals on the plasma membrane enzymes of Candida albicans. J Med Vet 
Mycol, 25, 403-13. 
296. Sutton, P., Moreland, A., Hutchinson, I.V. & Mullbacher, A. (1995) 
Investigation of the potential use of immunosuppressive agent gliotoxin in organ 
transplantation. Transplantation, 60, 900–902. 
297. Svirshchevskaya, E.V., Shevchenko, M.A., Huet, D. et al. (2009) Susceptibility 
of mice to invasive aspergillosis correlates with delayed cell influx into the 
lungs. Int. J. Immunogenet., 36 (5), 289–299.  
298. Swain, S.L., Weinberg, A.D., English, M., & Huston, G. (1990) IL-4 directs the 
development of Th2-like helper effectors. J Immunol., 145, 3796-3806. 
299. Thau, N., Monod, M., Crestani, B., Rolland, C., Tronchin, G., Latge, J. P. & 
Paris, S. (1994) rodletless mutants of Aspergillus fumigatus. Infect. Immun., 62, 
4380-4388. 
300. Thomson, A.W. (1989) FK-506 how much potential? Immunol today, 10, 6-9.  
368 
 
301. Thornton, S.J., Wasan, K.M. (2009) The reformulation of Amphotericin B for 
oral administration to treat systemic fungal infections and visceral leishmaniasis. 
Expert Opin. Drug Deliv., 6 (3), 271-284. 
302. Tiddens, H.A., Devadason, S.G. (2007) Delivery of therapy to the cystic 
fibrosis lung. In: Hodson M, Geddes D, Bush A, editors. Cystic fibrosis. London: 
Edward Arnold: 185-198. 
303. Tohyama, M., Kawakami, K., and Saito, A. (1996) Anti-cryptococcal effect of 
amphotericin B is mediated through macrophage production of nitric oxide. 
Antimicrob. Agents Chemother., 40, 1919-1923. 
304. Tolman, J.A., Nelson, N.A., Son, Y.J., et al. (2009) Characterization and 
pharmacokinetic analysis of aerosolized aqueous voriconazole solution. Eur J 
Pharm Biopharm, 72, 199-205. 
305. Tomee, J.F.C., Van der Werf, T. S., Latge, J. P., Koeter, G. H., Dubois, A. E. 
J., & Kauffman, H. F. (1994) Serologic monitoring of disease and treatment in a 
patient with pulmonary aspergilloma. Am. J. Respir. Crit. Care Med., 151, 199-
204. 
306. Torrado, J.J., Espada, R., Ballesteros, M.P., Torrado-Santiago, S. (2008) 
Amphotericin B Formulations and Drug Targeting. Journal of Pharmaceutical 
Sciences, 97, 2405-2425. 
307. Tsuda, K., Yamanaka, k., Kitagawa, H. Akeda, T., Naka, M., Niwa, K., 
Nakanishi, T., Kakeda, M., Gabazza, E.C., & Mizutani, H., (2012) Calcineurin 
Inhibitors Suppress Cytokine Production from Memory T Cells and Differentiation 
of Naıve T Cells into Cytokine-Producing Mature T Cells. PLOS ONE, 7 (2), 1-5. 
308. Usui, T., Preiss, J.C., Kanno, Y., Yao, Z.J., Bream, J.H., O'Shea, J.J., & 
Strober, W. (2006) T-bet regulates Th1 responses through essential effects on 
GATA-3 function rather than on IFNG gene acetylation and transcription. The 
Journal of Experimental Medicine, 203 (3), 755-766. 
309. Vandermeulen, G., Rouxhet, L., Arien, A., Brewster, M.E.  & Preat, V. (2006) 
Encapsulation of amphotericin B in poly (ethyleneglycol)-block-poly(-
caprolactone-co-trimethylenecarbonate) polymeric micelles. International Journal 
of Pharmaceutics, 309, 234-240. 
310. Vaughn, J.M., McConville, J.T., Burgess, D., et al. (2006) Single dose and 
multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm, 63, 
369 
 
95-102. 
311. Vermes, A., Guchelaar, H. J. & Dankert, J. (2000) Flucytosine: a review of its 
pharmacology, clinical indications, pharmacokinetics, toxicity and drug 
interactions. J Antimicrob Chemother, 46, 171-179. 
312. Vertut-Doi, A., Hannaert, P., & Bolard, J. (1988) The polyene antibiotic 
amphotericin B inhibits the Na+/K +pump of human erythrocytes. Biochem 
Biophys Res Commun, 157, 692-697. 
313. Verweij, P. E., Oakley, K. L., Morrissey, J., Morrissey, G., & Denning, D.W. 
(1998) Efficacy of LY303366 against amphotericin B-susceptible and-resistant 
Aspergillus fumigatus in a murine model invasive aspergillosis. Antimicrob. 
Agents Chemother., 42, 873-878. 
 
314. Vyas, S.P. & Gupta, S. (2006) Optimizing efficacy of amphotericin B through 
Nanomodification. International Journal of Nanomedicine, 1 (4), 417-432. 
315. Vyas, S.P., Quraishi, S., Gupta, S. & Jaganathan, K.S. (2005) Aerosolized 
liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm, 
296, 12-25. 
316. Walker, L.A., Gow, N.A., & Munro, C.A. (2010) Fungal echinocandin 
resistance. Fungal genet boil, 47, 117-126.  
317. Wallemacq, P.E. & Reding, R. (1993) FK506 (Tacrolimus), A Novel 
Immunosuppressant in Organ Transplantation: Clinical, Biomedical, and 
Analytical Aspects. CLIN. CHEM., 39 (11), 2219-2228. 
318. Walsh, T.J., Finberg, R.W., Arndt, C., Hiemenz, J., Schwartz, C., 
Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R.N., Dummer, S., 
Schuster, M., & Holcenberg, J.S. (1999) Liposomal amphotericin B for empirical 
therapy in patients with persistent fever and neutropenia. National Institute of 
Allergy and Infectious Diseases, Mycoses Study Group. N. Engl. J. Med., 340 
(10), 764-771. 
319. Walsh, T.J., Viviani, M.A., et al., (2000) New targets and delivery systems for 
antifungal therapy. Med. Mycol., 38 (1), 335-347. 
 
320. Wang, J.E., Warris, A., Ellingsen, E.A., Jørgensen, P.F., Flo, T.H., Espevik, 
T.,  Solberg, R.,  Verweij, P.E., &  Aasen, A.O. (2001) Involvement of CD14 and 
370 
 
toll-like receptors in activation of human monocytes by Aspergillus 
fumigatus hyphae. Infect. Immun, 69, 2402-2406. 
321. Waring, P. (1990) DNA fragmentation induced in macrophages by gliotoxin 
does not require protein synthesis and is preceded by raised inositol triphosphate 
levels. J Biol Chem, 265, 14476–14480. 
322. Wasan, E.K., Bartlett, K., Gershkovich, P., Sivak, O., Banno, B., Wong, Z., et 
al. (2009) Development and characterization of oral lipid-based amphotericin B 
formulations with enhanced drug solubility, stability and antifungal activity in rats 
infected with Aspergillus fumigatus or Candida albicans. Int J Pharm, 372, 76-84. 
323. Wasylnka, J. A., & Moore. M. M. (2002) Uptake of Aspergillus fumigatus 
conidia by phagocytic and nonphagocytic cells in vitro: quantitation using strains 
expressing green fluorescent protein. Infect. Immun., 70, 3156-3163. 
324. Wasylnka, J. A., & Moore. M. M. (2003) Aspergillus fumigatus conidia survive 
and germinate in acidic organelles of A549 epithelial cells. J. Cell Sci., 116, 1579-
1587. 
325. Watson, C. J. & Dark, J. H. (2012) Organ transplantation: historical 
perspective and current practice. Br. J. Anaesth., 108 (1), i29-i42. 
326. Werner, J. L., Metz, A. E., Horn, D., Schoeb, T. R., Hewitt, M. M., Schwiebert, 
L. M., Faro-Trindade, I., Brown, G. D., & Steele, C. (2009)  Requisite role for the 
dectin-1 beta-glucan receptor in pulmonary defence against Aspergillus 
fumigatus. J. Immunol., 182, 4938–4946. 
327. Wessels, J. G. H. (1993) Wall growth, protein excretion, and morphogenesis 
in fungi. New Phytol., 123, 397-413. 
328. White, M. H., Bowden, R. A., Sandler, E. S. & et al. (1998) Randomized, 
double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B 
in the empirical treatment of fever and neutropenia. Clin Infect Dis, 27, 296-302. 
329. White, P.L., Linton, C.J., Perry, M.D., Johnson, E.M. & Barnes, R.A. (2006) 
The evolution and evaluation of a whole blood polymerase chain reaction assay 
for the detection of invasive aspergillosis in haematology patients in a routine 
clinical setting. Clin. Infect. Dis., 42, 479-486. 
330. Wichmann, G., Herbarth, O. & Lehmann, I. (2002) The mycotoxins citrinin, 
gliotoxin, and patulin affect interferon-gamma rather than interleukin-4 production 
in human blood cells. Environ Toxicol, 17, 211-8. 
371 
 
331. Wood, K.M., Stone, G.M. & Peppas, N.A. (2008) Wheatgerm agglutinin 
functionalized complexation hydrogels for oral insulin delivery. 
Biomacromolecules, 9, 1293-8. 
332. Wright, J. R. (1997) Immuno-modulatory functions of surfactant. Physiol. Rev., 
77, 931-962. 
333. Yao, Z., Fanslow, W.C., Seldin, M.F., et al. (1995) Herpesvirus Saimiri 
encodes a new cytokine, IL-17, which binds to a novel cytokine 
receptor. Immunity, 3, 811–821. 
334. Yeghen, T., Kibbler, C.C., Prentice, H.G., et al. (2000) Management of 
invasive pulmonary aspergillosis in hematology patients: a review of 87 
consecutive cases at a single institution. Clin Infect Dis, 31, 859-68. 
335. Zeghal, M. (1999) Structure of polymer complexes in water. Auvray L. 
Europhys. Lett., 45 (4), 482-487.  
336. Zheng, C.F., Ma, L.L., Jones, G.J., et al. (2007) Cytotoxic CD4+ T cells use 
granulysin to kill Cryptococcus neoformans, and activation of this pathway is 
defective in HIV patients. Blood, 109 (5), 2049–2057. 
337. Zhu, J., Yamane, H., Cote-Sierra, J., Guo, L., & Paul, W.E. (2006) GATA-3 
promotes Th2 responses through three different mechanisms: induction of Th2 
cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-
specific factors. Cell Res., 16 (1), 3-10. 
338. Zhu, J. & Paul, W.E. (2008) CD4 T cells: fates, functions, and faults. Blood, 
112 (5), 1557-1558. 
339. Zimmerer, R. O. J. r., Pipkin, J.D., Somaraju, S., Suman, J.D., Su, G. & Dalby, 
R.N. (2004) In vitro characterization of a captisol-enabled budesonide inhalation 
solution in ultrasonic and air-jet nebulizers. In: Dalby, R.N., Byron, P.R., Peart, J., 
Suman, J.D., Farr, S.J., editors. Respiratory drug delivery IX. River Grove, IL: 
Davis Healthcare International Publishing; 461-464. 
 
 
